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Abstract 
 
Human Immunodeficiency Virus (HIV)-1 disease progression is variable within patients 
where some remain asymptomatic for long periods (elite controllers (EC)) while others 
rapidly progress to disease (rapid progressors (RP)), representing the ‘extreme 
phenotypes’. There is substantial heterogeneity in how these phenotypes are defined, and 
we examined the relative merit of published definitions using data on HIV-1 seroconverters. 
We propose standard definitions for future research of these rare groups: ECs – maintain 
consecutive HIV-RNA < 50 copies/ml for at least 6 months, RPs – at least one CD4 cell count 
< 100 cells/mm3 within one year of HIV-1 seroconversion. 
Evidence shows that less than 1% of individuals are EC and the majority should start 
treatment to maximise quality and length of life. We supported the ‘when to start’ evidence 
by demonstrating a 62% reduced risk of serious Aquired Immunodeficiency Syndrome 
(AIDS), non-AIDS events or death for those immediately initiating combination 
antiretroviral therapy (cART) (vs not immediately initiating) among those with high CD4 cell 
counts (>500cells/mm3) and high HIV-RNA (>100,000 copies/ml). We contributed towards 
the ‘what cART to start’ question; among individuals initiating boosted protease inhibitor, 
atazanavir might be preferable compared to lopinavir, with 30% lower mortality risk, and 
9% lower virological failure risk, which could lead to lower transmitted drug resistance 
(TDR). We found TDR was significantly decreasing throughout Europe, but remains 
prevalent (8.5% in 2012); therefore, genetic testing among newly diagnosed remains 
justifiable. 
For most, starting treatment is a lifelong commitment; however, some report on post 
treatment control (PTC) upon cART cessation. We found individuals having viral blips on 
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cART had shorter time to viral rebound upon stopping treatment, but most do not become 
PTC and initiate lifelong cART.  We investigated three cART associated toxicities, namely 
hypersensitivity reactions (HSR) due to abacavir (ABC) utilization, AIDS-defining 
neurological conditions related to cART, and immune reconstitution inflammatory 
syndrome (IRIS) shortly after cART initiation. We found that HSR from abacavir utilization 
is low (Incidence Rate (IR)=1.67/100 person-years follow-up), cART with high central 
nervous system penetration scores increase HIV-1 dementia risk, and apart from 
mycobacterial infections, unmasking IRIS may not be a cART complication in high-income 
countries.  
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1 Introduction 
 
 
 History of HIV 
 
Human Immunodeficiency Virus (HIV)-1 originated in chimpanzees in Central and Western 
Africa, and it is believed that its emergence in humans began in the early 1920’s in Kinshasa, 
or what is now the Democratic Republic of Congo1. The first officially reported cases of 
acquired immunodeficiency syndrome (AIDS), however, were not observed until 1981 in 
the United States, where a string of cases of Pneumocystis carinii pneumonia (PCP) and 
Kaposi’s sarcoma (KS) diagnosed in healthy young homosexual men was reported2, 3. Both 
PCP and KS are rare diseases that until 1981, only occurred in immunosuppressed 
individuals; it was therefore recognized that these men had a common immunological 
deficit. Originally, it was thought that AIDS was related to the homosexual lifestyle4, 5, but 
this idea was dismissed when AIDS cases appeared in injection drug users, blood 
transfusion and organ donation recipients6, 7, and in female partners of bisexual men8, 9.    
In May of 1983, a group of French doctors at the Pasteur Institute lead by Dr. Luc 
Montaginer discovered a new retro-virus named Lymphadenopathy-Associated Virus (LAV) 
from a single patient with AIDS which was thought to be the cause of AIDS10. In 1984, Dr. 
Rober Gallo’s team at the National Cancer Institute (NCI) in Maryland isolated a retrovirus 
called HTLV-III present in 48 individuals with AIDS and in none of the 115 individuals with 
no known risk for AIDS11. These two viruses were shown to be identical and were termed 
HIV-112.  A second HIV strain was discovered in 1985 in Senegal13 originating in West African 
Sooty mangabeys14, 15.  This virus was isolated in 1986 and subsequently termed HIV-216.  
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 The HIV-1 Life Cycle 
 
HIV-1 is an enveloped, RNA virus, a member of the Retroviridae family; and infects and 
replicates within a host for survival. HIV-1 infects and destroys CD4 T lymphocytes, an 
integral part of the cell mediated immune response that is required to combat viral 
pathogens. The virus binds to CD4 receptors on the host cell along with chemokine 
receptors (CCR5 or CXCR4) allowing for viral attachment and fusion which is followed by 
uncoating of the viral capsid upon entry into the cell, and allowing the viral RNA to enter 
the cytoplasm of the cell where reverse transcriptase is used to convert viral RNA into 
DNA17. Using viral integrase, the newly synthesised DNA becomes integrated into the host 
cell genome and transcription into messenger RNA (mRNA) occurs. mRNA is translated into 
viral proteins by the host cell which in turn create a provirus18. The provirus can remain 
active without replicating for many years, and presents as a cell type or anatomical site of 
latently-infected T-cells termed “viral reservoirs”.19 These cells are not detected by the 
immune system or modern treatment, meaning HIV-1 almost always returns when 
treatment is stopped20-22, except in rare reports of individuals who control viral replication 
upon stopping treatment, or post treatment controllers (PTC)23-30. When latently infected 
CD4 cells are activated, transcription begins, and the provirus creates HIV virons capable of 
infecting other cells, Figure 1.1. Each infected cell can create up to 10,000 new HIV virions 
over its life span, with up to 1010 HIV-1 virons created daily within an untreated individual31, 
32.  This high rate of viral replication coupled with reverse transcriptase that lacks 3’-5’ 
exonuclease proof reading activity makes HIV-1 prone to mutational errors, contributing to 
the genetic diversity of the virus.  
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Figure 1.1: The life cycle of HIV-1 and antiretroviral therapy target areas adapted from 
AIDSinfo and the US Department of Health and Human Services, 201933. 
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 The Global HIV Pandemic 
 
Since the beginning of the HIV pandemic, the Joint United Nations Program on HIV/AIDS 
(UNAIDS) estimates that 74.9 million individuals globally have acquired HIV, 32 million of 
whom have since died of AIDS related illnesses (data to the end of 2018)34. There are 
currently an estimated 37.9 million individuals living with HIV, approximately 1-2 million of 
which are infected with HIV-234, 35. HIV-2 is 55% genetically different, less transmissible, 
progresses slower than HIV-136, and is predominately found in West Africa or countries with 
direct economic links to West Africa.  HIV-1 is responsible for most (94-97%) of the AIDS 
pandemic with a global prevalence of 0.8%34, 37. There is substantial heterogeneity in the 
prevalence of HIV-1 between countries and regions worldwide, with the centre of the 
pandemic located in Africa, where an estimated 4.2% of the adult population (and two 
thirds of the worldwide pandemic) is living with HIV-137. This is in contrast to a much lower 
prevalence in Europe (0.4%) and the Americas (0.5%)37, Figure 1.2.  
It is impossible to ascertain exactly how many individuals have acquired HIV-1, as statistics 
do not encompass details of undiagnosed, recently diagnosed, or post-mortem diagnosed 
cases.  This uncertainty is reflected in the wide confidence intervals for prevalence 
estimates of HIV status (79% (67%-92%)) provided by UNAIDS34 using modelling techniques 
developed by Avenir Health38 to produce annual global HIV and AIDS statistics. It is 
acknowledged that inconsistencies exist in the data used to inform these statistics (which 
is country specific and varies based on the countries rates of HIV transmission and overall 
prevalence).  
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Figure 1.2: Global Prevalence of HIV among adults aged 15-49 according to the World 
Health Organization, published 2017 37. 
 
Figure 1.3: Global distribution of the major HIV-1 subtypes by Bbosa et al, Current Opinion 
in HIV and AIDS, 201939.  
 
Coupled with geographic diversity in prevalence, HIV-1 has high genetic variability with at 
least ten genetically distinct subtypes: A, B, C (the three most common), D, F, G, H J, K, L, 
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and numerous hybrid combinations of subtypes known as circulating recombinant forms 
(CRFs). Although each subtype is found in all parts of the world, distribution is 
geographically uneven,Figure 1.3. Subtype A for example comprises approximately 12% of 
the global prevalence of HIV-1 and is predominant in eastern Africa and eastern Europe. 
Subtype C accounts for nearly 50% of the global HIV-1 pandemic  and is most common in 
Africa and India, while subtype B accounts for around 10% of  global HIV-1 infections found 
predominantly  in Western Europe, the Americas and Australia39, 40. Although subtype B 
represents a small proportion of global infections, its predominance in resource rich 
countries has contributed to the an observed focus of drug development being based on 
its virology41, 42.  
 Natural Course of HIV disease and progression 
 
HIV-1 causes immunodeficiency marked by depletion of CD4-T lymphocytes, and in the 
absence of treatment, leads to opportunistic infections, AIDS, and death. After HIV-1 
infection, there is a transient rise in HIV-1 viral load and a drop in CD4-T lymphocytes until 
HIV-1 antibodies are formed. Subsequently, HIV-1 viral load drops to a somewhat steady 
state nadir, termed viral set point, and CD4-T cell counts rise43-48. From this point, the 
average time to AIDS before combinational therapy became available (1996) was 8-10 
years49-51, Figure 1.4.  
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Figure 1.4: Natural course of HIV disease and progression in a typical individual adapted 
from Anthony S. Fauci, Clinical Infectious Diseases, 2007 51. 
 
 
 PhD rationale and research objectives: extreme HIV-1 phenotypes and beyond 
 
 Viral pathogenesis is a dynamic process and varies widely, with some individuals 
progressing to AIDS less than a year after HIV-1 seroconversion, while others remain 
asymptomatic in the absence of treatment for more than 20 years52, 53.  These two ends of 
the clinical spectrum represent the extreme ranges of HIV-1, termed ‘extreme phenotypes’. 
Evaluating these sufficiently rare subsets of individuals with extreme HIV-1 phenotypes, is 
useful in advancing knowledge of the biology and pathogenesis of disease as well as viral 
control and progression of HIV-1 infection54-57. HIV-1 positive individuals who are able to 
naturally control the virus, termed elite controllers (EC), provide a natural model for disease 
control and understanding the biological mechanisms of this phenomenon and could 
provide insight into novel therapeutic targets and vaccine development57, 58. HIV-1 positive 
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individuals who quickly progress to disease, termed rapid progressors (RP), conversely 
could provide insight as to why some individuals develop AIDS, or die soon after HIV-1 
seroconversion, improving capacity to mitigate risk for individuals who acquire HIV-1 in the 
future. Although extreme phenotypes of HIV-1 have been intensely studied, there remains 
heterogeneity in how these extremes are defined in scientific research, making it difficult 
to ascertain the biological mechanisms underlying these phenotypes59.  In this PhD, we 
investigate how extreme phenotypes of HIV-1 have been previously defined in the 
literature and, using the most common terms as a guide, provide a framework for 
developing consensus definitions. Building on this framework, we use data on HIV-1 
seroconverters to assess the relative merit of the most commonly used definitions in the 
literature and suggest definitions for HIV-1 ECs and RP to be used in future research. 
 
Since the discovery of the virus in the 1980’s, advances in clinical care has transformed HIV 
diagnosis from a terminal illness to a chronic, treatable condition60.  However, 6 years after 
the first AIDS cases were reported, there was still no HIV-1 treatment. The pharmecutical 
company Burroughs and Wellcome were well known for their antivral drugs and put forth 
azidothymidine (AZT) to be tested by for it’s anti HIV properties by the NCI61.  In 1985, the 
NCI had shown AZT was potent against HIV invivo and after quick phase I and phase II 
randomized controlled trials, the United States Food and Drug Administration (FDA) 
approved AZT for use against HIV/AIDS on March 20, 1987, the quickest drug development 
in modern history62, 63. However, AZT was not as successful as originally hoped. There were 
reports of terrible side effects, where individuals felt worse on AZT compared to off it. 
Additionally, rapid mutation of HIV was observed in some cases resulting in AZT resistance 
and the onset of AIDS64.  It was not until 1996, almost 10 years after AZT came to market, 
that combination antiretroviral therapy (cART) was introduced. This expanded 
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monotherapy to a minimum of two active drugs from two different classes, where each 
class of drug interferes with different stages of the HIV-1 life cycle and infection process, 
Figure 1.1. Modern cART is more effective than monotherapy and has continually evolved 
with increasing genetic barriers to resistance, becoming more tolerable with fewer side 
effects, and reduced pill burden65, 66. There are currently 32 FDA approved HIV-1 drugs 
among 6 classes, Figure 1.5. cART has greatly reduced morbidity and mortality rates 67 and 
now life expectancy for HIV-1 positive individuals on cART is similar to that of the general 
population, where HIV-1 positive Europeans starting cART at 20 years have an average life 
expectancy of around 68 years old68.  cART, however is not a cure, a likely consequence of 
an inaccessible reservoir of latently infected cells. HIV positive individuals wanting the best 
prognosis, might need to make lifestyle adjustments (e.g. quitting smoking and injection 
drug use, maintaining regular exercise and eating a balanced diet) and commit and adhere 
lifelong medication to main control of the virus. Adherence is a major component of 
successful cART, and it is estimated that if adherence is less than 95%, viral breakthrough 
is likely to occur69.  There are some reports of individuals controlling viral replication after 
stopping cART23-30, in essence, creating HIV-1 ECs, but nearly all individuals experience viral 
rebound soon after cART cessation. A core question expanded on inthis PhD considers how 
we can use cART to prevent HIV-1 positive individuals from rapidly progressing to disease.  
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Figure 1.5: Timeline of FDA approval of HIV Medicine from 1987-2019s, adapted from 
AIDSinfo, for the National Institue of Health70. 
 
Although modern treatments are highly effective at suppressing viral replication, the exact 
timing of cART initiation has not always been clear with varying national and international 
guidelines. Several studies, including one we present here, suggest immediate cART 
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initiation upon HIV diagnosis irrespective of CD4 cell count, as this reduces the risk of 
developing serious illness or death by up to 57% 71-73. Although immediate treatment is 
advised, challenges of cART remain, for example, the lifelong pill burden, the risk of 
accumulated toxicities, risk of drug resistance with non-adherence, efficacy in non-B 
subtypes (as most of the drug development studies are in subtype B74), and financial 
pressures limiting access to care, particularly in resource-limited settings where the 
majority of HIV-1 positive individuals are not typically infected with subtype B HIV-1.   
In this PhD, we address these major questions in the natural history of HIV-1, and provide 
suggestions on how to optomize treatment, targeting post-treatment control, and reducing 
rapid disease progression of HIV-1 positive individuals. The data used to answer these 
questions is predominately from Europe, therefore acknowledgement that the majority of 
HIV-1 cases are subtype B is noted from the outset.    
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2 Methods 
 
The data used for this PhD was sourced from three main cohort collaborations, namely 
CASCADE75, EuroSIDA76, and HIV-CAUSAL77. Each collaboration has unique aims and 
combine data from hundreds of clinics, allowing questions to be investigated with more 
statistical power than from individual studies or clinics alone. For this reason, all three 
collaborations utilize a common protocol for data exchange called HIV Cohorts Data 
Exchange Protocol (HICDEP)78. HICDEP provides a standard format for HIV datasets and 
currently incorporates 32 data tables with codes for specific variables. Exact details on all 
the tables and codes are available on the HICDEP website https://hicdep.org/. Individual 
cohorts map their data to the HICDEP protocol which creates a standard format for 
merging, allowing big cohorts to easily and repeatedly formed by combining individuals 
identified in hundreds of sources. The first HICDEP protocol was formed in 2003 and has 
continually evolved with changes to clinical care of HIV positive individuals, for example, as 
new HIV drugs are developed, new codes are added to the HIV drug table. A list of the 
HICDEP tables each cohort routinely collects is provided in Table 2.1, and the associated 
HICDEP data dictionaries are available in Appendix 3. Details of each cohort coordinating 
centers are included in Appendix 2. 
 
 CASCADE 
 
 Study description 
Concerted action on seroconversion to AIDS and death in Europe (CASCADE) is a HIV-1 
cohort collaboration focusing on individuals with well estimated dates of HIV-1 
seroconversion. The study was established in 1997 and has expanded to include data from 
over 30,000 HIV-1 positive seroconverters drawn from 29 cohorts representing over 300 
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clinics across Europe (95%), Canada (1%), Australia (1%) and Sub-Saharan Africa (3%). The 
main aim is to collect routine clinical HIV data on newly infected and previously enrolled 
individuals, covering the entire duration of HIV-1 infection. Although the collaboration was 
formed in 1997, data was retrospectively collected, and some individuals seroconverted as 
early as 1980, with the most recent data update preformed in 2015. CASCADE data 
therefore uniquely provides the opportunity to study events occurring during and around 
HIV-1 seroconversion, the natural history of HIV-1 from the early 1980’s until 2015, 
convering the pre-treatment, monotherapy and modern cART eras, and differences in 
survival over time and through the advent of cART and into modern HIV-1 treatments. One 
of the main premises that formed the collaboration is that through pooling data, issues can 
be addressed that require more statistical power than any single study alone, for example 
studying rare groups of individuals such as HIV-1 ECs or HIV-1 RPs.  
 Data collection 
Seroconverters are enrolled into individual cohorts where data is collected from routine 
clinical practice, and therefore all individuals are typically followed up for the duration of 
their life. Date of seroconversion is estimated by three standard methods, most commonly 
as the midpoint between the last documented HIV-1 negative and the first positive HIV-1 
antibody test dates with an interval of less than three years between the two test dates 
(85%). For the remainder, date of seroconversion was estimated through laboratory 
evidence of seroconversion (polymerase chain reaction (PCR) positivity in the absence of 
HIV-1 antibodies or antigen positivity on Western blot) (13%), or as the date of a 
seroconversion illness (2%) with both an earlier documented negative and a later positive 
HIV-1 test not more than three years apart. The midpoint method and seroconversion 
illness method for estimating HIV-1 seroconversion are comparable as both methods 
require HIV-1 negative and positive test dates to be no further than three years apart.  
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Laboratory evidence of seroconversion is much more specific, and could indicate a different 
type of individual, for example someone that is experiencing seroconversion illness, or 
someone who is presenting at a clinic for other co-infections.  Participating cohorts were 
asked to send data incorporated in 10 HICDEP tables, which included  descriptive 
background and demographic data (tblBAS, see Appendix 3, page 191)  for complete 
variable list), laboratory measurements of CD4 cell counts (tblLAB_CD4, Appendix 3, page 
198) and HIV-RNA measurements (tblLAB_RNA, Appendix 3, page 204) which were 
performed by various in-house methods, antiretroviral treatment (tblART, Appendix 3, 
page 189) as well as other medications (tblMED, Appendix 3, page 208), virological data of 
all negative and positive HIV-1, Hepatitis C and B results (tblLAB_VIRO, Appendix 3, page 
205), nucleotide sequence data and resistance tests (tblLAB_RES, tblLAB_RES_LVL_1, 
Appendix 3, page 199), and death and last follow-up (tblLTFU, Appendix 3, page 206), Table 
2.1. Anonymized data for the CASCADE collaboration were collected and stored at the 
Medical Research Council Clinical Trials Unit at University College London in London, United 
Kingdom.  
 EuroSIDA 
 
 Study Description 
The EuroSIDA study is a prospective observational cohort study founded in 1994 and 
houses data on approximately 23,000 HIV-1 positive individuals accessing care in over 100 
hospitals in 35 European countries, and uniquely in all European Regions, as well as Israel 
and Argentina. EuroSIDA’s original objective was to follow the general population of HIV 
positive individuals living in Europe while assessing clinical progression and impact of cART 
on HIV prognosis, and over the two decades the objectives have broadened to also include 
monitoring adverse events on cART, longitudinal changes and regional differences in HIV 
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care and across Europe, and uptake of Hepatitis C (HCV) therapy among HIV/HCV co-
infected individuals. 
 Data Collection 
A principal investigator leading each clinic was responsible for enrolling patients, collecting 
and reporting data, maintaining ethical approval, and obtaining informed consent from all 
individuals. EuroSIDA collects data from routine clinical visits once annually using the 
electronic case report system REDCap79 and in the HICDEP data format. The data collected 
is similar to CASCADE with information on baseline patient clinical characteristics and 
demographics, standard HIV laboratory measurements of CD4 cell counts and HIV-RNA 
measurements, antiretroviral treatment information, AIDS and non-AIDS defining illness 
and date of death, Table 2.1. EuroSIDA additionally focuses on specific diseases and events, 
including laboratory information on renal function, liver function, cardiovascular health and 
non-AIDS defining cancers. EuroSIDA also requests plasma samples from all patients every 
6 months which are intermittently shipped to the central repository at the coordinating 
centre in Copenhagen. The EuroSIDA coordinating centre stores anonymized data at the 
Centre of Excellence for Health, Immunity and Infections (CHIP) in Copenhagen, Denmark 
and collaborated with the statistical centre at the Centre for Clinical Research, 
Epidemiology, Modelling and Evaluation (CREME) at University College London.  
 HIV-CAUSAL 
 
 Study description 
HIV-CAUSAL collaboration is a HIV-1 cohort collaboration, but with a different focus than 
CASCADE and EuroSIDA. This collaboration is formed from prospective cohort studies in 
Europe and the United States, based on standard clinical data collected within national 
health care systems with universal access to care. The consortia aims to address 
methodological problems around comparative effectiveness and safety research in HIV, the 
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most notable of which is how to appropriately handle time-dependent confounding in 
statistical models. Methods that have been pioneered by HIV-CAUSAL and included in this 
PhD are inverse probability weighting of marginal structural model to appropriately adjust 
for time dependent confounding80. Sample programs are freely available on the HIV-
CAUSAL website: https://www.hsph.harvard.edu/causal/software/.  
 Data Collection 
Recorded data include patient specific characteristics and demographic data, laboratory 
measurements of CD4 cell counts and plasma HIV-RNA measurements, antiretroviral 
treatment information, AIDS and non-AIDS defining illnesses and death dates, Table 2.1.  
Anonymized data were sent and stored at the HIV-CAUSAL Coordinating Center at Harvard 
University in Boston, USA.  
 Ethics 
 
All cohorts in each collaboration received approval from their individual ethics review 
boards to pool anonymized data for analyses and dissemination. 
 Data Validation 
 
All cohorts underwent unique verification of collected data using cohort specific quality 
assurance programs. These included, but are not limited to, the data checks recommended 
on the HICDEP website, data validity checks on dates of HIV acquisition, HIV treatment and 
other medications, laboratory measurements, and AIDS and other clinical events, death 
and loss to follow-up.  
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Table 2.1: HICDEP Data tables collected in CASCADE, EuroSIDA and HIV-CAUSAL. 
 Appendix, page CASCADE EuroSIDA HIV-CAUSAL 
tblART – Antiretroviral 
treatment 3, 189 X X X 
tblBAS – Basic clinical, 
background and demographic 
information 3, 191  X X X 
tblCENTER – Center information 3, 193  X  
tblCEP – Clinical events and 
procedures 3, 194  X X 
tblDIS – CDC-C and WHO Stage 
Diseases 3, 195 X X X 
tblLAB – Laboratory values 3, 196  X X 
tblLAB_BP – blood pressure 3, 197  X X 
tblLAB_CD4 – CD4 cell count 3, 198 X X X 
tblLAB_RES – Resistance testing 3, 199 X X X 
tblLAB_RES_LVL_1 - Nucleotide 
sequences (PRO, RT, GP41, 
GP120, ) 3, 201 X X X 
tblLAB_RES_LVL_2 – Mutations 3, 202  X X 
tblLAB_RES_LVL_3 – Resistance 
test result 3, 203  X X 
tblLAB_RNA – HIV-RNA values 3, 204 X X X 
tblLAB_VIRO - viro-/serology 3, 205 X X X 
tblLTFU – Death and drop-out 3, 206 X X X 
tblMED – Other medication 3, 208 X X X 
tblSAMPLES – Blood samples 3, 209  X  
tblVIS – Basic follow-up/visit 
related data 3, 201  X X 
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3 Extreme Phenotypes of HIV-1 
 
 Natural process of HIV-1 disease progression 
 
HIV is typically characterised by a period of viral replication and CD4 decline leading to AIDS 
and death in the absence of cART81, Secion 1.4, Figure 1.4. There are also variations in these 
markers between individuals over time82, 83, attributed to differences in the infecting virus 
(e.g. subtype, or an attenuated virus) and host genetic characteristic leading to variations 
in disease progression, where some remain clinically asymptomatic for long periods, while 
others progress rapidly to disease52, 53. These two ends of the clinical spectrum represent 
the extreme ranges of HIV, termed ‘extreme phenotypes’ are defined using host 
biomarkers, the two most common are assessing host immune function using CD4 cell 
counts, or host viral control measuring circulating plasma HIV-RNA (viraemia). Viral 
genetics also play a part in disease progression, for example, different subtypes within HIV-
1 have been shown to have varying disease progression rates84, 85.  
 Extreme ends of HIV-1 disease progression  
 
Evaluating sufficiently rare subsets of individuals among a relatively homogenous 
population with extreme HIV-1 phenotypes, is useful in advancing knowledge of the biology 
and pathogenesis of HIV-1 disease control and progression54-57. Genome wide association 
studies (GWAS) have identified common variants associated with HIV-1 viral control and 
HIV-1 disease progression, yet these studies do not capture all the variation in the genome 
and do not explain a large part of the “heritability” of extreme phenotypes, or the fraction 
of variability in a population explained by host genetics86. It is possible that co-existance of 
several variants with smaller effects, or rare variants with large effects could explain some 
of this missing heritability87. Rare variants are poorly detected by GWAS, as conventional 
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Sanger sequencing detects variants present in 20% of the population. Sequencing on the 
genetic variants that alter protein sequences, or whole genome sequencing, has been 
proposed to explain an additional proportion of HIV-RNA variability88, 89. Using exome 
sequencing and sampling individuals with extreme phenotypes can help to identify rare 
variants, as they are more likely found in the extreme traits90.   
The long term non-progressor (LTNP) phenotype was initially described to characterize 
individuals with slow clinical disease progression, defined by stable CD4 cell counts over a 
period of 10 years or more53, 91. Simultaneously, RP also became an area of research 
interest focused on poor immune response and rapid CD4 cell count depletion. With the 
introduction of HIV-RNA viral load assays in the mid-1990’s, research shifted to focus on 
the mechanisms which lead to host control of viral replication, and the EC phenotype 
became an area of intense study59.  HIV-1 EC provide a natural model for disease control 
and understanding the biological mechanisms of this phenomenon could provide insight 
into novel therapeutic targets and vaccine development57, 58.  On the opposite spectrum, 
HIV-1 RP provide an opportunity to investigate why individuals progress to disease; and 
could provide insight into ways we can better manage HIV treatment, HIV monitoring, and 
improve overall health to prevent disease progression.  
Heterogeneity in criteria used to define extreme phenotypes can introduce inconsistencies 
in results and make it difficult to identify the biological mechanisms underlying these 
phenotypes59. Despite a depth of research into these groups, definitions used are 
inconsistent therefore it is important to systematically review the literature to find and 
assess the relative merit of common links between definitions and provide a framework for 
developing consensus definitions. 
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 Systematic review of HIV-1 extreme phenotypes definitions 
 
We undertook a systematic review of the literature in accordance with Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA)92 guidelines and searched for 
terms relating to virological and clinical progression of HIV-1. We reviewed 501 articles 
published between January 1st, 2000 and 15th March 2012 and found a total of 714 
extreme phenotype definitions, 600 definitions for 26 terms used to describe slow 
progression/viral control extremes of HIV infection, and 114 definitions with eight terms 
used to define RP or lack of viral control93.  Substantial variation was evident among 
definitions in the literature, with a large proportion unique for progression (50-54%) and 
viral control (43-59%) related terms. This heterogeneity could represent important 
biological endophenotypes and select individuals with varying clinical outcomes59, 94-96, 
suggesting the need for harmonized definitions.  The three most common terms used for 
extreme phenotypes were LTNP, EC and RP, and their associated definitions were 1. LTNP: 
asymptomatic and ART-naive for 10 years during follow-up with all CD4 cell counts above 
500 cells/mm3 during this period, 2. EC: spontaneously maintaining HIV-RNA below 50 
copies/ml without cART, and 3. RP: HIV-1 infected with CD4 cell counts < 300 cells/mm3 
within three years after the last HIV-1 seronegative test. We also identified common 
components in existing definitions, Figure 3.1, where LTNPs were broadly defined by 
maintaining normal CD4 cell counts and remaining healthy for 10 years, viral controller 
phenotypes were broadly characterised by regulating HIV-RNA without cART, and RPs were 
characterised by a drop in CD4 cell counts or the development of AIDS within 3-5 years. 
This could provide a framework for developing consensus definitions of HIV-1 extreme 
phenotypes.  
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HIC-1 and HIC-2 refer to the two most commonly used definitions for HIV controllers. ART, antiretroviral therapy; EC, elite 
controller; HIC, HIV controller; LTNP, long-term nonprogressor; LTS, long-term survivor; NC, noncontroller; NP, 
nonprogressor; RP, rapid progressor; SP, slow progressor; VC, viremic controller. 
 
Figure 3.1: Characteristics of phenotypes by different terms in the literature from Gurdasani 
et al, AIDS, 201493. 
 
 Evaluation of HIV-1 elite controllers within a large seroconverter cohort 
collaboration 
 
HIV-1 EC, classified by maintaining control of HIV-RNA, was one of the most common 
phenotypes identified in the literature review, likely because these individuals lead the way 
for the development of new treatment strategies 57, 58. Following our literature review, it 
was unclear if any currently used definitions best identify this rare phenotype. We sought 
to assess the relative merit of common definitions of viral control using the CASCADE data 
on 25,6921 HIV-1 seroconverters97 (study details in Section 2.1). We evaluated 10 
commonly used definitions (Table 3.1) and estimated the proportions of individuals 
maintaining elite control during cART naïve follow-up time and evaluated disease 
                                                          
1 Patient population defined in Appendix 1, page 93-95. 
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progression comparing EC to non-EC. We also examined HIV-1 RNA copies/ml and CD4 cell 
counts cells/mm3 among EC during periods of EC and total cART naïve follow-up. Most 
definitions classified a sufficiently rare population (~1%) as EC’s, but definitions that require 
consecutive undetectable HIV-RNA measurements (HIV-RNA < 50 or 75 copies/ml) for at 
least six months were most sensitive to classifying individuals with the slowest disease 
progression, lowest HIV-RNA and highest CD4 cell counts during EC periods and total cART 
naïve follow-up, Table 3.2, Table 3.3.  We suggested this definition be used for future EC 
research.  
Table 3.1: 10 definitions of elite control from the literature applied to the CASCADE dataset; 
all require individuals to be AIDS-free and ART-naïve from Olson et al, PLOSone, 201497. 
 Definition   
A HIV-positive ≥6 months, with ≥2 consecutive HIV-RNA <75 copies/ml 98 
B HIV-positive ≥1 year, with ≥1 HIV-RNA <50 copies/ml 57 
C HIV-positive ≥1 year, with ≥1 HIV-RNA <75 copies/ml  99 
D HIV-positive ≥1 year, with ≥3 HIV-RNA <2000 copies/ml  100 
E HIV-positive ≥1 year, with ≥3 consecutive HIV-RNA <75 copies/ml spanning 
≥12 months 101 
F HIV-positive ≥1 year, with ≥3 consecutive HIV-RNA <75 copies/ml spanning 
≥12 months with no previous blips ≥1000 copies/ml 59 
G HIV-positive ≥2 years, with ≥2 HIV-RNA <75 copies/ml 102 
H HIV-positive ≥5 years, with ≥5 consecutive HIV-RNA <500 copies/ml 103 
I HIV-positive ≥10 years, with all measured HIV-RNA <50 copies/ml 104 
J HIV-positive ≥10 years, with ≥90% of HIV-RNA (≥2 HIV-RNA ever) <400 
copies/ml 105 
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Table 3.2: Estimated hazard ratios comparing non-elite and unknown to elite controllers 
(EC) for time from estimated HIV seroconversion to a composite endpoint of AIDS, Death, 
ART, or CD4 <350 cells/mm³ restricting entry to the risk set at 10 years post seroconversion 
using the CASCADE dataset applied to 10 definitions of EC found in the literature from Olson 
et al, PLOSone, 201497. 
Def. EC evaluated 
(experiencing 
composite endpoint) 
n (n)†† 
HR for time to composite 
endpoint† (95% CI) 
% (IQR*) ART-naïve 
follow-up time classified 
as EC 
Aғ 46 (4) 12·5 (4·7, 33·6) 100 (78-100) 
Bғ 53 (11) 4·6 (2·5, 8·3)‡ 100 (78-100) 
Cғ 86 (18) 4·8 (3·0, 7·7)‡ 99 (72-100) 
Dғ 134 (35) 4·0 (2·8, 5·7)‡ 97 (71-100) 
Eғ 36 (2) 19·0 (4·7, 76·4) 100 (78-100) 
Fғ 26 (5) 15·3 (3·8, 61·3) 92 (66-100) 
Gғ 60 (9) 7·5 (3·9, 14·5)‡ 100 (86-100) 
Hғ 56 (22) 2·9 (1·9, 4·4)‡ 100 (75-100) 
Iғ 4 (1) 3·4 (0·5, 24·0) 100 (100-100) 
Jғ 35 (3) 13·2 (4·2, 41·3) 100 (98-100) 
*IQR: Interquartile range 
††Number of ECs making it to 10 years follow up without experiencing composite endpoint and number 
subsequently experiencing composite endpoint. 
†Hazard ratios comparing ECs to Non-ECs (including those with unknown EC status) allowing for late entry 
at 10 years.  For each definition, p-values were obtained from unadjusted log-rank test for time to 
composite endpoint and were all highly significant p < 0·001 
‡ Statistically different HRs compared to definition E, F, and A from 1000 bootstrap replicates. No 
definitions were statistically different from definition J at ɑ = 0·05.  
ғ Definitions listed in Table 3.1 
Table 3.3: HIV-RNA and CD4 values during elite control (EC), and throughout ART-naïve 
follow-up using the CASCADE dataset applied to 10 definitions of EC found in the literature 
from Olson et al, PLOSone, 201497. 
Def. During Elite Control  During ART-naïve follow-up 
 HIV-RNA value* CD4 Value*  HIV-RNA value* CD4 Value* 
Aғ 50  (35, 276) 675  (454, 877)  66  (35, 495) 654  (441, 840) 
Bғ 425  (35, 11641) 573  (409, 792)  1043  (89, 13000) 548  (404, 751) 
Cғ 354  (50, 8700) 596  (427, 796)  660  (75, 11066) 567  (415, 764) 
Dғ 903  (287, 1863) 615  (478, 789)  1274  (370, 3304) 590  (451, 756) 
Eғ 50  (35, 81) 699  (528, 922)  50  (35, 165) 681  (527, 909) 
Fғ 50  (35, 50) 839  (654, 1070)  50  (35, 77) 796  (629, 1020) 
Gғ 113  (49, 1197) 644  (439, 824)  176  (50, 2160) 625  (438, 806) 
Hғ 76  (35, 283) 697  (541, 879)  89  (35, 356) 687  (530, 879) 
Iғ 35  (1, 35) 583  (575, 905)  35  (1, 35) 583 (575, 905) 
Jғ 50  (35, 127) 783  (628, 970)   50  (35, 169) 740  (583, 970) 
Note- all values are median (IQR) 
 *units are HIV-RNA copies/ml and CD4 cells/mm3 
ғ Definitions listed in Table 3.1 
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Beyond HIV-RNA control, HIV-1 positive individuals progress to disease at varied rates 
measured by CD4 cell counts. Individuals with slow and fast CD4 cell count progression, 
are termed long-term non-progressors and rapid progressors, respectively.  
 Characterisation of HIV-1 long term non-progressors (LTNP) within a large 
seroconverter cohort collaboration 
 
We sought to describe the characteristics of LTNP, and to identify factors associated with 
the loss of LTNP status using CASCADE data on HIV-1 seroconverters106. Using the most 
common definition of LTNP from the literature review, where individuals were required to 
be HIV-1 positive for more than 10 years, cART naïve and AIDS free with CD4 cell counts > 
500 cells/mm3, we found 283 of 49792 eligible individuals included in our analysis achieved 
LTNP status. Most individuals subsequently lost LTNP status (n=202/283), and this was 
associated with lower CD4 cell counts at 10 years after seroconversion (Hazard ratio (HR) 
95% confidence interval (CI) for loss of LTNP = 0.39 (0.24, 0.62) for CD4 = 900 vs. CD4 = 600 
cells/mm3). Excluding CD4 cell counts in the model, higher HIV-1 RNA at 10 years was 
associated with loss of LTNP status (HR for loss of LTNP = 1.38 (0.91, 2.13) for log10 HIV-RNA 
copies/ml = 4 vs. log10 HIV-RNA copies/ml = 3), Figure 3.2.  LTNP is rare and most individuals 
eventually lose this status (in our study 202/283 lost LTNP) likely due to slow CD4 cell 
decline and slow increases in plasma HIV-1 RNA.  
                                                          
2 Patient population defined in Appendix 1, page 101-104 
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Figure 3.2: Relative hazard of CD4 cell count (A) and HIV RNA load (B) at 10 years after 
seroconversion with loss of LTNP from van der Helm et al, Lancet HIV, 2014106. 
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Reasons why some individuals are able to maintain viral suppression or slow disease 
progression has not been fully elucidated, although several factors could be involved, 
including being infected with an attenuated virus107-109.  Several case reports show some 
LTNPs have HIV-1 viruses that have single nuclear polymorphisms, or large deletions in the 
nef, vpr, vif or rev genes107. Other studies have shown, however, that EC and LTNP are 
infected with a pathogenic virus, suggesting that host factors play a large part in controlling 
viral replication and maintaining high CD4 cell counts110. Host genetic factors from GWAS 
have uncovered CCR5Δ32, HLA-B57 polymorphisms, and single nucleotide polymorphisms 
(SNPs) in class I and III MHC sub regions to be associated with EC and LTNP status107, 111, 112. 
Notably, the only two known cures of HIV-1 were Timothy Brown i.e. the Berlin patient113, 
and the London patient114, which resulted from treating cancer with stem cell transplants 
using donors with the CCR5Δ32 mutation. However, these polymorphisms do not explain 
100% of the variability in viral load and CD4 cell counts. These studies do not assess the full 
spectrum of functional variants within the host coding regions which could explain further 
variability in viral load and CD4 cell count maintenance88, 89. Using definitions identified in 
our previous manuscripts, our collaborators sequenced the exome of 1327 eligible 
individuals (including n= 85 EC and n= 98 RP from the CASCADE cohort), and performed 
whole exome sequencing to identify rare variants associated with viral control115.  
Unfortunately, they found no strong exonic variants with large effect sizes contributing to 
the control of HIV infection. More recently, however, a study published by Nissen et al. 
(2018) sequenced the whole exome of seven LTNP and identified several rare variants in 
genes involved with HIV entry and inward trafficking, HIV transcription, cell homeostasis 
sensing and inflammation116, 117. Interestingly, this study found no significant variants 
associated with EC status. This suggests there are different pathogenesis and biological 
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mechanisms distinguishing viral control and immune preservation phenotypes, which 
warrants further investigation.  
 Evaluation of HIV-1 rapid progressors within a large seroconverter cohort 
collaboration 
 
Rapid progression is an extreme phenotype which can contribute to our understanding of 
early risk factors leading to disease progression. Studying these individuals could help guide 
clinical monitoring and aid in understanding when and what cART to initiate. However, they 
are less frequently studied then slow progressor and viral control counterparts, as seen by 
the number of articles and definitions relating to RP uncovered in our literature review (51 
unique definitions for RP compared to 209 unique definitions for LTNP and EC)93.  The 
optimal rate and CD4 cell count threshold for identifying this phenotype was unclear, so 
we sought to define the RP phenotype using CASCADE data on HIV seroconverters in the 
pre-cART era118 3. We found that low CD4 cell counts (CD4 <350 cells/mm3) during the first 
year after an HIV-1 positive test was not uncommon, where 2.8% of individuals experienced 
a CD4 cell count <100 cells/mm3 and 10% experienced at least one CD4 cell count 
measurement <231 cells/mm3. The risk of AIDS defining illness or death was substantially 
higher for those experiencing at least one CD4 cell count <100 cells/mm3 in the first year 
after HIV-1 diagnosis compared to individuals with CD4 cell counts at higher levels, Figure 
3.3. We concluded that individuals with at least one CD4 cell count <100 cells/mm3 
identified a rare group (2.8%) at the highest risk of disease progression and should be the 
basis for defining the RP phenotype. This suggests the importance of CD4 monitoring near 
HIV seroconversion, as it can play a part in identifying those at highest risk of progression 
and in need of immediate cART and potentially more frequent monitoring, aligning with 
                                                          
3 Patient population defined in Appendix 1, page 109-111. 
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current British HIV Association (BHIVA) guidelines119 which suggest more frequent 
monitoring among asymptomatic patients with lower CD4 cell counts who refuse cART.  
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Figure 3.3: Cumulative 
proportions of nadir CD4 cell 
count (left hand panel), relative 
risk of AIDS/death compared 
with individuals whose CD4 
counts remained at 500 cells 
per cubic millimeter (center 
panel), and mean AIDS-free 
survival time at 10 years 
follow-up (right hand panel) for 
individuals in CASCADE 
experiencing specific nadir 
levels within 1 year of SC during 
that period: all individuals 
seroconverted in the pre-cART 
era from Olson et al, JAIDS, 
2014118. 
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4 Treatment Optimization 
 
Exact timing of cART initiation has not always been clear with varying national and 
international guidelines. Until 2015, global cART guidelines varied widely and changed over 
time, Table 4.1.  The guidelines are for the majority of individuals who do progress to 
disease and require treatment to prevent AIDS and death, where their engagement in 
treatment is a key component its success. It is worth noting that these are just guidelines, 
and cART needs to be optimized within the individual. For example, the guidelines do not 
make specific recommenations for HIV-1 EC, who may, infact, not need treatment as they 
maintain favourable CD4 cell counts and control viral replication (HIV-RNA <50 copies/ml). 
Table 4.1: 2010 and 2015 cART initiation recommendations from the International AIDS 
Society (IAS), World Health Orginixatin (WHO), European Clinical AIDS Society (EACS) and 
BHIVA guidelines 
Governing 
Body 
2010 cART recommendations 2015 cART recommendations 
IAS Initiate when CD4 <500 
cells/mm3  
Immediate cART 
WHO Initiate when CD4 ≤ 350 
cells/mm3 
Initiate when CD4 <500 cells/mm3 
EACS Initiate when CD4 ≤ 350 
cells/mm3 
Initiate when CD4 <350 cells/mm3, 
considered when CD4 350-500 
cells/mm3 
BHIVA Initiate when CD4 ≤ 350 
cells/mm3 
Initiate before CD4 <350 cells/mm3 
 
Since 2015, the START71 and TEMPRANO72 trials showed 57% and 44% reduction in death 
or severe illness among individuals immediately initiating cART, respectively, these trials 
might not, however, be representative of clinical practice.  In 2015, data from HIV-CAUSAL 
highlighted a modest clinical benefit among individuals immediately initiating treatment: 
relative risk (RR) of death 1.02 (1.01, 1.02) compared to 1.06 (1.04, 1.08) for waiting to 
initiate when CD4 <500 cells/mm3 and CD4 < 350 cells/mm3 vs immediate initiation of cART, 
respectively73.  
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 The utility of HIV-RNA and HIV viremia copy/years in deciding when to start 
cART 
 
Most of the clinical evidence used to determine when to start cART is based on CD4 cell 
counts except where indications prompt advice for immediate treatment (e.g. pregnancy 
or some co-infections), but viral load measurements have an important role in the 
monitoring and staging of HIV-1 positive individuals.  HIV-RNA measurements have been 
used to tailor first line cART regimens, or determine when someone is failing their current 
cART regimen120, and can also assess HIV transmission risk121, 122. Importantly, HIV-RNA 
measurements could also help inform when to start treatment among those who do not 
want to initiate cART immediately and have high CD4 cell counts. It is unlikely that 
randomized evidence will be available to answer this question for two main reasons: first, 
evidence suggests all individuals with HIV-1 should immediately initiate cART71, 72 and 
second, randomized controlled trials (RCT) are extremely costly, so funding would be 
unlikely when two independent RCTs have provided good evidence linked to immediate 
cART initiation. In this case, we must rely on observational data to inform whether HIV-RNA 
should play a role in treatment initiation and optimization.  We sought to investigate the 
effect of initiation or deferring cART by varying levels of current HIV-RNA on HIV-1 disease 
progression. Although there is utility in obtaining a single HIV-RNA measurement, this fails 
to capture cumulative exposure to HIV-1 throughout the entire disease period. Viremia 
copy-years (VCY) is a measure of cumulative HIV-RNA exposure and could provide 
additional information beyond a single snapshot of HIV-RNA. VCY has been shown to 
predict AIDS and death in individuals on and off cART123-125 even after adjusting for viral 
load and CD4 cell count measurements. It is therefore important to determine whether 
cART initiation before the accrual of VCY could reduce morbidity and mortality, even among 
those with high CD4 cell counts. We also investigated the effect of initiating or deferring 
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cART by varying levels of VCY126. We used CASCADE data on 9,3534 HIV-1 seroconverters in 
the cART era, which incorporated serial HIV-RNA and CD4 cell count measurements on each 
individual throughout the entire HIV-1 clinical follow-up. Uniquely, we were able to 
estimate total cumulative viral exposure as well as current HIV-RNA values. It has previously 
been shown that there is a highly protective effect of immediate treatment initiation for 
individuals with baseline CD4 > 500 cells/mm3, with 57% reductions in the risk of serious 
AIDS or non AIDS events or death (HR = 0.43 (0.30, 0.62) compared to non initiators)71, and 
we specifically investigated whether or not individuals with CD4 ≥ 500 cells/mm3 but with 
high VCY or HIV-RNA would benefit from cART initiation. We found a 62% reduction in the 
risk of serious AIDS, non-AIDS events or death among those initiating cART (compared to 
non-initiators) with CD4 >500 cells/mm3 and the highest current HIV-RNA (HIV-RNA > 
100,000 copies/ml [HR = 0.38 (0.19, 0.77)]).  We also investigated the utility of VCY and 
found similar results with a benefit of cART initiation among individuals with CD4 >500 
cells/mm3 and high cumulative exposure to HIV-RNA; VCY >100,000 copy-years/ml [HR = 
0.41 (0.19, 0.87)], Figure 4.1. Our results support the findings from the START71 and 
TEMPRANO72 trials and suggest that the benefit of immediate cART initiation is likely to be 
the greatest in those with high HIV-RNA burden – our results can be used to inform clinical 
guidelines on when to start cART.  
                                                          
4 Patient population defined in Appendix 1, page 116-119. 
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*Units of measurement are as follows: CD4 cell count – cells/mm3; Viremia copy-years – copy-years/ml; 
current HIV-RNA – copies/ml 
Figure 4.1: The effect of initiating compared with deferring cART on time to AIDS/death by 
VCY and CD4 cell count modelled continuously with 3 knot splines using the CASCADE data 
set from Olson et al, JAIDS, 2016126. 
 
 What boosted protease inhibitor achieves the best immunologic, virologic and 
clinical outcomes?  
 
Another component of treatment optimization is identifying suitable cART regimens. More 
than 32 antiretroviral drugs70 are currently available with different efficacy127, toxicity128, 
129, genetic barriers to resistance130, central nervous system (CNS) penetration131, and pill 
burden132.  Randomized evidence has alluded to preferred drug regimens which, optimize 
viral suppression with low toxicity, and a majority of national and international guidelines 
now recommend first line cART regimens containing an integrase strand transfer inhibitor 
(INSTI) alongside two nucleoside reverse transcriptase inhibitor (NRTI) backbones133-136. 
boosted protease inhibitors (bPI) are also recommended as a part of first line therapy 
alongside two NRTI backbones, but bPIs can cause adverse metabolic events such as 
dyslipidaemia. New evidence suggests that INSTIs are as effective as bPIs, but more 
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tolerable, resulting in fewer treatment discontinuations137, 138. bPIs still have utility 
however, especially given their high genetic barrier to resistance130. For this reason, they 
are recommended for individuals who have poor adherence or if immediate cART initiation 
is necessary before resistance results are available134. Two of the most widely used bPIs are 
lopinavir and atazanavir, but limited evidence exists as to which one reduces adverse 
clinical outcomes.  The available RCT evidence comparing them only investigated viral 
suppression and did not focus on other important endpoints such as AIDS or death139-141. 
The aim of the second part of our study was therefore to compliment available RCTs by 
providing new evidence on clinical events (AIDS and death) among those initiating lopinavir 
or atazanavir boosted ritonavir as a part of their first line cART regimen using HIV-CAUSAL 
data, in which 6668 and 43015 individuals started lopinavir and atazanavir regimens, 
respectively142. We used logistic regression models to estimate the hazard ratio of time 
from treatment initiation to AIDS, AIDS or death, and virological failure within 12-months 
while maintaining treatment. We found evidence to support atazanavir bPIs are superior 
than lopinavir bPIs, with 30% and 33% reduced hazard rate of death or AIDS defining illness 
or death, and a 9% reduced hazard rate of virologic failure at 12-months (HR = 0.70 (0.53, 
0.91); 0.67 (0.55, 0.82); 0.91 (0.84, 0.99), respectively), Figure 4.2. Our results can improve 
current bPI guidelines, as we have shown individuals prescribed atazanavir have reduced 
risk of clinical events compared to those prescribed lopinavir. Therefore, among newly 
diagnosed individuals without access to resistance results, or among individuals who are 
less adherent to medication, atazanavir might be a preferable bPI as our estimates showed 
lower mortality risk, lower incidence of AIDS defining illness, and lower risk of virologic 
failure compared to lopinavir.   
                                                          
5 Patient population defined in Appendix 1, page 125-127. 
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Figure 4.2: Survival (left) and AIDS-free survival (right) for atazanavir vs lopinavir, HIV-
CAUSAL Collaboration, 2004–2013. The curves are standardized by the baseline covariates 
of sex, age, race, geographic origin, mode of acquisition, CD4 cell count, HIV RNA, calendar 
year, and years since HIV diagnosis from Cain et al, Clinical Infectious Diseases, 2015142. 
 
 Impact of transmitted drug resistance on cART initiation in a large 
seroconverter cohort collaboration 
 
Another component of cART optimization is the impact of HIV-1 drug resistance on viral 
suppression and its implications for available treatment choices. Poor adherence to cART 
can lead to the development of viral mutations69, 143-147 which are associated with HIV drug 
resistance and subsequent treatment failure. Not only is cART failure linked to adverse 
health outcomes148-150, but individuals failing treatment who develop HIV drug resistance 
can transmit resistant strains to others121, 151-157.  First line optimal treatment regimens are 
limited once an individual develops drug resistance, and although second line therapy 
successfully suppresses HIV-RNA, it can be less tolerable and have increased toxicity risk. 
An important first step is to monitor transmitted drug resistance (TDR) trends so we can 
assess how to prevent further spread of TDR. CASCADE data on HIV-1 seroconverters 
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provides a unique opportunity to investigate TDR. We analysed 47176 individuals in 
CASCADE seroconverting in the cART era (1996-2012) with HIV-1 genotypic resistance data 
available within 12 months of testing positive for HIV-1158. Individuals were categorized as 
having a TDR associated mutation if their virus contained one or more of the mutations 
mentioned in the Surveillance Drug Resistance Mutations list defined by the WHO159. Drug 
susceptibility was inferred from the viral genotypic resistance data that was submitted to 
the Stanford HIV database algorithm. We identified mutations associated with drugs in the 
first line recommendations according to categories A and B of EACS guidelines160.  Using 
logistic regression, we examined the association between TDR and year of HIV-1 
seroconversion adjusting for confounding factors. We observed a significant decline (p-
trend < 0.001) in the prevalence of TDR to any drug class during our study period 1996–
2012; odds ratio (OR) 0.92 (95% CI; 0.90, 0.95) per year. Estimated TDR started at 19.4% 
(8.2, 36.0) in 1996 (n = 36) and fell to 8.5% (5.9, 11.9) in 2012 (n = 352), Figure 4.3. The 
same decreasing trend over time was observed for transmitted NRTI resistance, OR = 0.89 
(0.86, 0.91) per year, non-nucleoside reverse transcriptase inhibitors (NNRTI) resistance, 
OR = 0.96 (0.93, 1.00) per year, and protease inhibitor resistance, OR = 0.93 (0.89, 0.97) per 
year. Of the individuals in our study, 296 (6.3%) had transmitted drug resistant mutations 
associated with high-level resistance according to the Stanford HIV database algorithm 
(Stanford score higher than three), and 190 (4%) individuals had a mutation associated with 
any drug recommended by EACS as part of first-line treatment (abacavir, lamivudine, 
dolutegravir, tenofovir, emtricitabine, elvitegravir, rilpivirine, raltegravir, ritonavir, 
darunavir, efavirenz, atazanavir, lopinavir). 2.62% of individuals had a mutation associated 
with high level resistance to efavirenz, markedly higher than any other drug, Figure 4.4. 
                                                          
6 Patient populatin defined in Appendix 1, page 132-135. 
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Although the rate of transmitted drug-resistant HIV-1 has decreased since 1996, a fair 
proportion of newly infected individuals (8.5%) are being diagnosed with drug-resistant 
strains. Resistance testing remains cost effective for baseline resistance above 1%161, 
therefore preforming resistance tests for newly diagnosed individuals remains justifiable. 
 
*Abbreviations: TDR – transmitted drug resistance; NRTI - nucleoside reverse transcriptase inhibitors; NNRTI - non- 
nucleoside reverse transcriptase inhibitors; PI - protease inhibitors 
ᶧstatistically significant decline (p<0.01 for TDR, NRTI and PI) in the prevelance of transmitted drug resistance over time 
using linear mixed models 
Figure 4.3: Temporal trends in transmitted drug resistance over time for individuals with at 
least one ART naïve nucleotide sequence within one year of testing positive for HIV: 
CASCADE data of HIV seroconverters from Olson et al, AIDS, 2018158. 
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Figure 4.4: High level resistance (Stanford scores >3; solid bars indicate a score of 5, checked 
bars indicate a score of 4) associated with first-line antiretroviral drugs recommended by 
the European AIDS clinical Society for individuals with at least one cART naive nucleotide 
sequence within 1 year of testing positive for HIV: CASCADE data of HIV seroconverters. 
ABC, abacavir; ATV/r,  atazanavir; DRV/r, darunavir; EVF, efavirenz; FTC, emtricitabine; 
LPV/r, lopinavir; NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside 
reverse transcriptase inhibitors; PIs, protease inhibitors; RPV, rilpivirine; TDF, tenofovir; 3TC, 
lamivudine adapted from Olson et al, AIDS, 2018158. 
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5 Outcomes on treatment 
 
With the advent of cART in the late 1990’s, HIV became a treatable and chronic condition 
that results in lifelong treatment and potential lifestyle adjustments such as regular 
exercise, balanced nutrition and ceasing smoking to reduce the risk of falling ill162. There 
are some rare reports of individuals who can control viral replication after stopping cART24, 
26, 27, but viral rebound and cART reinitiation at a later point in time is typical. cART is not 
perfect, and one size does not fit all; but recommended first line therapies are effective at 
suppressing viral replication. Treatment associated toxicities can develop either 
immediately or over time however, and this needs careful monitoring, and sometimes 
treatment changes due to adverse reactions, development of drug resistance, or new co-
infections for example.  
 Post treatment control of viral replication through cART 
 
Not only can cART reduce morbidity and mortality among HIV-1 positive individuals, but for 
a small proportion of individuals on cART, plasma viremia remains undetectable after cART 
cessation; in essence, creating HIV-1 ECs. This phenotype is termed post treatment control 
(PTC) and is more common among individuals initiating cART in primary HIV Infection 
(PHI)163 where the viral reservoir is small26, 164 and when individuals are less likely to have 
immune dysfunction compared to chronic infection165.  Studies reporting on PTC estimate 
around 0-26%23-30, 166, 167 of those interrupting treatment achieve PTC status. This is 
arguably the best possible outcome among those initiating treatment. Like EC’s, the 
biological mechanism underlying PTC is not fully elucidated. We know predictors of PTC 
from the ANRS VISCONTI Study, the SPARTAC trial, the CHAMP study, and studies in 
primates, which include small viral reservoir before cART, cART initiation in PHI, and long 
duration of therapy before treatment interruption (e.g. PTCs were treated for a median 
56 
 
36.5 months in the ANRS VISCONTI study)27, 163, 168-170. Transient periods of detectable 
viremia, or “blips”, while on cART initiated in PHI could play a role in predicting individuals 
who will not achieve PTC status, as they could indicate lack of cART adherence or lifestyle 
adjustments, poor drug absorbption, a larger viral reservoir, emergence of drug resistance, 
or intermediate immune activation. It is well documented that blips while on cART in 
chronic HIV infection is associated with subsequent virological failure171-174, so perhaps this 
is true of blips while in cART in PHI. As treatment interruptions have been associated with 
increased morbidity22, 175, 176 and should be avoided in individuals who are not likely to 
achieve PTC, our aim was to identify if blips among those initiating cART in PHI predict the 
probability of PTC status among individuals who subsequently stopped cART. Using 
CASCADE data on HIV-1 seroconverters, we included individuals who initiated cART within 
6 months of HIV-1 seroconversion166 7. Using Cox models, we examined the association 
between time from cART cessation to loss of viral control (two consecutive viral load 
measurements over 1000 copies/mL) and the magnitude and frequency of blips while on 
cART adjusting for other variables of interest including time on cART, time between HIV-1 
seroconversion to cART initiation, viral load at seroconversion, CD4 cell count at cART 
initiation, CD4 cell count at cART cessation, and cART class. We also adjusted for 
confounders: cART initiation year, age at HIV-1 seroconversion, sex, and HIV-1 transmission 
risk group. Of 228 stopping treatment, only 22 (10%) achieved PTC status. We found that 
time to loss of viral control was associated with a longer time interval between HIV 
seroconversion and cART initiation and viral blips on cART HR = 1.16 per month (1.04, 1.28); 
1.71 per blip (0.94, 3.10), respectively, but longer time on cART was associated with longer 
durations of viral control, HR = 0.84 (0.76, 0.92) per month increase, Table 5.1. We were 
                                                          
7 Patient population defined in Appendix 1, page 141-143. 
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the first study to provide evidence that blips on cART initiated in PHI are associated with 
viral rebound among individuals who eventually interrupt cART166. These results should be 
reviewed in future HIV-1 cure studies where planned treatment interruptions are, by 
definition, necessary. Individuals who have blipped on cART should be carefully considered 
for treatment interruption as viral rebound is more likely once cART is stopped compared 
to those that have not had a viral load blip while on cART that was initiated in PHI.   
Table 5.1: Multivariable analysis of the factors associated with virologic rebound among 
those stopping cART initiated within 6 months of HIV seroconversion using the CASCADE 
dataset from Fidler et al, AIDS, 2017166. 
  HR (95% CI) p-value 
Time on cART ғ 0.84 (0.76, 0.92) <0.001 
Time from SC to cART ⱡ 1.16 (1.04, 1.28) 0.006 
# blips >400 copies/ml 1.71 (0.94, 3.10) 0.077 
# mean HIV-RNA 
measurements/year 1.10 (1.02, 1.17) 0.005 
HIV-RNA at SC ₸ 1.15 (0.98, 1.35) 0.086 
cART initiation year 0.91 (0.84, 0.98) 0.016 
Time from cART to viral suppression 
ƪ ⱡ 0.99 (0.97, 1.02) 0.93 
CD4 at cART initiation Ω 0.99 (0.90, 1.08) 0.75 
CD4 at cART cessation Ω 1.10 (1.01, 1.20) 0.035 
ART class  0.33 
    NNRTI 1  
    PI 0.92 (0.57, 1.48) 
    3 N 1.32 (0.74, 2.36) 
    3 Class 0.24 (0.03, 1.79) 
    Integrase Inhibitor 0.77 (0.10, 6.12) 
SC age 1.00 (0.98, 1.02) 0.77 
Sex  0.49 
    Male 1  
    Female 0.75 (0.33, 1.69) 
HIV Risk Group  0.28 
    MSM 1  
    MSW 0.84 (0.44,1.58) 
    IDU 0.53 (0.14, 2.03) 
    OTH 0.23 (0.03, 1.73) 
ғ Per 6 month increase; ⱡ Per month increase; ₸Per log10 increase; Ω: per 100 cell increase; ƪ HIV-RNA < 50 copies/ml 
Abbreviations are: cART – combination antiretroviral therapy; SC – seroconversion; MSM – men who have sex with 
men; MSW – sex between men and women; IDU – injection drug use; OTH – other; NNRTI – non-nucleoside reverse-
transcriptase inhibitors; PI – protease inhibitor; 3N – three nucleoside reverse transcriptase inhibitors ; 3 class – drugs 
from 3 or more classes. 
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For the vast majority of HIV positive individuals, cART is not a functional cure, likely due to 
an inaccessible reservoir of latently infected cells20-22, a treatment interruption would 
therefore result in viral rebound. Numerous treatment interruption studies have been 
conducted177, the landmark SMART trial was the largest, randomizing 5472 individuals to 
continuous cART or episodic CD4 guided cART, stopping treatment when CD4 surpassed 
350 cells/mm3. This trial was stopped early, as it showed a 2.6-fold increased risk of an 
opportunistic infection or death among those not reveicing continuous cART22.  Therefore, 
guidelines do not recommend treatment interruptions as it is associated with increased 
morbidity22, 175, 176. The previous chapter highlighted randomized controlled trials (START71 
and TEMPRANO72) coupled with our observational evidence to suggest immediate cART 
reduces morbidity and mortality rates. Another benefit of cART is its role in HIV prevention. 
Several studies have confirmed that there is little to no risk of HIV transmission among 
individuals with undetectable viral load121, 151-156, 178, and it has also been shown that pre-
exposure prophylaxis (PrEP) in HIV negative individuals with tenofovir-emtricitabine 
(Truvada®) reduces the risk of HIV infection by up to 90%179 . This implies that time spent 
off cART among HIV positive individuals or undertaking treatment interruptions is non-
advantageous as it can result in transmission.  The key to reducing morbidity and mortality 
risk, and to reduce transmission of HIV to others, is timely cART initiation. However, cART 
does not come without disadvantages, for instance, there remains an ongoing risk of drug 
toxicity among individuals on cART, as well as pill burden can contribute to lack of 
adherence, causing viral breakthrough which can lead to the development of resistance 
associated mutations (RAMs).  
Individuals therefore need to be monitored once treatment is commenced. Infrequent 
monitoring could lead to delays in detecting treatment toxicity, viral breakthrough, AIDS or 
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other opportunistic infections, and delay timely cART re-configuration. On the other hand, 
frequent monitoring causes financial pressures on health care systems and can be 
unrealistic in low income countries such as sub-Saharan Africa where most HIV positive 
people reside. One of my collaborations with HIV-CAUSAL added to the body of evidence 
on when to monitor and suggested that less frequent monitoring (9-12 months compared 
to every 3 months) has little impact on clinical outcomes at 18 months among individuals 
on cART achieving undetectable HIV-1 RNA viral load, however, monitoring every 9-12 
months increases the risk of virologic failure compared with monitoring every three 
months180. 
 cART associated Toxicities 
 
With lifelong treatment being the standard of care for HIV positive individuals, there is an 
ongoing need to monitor immediate or accumulated toxicity, where people rapidly 
progress to disease or, in more serious cases, die. Reflecting on the recent upscale of cART 
and increasing use of antiretrovirals to prevent HIV transmission, it is ever more important 
to monitor toxicities, especially those that could result in long term disability or death and 
vary depending on treatment type. Three toxicities we investigated were hypersensitivity 
reactions due to abacavir (ABC) utilization, AIDS-defining neurological conditions related to 
cART penetrating the blood brain barrier, and immune reconstitution inflammatory 
syndrome (IRIS) shortly after cART initiation.  
 Abacavir associated hypersensitivity reactions 
The first toxicity investigated was hypersensitivity which can occur with abacavir utilization. 
ABC is a nucleoside reverse transcriptase inhibitor which remains a commonly used drug 
recommended as a part of first- and second-line therapy133, 181. In the absence of genetic 
screening, 5-8% of HIV positive individuals who initiate ABC experience hypersensitivity 
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reactions (HSR)182, 183, a multi-organ clinical syndrome which varies in severity184 and in rare 
cases, results in death185, 186. There is an increased risk of ABC related HSR among those 
who test positive for the HLA-B*5701 allele, and it is recommended that all individuals 
initiating ABC be screened for this allele to prevent avoidable complications181.  It is 
therefore important that ABC-associated HSR are continually monitored and additional 
associated risk factors are investigated. Using EuroSIDA data on 10,0768 HIV-1 positive 
individuals receiving cART between 2009 and 2016, we calculated the proportion of 
individuals receiving cART containing ABC and the incidence rate of HSR reactions among 
this group187. Poisson regression was used to identify factors associated with ABC 
discontinuation due to HSR. During our study period, 34% received ABC cART and 113 
discontinued within 6 weeks of ABC initiation, 13 because of reported HSR (incidence rate 
(IR) = 1.67 (0.97, 2.87) per 100-person years follow-up), Table 5.2. We found no significant 
factors associated with ABC discontinuation due to reported HSR or any toxicity.  These 
results are particularly important for those who initiate ABC as second line therapy as drug 
options become scarce. Some individuals switch to ABC because they have become 
resistant to other drugs, or switch to ABC from tenofovir due to decreasing renal 
function188, as ABC has no reported adverse effects on renal function189, 190.  
  
                                                          
8 Patient population defined in Appendix 1, page 149-151. 
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Table 5.2: Reasons and incidence rates for ABC discontinuation by reason for stopping 
treatment in the EuroSIDA cohort from 1/1/2009 to 4/1/2016. Individuals were censored at 
6 weeks after ABC initiation, ABC discontinuation or death, whichever came first from Roen 
et al HIV Medicine, 2017187. 
Reason for stopping treatment as reported to EuroSIDA Failures Rate 95% CI 
Any Reason 113 14.51 (12.07, 17.45) 
HSR or any toxicity 35 4.49 (3.23, 6.26) 
Any toxicity 22 2.82 (1.86, 4.29) 
Unknown 21 2.70 (1.76, 4.14) 
Patient's wish/decision 20 2.57 (1.66, 3.98) 
Other causes 17 2.18 (1.36, 3.51) 
Physician's decision 16 2.05 (1.26, 3.35) 
Toxicity – GI tract 16 2.05 (1.26, 3.35) 
HSR 13 1.67 (0.97, 2.87) 
Toxicity – Liver 2 0.26 (0.06, 1.03) 
Toxicity, predominantly CNS 2 0.26 (0.06, 1.03) 
Toxicity, predominantly kidneys 2 0.26 (0.06, 1.03) 
Treatment Failure 1 0.13 (0.02, 0.91) 
Concern of cardiovascular disease, including 
dyslipidaemia 1 0.13 (0.02, 0.91) 
Other Toxicity 1 0.13 (0.02, 0.91) 
Non-compliance 1 0.13 (0.02, 0.91) 
*Total person years follow-up = 778; Rate = per 100 person years 
 
 cART utilization and neurological AIDS  
The second toxicity investigated is not a consequence of one particular drug, but rather 
how cART as a whole impacts neurological AIDS defining illness. Neurological AIDS defining 
conditions have decreased since the advent of cART in the late 1990’s, but cART related 
neurotoxicity remains a concern. This depends on the concentration of drugs in the CNS 
which requires drug penetration through the blood brain barrier, a function not provided 
by all drugs. Higher concentrations of cART in the CNS likely decreases HIV-1 RNA in 
cerebrospinal fluid191, but could also be neurotoxic192.  The CNS Penetration Effectiveness 
(CPE) ranking system assesses a drugs penetration into the CNS and has been shown to be 
associated with HIV-1 RNA detected in cerebrospinal fluid191, 193-195, but it is unclear how 
CPE rank relates to clinical outcomes194, 196-199. Our aim was to examine the association 
between CPE scores and four neuroAIDS conditions, namely, HIV dementia, toxoplasmosis, 
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cryptococcal meningitis, or progressive multifocal leukoencephalopathy. Using HIV-
CAUSAL data on 61,9389 individuals starting cART, we classified individuals into low, 
medium or high CPE scores and estimated the hazard ratio for each neuroAIDS condition 
using the low CPE score as the reference group200. We found a significant association 
between high CPE score and HIV dementia, HR = 1.01 (0.73, 1.39) and 1.74 (1.15, 2.65) for 
medium and high CPE scores compared to low CPE scores, respectively,Table 5.3. We found 
no evidence for an association between CPE scores and toxoplasmosis, HR = 0.80 (0.56, 
1.15) and 0.90 (0.50, 1.62), cryptococcal meningitis, HR = 1.08 (0.73, 1.62) and 1.13 (0.61, 
2.11) or progressive multifocal leukoencephalopathy, HR = 1.08 (0.73, 1.58) and 1.32 (0.71, 
2.47).   
  
                                                          
9 Patient population defined in Appendix 1, page 158-161. 
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Table 5.3: Hazard ratios for CPE score by neuroAIDS condition in the HIV-CAUSAL 
Collaboration dataset 1998–2013 from Caniglia et al, Neurology, 2014200. 
CPE Score 
Person 
years 
No. of 
events 
Unadjusted 
hazard ratio 95% CI 
Adjusted 
hazard ratioa 95% CI 
HIV Dementia       
 Low 140,962 127 1 -- 1 -- 
 Medium 86,799 72 0.97 (0.72,1.30) 1.01 (0.73, 1.39) 
 High 32,097 36 1.55 (1.06, 2.26) 1.74 (1.15, 2.65) 
Opportunistic Infections b      
 Low 140,553 245 1 -- 1 -- 
 Medium 86,455 134 1.09 (0.88, 1.34) 0.99 (0.80, 1.22) 
 High 31,985 49 1.18 (0.87, 1.62) 1.08 (0.77, 1.52) 
Toxoplasmosis       
 Low 140,983 106 1 -- 1 -- 
 Medium 86,807 45 0.86 (0.60, 1.22) 0.80 (0.56, 1.15) 
 High 32,099 18 0.94 (0.57, 1.57) 0.90 (0.50, 1.62) 
Cryptococcal meningitis      
 Low 141,098 64 1 -- 1 -- 
 Medium 86,818 48 1.35 (0.92, 1.98) 1.08 (0.73, 1.62) 
 High 32,121 16 1.43 (0.83, 2.48) 1.13 (0.61, 2.11) 
Progressive multifocal leukoencephalopathy    
 Low 141,109 81 1 -- 1 -- 
 Medium 86,849 43 1.12 (0.77, 1.64) 1.08 (0.73, 1.58) 
  High 32,116 17 1.36 (0.80, 2.33) 1.32 (0.71, 2.47) 
Abbreviations: CI - confidence interval; CPE - CNS Penetration Effectiveness. 
a Adjusted for cohort, month of follow-up, baseline CD4 cell count, baseline HIV RNA level, sex, acquisition group, 
calendar year, age, geographic origin, race, years since HIV infection, and type of drug regimen, as well as time-varying 
CD4 cell count, RNA level, time since last measurement, and AIDS. Stabilized inverse probability weights were used to 
account for censoring due to infrequent follow-up. 
b Includes toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy. 
 Opportunistic infections and AIDS malignancies shortly after initiating cART 
The last complication of cART we investigated also is a consequence of introducing multiple 
drugs, where some patients initiating cART experience inflammatory reactions shortly after 
treatment initiation, termed IRIS201-203. IRIS can trigger new opportunistic infections, 
worsen existing opportunistic infections and may be associated with excess morbidity204. It 
has also been linked to a multitude of conditions such as mycobacterial and other 
infections203, 205-212, cancer213, 214, rheumatoid arthritis215, and sarcoidosis216. The HIV-
CAUSAL collaboration reported on increased incidence of tuberculosis by 36% shortly after 
cART initiation among older individuals or those with CD4 cell counts < 50 cells/mm3 212, 
which is suggestive of IRIS. Our intent was to extend this study to include other AIDS 
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defining events suggested to be associated with IRIS, namely, tuberculosis, mycobacterium 
avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal 
leukoencephalopathy (PML), herpes simplex virus (HSV2), KS, non-Hodgkin lymphoma 
(NHL), cryptococcosis, and candidiasis217. Cox proportional hazards models were used to 
estimate the hazard ratios for time to AIDS defining event for no cART versus cART for less 
than 3 months and cART for 3 or more months, adjusting for potential confounders of CD4 
cell count, HIV-RNA, sex, HIV transmission risk group, calendar year, geographical origin, 
time since HIV-1 diagnosis, and cohort. There were 96,56210 eligible individuals for this 
study and the incidence rate for each AIDS defining condition was 2.3 for tuberculosis, 0.4 
for MAC, 0.3 for CMV retinitis, 0.3 for PML, 1.6 for HSV, 1.9 for KS, 1.2 for NHL, 0.4 for 
cryptococcosis, and 1.4 for candidiasis. Compared with no cART, Hazard ratio for each AIDS 
defining for cART < 3 months was 1.21 (0.90–1.63) for tuberculosis, 2.61 (1.05–6.49) for 
MAC, 1.17 (0.34–4.08) for CMV retinitis, 1.18 (0.62–2.26) for PML, 1.21 (0.83–1.75) for HSV, 
1.18 (0.87–1.58) for KS, 1.56 (0.82–2.95) for NHL, 1.11 (0.56–2.18) for cryptococcosis and 
0.77 (0.40–1.49) for candidiasis, Table 5.4. Compared to no cART, there was a reduced risk 
in all AIDS defining events among individuals on cART for more than three months.  
  
                                                          
10 Patient population defined in Appendix 1, page 166-169. 
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Table 5.4: Hazard ratios of AIDS-defining events by time since initiation of combined 
antiretroviral therapy, HIV-CAUSAL Collaboration 1996–2013 from Lodi et al, AIDS, 2014217. 
 Event Time since 
cART 
initiation 
N 
cases 
Person-
years 
Incidence 
rates per 
1000 person 
years 
Hazard Ratio  
(95% CI) 
Tuberculosis No cART 422 143523.33 2.9 1 
 <3 months 97 9259 10.5 1.21 (0.90–1.63) 
 ≥3 months 379 236095.92 1.6 0.36 (0.26–0.49) 
Mycobacterium 
Avium Complex No cART 46 143936.5 0.3 
1 
 <3 months 37 9306.83 4 2.61 (1.05–6.49) 
 ≥3 months 80 238799.67 0.3 0.31 (0.16–0.59) 
CMV Retinitis No cART 35 143938.83 0.2 1 
 <3 months 12 9308.42 1.3 1.17 (0.34,4.08) 
 ≥3 months 58 238917.67 0.2 0.13 (0.04–0.39) 
PML No cART 38 143944 0.3 1 
 <3 months 19 9307.42 2 1.18 (0.62–2.26) 
 ≥3 months 56 238960.75 0.2 0.21 (0.06–0.71) 
Herpes Simplex 
Virus No cART 254 143476.42 1.8 
1 
 <3 months 42 9282 4.5 1.21 (0.83–1.75) 
 ≥3 months 324 236713.5 1.4 0.69 (0.51–0.92) 
KS No cART 404 143755.17 2.8 1 
 <3 months 95 9250.67 10.3 1.18 (0.87–1.58) 
 ≥3 months 249 236065.5 1.1 0.14 (0.10–0.21) 
Non Hodgkin 
Lymphoma No cART 198 143875.92 1.4 
1 
 <3 months 38 9288.17 4.1 1.56 (0.82–2.95) 
 ≥3 months 252 237871.5 1.1 0.40 (0.27–0.58) 
Cryptococcosis No cART 60 143924.67 0.4 1 
 <3 months 21 9305.67 2.3 1.11 (0.56,2.18) 
 ≥3 months 58 238860.92 0.2 0.06 (0.02–0.19) 
Candidiasis No cART 275 143745.33 1.9 1 
 <3 months 36 9275.67 3.9 0.77 (0.40–1.49) 
  ≥3 months 224 237213.75 0.9 0.13 (0.09–0.20) 
cART Combined antiretroviral therapy; CMV cytomegalovirus;  KS Kaposi’s Sarcoma; MAC Mycobacterium 
avium complex; PML Progressive multifocal leukoencephalopathy. 
 
cART has greatly reduced morbidity and mortality for HIV positive individuals, and reduced 
transmission risk to others rationalising current guidelines for immediate treatment of all 
HIV positive individuals136. There are, however, treatment associated toxicities which need 
clinical monitoring, and in some instances require adjustments in medication. cART is a 
lifelong commitment, and any deviations in treatment adherence can lead to the 
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emergence of mutations that are associated with HIV drug resistance. Although cART has 
greatly improved the prognosis and quality of life of HIV positive individuals, adverse 
outcomes while on treatment persist and there is a greater need for careful monitoring and 
continued research as life expectancy increases.  
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6 Discussion 
 
 Main findings of the PhD 
 
We identified substantial heterogeneity in how extreme phenotypes of HIV-1 are defined 
in the literature which could lead to difficulties identifying the biological mechanisms 
underlying these phenotypes. We propose standardized definitions which can be used for 
future research of these rare groups118. Once standardized definitions are adopted, the 
same biological and clinical phenotpyes will be studied allowing for better interpretation 
across studies. This is particularily important for HIV-1 elite controllers who can be used as 
a model for cure.   
Reflective to the very small proportion of individuals who can control viral replication (we 
estimate <1%97), our focus moved to determine ‘when’ and ‘what’ cART regimens should 
be initiated.  We added to the existing randomized71, 72 and observational evidence73 
suggesting immediate cART for all HIV-1 positive individuals, irrespective of CD4-T cell 
counts. We demonstrated a 62% reduced risk of serious AIDS, non AIDS events or death for 
those immediately initiating cART (vs not immediately initiating) among those with high 
CD4 cell counts (>500 cells/mm3) and high HIV-RNA (>100,000 copies/ml)126.  Despite the 
move towards immediate cART119, 133, 134, 136, some individuals still chose not to initiate 
treatment.  Our estimates can inform when individuals off cART should initiate (e.g 
individuals with high HIV-RNA values >100,000 copies/ml and high CD4 cell counts > 500 
cells/mm3 could benefit from cART) and our study design compares that with the 
challenges of initiating lifelong therapy such as adherence and adverse side effects.  
Beyond the ‘when to start’ question, we also contributed towards the ‘what cART regimen 
to start’ question. We demonstrated that if one is to initiate a bPI, atazanavir might be 
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preferable compared to lopinavir as it has a 30% lower mortality risk, 33% lower incidence 
of AIDS and death and 9% lower risk of virological failure compared to lopinavir142. Our 
estimates can help to optimize bPIs as a part of first line therapy by showing improved 
survival, reducing virologic failure, and preventing rapid disease preogression among those 
taking atazanivir compared to lopinavir.  Of course, cART is personal, and some individuals 
may not want to take atazanavir, for example due to drug drug interactions, but our 
extimates can serve as a guide for clinicians to recommend the best line of care. We also 
found both atazanavir and lopinavir had low levels of TDR in Europe (0.33% and 0.22%, 
respectively), but the most common transmitted mutation associated with high level 
resistance was to the drug efavirenz (2.62%)158. Our results show TDR is significantly 
decreasing throughout Europe, yet it still prevalent (8.5% in 2012158) and genetic testing 
for resistant strains among newly diagnosed remains cost-effective and justifiable161.  
Most individuals who start treatment will need to continue throughout their lifetime which 
can results in toxicities that need continual monitoring. However, very early cART initiation 
can potentially lower the viral reservoir to levels found among ECs218, 219, with some reports 
of post treatment control upon stopping cART23-30. In this study, we found that individuals 
with viral blips on cART initiated in PHI had shorter time to viral rebound upon stopping 
treatment166, implying there should be caution about stopping treatment among those 
experiencing blips during early cART. We also found a longer duration on cART initiated in 
PHI is associated with a greater chance of PCT166, suggesting this could be a pathway to 
achieving cure.  Among the majority of HIV-1 positive individuals who do not become PTC 
and initiate life-long cART, a multitude of treatment associated-toxicities have been 
reported. We investigated three in this PhD: hypersensitivity reactions due to ABC 
utilization, AIDS-defining neurological conditions related to cART penetrating the blood 
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brain barrier, and immune reconstitution inflammatory syndrome (IRIS) shortly after cART 
initiation. We found that hypersensitivity due to abacavir utilization is low (IR = 1.67 (0.97, 
2.87) per 100 person years follow-up187), cART therapies with a high CNS penetration score 
increase the risk of HIV dementia but not other neurological AIDS conditions200, and apart 
from mycobacterial infections, unmasking IRIS does not appear to be a complication of 
cART in high-income countries217.  
cART has greatly improved the quality and longevity of life for those diagnosed with HIV-1. 
With 32 FDA approved HIV drugs on the market however, Figure 1.5, personal optimization 
of cART is essential.  Some of the major influences for an individual’s cART regimens include 
drug tolerability, absorbtion and interactions alongside consideration of adherence and pill 
burden issues. cART is complex and can take time to get the right combination for a given 
person; it is also a life-long commitment which requires good adherence. Suboptimal cART 
adherence rates less than 95%69, can result in viral breakthrough which can lead to the 
development of drug resistance and the possibility of transmitting resistant strains of HIV-
1 to others. Not only does TDR result in limited treatment options for newly diagnosed 
individuals acquiring TDR strains, resistance testing is expensive to implement ($30-
$400/test)161, 220, especially in resource-limited settings where 25 times more new 
infections are reported each year compared to Western Europe221. Some suggest reducing 
pill burden increases adherence and thus reducing viral breakthrough, but arguably the 
best solution would be to find a functional cure without the need for ongoing treatment 
and its multitude of side effects. Given that natural control of viral replication is rare (<1%), 
the next best thing would be to make individuals become ECs through therapy or other 
means. The two known functional cures of HIV, namely the Berlin and the London patient, 
were achieved through stem cell transplants – a very risky and life-threatening procedure 
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which was appropriate in these cases only due to their secondary cancer diagnoses. These 
treatments are not scalable solutions. Our research contributes towards understanding the 
mechanisms of viral control as well as tailoring therapy and monitoring disease to improve 
treatment outcomes with the end goal of promoting the EC and PTC phenotypes. Our 
research findings can be applied to resource poor areas such as sub-Saharan Africa, the 
epicentre of the HIV-1/AIDS pandemic.  
 Limitations 
 
There are some limitations that should be noted.  
 Cohort data limitations 
Cohort data was used for these analyses which comes from clinical practice, where 
individuals undergoing regular patient care and health outcomes were observed. 
Extrapolation of results to less routinely controlled patients therefore may not be practical. 
Collaborations used were uniquely large, achieved through pooling data throughout 
Europe, North America, and Australia using HICDEP data formatting.  It is important to note 
these data are more heterogeneous than in randomized clinical trials where strict study 
visit timelines and standardized data collection and analytic processes.  
 Variability in laboratory measurements  
Details of laboratory data collection is cohort specific and not always consistent across 
cohorts and over time. Laboratory measurements of HIV-RNA measurements, CD4 cell 
counts, HIV sequencing, and other virology assessments, were performed in the country of 
care using a variety of in house and commercial methods and assays. The data on assays 
used were requested to be documented in each LAB file, where available, and our models 
tried to account for the varying techniques used.  
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6.2.2.1 Variability of HIV-RNA viral load 
There are a number of HIV-RNA assays that have been available throughout our study 
period, with current standard HIV-RNA assays show good agreement in viral load 
measurements222-225; yet not to the same extent at the lower limit of detection (20, or 40 
copies/ml)222, 226, which could lead to misclassification of EC and LTNP. In addition, the 
lower limits of detection for HIV-RNA have dramatically changed over the study period, 
starting at 1000 copies/ml when the assays first became available, and are now as low as 
20 copies/ml. This makes comparing temporal trends of viral suppression challenging, 
which too has particular importance for HIV-1 ECs and LTNPs, whose suppressed HIV-RNA 
values, by definition, are essential to their categorization. We have tried to account for this 
by looking at different thresholds for undetectable HIV-RNA in our search for an 
appropriate definition. Given that the lower limit for available assays has been less than 
1000 copies/ml for at least 10 years justifies our suggested definitions.   
6.2.2.2 Variability of CD4 cell counts 
Like HIV-RNA assays, the numerous methods of analysing CD4 cell counts are variable. This 
could lead to RP misclassification and, until 2015, impact how individuals were assessed for 
cART eligibility. Until 2000, the recommended methods for assessing total CD4 T-cell count 
involved multiple platforms (hematology instruments and a flow cytometry) and three 
independently derived values, namely whole blood cell count, percent of lymphocytes and 
percentage of CD4 cells. This method was highly variable as measurement error for each 
step was compounded when deriving the total CD4 cell counts.  In the late 1990’s, a single 
platform approach was introduced which allowed CD4 cell counts to be derived directly 
from the flow cytometric analysis, removing the multiplicative effect of errors that could 
occur when using dual platforms227. It has been shown that the differences between dual 
and single platform analysis is relatively small, 8%228, and the variation is smaller as CD4 
cell counts decrease, with the bias at CD4 < 350 cells/mm3 ranging from -35.2 to +13.1 
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cells/mm3 and bias at CD4 > 350 cells/mm3 ranging from -70.7 to +47 cells/mm3 229.  Even 
though the CD4 cell counts were analysed in multiple laboratories utilizing different 
methods, the errors between methods are relatively small and likely have a negligible 
impact on our findings throughout our study period.  
 Future work: expanding our study beyond the predominately HIV-1 B subtype 
 
Data used for this PhD was predominately from Europe, the Americas and Australia where 
a majority of the population is male with HIV-1 subtype B infections. Globally, subtype B 
only accounts for around 10% of HIV-1 infections40, yet is the most studied HIV-1 subtype230 
because it is the most common in the richest countries of the world where much of the 
research funding and drug development is based41, 42. There are reports of different 
virulence and disease progression rates between subtypes231-234 which would imply 
extreme phenotypes also vary between HIV-1 subtypes. For example, a recent study in 
African women with subtype C infection (globally the most dominant strain of HIV-1) by 
Garrett et al. presented at the 2019 Conference on Retroviruses and Opportunistic 
Infections (CROI) found a higher proportion (35%) of individuals with a CD4 cell count <350 
cells/mm3 within the first year of infection235 which is slightly higher than our mainly 
subtype B setting with an estimated 25% experiencing a CD4 <350 cells/mm3 within one 
year118.  It has also been shown that subtype C has slower progression than subtype A or 
D232, the latter of which has the fastest rates of progression84, 231, 233, 234. This heterogeneity 
in progression rates among other subtypes, suggests that RP varies among HIV-1 subtype 
and could be worse among non-subtype B populations prompting further research in 
defining extreme phenotypes among individual subtypes and in resource-limited settings. 
There is some work looking at predictors of RP in subtype C, but this does not assess the 
merit of definitions, rather using what appears to be definitions created for subtype B85. 
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This further promotes the need of immediate cART initiation, even in resource-limited 
settings, where the majority of the HIV-1 pandemic is located and non-B subtypes prevail. 
In addition to varying extreme phenotypes among subtypes, it is possible there are 
differences in response to cART and toxicity development between subtypes. Many studies 
analysing virologic response to cART have found no significant differences when comparing 
subtype B to all other subtypes236-241, however, all non-B subtypes tend to be grouped 
together. There are a handful of studies comparing specific subtypes; Geretti et al showed 
faster viral suppression in subtype A and C compared to B (HR = 1.35 (1.04, 1.74) and 1.16 
(1.01, 1.33), respectively) 242; Easterbrook et al showed a higher virological rebound (HIV-
RNA > 400 copies/ml at 6 months 70% vs 45%) after cART cessation for subtype D compared 
to  B and for subtype A compared to B (35% vs 45%)84. However, Paraskevis et al found 
individuals with subtype A had improved virological response compared to subtype B (HR 
= 1.35 (1.08, 1.68))243; and Touloumi et al found little differences in virologic and 
immunologic response to cART between subtypes, but subtype CRF01_AE and A achieving 
HIV-RNA <500 copies/ml earlier than subtype B (HR = 1.37 (1.01, 1.86) and 1.29 (0.96, 1.72), 
respectively) 244. These studies all had small sample sizes for non-B subtypes and yet they 
highlight that there are subtle differences in response to treatment. In the ‘test and treat’ 
era, more research is needed comparing the efficacy in viral suppression, sustained viral 
suppression, viral rebound, and CD4 T-cell responses between all subtypes and specific 
drugs.  
 Importance of cohort studies in research 
 
Although there are limitations with cohort data, HIV-1 cohorts play an important role in 
understanding HIV-1 pathogenesis and disease progression. Cohort studies take over 
answering questions where clinical Phase III trials stop by informing on the pragmatic 
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effectiveness of interventions at a population level.  They also enable evaluation of long-
term outcomes, or rare events and toxicities that are beyond the scope of RCTs. For 
example, we have investigated the utilization of ABC and the incidence of HSR, a very rare 
outcome that requires large populations with longitudinal structured data to monitor. 
Without cohorts like EuroSIDA, hypersensitivity reactions among those prescribed ABC in 
Europe would be difficult to monitor. Cohorts are also uniquely able to monitor the trends 
of the HIV-1 epidemic, for example, as we have done by looking at the temporal trends of 
TDR in Europe.  
Finally, cohorts help to identify and target future problems as HIV treatment and clinical 
care evolves. For example, a newly identified side effect of Integrase strand transfer 
inhibitors (INSTIs) is a significant amount of weight gain, and cohorts have been at the 
forefront of identifying this problem245-247. The infrastructure of cohorts allows us to 
identify emerging problems, quantify the problem and assess interventions.   
 Final Remarks 
 
We have suggested definitions for extreme phenotpyes of HIV-1 in a predominately 
subtype B cohort which can be used in future research aiming to understand the biological 
mechanisms of HIV-1 elite control and rapid progression. We also have contributed to the 
‘when to start’ and ‘what to start’ questions among individuals with HIV-1 and contributed 
towards understanding toxicities developed after cART initiation, Table 6.1.  
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Table 6.1: Main Findings of the PhD 
Chapter Question Key Findings 
10  What is the heterogenity 
in extreme phenotypes in 
published literature? 
 
 What are the best 
definitions for EC and RP 
moving forward? 
 Substantial heterogeneity in slow progressor 
definitions, 600 definitions, 26 terms used. EC and 
LTNP were most common terms used in literature 
 Substantial heterogeneity in fast progressor 
definitions, 114 definitions, 8 terms used, RP most 
common term used in literature 
 Consecutive undetectable HIV-RNA measurements 
(HIV-RNA < 50 or 75 copies/m) for at least six 
months were mose sensitive in classifying 
individuals with the slowest disease progression, 
lowest HIV-RNA and highest CD4 cell counts during 
EC periods and total cART naïve follow-up 
 Individuals with at least one CD4 cell count <100 
cells/mm3 identified a rare group (2.8%) at the 
highest risk of disease progression 
11  What is the utility of HIV-
RNA and HIV-RNA copy-
years in deciding when to 
start cART? 
 What first line bPI 
acheives the best 
immunologic, virologic 
and clinical outcomes? 
 What are the TDR trends 
in Europe and how does 
this impacts treatment 
options? 
 62% reduction in the risk of serious AIDS, non-AIDS 
events or death among those initiating cART 
(compared to non-initiators) with CD4 >500 
cells/mm3 and the highest current HIV-RNA (HIV-
RNA > 100,000 copies/ml [HR = 0.38 (0.19, 0.77)]) 
 Atazanavir is superior to lopinavir with 30% and 
33% reduced HR of death and AIDS or death, 
respectively, and 9% reduction in the HR of 
virologic failure at 12-months 
 TDR is decreasing in Europe (19.4% in 1996 
reduced to 8.5% in 2012), but resistance testing 
among newly diagnosed remains justifiable 
12  Can we create PTCs and 
do viral blips on cART 
predict PTC? 
 Are HSR common among 
those utilizing ABC? 
 Are cART regimens with 
high CPE scores 
neurotoxic? 
 Do individuals experience 
IRIS after cART 
 PTC is rare: 22/228 (10%) stopping cART acheived 
PTC status. Blips and longer time interval between 
SC and cART were associated with loss of viral 
control HR = 1.16 per month (1.04, 1.28); 1.71 per 
blip (0.94, 3.10), respectively 
 A longer time on cART was associated with a 
longer time to loss of viral control HR = 0.84 (0.76, 
0.92) 
 HSR among ABC utilizers is rare (IR = 1.67 (0.97, 
2.87) per 100 person-years follow-up) 
 cART regimens with high CPE scores are associated 
with HIV dementia HR = 1.74 (1.15, 2.65), but not 
other neurologicalAIDS conditions 
 Apart from MAC, HR = 2.61 (1.05, 6.49), 
unmasking IRIS does not appear to be a 
complication of cART in high income settings 
Abbreviations are as follows: EC – elite controllers; LRNP – long term non progressors RP – rapid progressors; bPI – 
boosted protease inhibitor; TDR – transmitted drug resistance; PTC – post treatment controller; cART – combination 
antiretroviral therapy; HSR – hypersensitivity reaction; ABC – abacavir; CPE clinical penetrative effectiveness; IRIS – 
immune reconstitution inflammatory syndrome; MAC - Mycobacterium avium complex 
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EDITORIAL REVIEW
A systematic review of definitions of extreme
phenotypes of HIV control and progression
Deepti Gurdasania,b, Louise Ilesa,b, David G. Dillona,b,
Elizabeth H. Younga,b, Ashley D. Olsonc, Vivek Naranbhaid,e,
Sarah Fidlerf, Effrossyni Gkrania-Klotsasg, Frank A. Posth,
Paul Kellama,i, Kholoud Porterc, Manjinder S. Sandhua,b,
on behalf of the UK HIV Genomics Consortium
The study of individuals at opposite ends of the HIV clinical spectrum can provide
invaluable insights into HIV biology. Heterogeneity in criteria used to define these
individuals can introduce inconsistencies in results from research and make it difficult
to identify biological mechanisms underlying these phenotypes. In this systematic
review, we formally quantified the heterogeneity in definitions used for terms referring
to extreme phenotypes in the literature, and identified common definitions and
components used to describe these phenotypes. We assessed 714 definitions of HIV
extreme phenotypes in 501 eligible studies published between 1 January 2000 and
15 March 2012, and identified substantial variation among these. This heterogeneity in
definitions may represent important differences in biological endophenotypes and
clinical progression profiles of individuals selected by these, suggesting the need for
harmonized definitions. In this context, we were able to identify common components
in existing definitions that may provide a framework for developing consensus
definitions for these phenotypes in HIV infection.
 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2014, 28:149–162
Keywords: definitions, elite controllers, extreme-trait designs, HIV, HIV
controllers, long-term nonprogressors, phenotypes, slow progressors, systematic
review, viremic controllers
Introduction
Individuals with HIV infection show variable rates of
disease progression and viral control. Whereas some
subgroups of individuals control infection very well and
remain asymptomatic for several years, others show rapid
immunological and clinical progression. A number of
terms have been used to describe individuals at these
extremes of the clinical spectrum, including ‘long-term
nonprogressors’ (LTNPs) [1–5], ‘elite controllers’ [6,7],
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‘slow progressors’ [8–10], ‘HIV controllers’ (HICs) [11],
‘viremic controllers’ [1], ‘noncontrollers’ [12], and ‘rapid
progressors’ [13–15]. These terms represent extremes
within the virological and clinico-immunological range of
disease, with LTNPs and rapid progressors lying on oppo-
site extremes of the clinico-immunological distribution,
and elite controllers and noncontrollers lying on opposite
ends of the spectrum of viral control. The study of these
individuals has provided valuable insights into the biology
and pathogenesis of disease control and progression
[5,16,17]. Indeed, elite controllers have been regarded as
a natural model for disease control, and understanding the
underlying biological mechanisms of this phenomenon
could provide novel therapeutic targets [17,18].
Although these groups have been the focus of intense
study, there is no consistency in how they have been
defined. Studies suggest that different definitions may
select for groups with varying clinical outcomes, and
represent different biological endophenotypes [1,14,19].
This variability in definitions also has important
implications for the design of future biological research
in HIV and for the interpretation of results from existing
literature. Recommendations for consensus definitions
are needed. To examine variability in these definitions,
we conducted a systematic review of the literature. Here,
we describe heterogeneity in the definitions used,
and identify common definitions that may provide a
framework for developing consensus definitions for
extreme HIV clinical phenotypes.
Methods
Search strategy
This systematic review was conducted and reported in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [20]. We used a combination of MeSH and
non-MeSH terms representing extremes of virological
and clinical progression in HIV in PubMed, and reviewed
abstracts for all articles available between 1 January 2000
and 15 March 2012 (Fig. 1). Terms representing extremes
of disease progression and control were included in the
search strategy, as shown in Fig. 1. A total of 1639 abstracts
were reviewed in order to shortlist relevant publications
(Fig. 1, Supplementary Data 1, http://links.lww.com/
QAD/A411). We further reviewed the full-text articles if
the abstract or title mentioned an extreme phenotype
term for disease progression or control in HIV infection
and pertained to HIV infection in human adults. Extreme
phenotypes in both HIV-1 and HIV-2 infection were
considered for the purposes of this review. Articles were
excluded if there was no mention of disease progression or
control in the abstract or title, or if extreme phenotype
definitions applied to children (<18 years of age) or to
studies in animals. Articles were also reviewed if it was
unclear whether they met the inclusion or exclusion
criteria for the analysis.
On reviewing 1639 abstracts, we identified 730 articles
for full-text review, and 501 studies were included in the
final analysis (Fig. 1, Supplementary Data 2, http://
links.lww.com/QAD/A412). Full-text articles were
reviewed for terms referring to extreme phenotypes in
HIV infection, and definitions were entered into a
database. We listed terms that described extremes of the
clinical spectrum in HIV infection through this review.
These included words and phrases used to describe
extreme groups in each article, such as ‘LTNPs’, ‘elite
controllers’, ‘slow progressors’, ‘viremic controllers’,
‘rapid progressors’, or ‘noncontrollers’ (Table 1). These
phrases will hereby be referred to as ‘terms’, and represent
variously defined phenotypes of HIV control and
progression. The set of clinical and immunological
criteria used to describe the terms in each study are
referred to as ‘definitions’ (Table 2). The data obtained
using the search strategy were independently reviewed by
two investigators (DG and LI) to identify articles for
inclusion and to assess observer bias. Data obtained by the
two investigators were then synthesized and collated. Any
discrepancies in results were resolved by a consensus
discussion. The database was examined for any duplicate
definitions and these were deleted.
Data retrieval
Definitions, as described above, were collated on an
electronic database. Definitions were only included if they
incorporated at least one quantitative element and
pertained to extreme phenotypes in the context of the
natural course of HIV infection. Purely conceptual defini-
tions of phenotypes without any quantitative element and
definitions pertaining to extremes of viral or immuno-
logical control following antiretroviral treatment were not
included in the analysis. However, definitions were
included if they referred to extremes in the natural
progression of HIV infection or viral control, even if they
did not explicitly specify individuals being antiretroviral
therapy (ART)-naive, as long as definitions did not pertain
specifically to treatment-related viral control/disease
progression phenotypes. Articles reviewing HIV pheno-
types, listing several definitions, were not included. Studies
describing case series with no defining criteria were not
included in the analysis (Fig. 1, Supplementary Data 2,
http://links.lww.com/QAD/A412).
When more than one definition was applied to a term, we
listed this as two separate definitions in the database.
Conversely, if more than one term was used to describe a
group of individuals, definitions were listed under all
terms used to refer to the individuals in the study.
Therefore, the number of definitions may be different
from the number of studies listed, as more than one term
may appear in a single study and/or more than one
definition may apply to a single term in a study. For
150 AIDS 2014, Vol 28 No 2
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example, in one study, the terms ‘LTNPs’ and ‘slow
progressors’ were used synonymously, and were defined as
HIV-infected individuals who maintain CD4þ cell counts
above 500/ml for at least 10 years after seroconversion or
suppress viral replication to levels of HIV-1-RNA below
300 copies/ml and maintain CD4þ cell counts of at least
1000/ml for at least 6 years [21]. In this case, maintenance
of CD4þ cell counts above 500 cells/ml for more than 10
years following seroconversion, and suppression of viral
loads to below 300 copies/ml with maintenance of CD4þ
cell counts above 1000 cells/ml for 6 years, were
considered as separate independent definitions of long-
term nonprogression/slow progression. In addition, both
definitions were listed under the terms LTNPs and
slow progressors separately, as both terms were used to
describe this group. Thus, although these definitions
pertained to one study, they were included as four
separate data points in the review, two for LTNPs and two
for slow progressors. Lists of collated definitions for
all terms can be found in Supplementary Data 3 and
4, http://links.lww.com/QAD/A414, http://links.lww.
com/QAD/A413.
Data synthesis
Of 1639 papers examined, 501 articles included definitions
of terms used to describe extremes of disease progression or
viral control. We listed all terms applying to definitions of
extreme groups in the clinical/virological spectrum of
HIV, and examined definitions within these groups. For
the purposes of listing definitions, terms representing
similar extreme groups were collapsed as shown in Table 1
and Fig. 2. For example, the term ‘slow progressors’
encompasses the terms ‘slow progressors’ and ‘long-term
slow progressors’, and the term ‘elite controllers’ encom-
passes the terms ‘elite controllers’ and ‘elite suppressors’.
Table 1 describes these individual terms, their frequency,
and the terms collapsed under generic term labels.
To facilitate comparison of definitions, and explore
heterogeneity among definitions and terms, we collapsed
Extreme phenotypes of HIV control and progression Gurdasani et al. 151
Terms input into pubmed:
“HIV long-term survivors”[Mesh] or long-term nonprogress*[title/abstract] or long-term non-
progress*[title/abstract] or long-term non-progress*[title/abstract] or slow progress*[title/abstract] or
LTNP[title/abstract] or elite controller[title/abstract] or elite control[title/abstract] or viral
control*[title/abstract] or virological control*[title/abstract] or viremic control*[title/abstract] or viraemic
control*[title/abstract] or rapid progress*[title/abstract] or chronic progress*[title/abstract] or typical
progress*[title/abstract] or accelerated progress*[title/abstract] or fast progress*[title/abstract] or non-
controller*[title/abstract] or non controller*[title/abstract] or controller*[title/abstract]
and
[Mesh] or HIV[title/abstract] or AIDS[title/abstract] or acquired immunodeficiency
syndrome[title/abstract] or “acquired immunodeficiency syndrome”[Mesh]
Limits: only articles after 1st January 2000 until 15th March 2012
1639 article abstracts reviewed
Article not in English: 75
Abstract not available: 18
No mention of extremes of progression or control in
abstract: 665
Extreme phenotypes defined in children: 83
Animal studies: 68
Full text not available: 18
No definition provided: 170
Conceptual definition only (no quantitative element): 25
Treatment-related extremes examined: 6
Review of many definitions: 4
Extreme phenotypes defined in children: 4
Animal studies: 2
730 potentially eligible studies: review full text
501 studies included
Fig. 1. Search strategy.
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definitions that contained common components and
component thresholds for clinical and immunological
criteria under each term (Table 3). These broad
components were identified by reviewing all definitions
for each term. The term ‘component’ here refers to
categories of common clinical and immunological
criteria used in definitions, and ‘component threshold/
categories’ refers to the thresholds or categories used for
these components in each definition (Table 2). For
example, key components identified for definitions of
LTNPs were duration of follow-up, CD4þ cell count
threshold, HIV-RNA thresholds, CD4þ cell slopes and
clinical criteria, such as asymptomatic or AIDS-free
follow-up (Table 3). To identify unique definitions for
each term, we then collapsed definitions based on each
distinct combination of components and component
thresholds or categories, with a view to grouping broadly
similar definitions. We only collapsed definitions
for terms for which we had identified more than
10 definitions in the literature. When different duration
Extreme phenotypes of HIV control and progression Gurdasani et al. 153
Table 2. Glossary of descriptors used in review.
Definitions
Terms Words or phrases describing extremes of the clinico-immunological and virological
spectrum in HIV infection, e.g., ‘elite controllers’.
Definitions The set of clinical and immunological criteria used to describe the terms in each study. For example,
elite controllers are HIV-infected individuals who suppress plasma HIV-RNA levels to
<50copies/ml without antiretroviral treatment.
Component Broad categories of common clinical and immunological criteria used in definitions. For example,
‘HIV-RNA level’ is a component of definitions for elite controllers
Component threshold/
category
Thresholds or categories for the specific component in each definition. For example, a HIV-RNA
threshold of <50 copies/ml in definitions of elite controllers
Descriptions of HIV extreme phenotypes listed from 501 articles
Collation of terms and definitions in broad groups
Slow progression/viral control extreme:
19 terms
Terms with > 10 definitions:
7 terms
LTNP:
265
definitions
(159
unique)
SP:
(collated
from SP and
LTSP)
71
definitions
(48 unique)
LTS:
20
definitions
(17 unique)
NP:
(collated
from NP
and CNP)
13
definitions
(11 unique)
EC:
(collated
from EC and
ES)
117
definitions
(50 unique)
HIC:
(collated
from HIC
and C)
54
definitions
(30 unique)
VC:
32
definitions
(19 unique)
NC:
16
definitions
(8 unique)
RP:
(collated
from RP
and FP)
90
definitions
(51 unique)
Rapid progression/viral non-control extreme:
7 terms
Terms with > 10 definitions:
2 terms
Slow progression/viral control extreme
26 terms, 600 definitions
Rapid progressionn/viral non-control extreme
8 terms, 114 definitions
Fig. 2. Data synthesis: a process for collapsing and categorizing individual terms and definitions. C, controller; CNP, clinical
nonprogressor; EC, elite controller; ES, elite suppressor; FP, fast progressor; HIC, HIV controller; LTNP, long-term nonprogressor;
LTS, long-term survivor; LTSP, long-term slow progressor; NC, noncontroller; NP, nonprogressor; RP, rapid progressor; SP, slow
progressor; VC, viremic controller.
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thresholds were applied to different components in a
definition (e.g., duration of asymptomatic follow-up,
duration of CD4þ cell level below a threshold), only the
greatest duration was considered, as this would be the
minimum duration of follow-up needed to meet the
criteria for a given definition. When multiple HIV-RNA
assays were used, the assay with the highest threshold for
lower limit of detection was considered.
After collapsing, definitions with a distinct combination
of components and component thresholds/categories
were identified as being unique. The proportion of
unique definitions was calculated for each term. This
proportion reflects the heterogeneity of definitions in
literature. We ranked definitions identified in this way by
frequency of occurrence, and listed the most common
definitions for each term. The salient features of each
definition were listed based on common components
identified across definitions, to describe the most
common components used to define terms referring to
HIV extreme phenotypes in the literature. We also
compared the frequency of component thresholds used in
definitions of different terms, in order to assess the overlap
of components and component thresholds/categories
between definitions of different terms.
Results
On reviewing 501 articles, 600 definitions were listed for
26 terms used to describe slow progression/viral control
extremes in HIV infection and 114 definitions for eight
terms used to define fast progressor/viral noncontrol
extremes in HIV infection (Fig. 2). The various terms
used to describe these extremes in the literature are
outlined in Table 1. Following collapsing of terms under
broad groups, 19 terms for slow progression/viral control
phenotypes and seven terms for rapid progression/
noncontrol phenotypes were examined (Table 1, Fig. 2).
Of the 26 terms listed, only nine terms that included
more than 10 definitions each, were considered for
further analysis (Fig. 2). The most common terms used in
studies of slow progression extremes were ‘LTNP’ (265
instances), followed by ‘slow progressor’ (71 instances;
Table 1), ‘long-term survivor (LTS)’ (20 instances), and
‘nonprogressors’ (13 instances). Common terms used to
describe the extreme of viral control were ‘elite con-
trollers/elite suppressors’ (117 instances), ‘viremic con-
troller’ (32 instances), and ‘HIC/controller’ (54 instances;
Table 1). Fewer terms were identified for the rapid
progression extremes in HIV infection, with 90 instances
of ‘rapid progressors/fast progressors’ (Table 1). For the
extreme of noncontrol of HIV, ‘noncontroller’ was the
commonest term used, with 16 definitions appearing in
the literature.
We also examined the pattern of term usage by time of
publication. We observed a greater diversity of terms used
to describe viral control and noncontrol phenotypes in
the period 2006–2012 as compared to the literature
published between 2000 and 2005 (Fig. 3). Notably,
terms pertaining to viral control phenotypes, such as ‘elite
controller’, ‘HIC’, ‘viremic controller’, and ‘noncon-
troller’ seem to be used almost exclusively from 2006
onward, indicating the more recent interest in viral
control-related phenotypes as compared with clinical
phenotypes of nonprogression or rapid progression in
the literature.
Redundancy of definitions in the literature
The total number of definitions and the number of
unique definitions identified for each term are presented
in Table 4. Heterogeneity in definitions was high, with a
large proportion of definitions being unique for
progression (54–85%) and viral control (43–59%)-related
terms. Unique definitions for all terms can be found in
154 AIDS 2014, Vol 28 No 2
Table 3. Broad components used to collapse definitions of progression and control HIV phenotypes.
Components of slow progression/viral control phenotype
definitions (terms – LTNP, SP, LTS, NP, EC, HIC, and VC)
Components of rapid progression/viral noncontrol
phenotype definitions (terms RP and NC)
Components Component threshold/category Component Component threshold/category
Duration of follow-up Minimum duration of follow-up in years Duration of follow-up Minimum duration of follow-up in years
CD4þ cell count CD4þ cell count threshold in count/ml CD4þ cell endpoint CD4þ cell count threshold in count/ml
HIV-RNA level Plasma HIV-RNA threshold in copies/ml HIV-RNA level Plasma HIV-RNA threshold in copies/ml
Clinical symptoms Asymptomatic/AIDS-free/OI free (yes/no) CD4þ cell slope Numeric threshold of decline in cells/ml per year
CD4þ cell slope Numeric threshold of decline
in cells/ml per year or qualitative
(e.g., ‘stable’ CD4þ cell levels)
AIDS endpoint AIDS endpoint present in definition (yes/no)
Viral blips Threshold for occasional spikes in
HIV-RNA levels allowed
ART endpoint ART endpoint present in definition (yes/no)
Death endpoint Death endpoint present in definition (yes/no)
Seroconversion status Seroconversion status known (yes/no/unspecified)
ART, antiretroviral therapy; EC, elite controllers; HIC, HIV controllers; LTNP, long-term nonprogressors; LTS, long-term survivors; NC,
noncontrollers; NP, nonprogressors; OI, opportunistic infection; RP, rapid progressors; SP, slow progressors; VC, viremic controllers.
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Supplementary Tables 1–9, http://links.lww.com/
QAD/A415.
Description of extreme phenotypes in the
literature
Long-term nonprogressors
Of 265 definitions of LTNPs, 159 were unique
when combinations of duration of follow-up, CD4þ
cell thresholds, CD4þ cell slopes, clinical symptoms, and
viral load components were considered. There was
substantial variation in components and component
thresholds (Fig. 4, Supplementary Table 10, http://
links.lww.com/QAD/A415). Duration of follow-up
varied between 1 and 25 years among definitions, with
10 years being the most common duration of follow-up
required (Fig. 4). Although CD4þ cell thresholds were a
prominent feature of LTNP definitions, with 74% of all
definitions including a CD4þ cell threshold criterion,
thresholds showed marked variation across definitions
with a range between 300 and 1000 cells/ml. The most
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Fig. 3. Frequency of term usage by calendar period. AP, accelerated progressor; AVI, aviremic individual; C, controller; CLTNP,
clinical long-term nonprogressor; CNP, clinical nonprogressor; EC, elite controller; ES, elite suppressor; FP, fast progressor; HIC,
HIV controller; HVL, high viral load individual; LTA, long-term asymptomatic; LTNP, long-term nonprogressor; LTNP-C, long-
term nonprogressor controller; LTNP-EC, long-term nonprogressor-elite controller; LTNP-VC, long-term nonprogressor-viremic
controller; LTS, long-term survivor; LTSP, long-term slow progressor; LVLI, low viral load individual; MHVL, medium-high viral
load individual; NC, noncontroller; NP, nonprogressor; NVS, natural viral suppressor; RC, relative controller; RP, rapid progressor;
SFP, super fast progressor; SP, slow progressor; VC, viremic controller; VI, viremic individual; VNC, viremic noncontroller; VNP,
viremic nonprogressor; VS, viral suppressor.
Table 4. Proportion of unique definitions within each term.
Phenotype Terms Total number of definitions Unique definitions (%)
Slow progression LTNP 265 159 (60%)
SP 71 48 (69%)
LTS 20 17 (85%)
NP 13 11 (85%)
Viral control EC 117 50 (43%)
HIC 54 30 (56%)
VC 32 19 (59%)
Rapid progression RP 90 51 (54%)
Viral noncontrol NC 16 8 (50%)
EC, elite controller; HIC, HIV controller; LTNP, long-term nonprogressor; LTS, long-term survivor; NC, noncontroller; NP, nonprogressor; RP, rapid
progressor; SP, slow progressor; VC, viremic controller.
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frequent CD4þ cell threshold was 500 cells/ml (Fig. 4,
Supplementary Table 10, http://links.lww.com/QAD/
A415). A component including a HIV-RNA threshold
was less common, with only 36% of definitions including
a viral load criterion. The absence of clinical symptoms
also appeared to be a prominent criterion, with around
58% of definitions including a criterion of being
asymptomatic, without opportunistic infection or
AIDS-free. CD4þ cell slopes were also common features
of definitions, with 31% of definitions including a
criterion for stability of CD4þ cell counts (Fig. 4).
Slow progressors
Of 71 definitions identified for slow progressors, 69%
were unique with respect to the components described
(Table 4). As with LTNP definitions, duration of follow-
up was an important component, with 90% of definitions
including a criterion for minimum duration of follow-up
(Fig. 4). There was marked variation in duration
thresholds, ranging from 10 months to 16 years, the
most frequently appearing threshold being 8 years of
follow-up (Fig. 4, Supplementary Table 10, http://
links.lww.com/QAD/A415). In general, the duration of
follow-up needed to define slow progressors was lower
than that for LTNPs (Supplementary Table 10, http://
links.lww.com/QAD/A415). CD4þ cell thresholds and
the absence of clinical symptoms were also important
components, with 72 and 52% of definitions including
these, respectively (Fig. 4). As with LTNPs, a CD4þ cell
threshold of 500 cells/ml was most common, with
thresholds ranging from 200 to 1000 cells/ml (Supple-
mentary Table 10, http://links.lww.com/QAD/A415).
The frequency of various component thresholds can be
found in Supplementary Table 10, http://links.lww.com/
QAD/A415. CD4þ cell slope and HIV-RNA thresholds
were less common for these definitions, with only 21 and
20% of definitions including each of these components,
respectively (Fig. 4).
Long-term survivors
Of 20 definitions listed for LTSs, 17 were unique
(Table 4). As expected, duration of follow-up was a
prominent component with 10 years being the most
frequent threshold (Supplementary Table 10, http://
links.lww.com/QAD/A415). CD4þ cell thresholds were
also prominent components, with 12 definitions includ-
ing a threshold, the commonest being 500 cells/ml
(Table 4). Clinical criteria of symptom/AIDS-free
follow-up were also common with 50% of definitions
including this component (Table 4, Supplementary
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Slow progression phenotypes
Terms(no. of
definitions)
Components
Duration of
follow up
LTNP (n = 265)
251 (95%)
10 years
195 (74%)
500 cells/µl
96 (36%)
'low/BDL'
153 (58%)
82 (31%)
'stable'
15 (21%)
'stable'
7 (35%)
'stable' 1 (8%)
4 (3%)
'stable' 2 (4%) 2 (6%)
37 (52%) 10 (50%) 9 (69%) 15 (13%) 6 (11%) 1 (3%)
14 (20%)
10 000
copies/ml
1 (5%) 3 (23%) 100 (100%)450 copies/ml
100 (100%)
2000/400
copies/ml
100 (100%)
2 000
copies/ml
51 (72%)
500 cells/µl
12 (60%)
500 cells/µl
10 (77%)
500 cells/µl 22 (19%)
5 (9%)
'high/normal' 5 (16%)
64 (90%)
8 years
12 (60%)
10 years
11 (85%)
10 years
51 (44%)
1 year
39 (72%)
10 years
16 (50%)
1 year
SP (n = 71) LTS (n = 20) NP (n = 13) EC (n = 117) HIC (n = 54) VC (n = 32)
CD4+ count
HIV-RNA
level
Clinical
symptoms
CD4+ slope
Viral control phenotypes
Fig. 4. Predominant components and common thresholds used in definitions of slow progression/viral control terms in
HIV infection. The figure depicts the number of definitions (with proportions in parentheses) for slow progressor/viral control
terms that include specific components and component thresholds as part of the definition. The most frequent component
threshold applied for each of these also represented, where a single common threshold could be identified. BDL, below detection
limit; EC, elite controller; HIC, HIV controller; LTNP, long-term nonprogressor; LTS, long-term survivor; NP, nonprogressor; SP,
slow progressor; VC, viremic controller.
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Table 10, http://links.lww.com/QAD/A415). HIV-
RNA levels and CD4þ cell slopes appeared to be less
prominent components in these definitions.
Nonprogressors
A total of 13 definitions were identified for nonpro-
gressors, of which 11 were unique (Table 4). Duration of
follow-up and CD4þ cell threshold components were
prominent in this group, with 10 years and 500 cells/ml
being the most common thresholds, respectively. HIV-
RNA levels, clinical criteria, and CD4þ cell slopes only
appeared in a minority of definitions (Fig. 4).
Elite controllers
A total of 117 definitions were identified for elite
controllers, of which 50 were unique (Table 4). As
expected from the terminology, HIV-RNA thresholds
appeared in all definitions listed, with thresholds ranging
from 40 to 500 copies/ml (Fig. 4, Supplementary
Table 10, http://links.lww.com/QAD/A415). The most
frequent HIV-RNA threshold used was 50 copies/ml.
Only five definitions included a criterion for occasional
blips in viral load (Fig. 4). Duration of follow-up also
appeared to be important with 44% of definitions
including a minimum duration of follow-up criterion.
Duration thresholds varied from 6 months to 16 years,
with a threshold of 1 year being most frequent
(Supplementary Table 10, http://links.lww.com/QAD/
A415). CD4þ cell thresholds appeared only in 19% of
definitions, in contrast with LTNPs and slow progressors,
wherein 74 and 72% of definitions included this com-
ponent.
HIV controllers
A total of 54 definitions for HICs were identified, of
which 56% were unique (Table 4). All definitions
included a HIV-RNA threshold (Fig. 4). HIV-RNA
thresholds varied from 40 to 10 000 copies/ml, with 400
and 2000 copies/ml both being common thresholds
applied (Supplementary Table 10, http://links.lww.com/
QAD/A415). Duration of follow-up was also an
important component of these definitions, with 72% of
definitions including a cut-off for the minimum duration
of follow-up required (Fig. 4). Thresholds of 10 years and
1 year appeared to be most common for these definitions,
which can be seen as a product of the two most common
definitions of this term (Supplementary Table 10, http://
links.lww.com/QAD/A415, Table 5).
Viremic controllers
Of 32 definitions applied to viremic controllers, the
majority (59%) were unique, suggesting marked varia-
bility in definitions used (Table 4). As with elite
controllers and HICs, all definitions included a HIV-
RNA threshold (Fig. 4). Thresholds were generally
higher in comparison with elite controller definitions and
varied between 500 and 15 000 copies/ml, with a
threshold of 2000 copies/ml being most common (22/
32 definitions; Supplementary Table 10, http://
links.lww.com/QAD/A415). CD4þ cell thresholds
appeared as components in five of 30 definitions, and
there was marked variability in thresholds used (Supple-
mentary Table 10, http://links.lww.com/QAD/A415).
As with elite controllers and HICs, clinical criteria only
appeared in a minority of definitions.
Rapid progressors
Of 90 definitions identified for the terms ‘rapid
progressor’ or ‘fast progressor’, 51 definitions were
unique based on combinations of components considered
(Table 4). CD4þ cell thresholds and AIDS endpoints
appeared to be the most common components of
definitions, with 56% of definitions including a CD4þ
cell endpoint, and 48% of definitions including an AIDS
endpoint (Fig. 5). Among CD4þ cell endpoints, a
threshold of 300 cells/ml was the most frequent (Fig. 5,
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Table 5. Common definitions identified for common terms used to describe extremes in HIV infection.
Term Commonest definitiona Frequency
LTNP Asymptomatic and ART-naive for 10 years during follow-up with all CD4þ cell
counts above 500cells/ml during this period
15/265
SP Seropositive asymptomatic individuals infected for 8 or more years with a CD4þ
T-cell count above 500cells/ml in the absence of ART.
16/71
EC Spontaneously maintain viral loads below 50copies/ml without ART 33/117
HIC HIV-infected patients who had been seropositive for >10 years and had received
no ART for whom >90% of the HIV-RNA measurements were <400 copies/ml
8/54
Alternate definition: HIV-infected individuals with at least three measurements of
plasma HIV-RNA <2000copies/ml over at least a 12-month period in the absence
of ART
7/54
VC Infected with HIV and maintaining viral loads of <2000 RNA copies/ml without
ART
4/32
RP HIV infected with CD4þ T-cell counts of <300cells/ml within 3 years after the
last HIV-seronegative test
17/90
NC HIV-infected individuals with plasma HIV-RNA >10000 copies/ml without ART 6/16
ART, antiretroviral therapy; EC, elite controller; HIC, HIV controller; LTNP, long-term nonprogressor; NC, noncontroller; RP, rapid progressor; SP,
slow progressor; VC, viremic controller.
aSingle dominant definitions could not be identified for long-term survivors and nonprogressors and are, therefore, not presented here.
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Supplementary Table 11, http://links.lww.com/QAD/
A415). Time to end-point was a prominent component
of definitions, with 92% of definitions including a
duration component, the most frequent threshold being
3 years (Fig. 5, Supplementary Table 11, http://links.lww.
com/QAD/A415). Known date of seroconversion
appeared to be a prominent component, with 80% of
definitions including this (Fig. 5). However, many
definitions did not specify time since seroconversion,
including either time from diagnosis or only CD4þ cell
slope-based criteria. HIV-RNA thresholds were rare (6%)
among these definitions (Fig. 5). Death and ART
initiation were also used as endpoints in a small number
of definitions (3% each).
Noncontrollers
There were only 16 definitions of noncontrollers listed,
of which eight were found to be unique based on
combinations of components (Table 4). All definitions
included a HIV-RNA component, with 10 000 copies/ml
being the most common cut-off used (Fig. 5). CD4þ cell
endpoints were also used in two definitions (Fig. 5,
Supplementary Table 11, http://links.lww.com/QAD/
A415), but no clinical endpoints appeared in any
definition.
Common definitions of HIV phenotypes
The most frequently occurring definitions for each term
are listed in Table 5. Single dominant definitions that were
clearly much more common than others could be
identified for most terms, except HICs for whom two
common definitions were identified (Table 5). Although
common definitions are clearly identified for each term, it
can be seen that these still represent the minority of all
definitions listed (Table 5). It is also clear that, although
there are marked differences in the components of
definitions for each term, in most cases specific
component thresholds can be identified for each term
that are far more common than others (Figs. 4 and 5).
Using the most common components and component
threshold/category within components to derive com-
mon definitions produced identical results to those
produced by grouping individual definitions (Figs. 4 and
5 and Table 5). For example, the most common definition
for LTNP was an HIV-infected individual who is
asymptomatic and ART-naive for 10 years during
follow-up with all CD4þ cell counts above 500 cells/ml
during this period, which combines the most common
components and component thresholds/categories listed
for definitions of this term (Fig. 4).
Overlap between definitions
There was substantial overlap between components across
terms, with 36% of LTNP definitions including HIV-
RNA threshold criteria and 19% of elite controller and
16% of viremic controller definitions including CD4þ
cell threshold components (Fig. 4). There was marked
overlap between components and thresholds/categories
used across all slow progression terms, with substantial
overlap between components of LTNPs, slow progressors
and nonprogressors, and between viremic controller and
HICs (Supplementary Table 10, http://links.lww.com/
QAD/A415).
Broad phenotypes represented by different
terms
On the basis of our review, we sought to characterize
the broad HIV phenotypes represented by different terms
in the literature. On considering components and
component thresholds/categories of definitions for
slow progression-related terms, the clinical phenotypes
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Terms (no. of
definitions)
Components
Duration of
follow-up
RP (n = 90) NC (n = 16)
83 (92%)
3 years 0 (0%)
2 (13%)
1 (7%)
16 (100%)
10 000 copies/ml
0 (0%)
0 (0%)
0 (0%)
0 (0%)
41 (56%)
300 cells/µl
10 (11%)
5 (6%)
43 (48%)
3 (3%)
3 (3%)
72 (80%)
CD4+ endpoint
CD4+ slope
HIV-RNA levels
AIDS endpoint
ART endpoint
Death endpoint
Known date of
seroconversion
Fig. 5. Predominant components and common thresholds
used in definitions of rapid progression/noncontroller terms
in HIV infection. The figure depicts the number of definitions
(with proportions in parentheses) for rapid progressor/non-
controller terms that include specific components and com-
ponent thresholds. The most frequent component threshold
applied for each of these also represented, wherein a single
common threshold could be identified. NC, noncontroller;
RP, rapid progressor.
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represented by LTNPs, LTSs, and nonprogressors were
broadly similar, and represented individuals who main-
tained normal CD4þ cell counts, and remained healthy at
least for 10 years of observed follow-up. In general, slow
progressors represented a less stringent phenotype, and
thresholds for duration of follow-up required tended to
be lower (Supplementary Table 10, http://links.lww.
com/QAD/A415). The relative representation of viral
control phenotypes could be broadly characterized, with
elite controllers representing the most extreme phenotype
of viral control, and viremic controllers representing
higher levels of viremia (Fig. 6). For HICs, two broad
phenotypes seemed to predominate: one appeared to be
similar to elite controllers, but with control of viremia to
below 400 copies/ml over at least 10 years, and the second
encompassing elite controller and viremic controller
phenotypes (Fig. 6).
Discussion
In this systematic review, assessing 714 definitions of HIV
extreme phenotypes in 501 eligible studies, we identified
substantial variation among definitions used to describe
extreme phenotypes in HIV infection. This heterogen-
eity in definitions may represent important differences in
biological endophenotypes [14] and clinical progression
profiles [1,22] of individuals selected by these, suggesting
the need for harmonized definitions. In this context, we
were able to identify common components in existing
definitions that may provide a framework for developing
consensus definitions for HIV extreme phenotypes.
Although recent studies have focused on extreme
phenotypes in HIV infection as natural models of viral
control and the extremes of disease progression in HIV,
little is known about the impact of heterogeneity in
definitions on clinical and biological phenotypes cap-
tured. This heterogeneity has implications for the design
of studies exploring HIV biology and for the interpret-
ation of existing research. Although several studies have
referred to this marked variation in definitions, and the
need for standardized phenotype definitions [2,22],
the full extent of variability in the literature has never
been formally quantified. To our knowledge, this is
the first study that has attempted to address this in a
systematic manner. Formal evaluation of the impact of
varying definitions on clinical outcomes and characteriz-
ing biological endophenotypes is essential to develop
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Increased rate of clinical disease progression of HIV infection
LTNP, LTS and NP
EC HIC-1
HIC-2
Decrease host control of virus replication
VC NC
Remain healthy and maintain
stable CD4+ counts above 500
cells/µl for prolonged periods
(usually over ten years)
Spontaneously
maintain
undetectable
HIV RNA levels
(< 50 copies/ml)
without ART
Spontaneously
maintain HIV
RNA levels
< 400
copies/ml
for
at least 10 yrs
Spontaneously
maintain HIV
RNA levels
between 50–
2 000 copies/ml
without ART
Maintain HIV RNA levels
> 10 000 copies/ml in the
absence of ART
Remain healthy and maintain
stable CD4+ counts above 500
cells/µl for prolonged periods
(usually over 8 years)
Rapid immunological or clinical
progression characterised by a
drop in CD4+ counts to < 300
cells/µl within 3 years or
development of AIDS within 3–5
years of infection
SP RP
Fig. 6. Relative characteristics of phenotypes referred to by different terms in the literature. HIC-1 and HIC-2 refer to the two
most commonly used definitions for HIV controllers. ART, antiretroviral therapy; EC, elite controller; HIC, HIV controller; LTNP,
long-term nonprogressor; LTS, long-term survivor; NC, noncontroller; NP, nonprogressor; RP, rapid progressor; SP, slow
progressor; VC, viremic controller.
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harmonized definitions that will represent clinical and
biological phenotypes of interest.
Understanding the impact of variability in phenotype
definitions on clinical outcomes in HIV is important, as
the literature suggests that small variations in phenotype
definitions can substantially impact the trajectory of
disease progression in patients selected. In one study,
varying the duration of follow-up threshold for LTNPs
resulted in the selection of groups with markedly different
survival times [1]. A recent study showed that allowing for
at least one nadir CD4þ cell count below 500 cells/ml
among LTNPs can lead to a significant reduction in the
time to disease progression compared with individuals
who maintain all CD4þ cell counts above this threshold
[22]. This is consistent with research within the French
Hospital Database that showed that a positive CD4þ cell
slope was a more selective criterion than a longer duration
of HIV infection (10 years instead of 8 years), for selecting
patients who were asymptomatic and ART-naive several
years after being infected by HIV [2]. Similar findings
have been demonstrated with viral control phenotypes;
individuals with viral loads less than 50 copies/ml (elite
controllers) have markedly improved AIDS-free survival
compared with individuals with viral loads between 50
and 2000 copies/ml [1]. Prevalence of phenotypes
represented can also vary markedly with small changes
in definitions. For example, in the French Hospital
Database, increasing the CD4þ cell threshold in LTNPs
from 500 to 600 cells/ml changed the prevalence of the
phenotype from 22 to 11% in the cohort, and addition of
a criterion for positive CD4þ cell slope further reduced
the prevalence to 2.8% [2]. This is of particular relevance
to studies that aim to recruit individuals with extreme
phenotypes for further characterization of mechanisms of
immune-virological control.
Variation in extreme phenotype definitions may also
impact on the underlying biological endophenotype
being examined. Our study suggests that there is marked
overlap between components of definitions referring to
different terms in the literature, which makes it difficult to
delineate phenotypes represented by different terms. It is
important to distinguish these terms in the literature, as
different phenotypes may capture different underlying
biology. Indeed, it has been shown that protective and
high-risk alleles known to be associated with disease
control and progression in HIV infection, show a graded
change in frequency along the clinical spectrum of disease
[14]. The limited overlap between LTNP and EC
phenotypes in some studies, with only 8–32% of LTNPs
meeting criteria for elite control [2,22,23], suggests that
slow progression and viral control phenotypes are only
modestly correlated, and may potentially represent
distinct biological phenotypes. A recent genome wide
association study further substantiated this with the
discovery of a new locus associated with LTNP,
when individuals who were EC (HIV-RNA levels
<100 copies/ml) were excluded from the cohort [19],
suggesting that the determinants of viral control and slow
progression phenotypes may be distinct.
Major strengths of our study include the comprehensive
search strategy applied and the large number of articles
reviewed. As the correlation between the studies short-
listed for review by the two reviewers was high (>95%),
there is unlikely to be substantial observer bias in the
review process. We acknowledge that our review of
definitions also has several limitations. Our search strategy
was only restricted to one search engine, to published
articles, and to articles available after the 1 January 2000,
which may have limited the sensitivity of the search.
Additionally, we did not examine definitions by
differences in HIV subtypes and clades, and extreme
phenotypes represented by definitions in these groups
may differ. In spite of these limitations, we believe that
our review is a fair representation of the heterogeneity in
definitions observed in the literature, and the lower
sensitivity of the review would only underestimate
existing heterogeneity among definitions. Moreover, to
our knowledge, this is the first attempt to formally
characterize the variability in definitions of these terms in
literature, and identify common components used to
define these terms.
Given the possible differences in biological and clinical
phenotypes captured by different definitions, it is
important to standardize case definitions of these
phenotypes for consistency in methods and ease of
interpretation across studies. Although the various studies
described have provided clues to the clinical and
biological correlates of different definitions, the literature
examining this is limited and further research specifically
addressing variation in these phenotypes with varying
definitions of phenotypes is essential to develop a
framework for consensus definitions.
Several attributes of definitions must be considered when
formulating consensus definitions. First, phenotype
definitions should capture a truly extreme phenotype,
as sampling from extremes can be a powerful way to
examine HIV biology. This approach has been shown to
be effective [19,24,25] in identifying genetic variants
associated with HIV control and progression. Second,
definitions should represent biologically relevant endo-
phenotypes, so that underlying biology associated with
these can be examined efficiently. Further research
specifically examining the heritability and underlying
biology of different phenotypes is needed in order to
establish which phenotypes are likely to be most
biologically relevant. Third, the phenotype definition
should include components that are clinically relevant and
adequately stable to predict long-term clinical outcomes.
It is also important that the components described can be
easily assessed and data for these can be readily extracted
from existing cohorts. This would require systematic
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assessment of clinical outcomes of commonly used
definitions in large-scale consortia, which have adequate
numbers of these rare individuals, and appropriate data on
seroconversion and detailed clinical outcomes. While
ascertaining the most useful definitions for extreme HIV
phenotypes is challenging, our study shows that in spite of
the large amount of heterogeneity observed in defi-
nitions, common components and thresholds used in
definitions can be identified for most terms, indicating
that there are common threads that have been used to
define these groups in the literature, which could provide
the framework for consensus definitions. Further work
specifically examining the biological characteristics and
differences in clinical progression, among these groups of
individuals is needed in order to inform the utility of
different definitions in HIV research.
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Abstract
Background: Understanding the mechanisms underlying viral control is highly relevant to vaccine studies and elite control
(EC) of HIV infection. Although numerous definitions of EC exist, it is not clear which, if any, best identify this rare
phenotype.
Methods: We assessed a number of EC definitions used in the literature using CASCADE data of 25,692 HIV seroconverters.
We estimated proportions maintaining EC of total ART-naı¨ve follow-up time, and disease progression, comparing to non-EC.
We also examined HIV-RNA and CD4 values and CD4 slope during EC and beyond (while ART naı¨ve).
Results: Most definitions classify ,1% as ECs with median HIV-RNA 43–903 copies/ml and median CD4.500 cells/mm3.
Beyond EC status, median HIV-RNA levels remained low, although often detectable, and CD4 values high but with strong
evidence of decline for all definitions. Median % ART-naı¨ve time as EC was $92% although overlap between definitions was
low. EC definitions with consecutive HIV-RNA measurements ,75 copies/ml with follow-up$ six months, or with 90% of
measurements ,400 copies/ml over $10 year follow-up preformed best overall. Individuals thus defined were less likely to
progress to endpoint (hazard ratios ranged from 12.5–19.0 for non-ECs compared to ECs).
Conclusions: ECs are rare, less likely to progress to clinical disease, but may eventually lose control. We suggest definitions
requiring individuals to have consecutive undetectable HIV-RNA measurements for $ six months or otherwise with .90%
of measurements ,400 copies/ml over $10 years be used to define this phenotype.
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Introduction
HIV is typically characterised by a period of viral replication
and CD4 cell decline leading to AIDS and death in the absence of
antiretroviral therapy (ART). [1] Differences in the evolution of
both markers over time, however, result in large variations in
disease progression among HIV-positive individuals. [2,3] The
long-term non-progressor (LTNP) phenotype was initially de-
scribed to characterise individuals who experienced slow disease
progression and stable CD4 counts over a number of years. [4,5]
With the introduction of HIV-RNA assays in the mid-1990s,
research shifted to focus on mechanisms which lead to control of
viral replication [6].
A small proportion of individuals have been described who are
able to suppress viral replication to undetectable levels for
extended periods of time without use of ART, delaying the onset
of AIDS. [7,8] Many terms are used in the literature for such
individuals, with the most common being elite controllers (EC). [8]
Mechanisms of EC remain unclear, although it is now believed
that host response, including CD4 and CD8 T cell-specific
immune response, [9,10] as well as HLA Class I alleles, [11] are
likely to be the main mechanisms of control, rather than infection
by defective virus, as initially postulated. [12] Whatever the
mechanisms, a study of this group of individuals gives potential for
the development of new treatment strategies, can guide research
on HIV vaccines,[13–16] and provide models for a functional cure
of HIV [17,18].
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Since the publication of initial definitions of EC, as was the case
with the long-term non-progressor (LTNP) phenotype, many more
definitions have been proposed; presumably to arrive at one
definition which best defines true EC. There are currently
numerous definitions, each of which differs by the follow-up time
required and the number and threshold of undetectable HIV-
RNA measurements.[6–8,15,16,19–23] It is not known which, if
any, best characterise this rare phenotype, however. This is
important to ensure that any difference between elite controllers
and non-controllers can be attributed to the phenotype itself. An
assessment of the relative merits of each definition has never been
undertaken or a comparison between them preformed.
The CASCADE (Concerted Action on SeroConversion on
AIDS and Death in Europe) Collaboration, of HIV-positive
individuals followed-up since HIV seroconversion, offers a unique
opportunity to assess the ability of these definitions to capture EC.
Using data from CASCADE, we aimed to evaluate a number of
commonly-used definitions to estimate prevalence of EC and
associated factors, proportion of total follow-up time spent as elite,
and to describe CD4 and HIV-RNA values during EC and
beyond the EC period.
The work provides the basis for choosing a definition
appropriate to the objectives of future research on this rare
phenotype.
Materials and Methods
Study Population
We used pooled data from the CASCADE September 2011
data release in EuroCoord (www.EuroCoord.net), which consists
of 25,629 seroconverters from 28 cohorts across Europe, Canada,
Australia and sub-Saharan Africa. [24] Date of seroconversion is
estimated by various methods, most commonly as the midpoint
between the last documented HIV negative and the first positive
HIV antibody test dates with an interval of ,3 years between the
two test dates (85%). For the remainder, date of seroconversion
was estimated through laboratory evidence of seroconversion
(PCR positivity in the absence of HIV antibodies or antigen
positivity with fewer than four bands on Western blot) (13%), or as
the date of a seroconversion illness (2%) with both an earlier
documented negative and a later positive HIV test not more than
3 years apart. Anonymized data for the CASCADE collaboration
are collected and stored at the Medical Research Council Clinical
Trials Unit at University College London. Access is available to
bona fide researchers through submission of a proposal to the
Steering Committee which is reviewed by CASCADE investiga-
tors.
Elite Control Definitions
We undertook a systematic review of the literature, which is
described elsewhere [25]. Briefly, we searched for terms previously
used to describe control of HIV infection including ‘‘Long term
non-progressors’’, ‘‘LTNP’’, ‘‘elite controller’’, ‘‘elite control’’,
‘‘viral controller’’ and ‘‘viral control’’ and evaluated 10 EC
definitions (Table 1).[6–8,15,16,19–23] The list of definitions
included in this paper is not intended to be exhaustive; rather it is
representative of the spectrum by which the elite control
phenotype is defined in the literature. Three definitions were
most commonly used, all requiring HIV positive individuals to
meet the following criteria while ART-naive and AIDS-free: 1)
Definition E, used by the International HIV Controllers Consor-
tium, of individuals who maintain HIV-RNA levels below 75
copies/mL for at least 1 year, [8] 2) Definition F, an adaptation of
definition E allowing no previous HIV-RNA levels .1000 copies/
ml, [6] and 3) Definition J, initially proposed by the ANRS, of
individuals known to be HIV positive for$10 years with$2 HIV-
RNA measurements, $90% of which were required to be ,400
copies/ml [7].
Statistical Methods
We identified three groups of individuals for each definition:
those who fulfilled it, those who did not, and those whose EC
status could not be determined, e.g. because insufficient follow-up
or ART-naive HIV-RNA measurements were not available. For
each definition we estimated the proportion of EC excluding
individuals whose EC status was unknown from the denominator.
Because there were large numbers with unknown status, we also
estimated proportion of EC by assuming them to be non-EC and
including them in the denominator, thus providing minimum
proportion estimates.
For each definition we estimated the proportion of time they
remained as EC by considering all available ART-naive follow-up.
To estimate the effect of EC status on disease progression we
restricted entry to the risk set at 10 years post seroconversion, as
this was the longest duration of follow-up required by all
definitions considered, and used multivariable time dependent
Cox proportional hazards models to estimate the hazard ratio for a
Table 1. 10 definitions of elite control from the literature applied to the CASCADE dataset; all require individuals to be AIDS-free
and ART-naı¨ve.
Definition
A HIV-positive $6 months, with $2 consecutive HIV-RNA ,75 copies/ml [22]
B HIV-positive $1 year, with $1 HIV-RNA ,50 copies/ml [16]
C HIV-positive $1 year, with $1 HIV-RNA ,75 copies/ml [15]
D HIV-positive $1 year, with $3 HIV-RNA ,2000 copies/ml [21]
E HIV-positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months [8]
F HIV-positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml [6]
G HIV-positive $2 years, with $2 HIV-RNA ,75 copies/ml [19]
H HIV-positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml [23]
I HIV-positive $10 years, with all measured HIV-RNA ,50 copies/ml [20]
J HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml [7]
doi:10.1371/journal.pone.0086719.t001
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composite endpoint of AIDS, death (all cause), ART initiation or
CD4,350 cells/mm3 comparing non-ECs and unknowns to ECs.
We formally tested differences in hazard ratios between the
definitions by using 1000 bootstrap replicates. Definition I was
excluded from the bootstrap analysis as there were few follow-up
measurements among a small number of elite controllers providing
unstable estimates.
We described median and interquartile ranges (IQR) of HIV-
RNA and CD4 levels, based on median individual values, while
classified as EC and during total ART-naı¨ve follow-up time. CD4
slopes were estimated using a linear mixed model on the square
root scale, while classified as an elite controller, and also during
total ART-naı¨ve follow-up time.
Results
Data from 28 cohorts of 25,692 individuals formed the base
from which sub-populations of EC and non-EC were drawn
according to each definition. Median (IQR) year of HIV
seroconversion was 1999 (1992, 2005) and median age at
seroconversion 31 years (25, 37). HIV risk groups were MSM
(55%), MSW (26%) or IDU (14%), and the majority were male
(78%).
Proportion Classified as EC and Patient Characteristics
The proportion classified as EC by each definition was 0.15–
7.70% and did not necessarily reflect the length of follow-up
required by the definition (Table 2). While variations in age, sex
and risk group were observed for each definition, no consistent
differences were observed across definitions.
The number of individuals fulfilling two definitions was
generally low with 33% of individuals overlapping by ,30% with
another definition (Table 3).
Total Time Spent as EC
The risk of composite endpoint was consistently significantly
higher for non-EC/unknown compared to ECs for all definitions,
with hazard ratios ranging from 2.9–19.0 and being greatest for
definitions A, E, F and J (Table 4). 1000 bootstrap replicates
confirmed the superiority of A, E and F (a= 0.05) above
definitions B, C, D, G and H, the former 3 definitions not being
statistically different from each other. Definition J was not
statistically superior to any other definition.
Considering all available ART-naı¨ve follow-up from serocon-
version, the proportion of time spent as EC, according to each
definition, was remarkably high with median follow-up$92% for
all definitions, although 25% of EC, according to definitions C, D
and F, spent #72% of their ART-naı¨ve follow-up time as EC
(Table 4). Figure 1 illustrates total ART-naive follow-up for all
individuals classified as EC by definitions A, E, F, and J.
HIV-RNA and CD4 Values during EC Status
Median HIV-RNA during the time of EC was generally low for
all definitions varying from 35–903 copies/ml and median CD4
levels high at .500 cells/mm3 (Table 5). There was strong
evidence of CD4 loss during this EC period, however, for at least 5
of the 10 definitions considered. For the remaining definitions,
Table 2. Number of elite controllers (EC), their proportion, and demographic characteristics applying the CASCADE dataset to 10
definitions of EC found in the literature.
Def.
EC
(n)
Non-EC
(n)
Unknown{
(n)
EC
Proportion
Best
Estimate`
n (%)
EC
Proportion
Minimum
Estimate
n (%)
Seroconversion
Age (Median)
Male
(%)
MSM
(%)
IDU
(%)
MSW
(%)
ECs
Non
ECs ECs
Non
ECs ECs
Non
ECs ECs
Non
ECs ECs
Non
ECs
A 282 20951 4396 1.33 1.10 32 31 74 78 53 57 11 11 32 27
B 495 19568 5566 2.47 1.93 32 31 79 78 59 56 15 11 23 28
C 827 19236 5566 4.12 3.23 32 31 74 78 54 56 11 11 31 27
D 1416 16964 7249 7.70 5.52 30 31 67 79 49 58 11 10 36 27
E 174 17160 8295 1.00 0.68 33 31 75 78 52 57 13 10 30 28
F 95 17239 8295 0.55 0.37 32 31 63 78 37 57 18 10 38 28
G 392 16891 8346 2.27 1.53 32 31 76 77 55 56 12 11 30 28
H 146 10899 14584 1.32 0.57 31 30 74 77 47 55 18 13 29 27
I 10 6694 18925 0.15 0.04 26 29 80 77 30 53 60 18 0 25
J 47 6554 19028 0.71 0.18 31 29 74 77 34 53 28 17 30 25
{Individuals in the cohort without adequate follow-up or number of HIV-RNA measurements to classify them as EC or non-EC.
`Based on number of seroconverters whose EC status could be determined.
HIV risk groups: MSM: Men who have sex with men; IDU: Injection drug users; MSW: Heterosexual contact.
Assuming all individuals with unknown EC status are non-EC.
A: HIV-positive$6 months, with$2 consecutive HIV-RNA,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-RNA,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning
$12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml, G:HIV- positive $2
years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml, I: HIV- positive $10 years, with all measured HIV-RNA
,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t002
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slopes were either level (no strong evidence of CD4 loss) or
otherwise with a statistically significant positive slope. Such
positive slopes are likely due to short follow-up, chance, or
possibly informative censoring, as follow-up is censored for those
with a negative slope once ART is initiated [26]. Median HIV-
RNA, CD4 values and CD4 slopes during EC status excluding
counts within 6 months of seroconversion showed similar results
(data not shown).
HIV-RNA and CD4 Values during Total ART-naı¨ve Follow-
up
As expected, throughout available ART-naı¨ve follow-up,
median HIV-RNA values were generally higher, and CD4 counts
lower than those considering only the time spent as EC.
Nevertheless, median HIV-RNA throughout ART-naı¨ve follow-
up was low, ,200 copies/ml for most definitions, and median
CD4 values were .500 cells/mm3 for all definitions (Table 5).
Table 3. Two-way overlap of 10 definitions of elite control found in the literature applied to the CASCADE dataset.
Def. A, n (%) B, n (%) C, n (%) D, n (%) E, n (%) F, n (%) G, n (%) H, n (%) I, n (%) J, n (%) Total
A – 195 (39) 279 (34) 275 (19) 174 (100) 95 (100) 250 (64) 113 (77) 4 (40) 35 (74) 282
B 195 (69) – 495 (60) 341 (24) 119 (68) 45 (47) 286 (73) 94 (64) 10 (100) 36 (77) 495
C 279 (99) 495 (100) – 542 (38) 174 (100) 95 (100) 392 (100) 133 (91) 10 (100) 42 (89) 827
D 275 (98) 341 (69) 542 (66) – 174 (100) 95 (100) 354 (90) 146 (100) 4 (40) 41 (87) 1416
E 174 (62) 119 (24) 174 (21) 174 (12) – 95 (100) 165 (42) 95 (65) 3 (30) 31 (66) 174
F 95 (34) 45 (9) 95 (11) 95 (7) 95 (55) – 91 (23) 53 (36) 3 (30) 25 (53) 95
G 250 (89) 286 (58) 392 (47) 354 (25) 165 (95) 91 (96) – 125 (86) 6 (60) 41 (87) 392
H 113 (40) 94 (19) 133 (16) 146 (10) 95 (55) 53 (56) 125 (32) – 3 (30) 29 (62) 146
I 4 (1) 10 (2) 10 (1) 4 (0) 3 (2) 3 (3) 6 (2) 3 (2) – 6 (13) 10
J 35 (12) 36 (7) 42 (5) 41 (3) 31 (18) 25 (26) 41 (10) 29 (20) 6 (60) – 47
Total 282 495 827 1416 174 95 392 146 10 47
Example: 95 seroconverters were classified as EC by definition F of whom 25 (26%) were classified as EC by definition J. Conversely, of 47 seroconverters classified as EC
by definition J, 25 (53%) were classified as EC by definition F.
A: HIV-positive$6 months, with$2 consecutive HIV-RNA,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-RNA,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning
$12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml, G:HIV- positive $2
years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml, I: HIV- positive $10 years, with all measured HIV-RNA
,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t003
Table 4. Estimated hazard ratios comparing non-elite controllers (EC) and unknown to EC for time from estimated HIV
seroconversion to a composite endpoint of AIDS, Death, ART, or CD4,350 cells/mm3 restricting entry to the risk set at 10 years
post seroconversion using the CASCADE dataset applied to 10 definitions of EC found in the literature.
Def.
EC evaluated (experiencing
composite endpoint) n (n){{
HR for time to composite
endpoint{ (95% CI)
% (IQR) ART-naı¨ve follow-up
time classified as EC
A 46 (4) 12.5 (4.7, 33.6) 100 (78–100)
B 53 (11) 4.6 (2.5, 8.3)` 100 (78–100)
C 86 (18) 4.8 (3.0, 7.7)` 99 (72–100)
D 134 (35) 4.0 (2.8, 5.7)` 97 (71–100)
E 36 (2) 19.0 (4.7, 76.4) 100 (78–100)
F 26 (5) 15.3 (3.8, 61.3) 92 (66–100)
G 60 (9) 7.5 (3.9, 14.5)` 100 (86–100)
H 56 (22) 2.9 (1.9, 4.4)` 100 (75–100)
I 4 (1) 3.4 (0.5, 24.0) 100 (100–100)
J 35 (3) 13.2 (4.2, 41.3) 100 (98–100)
{{Number of Elites making it to 10 years follow up without experiencing composite endpoint and number subsequently experiencing composite endpoint.
{Hazard ratios comparing ECs to Non-ECs (including those with unknown EC status) allowing for late entry at 10 years. For each definition, p-values were obtained from
unadjusted log-rank test for time to composite endpoint and were all highly significant p,0.001.
`Statistically different HRs compared to definition E, F, and A from 1000 bootstrap replicates. No definitions were statistically different from definition J at a= 0.05.
A: HIV-positive$6 months, with$2 consecutive HIV-RNA,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-RNA,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning
$12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml, G:HIV- positive $2
years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml, I: HIV- positive $10 years, with all measured HIV-RNA
,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t004
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Of note, however, CD4 slopes during total ART-naı¨ve follow-
up were significantly negative (a= 0.05) for all but one definition.
HIV-RNA and CD4 values and CD4 slopes showed consistent
results when CD4 values within 6 months of seroconversion were
excluded (data not shown).
Discussion
Using the large size of the CASCADE dataset we were able to
provide reliable estimates of the proportion likely to be elite
controllers in an HIV-positive population. Our findings confirm
that, by whichever definition, elite control is a rare phenotype
likely to comprise around 1% of individuals. This is in line with
estimates reported by others [7,8,23] although it should be noted
that the choice of denominator may distort the proportion (for
example, considering all individuals regardless of their length of
follow-up or HIV infection duration will tend to under-estimate
this proportion of ECs). Interestingly, we also find evidence that
ECs may eventually lose control of viraemia.
Definitions A, E, F and J which require low consecutive or a
high proportion of low HIV-RNA measurements are best at
capturing individuals with the slowest disease progression. When
restricting the dataset to those with 10 years of follow-up,
definitions A, E and F and J demonstrated the lowest hazard of
AIDS, Death, ART or CD4,350 cells/mm3 compared to
definitions with single measurements or higher levels of viremia.
Definition J, with the longest follow-up of 10 years was not
significantly different from all other definitions, although this is
likely due to low numbers of individuals classified by this
definition.
The proportion classified as EC varied according to each
definition, with definition D, requiring an HIV-RNA threshold of
,2000 copies/ml, classifying the greatest proportion as EC. This
definition performed particularly poorly overall with the highest
median HIV-RNA and fastest CD4 cell loss while classified as EC
and during ART naı¨ve follow-up. Given that the lower limit for
available assays has been less than 1000 copies/ml for at least 10
years, inclusion of 2000 copies/ml limit is justifiably termed ‘‘viral
controllers’’ rather than EC. The requirement of only one HIV-
RNA measurement below a certain threshold (B and C) also
resulted in relatively high proportions of EC (2.47% and 4.12%,
respectively), agreeing with studies previously reporting propor-
tions of individuals with $1 HIV-RNA undetectable [27,28], and
suggesting that one undetectable measurement is insufficient in
defining EC status. HIV-RNA values were relatively high during
EC period for both definitions with the upper quartile experienc-
ing HIV-RNA values .8000 copies/ml. Similarly, even while
classified as EC, CD4 cell counts were significantly declining.
Thus, the use of at least two HIV-RNA counts results in more
Figure 1. Total ART-naı¨ve follow-up time spent as an elite controller for 4 of the best performing definitions: a) A , b) E , c) F ,and
d) J using the CSCADE dataset. A: HIV-positive $6 months, with $2 consecutive HIV-RNA ,75 copies/ml; E: HIV- positive $1 year, with $3
consecutive HIV-RNA ,75 copies/ml spanning $12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12
months with no previous blips $1000 copies/ml, J: HIV- positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.g001
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robust measures of stable viraemia and thus captures individuals
with lower risk of disease progression.
In contrast, definitions I, J, E and F had the lowest proportion
classified as EC varying between 0.15–1.00%. While this is
expected for definitions that required ten years of follow-up (I and
J), definition E and F, requiring only one year follow-up seemed to
capture an equally rare group. The proportion of EC according to
definition F was much lower than for definition E, indicating that
inclusion of a criterion and threshold for viral blips, as defined by
spikes in viral replication and subsequently maintaining control,
does impact the group of individuals captured by the definition.
This is consistent with studies suggesting that blips are not
uncommon among elite controllers. [7,29] In addition to selecting
for a rare group, definitions E, F and J also selected groups with
the lowest risk for the composite outcome, suggesting that these
definitions capture a rare and extreme group on the clinical
spectrum of HIV infection. Unsurprisingly, definition I led to the
classification of the smallest proportion (0.15%) of EC. This is the
most stringent definition as all HIV-RNA measurements needed to
have been quantified by assays with a lower limit of detection ,50
copies/ml for $10 years. The denominator from which this
population has been drawn is, by definition, limited to the most
recent period when routinely used assays had such low detection
limits. Median HIV-RNA and CD4 values for those classified as
EC by this definition are based on few measurements and are,
therefore, unreliable.
Interestingly, a greater duration of follow-up did not necessarily
lead to a more clinically-extreme group of individuals being
identified, as definition E and J performed similarly, in spite of E
requiring only 1 year of follow-up. There were 16 individuals
classified by J but not by E. Six of these 16 were known to have
naı¨ve HIV-RNAs between 75 and 400 copies/ml, while HIV-
RNA for the remaining 10 individuals were measured using assays
with a 400 copies/ml lower detection threshold. Of 143
individuals classified as EC by E but not by J, 113 had ,10
years of naı¨ve follow-up. It may, therefore, be that overlap could
be greater had all individuals been measured for the same duration
with similar assays. In addition, median CD4 counts, HIV-RNA
levels and CD4 slopes during the ART-naı¨ve period were also
similar for these definitions. This observation may have important
implications for the design of future studies, as it seems to suggest
that stringent definitions requiring only one year of follow-up, with
consecutive undetectable HIV-RNA measurements, can identify
an extreme group comparable to that identified by definitions
requiring much longer follow-up and higher HIV-RNA threshold.
There is, therefore, potential to sampling of participants in such
studies from a much wider cohort of individuals.
It is important to note that, despite the fairly low levels of
viraemia in individuals classified as EC over extended periods,
there was strong evidence of CD4 cell loss, the exception being
those classified as EC by definition I, which was based on relatively
few measurements. Whether true LTNP status exists remains
unknown [30,31]. Our findings lead us to conclude, however, that
this is unlikely among elite controllers.
Our study has several strengths. First, the large size of our
cohort allows us to make reliable comparisons of different
definitions of such a rare group of individuals. Second, the
availability of seroconversion information allows for a meaningful
assessment of time to clinical outcomes to be made. Finally, and
most importantly, until now, examination of CD4 and HIV-RNA
changes in studies has been restricted to the period in which HIV-
positive individuals fulfil the respective definition. [29,32,33] Due
to the detailed information available to us, we were able to study
evolution of both these markers over an extended period of follow-
up, beyond the duration of EC as defined.
The main limitation to this study is for each definition, the
number of individuals with unknown EC classification varied
which could have introduced bias in proportion estimates. This is
most evident in definition J, requiring .2 HIV-RNA measure-
ments and at least 10 years of follow-up with .19,000 individuals
Table 5. HIV-RNA and CD4 values and estimated CD4 slope during elite control (EC), and throughout ART-naı¨ve follow-up using
the CASCADE dataset applied to 10 definitions of EC found in the literature.
Def. During Elite Control During ART-naı¨ve follow-up
HIV-RNA value CD4 Value CD4 slope{ (95% CI) HIV-RNA value CD4 Value CD4 slope{ (95% CI)
A 50 (35, 276) 675 (454, 877) 0.04 (0.01, 0.08) 66 (35, 495) 654 (441, 840) 20.09 (20.12, 20.06)`
B 425 (35, 11641) 573 (409, 792) 20.16 (20.19, 20.12)` 1043 (89, 13000) 548 (404, 751) 20.28 (20.30, 20.25)`
C 354 (50, 8700) 596 (427, 796) 20.18 (20.21, 20.15)` 660 (75, 11066) 567 (415, 764) 20.31 (20.34, 20.29)`
D 903 (287, 1863) 615 (478, 789) 20.27 (20.29, 20.25)` 1274 (370, 3304) 590 (451, 756) 20.43 (20.45, 20.41)`
E 50 (35, 81) 699 (528, 922) 0.06 (0.01, 0.10) 50 (35, 165) 681 (527, 909) 20.06 (20.10, 20.02)
F 50 (35, 50) 839 (654, 1070) 0.05 (20.00, 0.11) 50 (35, 77) 796 (629, 1020) 20.08 (20.13, 20.03)
G 113 (49, 1197) 644 (439, 824) 20.06 (20.09, 20.03)` 176 (50, 2160) 625 (438, 806) 20.15 (20.18, 20.13)`
H 76 (35, 283) 697 (541, 879) 20.09 (20.12, 20.05)` 89 (35, 356) 687 (530, 879) 20.23 (20.26, 20.20)`
I 35 (1, 35) 583 (575, 905) 20.07 (20.24, 0.09) 35 (1, 35) 583 (575, 905) 20.05 (20.21, 0.11)
J 50 (35, 127) 783 (628, 970) 20.03 (20.09, 0.02) 50 (35, 169) 740 (583, 970) 20.11 (20.16, 20.06)`
Note- all values unless otherwise stated are median (IQR).
{CD4 slope modelled on the square root scale with linear mixed models, specific p-values for CD4 slope and median number of CD4 measurements are presented in
Table S1.
`CD4 slope highly significant p,0.001.
T- Number of total CD4 and HIV-RNA measurements A: HIV-positive $6 months, with $2 consecutive HIV-RNA ,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-
RNA ,50 copies/ml, C: HIV- positive $1 year, with $1 HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year,
with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning$12 months with
no previous blips $1000 copies/ml, G:HIV- positive $2 years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/
ml, I: HIV- positive $10 years, with all measured HIV-RNA ,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t005
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with either insufficient follow-up or number of HIV-RNA
measurements. To examine the impact of missing data on this,
for each definition we classified individuals with inadequate
information (insufficient number of HIV-RNA measurements or
follow-up requirements specified by the definition) as EC and then
as non-EC. The proportion of EC; however, may theoretically
range from 0.04, if all unknowns are classified as non-EC, to 74%,
if all unknowns are classified as EC (data not shown) indicating the
difficulties with estimating the true proportion of this group in the
presence of missing data. In spite of these possible limitations, our
study highlights important differences captured by different EC
definitions.
In conclusion, identification of a rare and extreme group may
be possible even with definitions requiring a relatively short period
of follow-up. We have shown that definitions requiring 6 months
or more of follow-up with consecutive measurements requiring
HIV-RNA #75 copies/ml preform just as well as definitions
requiring $10 years follow-up with HIV-RNA measured using
assays with a higher detection limit. Although Definition E
preforms best overall in terms of percent classified, time to
composite endpoint, percent of naı¨ve follow-up time spent as EC,
HIV-RNA, and CD4 decline, definition A (2 consecutive HIV-
RNA ,75 copies/ml over 6 months), F (similar to E, but not
allowing for blips above 1000 copies/ml) and J (10 years of follow-
up with 90% HIV-RNA,400 copies/ml) also have their merits. It
is unlikely, however, that elite control is an indefinite state, and
that the few HIV-positive individuals who spontaneously control
HIV replication may eventually need treatment or develop AIDS
given the on-going, albeit slow, CD4 cell loss. However, ECs are
much less likely to progress to clinical disease compared with non-
ECs, and a better understanding of the mechanisms that lead to
such control over extended periods may lead to new therapeutic
strategies or the development of HIV vaccines.
Supporting Information
Table S1 Number of HIV-RNA and CD4 measurements
during elite control and ART naı¨ve follow-up, time from
SC to first HIV-RNA and number of HIV-RNA measure-
ments within 6 months of HIV positive test date using
the CASCADE dataset from 10 definitions found in the
literature. Note- all values unless otherwise stated are median
(IQR) {CD4 slope modelled on the square root scale with linear
mixed models A: HIV-positive $6 months, with $2 consecutive
HIV-RNA ,75 copies/ml; B: HIV- positive $1 year, with $1
HIV-RNA ,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3
HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3
consecutive HIV-RNA ,75 copies/ml spanning $12 months F:
HIV- positive $1 year, with $3 consecutive HIV-RNA ,75
copies/ml spanning $12 months with no previous blips $1000
copies/ml, G:HIV- positive $2 years, with $2 HIV-RNA ,75
copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-
RNA ,500 copies/ml, I: HIV- positive $10 years, with all
measured HIV-RNA ,50 copies/ml, J: HIV-positive $10 years,
with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
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Articles
Characterisation of long-term non-progression of HIV-1 
infection after seroconversion: a cohort study
Jannie J van der Helm, Ronald Geskus, Sara Lodi, Laurence Meyer, Hanneke Schuitemaker, Barbara Gunsenheimer-Bartmeyer, 
Antonella d’Arminio Monforte, Ashley Olson, Giota Touloumi, Caroline Sabin, Kholoud Porter, Maria Prins, on behalf of CASCADE Collaboration 
in EuroCoord
Summary
Background Some individuals remain AIDS-free with a high and stable CD4 cell count without antiretroviral 
therapy (ART) for many years. We estimated long-term progression-free survival after HIV seroconversion and 
aimed to identify factors associated with loss of long-term non-progression (LTNP) status.
Methods For this cohort study, we used data for individuals with well-estimated dates of HIV-1 seroconversion 
from the CASCADE Collaboration a network of 28 HIV seroconverter cohort studies in Europe, Australia, Canada, 
and sub-Saharan Africa. The fi rst cohort began enrolling patients in 1979, and for this analysis we used data 
pooled in May 1, 2011. We defi ned non-progression as being HIV-positive without AIDS, ART-naive, and with CD4 
counts of 500 cells per μL or higher. We defi ned LTNP as non-progression during the fi rst 10 years after 
seroconversion. We used longitudinal methods to characterise LTNP.
Findings Of the 4979 HIV seroconverters in our dataset, 3708 (75%) were men. Median time to progression was 
2·07 years (95% CI 1·96–2·17), giving estimated progression-free survivals of 18·4% (17·2–19·6) 5 years, 4·0% 
(3·6–4·5) 10 years, and 1·4% (0·9–1·5) 15 years after seroconversion. The rate of progression did not change 
beyond 10 years after seroconversion (0·28 [95%CI 0·26–0·31] per person-year at 10 years after seroconversion, 
0·24 [0·19–0·29] per person-year at 15 years, and 0·18 [0·10–0·33] per person-year at 20 years). At 10 years since 
HIV seroconversion, 283 individuals had LTNP, of whom 202 subsequently lost this status (median time to loss of 
status 2·49 years [2·05–2·92]). In univariable analyses, loss of LTNP status was associated with CD4 cell count at 
10 years after seroconversion (p<0·0001) and HIV RNA load at 10 years after seroconversion (p=0·005), but not 
age (p=0·544), mode of infection (p=0·621), sex (p=0·676), or calendar year of seroconversion (p=0·397). In the 
multivariable analyses, loss of LTNP status was associated with lower CD4 counts at 10 years after seroconversion 
(p<0·0001). After exclusion of CD4 cell counts from the model, higher HIV RNA load at 10 years after 
seroconversion was independently associated with loss of LTNP status (p=0·009).
Interpretation Progression-free survival is rare. Most individuals with LTNP eventually lose immunological and 
clinical control of HIV infection eventually.
Funding European Union Seventh Framework Programme.
Introduction
Before the advent of combination antiretroviral treatment 
(ART) in 1996, median time from primary HIV infection to 
the development of AIDS ranged from 5 years to 11 years.1 
With widespread use of com bination ART, this period has 
lengthened sub stantially. Some individuals remain 
AIDS-free with a high and stable CD4 cell count without 
ART for many years.2 In the mid-1990s, much research 
focus was on studying such individuals with long-term 
non-progression (LTNP). Since viral load measurements 
became available,3 this interest has shifted to individuals 
who were able to naturally suppress the virus (known as 
HIV-controllers or elite controllers).4 Findings from basic 
science studies of biological samples from these patients 
might yield important information about the correlates of 
control of infection—this information could be benefi cial 
for the development of therapeutic vaccines.5
Studies of LTNP are diffi  cult to compare because of 
heterogeneity in the defi nitions of non-progression, study 
design, and lengths of follow-up.6–10 Moreover, these 
studies are often limited by small sample size and 
missing information about date of seroconversion. 
Additionally, LTNP has generally been established cross-
sectionally at a fi xed time (eg, at 8 years after infection).6,7 
Some researchers have suggested some people with 
LTNP have slow progression:11 these people eventually 
have disease progression rather than being a distinct 
subpopulation able to naturally control the development 
of HIV infection.12,13 Moreover, how rare or common non-
progression is beyond 10 years after infection is unknown, 
as is whether individuals with LTNP have no signs of HIV 
disease progression with continued follow-up.
The CASCADE Collaboration is, to our knowledge, one 
of the largest groups of HIV-positive individuals worldwide 
with known dates of HIV seroconversion, of diverse risk 
groups, and with long (>10 years) follow-up. As such, the 
study provides a unique opportunity to study LTNP. We 
therefore examined the probability of progression-free 
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survival, the rate of loss of non-progression status, and 
epidemiological characteristics of those with LTNP at 
10 years after HIV seroconversion. We also assessed the 
probability of an individual retaining an LTNP status and 
the factors associated with loss of LTNP status after 10 years 
of HIV infection.
Methods
Study population
Concerted action on seroconversion to AIDS and death in 
Europe (CASCADE) is a collaboration within EuroCoord), 
a network of 28 HIV-1 seroconverter cohort studies in 
Europe, Australia, Canada, and sub-Saharan Africa. All 
collaborating cohorts received approval from their 
regulatory or national ethics review boards (appendix). 
Details of CASCADE are described elsewhere.14 Briefl y, 
CASCADE data comprise 25 629 HIV-positive individuals 
who had their sero conversion date estimated by the 
midpoint between a last negative and fi rst positive test 
separated by a maximum of 3 years (n=21 670 [85%]), the 
date of laboratory evidence of seroconversion (n=3231 
[13%]), the date of seroc onversion illness together with 
negative and positive tests separated by a maximum of 
3 years (n=522 [2%]), or the most likely date that infected 
factor VIII concentrate infusion for men with haemophilia 
was given (n=206 [1%]; we used a back-calculation method 
to estimate the time the infected blood product was used). 
The fi rst cohort began enrolling patients in 1979, and for 
this analysis we used data pooled in May 1, 2011.
For these analyses, we included individuals aged 
15 years or older at seroconversion who had at least 
two CD4 cell count measurements 6 months or more 
after seroconversion, of which at least one was in the fi rst 
10 years after seroconversion. The estimated date of 
seroconversion had to be at least 10 years before the 
administrative censoring date of each individual cohort 
to allow for potential follow-up beyond 10 years.
Defi nition of long-term non-progression
We defi ned non-progression as being HIV-positive and 
AIDS-free, ART-naive, and never having a CD4 count 
below 500 cells per μL. We defi ned the end of non-
progression status as ART initiation, development of an 
AIDS event, or fi rst measurement of a CD4 count below 
500 cells per μL, whichever occurred fi rst. Because CD4 
counts might drop sharply soon after seroconversion 
and subsequently rebound,2 we excluded those 
measured in the fi rst 6 months after HIV seroconversion. 
We defi ned LTNP as non-progression during the fi rst 
10 years after seroconversion. AIDS diagnosis was based 
on the Centers for Disease Control revised case 
defi nition.15
Statistical analyses
We calculated follow-up from HIV seroconversion until 
the date of event or censoring. Individuals were included 
in the risk set from the later date of cohort enrolment or 
fi rst CD4 cell count measurement 6 months or more after 
seroconversion. We censored follow-up at the date when 
individuals were last assessed for CD4 cell count or ART, 
Total study 
population (N=4979)
Individuals with 
LTNP (N=283)
Total follow-up (person years)* 12 478·2 2742·3
Median age at HIV seroconversion (years) 28·4 (24·1–34·0) 26·7 (22·9–31·1)
Mean (SD) age at HIV seroconversion (years) 29·8 (8·2) 28·0 (7·5)
Route of HIV infection
Sex between men 2371 (48%) 115 (41%)
Sex between men and women 1088 (22%) 65 (23%)
Injection drug use 1035 (21%) 74 (26%)
Contaminated factor VIII given to men with haemophilia 74 (2%) 4 (1%)
Mixed route or other† 312 (6%) 21 (7%)
Unknown 99 (2%) 4 (1%)
Sex
Male 3708 (75%) 204 (72%)
Ethnic origin
Same country where enrolment took place‡ 3084 (62%) 182 (64%)
Western Europe, diff erent to country of enrolment 631 (13%) 50 (18%)
Outside western Europe, diff erent to country of enrolment 250 (5%) 13 (5%)
Unknown 1014 (20%) 38 (13%)
Median calendar year of HIV seroconversion 1992 (1989–1996) 1990 (1987–1993)
Hepatitis C virus infection ever
No 1202 (24%) 55 (19%)
Yes 1162 (23%) 87 (31%)
Unknown 2615 (53%) 141 (50%)
CD4 cell count characteristics§
Total median number of measurements since 
seroconversion
22 (10–38) 19 (11–28)
Median number of measurements during follow-up 2 (1–5) 9 (4–18)
Median time in years between measurements during 
follow-up
0·40 (0·25–0·56) 0·47 (0·30–0·64)
Median fi rst count after HIV seroconversion (cells per μL) 700 (590–875) 840 (690–1078)
Median lowest count in the fi rst 10 years after HIV 
seroconversion (cells per μL)
315 (180–468) 629 (567–740)
Median maximum count in the fi rst 10 years after HIV 
seroconversion (cells per μL)
881 (713–1115) 1090 (825–1342)
Median count at 10 years after HIV seroconversion (or latest 
before)
·· 756 (627–971)
HIV RNA load characteristics§ ¶
Median number of measurements in fi rst 10 years after HIV 
seroconversion
12 (5–20) 6 (2–13)
Median fi rst load (log10 copies per μL) 4·04 (3·30–4·65) 3·20 (2·70–3·84)
Median lowest load in the fi rst 10 years after HIV 
seroconversion (log10 copies per μL)
2·30 (1·69–3·14) 2·76 (2·26–3·36)
Median maximum load in the fi rst 10 years after HIV 
seroconversion (log10 copies per μL)
4·77 (4·15–5·29) 3·79 (3·25–4·36)
Median load at 10 years after HIV seroconversion or latest 
before (log10 copies per μL)
·· 3·43 (2·70–4·13)
Data are n (%) or median (IQR) unless otherwise stated. LTNP=long-term non-progression. *Since cohort enrolment 
or fi rst CD4 cell count measurement 6 months or more after seroconversion (whichever was later) until event or 
censoring. †Mixed route (ie, sex between men and injection drug use; injection drug use and heterosexual contact) or 
other (eg, nosocomial infection). ‡Several European countries and Canada. §Excludes CD4 cell count measurements 
and HIV RNA measurements in the fi rst 6 months after HIV seroconversion. ¶Missing values: 1040 for total study 
population and 87 for individuals with long-term non-progression.
Table 1: Baseline characteristics
For more on EuroCoord see 
http://www.EuroCoord.net
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whichever occurred fi rst. We used Kaplan-Meier methods 
to estimate the probability of progression-free survival in 
all individuals and in those who were free of progression at 
10 years after seroconversion. To investigate trends in the 
rate of loss of non-progression status, we estimated hazard 
rates over time since sero conversion with Poisson 
regression. Restricted cubic splines were used to allow for 
smoothly varying trends of the hazard over time. We used 
a Cox proportional hazards model to identify determinants 
associated with loss of LTNP status beyond 10 years. 
Factors considered were age at sero conversion, mode of 
infection, sex, calendar year of sero conversion, baseline 
CD4 cell count (fi rst measure ment between 6 months and 
3 years after HIV seroconversion), lowest CD4 cell count in 
the fi rst 10 years after sero conversion, CD4 cell count at 
10 years from HIV sero conversion (or the latest in the 
preceding 3 years), baseline HIV RNA load (fi rst 
measurement between 6 months and 3 years after HIV 
seroconversion), and HIV RNA load at 10 years of HIV 
seroconversion (or the latest in the preceding 3 years). We 
used restricted cubic splines to model the eff ect of CD4 cell 
count and HIV RNA. We imputed missing HIV RNA 
values and values below the detection limit using multiple 
imputation techniques (appendix). We imputed missing 
mode of infection (four individuals) at random using the 
distribution of the corresponding variable. All p values 
were based on null hypotheses against two-sided 
alternatives. We regarded p values less than 0·05 as 
statistically signifi cant.
The robustness of the estimated progression-free survival 
and retention of LTNP status was checked with sensitivity 
analyses with respect to the role of CD4 count below 
500 cells per μL in the defi nition of non-progression. We 
did three separate sensitivity analyses. First, we estimated 
the time when the CD4 count would have dropped below 
500 cells per μL on the basis of individual CD4 slopes 
(which were based on CD4 counts measured before ART 
initiation only). We obtained these estimates by fi tting a 
linear regression model for each individual with time as the 
only covariate. We applied a square-root transformation to 
the CD4 cell count to better normalise the marker 
distribution as previously described.16 We applied left 
truncation by including individuals in the risk set from 
their fi rst CD4 measurement onwards. Therefore, 
individuals were excluded from the analysis if the estimated 
CD4 value was below 500 cells per μL at the moment of the 
fi rst measurement. Second, with the same method, we 
required at least four CD4 cell counts to estimate the 
individual slopes instead of two. Third, we defi ned 
progression as two consecutive CD4 counts below 500 cells 
per μL rather than one. Therefore, individuals had to have 
at least three CD4 cell counts. We censored follow-up on 
individuals who did not have two consecutive CD4 counts 
below 500 cells per μL at the date of the penultimate count. 
When an individual had two consecutive CD4 counts 
below 500 cells per μL, we estimated the time to crossing 
below the 500 cells per μL threshold by interpolation 
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Figure 3: Kaplan-Meier estimate of the probability of retaining LTNP status after 10 years of HIV-
seroconversion
The shaded area is the 95% CI. LTNP=long-term non-progression.
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Figure 2: Rate of progression by year since HIV seroconversion in HIV-infected individuals (n=4979)
The shaded area is the 95% CI.
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Figure 1: Kaplan-Meier estimate of the probability of HIV progression-free survival in HIV-positive individuals 
(n=4979) with a known interval of HIV-seroconversion.
The shaded area is the 95% CI.
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between the fi rst count and the previous one, which, by 
defi nition, was 500 cells per μL or higher.
We used SPSS (version 19.0), Stata (version 11.2), and 
R (version 3.0.1)17 for the analyses.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had fi nal 
responsibility for the decision to submit for 
publication.
Results
Most participants were men and the most frequent 
route of infection was sex between men, followed by sex 
HR (95 % CI) p value Adjusted HR (95 % CI)* p value Adjusted HR (95 % CI)† p value
Age at seroconversion (per 10-year increase) 0·94 (0·77–1·15) 0·544 1·07 (0·83–1·38) 0·588 1·06 (0·83–1·37) 0·622
Age at seroconversion (years) 0·319
15–24 1
25–29 0·90 (0·65–1·25)
30–34 0·66 (0·42–1·04)
≥35 0·86 (0·55–1·34)
Mode of infection‡ 0·621 0·851
Sex between men or sex between a man and a 
woman
1 1 1 0·959
Injection-drug use or receipt of contaminated factor 
VIII concentrate in people with haemophilia 
1·08 (0·80–1·44) 1·04 (0·70–1·54) 0·99 (0·67–1·45)
Sex 0·676
Male 1 1 0·197 1
Female 1·07 (0·78–1·46) 1·29 (0·87–1·22) 1·22 (0·83–1·79) 0·316
Calendar year of HIV seroconversion (per year 
increase)
0·98 (0·95–1·02) 0·397 0·82 (0·49–1·38) 0·449 0·97 (0·92–1·02) 0·254
Calendar year of HIV seroconversion 0·719
<1989 1
1989–1992 0·86 (0·62–1·20)
1993–1996 0·83 (0·58–1·19)
≥1997 0·80 (0·35–1·81)
Baseline CD4 count (cells per μL)§ 0·290
600 1
900 0·80 (0·52–1·23)
Lowest CD4 count in the fi rst 10 years after 
seroconversion (cells per μL)§
0·084
600 1
900 0·63 (0·40–0·99)
CD4 count at 10 years of HIV seroconversion (cells per 
μL)§
<0·0001 <0·0001 
600 1 1
900 0·36 (0·23–0·55) 0·39 (0·24–0·62)
Baseline HIV RNA (log10 copies per μL) ‡ § 0·090
3 1
4 1·27 (0·85–1·91)
HIV RNA at 10 years of HIV seroconversion (log10 
copies per μL) ‡ §
0·005 0·120 0·009
3 1 1 1
4 1·40 (0·92–2·13) 1·24 (0·81–1·86) 1·38 (0·91–2·13)
LTNP=long-term non-progression. HR=hazard ratio. *Adjusted for all factors for which adjusted HRs are shown; owing to the strong correlation between the measurements 
of baseline CD4 count, lowest CD4 count, and CD4 count at 10 years since infection, these three covariates were not included together in the multivariable model; baseline 
HIV RNA and HIV RNA at 10 years since infection were not included together in the same model. †Adjusted for all factors for which adjusted HRs are shown; CD4 cell count is 
not included in the model because it is included in the defi nition of progression; owing to the strong correlation between the measurements baseline HIV RNA and HIV RNA 
at 10 years since infection these two covariates were not included together in the same model. ‡Missing mode of HIV infection (n=4) and missing HIV RNA values (n=87) 
were imputed. §HR estimated with restricted cubic splines.
 Table 2: Cox proportional hazard analyses of factors associated with of loss of LTNP status in 283 individuals with known dates of HIV-seroconversion 
identifi ed as having LTNP at 10 years after HIV seroconversion
See Online for appendix
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between men and women, injection drug use, and 
receipt of contaminated factor VIII concentrate in 
people with haemophilia (table 1). The median year of 
HIV seroconversion was 1992 and all included 
individuals were from high-income countries, except 
for three individuals who were included in cohorts in 
Africa (table 1).
4246 individuals progressed within 10 years of HIV 
infection: 3253 with CD4 counts below 500 cells per μL, 
729 started ART, 81 had AIDS event, and 183 had a 
combination of these signs of progression. The median 
time to progression was 2·07 years (95% CI 1·96–2·17). 
The estimated progression-free survival probability at a 
given time since seroconversion was 18·4% (17·2–19·6) 
at 5 years, 4·0% (3·6–4·5) at 10 years, 1·4% (0·9–1·5) at 
15 years, and 0·3% (0·2–0·6) at 20 years (fi gure 1).
The rate of progression over time since HIV sero-
conversion decreased sharply in the fi rst years after sero-
conversion from 0·45 (0·43–0·48) per person-year in the 
fi rst year to 0·32 (0·30–0·33) per person-year at 5 years 
after seroconversion (fi gure 2). Thereafter, the rate 
continued to decrease, but slowly, to 0·24 (0·19–0·29) 
per person-year at 15 years and 0·18 (0·10–0·33) per 
person-year at 20 years after sero conversion.
After 10 years of HIV infection, 283 individuals were 
classifi ed as having LTNP (table 1). Of these people with 
LTNP, 202 lost this status after 10 years of HIV 
seroconversion: 150 because of decrease in CD4 cell 
count to below 500 cells per μL, 28 started ART, seven 
had an AIDS event, and 17 had a combination of these 
signs of progression. Median time to loss of LTNP status 
was 2·49 years (95% CI 2·05–2·92; fi gure 3). The 
estimated progression-free survival in those with LTNP 
was 29·6% (23·8–35·6) at 15 years from seroconversion 
and 8·6% (4·3–14·8) at 20 years from seroconversion.
In univariable analysis the loss of LTNP status was 
associated with lower CD4 cell count and higher HIV 
RNA load at 10 years after HIV seroconversion (table 2). 
In multivariable analysis, the loss of LTNP status was 
independently associated with a lower CD4 count at 
10 years after seroconversion (table 2). The adjusted 
hazard of loss of LTNP status decreased with increasing 
CD4 cell count (p<0·0001; fi gure 4). Although not 
statistically signifi cant, the adjusted hazard of loss of 
LTNP status seemed to increase with increasing HIV 
RNA at 10 years after HIV seroconversion (p=0·12; 
fi gure 4). We detected no associations between loss of 
LTNP status and age at HIV seroconversion, route of 
infection, sex, or calendar year of seroconversion. After 
exclusion of CD4 cell count from the model because it 
was part of the defi nition of non-progression, we noted 
that a higher HIV RNA at 10 years after HIV sero-
conversion was independently associated with loss of 
LTNP status (p=0·009; table 2). When we included 
baseline CD4 cell counts and HIV RNA in the model 
instead of the values measured at 10 years after 
seroconversion, we saw no association between loss 
of LTNP status and HIV RNA (p=0·18) or CD4 cell 
count (p=0·72).
The CD4 cell count and HIV RNA trajectories for the 
seven individuals who still qualifi ed as having LTNP at 
20 years after HIV seroconversion were heterogeneous 
with respect to demographic characteristics; six of them 
were male, all routes of infection were present, age at 
HIV seroconversion ranged between 19 years and 
33 years, and they were enrolled into six diff erent cohorts. 
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Figure 4: Association of CD4 cell count (A) and HIV RNA load (B) at 10 years after seroconversion with loss of LTNP
Data are for 283 HIV-positive individuals with a known interval of HIV-seroconversion who had long-term 
non-progression (LTNP) at 10 years after HIV seroconversion. The shaded area is the 95% CI. (A) Adjusted hazard 
of CD4 cell count with reference 600 cells per μL together with rug plot of CD4 cell counts for people with event 
(top) and without event (bottom). (B) Adjusted hazard of log HIV RNA load with reference 3 log HIV RNA load 
together with rug plot of RNA values for those with event (top) and without event (bottom).
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Two of the individuals subsequently lost LTNP status 
(individuals 4 and 7; fi gure 5). Individual 1 had an 
increase in viral load, which might indicate progression. 
The other four individuals did not have signs of clinical 
or immunological progression and their viral load 
remained stable (fi gure 5).
In the fi rst and third sensitivity analyses, the median 
duration to progression and the median progression-
free survival times after LTNP were very similar (data 
not shown). In the second sensitivity analyses, the 
median progression-free survival time increased 
slightly to 2·87 years (2·69–3·00). The estimated pro-
gression-free survival at a given time from sero-
conversion was slightly higher at 26·3% (24·7–27·8) at 
5 years, 6·7% (6·0–7·5) at 10 years, and 2·5% (2·0–3·0) 
at 15 years. Median progression-free survival time after 
LTNP was similar to that seen in the main analysis 
(data not shown).
Discussion In our large cohort study we found that LTNP 
is rare, with progression-free survival decreasing rapidly, 
being about 18% 5 years after seroconversion and about 
4% 10 years after seroconversion. To the best of our 
knowledge, our study is the fi rst to report median time 
from seroconversion to loss of non-progression, which 
was 2·07 years (IQR 1·14–3·99). By contrast with our 
fi ndings, cross-sectional estimates of LTNP from other 
studies have ranged from 0·2% to 22·3%, depending on 
the defi nition used (panel).6,7,18,19 Estimation of the 
prevalence of individuals with LTNP, especially when the 
date of HIV seroconversion is unknown, might result in 
the exclusion of people with more rapid progression and, 
therefore, might lead to an overestimation of the 
prevalence. In our study, the rate of progression decreased 
rapidly over the fi rst few years after sero conversion but 
remained constant beyond 5 years. Although our data lend 
support to previous suggestions that individuals with 
LTNP are more likely to represent the end of the tail from a 
distribution than a distinct subpopulation, we cannot 
exclude the possibility that some individuals will never 
have disease progression.8,11,12
Individuals with LTNP at 10 years after seroconversion 
were heterogeneous in terms of their demographic 
characteristics and viral load, as were those who remained 
free of progression for 20 or more years. To identify 
underlying mechanisms of LTNP, stringent and uniform 
defi nition criteria are important because a small change 
in defi nition might have a large eff ect on the apparent 
outcome.6,20 The criteria we used to defi ne LTNP were 
stringent with respect to follow-up and CD4 cell counts.6,7 
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Figure 5: CD4 cell counts (A) and HIV RNA loads (B) in seven individuals 
who remained progression-free for 20 or more years after HIV 
seroconversion
(A) Blue dots are values recorded during follow-up, green dots are values 
recorded after an individual’s follow-up was censored, and red dots are values 
recorded after an event had taken place (CD4 count <500 cells per μL). 
(B) Solid dots are values above the detection limit; circles are values below the 
detection limit of the HIV RNA test.
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The results of retention of LTNP status did not change in 
the sensitivity analyses, and all analyses substantiated 
the fi nding that LTNP is uncommon.
Although the reason for the slow—or absent—pro-
gression in people with LTNP is unclear, several factors 
are likely involved,21,22 including infection with an 
attenuated virus.23,24 However, fi ndings from previous 
studies also suggest that non-progressors are infected 
with a pathogenic virus, lending support to the idea that 
host, rather than viral, factors play a large part in the 
absence of disease progression.22 Host genetic factors 
such as CCR5Δ32 deletion and heterozygous HLA-B57 
alleles have been described.21 A genome-wide association 
study showed fi ve single-nucleotide polymorphisms in 
class I and III MHC subregions that were associated with 
LTNP.5 Few studies have been done of the immunological 
variables in people with LTNP, and researchers who did a 
review of available studies recommended the study of 
T-cell subsets with proinfl ammatory and anti-infl am-
matory properties such as Th17 and regulatory T-cells 
and their role in the preservation of normal CD4 cell 
counts in those with LTNP.22 Another review showed the 
eff ect of heritability of HIV on viral load.25 Phylogenetic 
analysis might, therefore, be of interest to identify any 
role of heritability of the virus on LTNP.
Only two studies have assessed on the loss of LTNP 
status by use of data from HIV seroconverters. Findings 
from a study from San Francisco showed a median time 
to loss of LTNP status after 10 years of HIV infection of 
14 years (95%CI 13·0–14·7), slightly longer than our 
estimate of 12·5 years (12·1–12·9).2 The second study, 
done in France, showed a time to loss of LTNP status 
similar to ours, but was estimated after 8 years rather 
than 10 years since HIV infection.26 Older age at HIV 
seroconversion is associated with more rapid pro-
gression to AIDS and death,1 as was shown in our study, 
with age associated with loss of non-progression in the 
total study population (data not shown). Our fi ndings 
suggest that once someone had been free of progression 
for 10 years or longer, age is no longer signifi cantly 
associated with progression—a fi nding also seen in the 
French study.26
The identifi cation of people with LTNP might become 
challenging in the future if the trend towards earlier 
initiation of combination ART continues; although the 
individual benefi ts of earlier ART remain debatable, 
treatment guidelines now recognise the possibility that 
the initiation of ART at a very early time during HIV 
infection to prevent HIV transmission (so-called 
treatment as prevention) could have public health 
benefi ts.27,28 Progression-free survival in our study was 
low, indicating that, if earlier start of ART is 
implemented, for most this earlier start will be a few 
years, which might be short in comparison with the 
many years of treatment to follow.
An overlap between the LTNP group and HIV-
controllers and elite-controllers has been reported.18,29 In 
our study, 30 (21%) of the identifi ed people with LTNP 
also met the criteria for HIV control, as described in a 
previous study from CASCADE Collaboration that 
identifi ed 140 HIV controllers (data not shown).30
Limitations of our study included the fact that all 
individuals, apart from three, were included in high-
income countries and that we were not able to estimate 
ethnicity-specifi c progression-free survival. Therefore, 
our results might not be generalisable to other 
countries. However, both white and non-white 
individuals were identifi ed as LTNP, suggesting that 
the possibility to have LTNP is not restricted to one 
ethnic group. Also, coding imperfection might have 
occurred and we cannot rule out residual and 
unmeasured confounding.
Although lifetime natural control of HIV is unlikely, 
further studies of host immunity and genetics using 
biological samples of the few individuals with durable 
control might help in the development of therapeutic 
vaccines.
Contributors
JvdH obtained data, contributed to the design of the study, drafted the 
paper, and did the statistical analysis, analysis, and interpretation of 
data. RG obtained data, contributed to the design of the study, did 
statistical analysis, analysis, and interpretation of data, critical revised 
the paper, and supervised analysis. SL obtained data, revised the paper, 
and did the statistical analysis, analysis, and interpretation of data. LM, 
HS, BGB, AdAM, AO, GT, and CS contributed to the obtaining of data, 
analysis and interpretation of the data, and revision of the paper. KP 
obtained data, coordinated the data pooling, analysis, and interpretation 
of data, revised the paper, and obtained funding. MP obtained data, 
contributed to study concept and design, did the analysis and 
interpretation of data, provided important input for the drafting and 
Panel: Research in context
Systematic review
We searched PubMed using the search term “HIV” with “long-term non-progression”, 
“long-term non-progressor”, “LTNP”, “long-term survivor”, and “survivor”. Most 
retrieved studies of long-term non-progression (LTNP) were from the mid-1990s. When 
viral load measurements became availabe, most studies were in HIV controllers and elite 
controllers. The few, more recent (in the past 5 years), studies of LTNP were included in a 
2013 review8 that concluded that prevalence estimates diff er widely because they partly 
depend on the required period of follow-up. Also, very few individuals defi ned as LTNP 
have been followed up beyond 8 years of seroconversion and all of those who were 
followed up remained without any evidence of disease progression. Most studies report 
prevalence estimates of LTNP. We identifi ed no study that reported median time from 
HIV seroconversion to loss of non-progression status.
Interpretation
Findings from our large study of long-term non-progression in HIV seroconverters 
with more than a decade of follow-up showed that progression-free survival after 
seroconversion is low (median time to loss of status 2·07 years and 18% at 5 years after 
infection). This fi nding is of interest in this era with ongoing debate over the benefi ts 
of early initiation of antiretroviral treatment. Most individuals with LTNP will lose 
immunological and clinical control of HIV infection eventually. Progression-free 
survival is a rare but real occurrence. Studies of host and viral factors of these 
individuals with LTNP might yield important information about the correlates of 
control of infection.
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BASIC AND TRANSLATIONAL SCIENCE
Evaluation of Rapid Progressors in HIV Infection as an
Extreme Phenotype
Ashley D. Olson, MA, Marguerite Guiguet, PhD,†‡ Robert Zangerle,§ John Gill, MD,k
Santiago Perez-Hoyos, PhD,¶ Sara Lodi, PhD,# Jade Ghosn, PhD,** Maria Dorrucci, PhD,††
Anne Johnson, PhD,‡‡ Mette Sannes, PhD,§§ Santiago Moreno, PhD,kk and Kholoud Porter,*
for CASCADE Collaboration in EuroCoord
Design: Rapid CD4 cell loss represents an HIV phenotype used to
identify causal variants of accelerated disease progression. The
optimal rate and threshold for identifying this extreme phenotype in
recently infected individuals is unclear.
Methods: Using a cohort of patients with known dates of HIV-1
seroconversion (SC), CASCADE (Concerted Action on SeroConver-
sion on AIDS and Death in Europe), we identified proportions
experiencing nadir CD4 cell levels within 1 year of SC, and assessed
their mean AIDS-free survival time at 10-year follow-up and hazard of
AIDS/death, compared with those whose CD4 remained .500 cells
per cubic millimeter. Follow-up was censored at December 31, 1996
to avoid bias due to combination antiretroviral therapy initiation.
Results: Of 4876 individuals, 2.8%, 7.3%, and 24.9% experienced $1
CD4,100, 200, and 350 cells per cubic millimeter, respectively, within
1 year of SC. Minimum CD4 levels of 30, 166, 231, and 506 cells per
cubic millimeter were experienced during this period by 1%, 5%, 10%,
and 50% of individuals, respectively. Mean (95% confidence interval)
AIDS-free survival at 10 years follow-up was 2.9 (2.3 to 3.6), 5.5 (5.0 to
6.1), 6.7 (6.5 to 7.0), 7.4 (7.2 to 7.6), and 8.1 (7.9 to 8.3), for those
with minimum counts #100, 100–200, 200–350, 350–500, .500
cells per cubic millimeter, respectively. Using counts of .500 cells
per cubic millimeter as reference, the hazard ratios (95% confidence
interval) of AIDS/death were 15.0 (11.9 to 18.9), 3.6 (2.9 to 4.5),
2.1 (1.8 to 2.4), and 1.5 (1.3 to 1.7), respectively. The hazard ratio
increased to 37.5 (26.5 to 53.1) when a minimum CD4 count ,100
was confirmed within 1 year of SC.
Conclusion: At least 1 CD4#100 cells per cubic millimeter within
the first year of SC identifies a rare group of individuals at high risk
of disease progression and could form the basis for defining the rapid
progressor phenotype.
Key Words: HIV, rare phenotype, disease progression, genetics
(J Acquir Immune Defic Syndr 2014;67:15–21)
INTRODUCTION
Rapid HIV disease progression is an extreme HIV
phenotype, although there is little consensus on a definition.
Differences in HIV disease progression can be assessed by
variability in biomarkers related to HIV disease, the 2 most
common of which being CD4 and HIV-RNA. Variability in
HIV-RNA, specifically low-circulating HIV-RNA, has
defined those with slow disease progression, termed long-
term nonprogressor or elite controller phenotypes, which are
of particular importance to vaccine studies.1–10 Rapid progres-
sion, however, is equally important as it also contributes to
our understanding of early risk factors of disease progression.
This may in turn help optimize the frequency of clinical mon-
itoring and antiretroviral therapy initiation.
In addition to the well-documented relationship between
slow disease progression and low HIV-RNA, there is also known
variation in CD4 levels at or shortly after seroconversion (SC). A
number of studies to date have defined rapid progression based
on various levels of immunosuppression,11–21 but it is not yet
clear if this variability in CD4, 1 early measure or consecutive
low CD4 measurements do, indeed, constitute rapid progres-
sion and how this rare phenotype should be defined.
The CASCADE (Concerted Action on SeroConversion
on AIDS and Death in Europe) Collaboration, of HIV-
positive individuals followed-up since HIV SC offers a unique
opportunity to evaluate HIV rapid progression. Using data
from CASCADE, we aim to document low CD4 near SC and
examine HIV rapid disease progression. This work provides
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the basis for choosing a definition appropriate to the
objectives of future research on this extreme phenotype.
METHODS
Study Population
We used data from the CASCADE 2011 data release
in EuroCoord (www.EuroCoord.net), which consists of
25,629 seroconverters from 28 cohorts across Europe, Can-
ada, Australia, and sub-Saharan Africa.22 Date of HIV SC
were estimated by various methods, most commonly as the
midpoint between the last documented HIV-negative and the
first positive HIV antibody test dates with an interval of ,3
years between the 2 test dates (85%). For the remainder, date
of SC was estimated through laboratory evidence of SC
(polymerase chain reaction positivity in the absence of
HIV antibodies or antigen positivity with fewer than 4 bands
on Western blot) (13%), or as the date of a SC illness (2%)
with both an earlier documented negative and a later positive
HIV test not more than 3 years apart. All cohorts contribut-
ing data to CASCADE received approval from their individ-
ual ethics review boards.
Rapid Progression
Because of the inconsistency of definitions described in
the literature,11–21 with nadir CD4 cell counts ranging between
200 and 500 cells per cubic millimeter and follow-up ranging
between 6 months and 8 years, we sought to identify those at
highest risk of disease progression by severity of immuno-
suppression in early infection. We evaluated the frequency of
low CD4 counts during the first year after SC and estimated
the mean survival time at 10 years of follow-up and hazard of
AIDS/death by nadir CD4 levels compared with individuals
whose CD4 measurements remained above such levels during
that period.
Statistical Methods
For all estimates, we considered only data from
individuals who met the requirements for length of follow-
up and minimum number of CD4 measurements. More
specifically, only individuals with at least 1 CD4 count
measured within the first year of SC could contribute
information to assessing the risk associated with experiencing
any specific nadir CD4 cell count within 1 year.
To provide estimates of the prevalence of low CD4
near SC, we calculated proportions experiencing various
nadir CD4 levels within the first year of SC by mode of
HIV transmission and age categories and plotted the
cumulative proportion of individuals experiencing different
nadir CD4 levels.
We used Cox proportional hazards models to estimate
the relative hazard of AIDS/death among eligible individ-
uals. As the nonproportionality assumption was not met in
3 of the 4 models, we used log-rank P values.23 We esti-
mated restricted mean AIDS-free survival times (the area
under the length of AIDS-free survival curves) at 10 years
of follow-up using clinically relevant CD4 categories
(,100, 100–200, 200–350, 350–500, and .500 cells/
mm3) using pseudovalues, as described previously.23,24
The follow-up time of 10 years was chosen as this is the
median time to AIDS in the pre–combination antiretroviral
therapy (cART) era for individuals infected between 25 and
35 years of age and was close to the last observed event
time.25 We also used fractional polynomials to explore the
relationship of nadir CD4 measurements to the hazard of
AIDS/death and restricted mean AIDS-free survival.26 For
all models, we adjusted for the following potential con-
founders: sex, mode of HIV transmission, age at SC, and
year at SC. Age and year of SC were modeled using
restricted cubic splines with 3 knots.27 For all analyses,
follow-up was censored at the earliest of AIDS or death date
or on December 31, 1996 to avoid bias because of treatment
initiation. AIDS was defined using the European case definition,
which excludes CD4 ,200 cells per cubic millimeter.28
In sensitivity analyses, we investigated the proportions
experiencing nadir CD4 measurements within 6 months of SC
TABLE 1. Baseline Characteristics for (A) 4876 Individuals
With $1 CD4 Cell Measurement(s) Within 1 year of SC
Included in Analysis and (B) 6084 Individuals Not Included in
the Analysis but Seroconverting in the Pre-cART Era Using the
CASCADE Data Set
A B
Risk category, n (%)
MSM 2564 (53) 2612 (43)
MSW 1026 (21) 1741 (29)
IDU 1085 (22) 1243 (21)
Other/unknown 201 (4) 486 (7)
Sex, n (%)
Male 3798 (78) 4638 (76)
Female 1078 (22) 1446 (24)
SC year
Median (IQR), yrs 1992 (1989–1994) 1991 (1988–1994)
SC age
Median (IQR), yrs 29 (25–35) 28 (24–33)
,20, n (%) 239 (5) 454 (7)
$20–30, n (%) 2481 (51) 3377 (56)
$30–40, n (%) 1479 (30) 1613 (27)
$40, n (%) 677 (14) 640 (11)
Geographical origin, n (%)
Europe 3652 (78) 4765 (75)
Africa 117 (3) 170 (2)
Americas 50 (1) 77 (1)
Unknown/Other 1057 (18) 1072 (22)
Time from SC to nadir CD4:
median (IQR), mo
7.4 (4.5–9.8) —
Time from SC to first CD4:
median (IQR), mo
5.2 (3.0–7.9) —
Number of CD4 counts:
median (IQR)
2 (1–2) —
Follow-up time: median (IQR) 3.8 (1.9–6.1) —
IDU, injection drug users; MSM, men who have sex with men; MSW, heterosexual
contact.
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and the hazard of AIDS/death observed by these minimum
levels. We also investigated if confirmed CD4 measurements
(ie, 2 counts) had an impact on the proportion, mean AIDS-
free survival times, and hazard of AIDS/death within 6
months and 1 year of SC. Additionally, as the individuals
in CASCADE are geographically diverse, we stratified all
analysis by geographical origin. Analyses were conducted
using Stata/IC 13.0.
RESULTS
Baseline Characteristics
Of 25,629 seroconverters, 20,753 were excluded for
following reasons: 14,669 seroconverted after 1997, 6074 had
no CD4 measurements within the first year of SC, 6 had an
unknown AIDS date and 4 were ,15 years of age at SC. Of
the remaining 4876 individuals who were studied, 53% were
men infected through sex between men (men who have sex
with men), 21% through heterosexual contact, 22% through
injection drug use, and the remainder were hemophiliacs or
with unknown risk categories. The majority (78%) were male
seroconverting at a median [interquartile range [IQR]) 29
(25–35) years old between 1982 and 1996. Median (IQR)
time from SC to the lowest CD4 was 7.4 (4.5–9.8) months.
Geographical origin was predominately European (78%) with
few individuals from Africa (3%) and the Americas (1%)
(Table 1). HIV subtype was missing for .80% of individuals
in this analysis, but of those with known subtype, the data
comprised mainly subtype B (.90%).
Baseline characteristics of the 6084 individuals serocon-
verting in the pre-cART era excluded from this analysis and
the sensitivity analysis were similar to the 4876 individuals
included in this analysis (Table 1) (see Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A542).
CD4 Near SC
Median (IQR) initial CD4 count during the first year of
SC was 550 (384–726). A total of 138 (2.8%), 356 (7.3%),
and 1213 (24.9%) experienced at least 1 CD4 below 100,
200, and 350 cells per cubic millimeter, respectively, in the
first year of SC (Fig. 1, Table 2). About 1%, 5%, 10%, and
50% of individuals experienced at least 1 CD4 ,30, 166,
231, and 506 cells per cubic millimeter, respectively, within
the first year of SC (Table 2). Higher CD4 cell levels were
experienced by younger individuals and those infected
through injection drug use (Table 2).
In sensitivity analyses, data were available from 2641,
2825, and 894 individuals with a confirmed CD4 within 1
year of SC, at least 1 CD4 within 6 months, and a confirmed
CD4 within 6 months, respectively. Nadir CD4 percentiles
remained qualitatively similar to those obtained from the
main analysis (see Table S2, Supplemental Digital Content,
http://links.lww.com/QAI/A542).
FIGURE 1. Cumulative proportions of nadir CD4 cell count (left hand panel), relative risk of AIDS/death compared with in-
dividuals whose CD4 counts remained at 500 cells per cubic millimeter (center panel), and mean AIDS-free survival time at 10
years follow-up (right hand panel) for individuals in CASCADE experiencing specific nadir levels within 1 year of SC during that
period: all individuals seroconverted in the pre-cART era.
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Predicted Mean Survival Time at
10-Year Follow-Up
The AIDS-free survival expectancy at 10 years follow-up
significantly increased as nadir CD4 count measured within the
first year of SC increased (Fig. 1, Table 3). Compared with
individuals experiencing nadir CD4 counts ,100 cells per
cubic millimeter within the first year of SC, those with nadir
CD4 of 100–200, 200–350, 350–500, and .500 have an
increased AIDS-free survival expectancy of 2.6 (1.7–3.4), 3.8
(3.1–4.45), 4.5 (3.8–5.2), and 5.2 (4.5–5.5) years, respectively,
during the first 10 years of HIV infection.
In a sensitivity analysis, the AIDS-free survival expec-
tancy was qualitatively similar to results in the main analysis,
increasing as nadir CD4 count and confirmed minimum CD4
measurements increased within 1 year and the 6 months of SC
(Table 3). Predicted mean survival at 10 years follow-up was
qualitatively similar when stratifying by geographical origin
(data not shown).
Risk of AIDS/Death by Nadir CD4
The risk of AIDS/death increased as nadir CD4 count
measured in the first year decreased. For individuals experi-
encing at least 1 count ,100 cells per cubic millimeter, there
was a 15-fold increased risk of AIDS/death compared with
those whose nadir CD4 count remained .500 cells per cubic
millimeter. Hazard of AIDS/death was significantly higher
for those with nadir counts ,500 cells per cubic millimeter,
(Fig. 1, Table 3).
In sensitivity analyses, the risk of AIDS/death was
qualitatively similar to results in main analyses. As
expected, however, the risk was greatly elevated for those
experiencing confirmed counts, namely; hazard ratio (95%
confidence interval) 15.0 (11.9 to 18.9) vs. 37.5 (26.5 to
53.1) for CD4 #100 cells per cubic millimeter and 3.6 (2.9
to 4.5) vs. 6.3 (4.5 to 8.8) for CD4 100–200 cells per cubic
millimeter comparing a single minimum CD4 count with
a confirmed CD4 count within 1 year of SC. This same
pattern was observed when comparing nadir CD4 with
a confirmed minimum CD4 count within 6 months of SC,
(Table 3). There was a similar trend of higher risk of AIDS/
death for lower CD4 cell counts when stratifying by geo-
graphical origin (data not shown).
DISCUSSION
Individuals experiencing 1 or more CD4 cell count #100
cells per cubic millimeter within the first year of SC provide
a rare group (2.8%) of HIV-positive individuals at the highest
risk of disease progression with remarkably short mean
AIDS-free survival of 2.9 years. These results suggest that
CD4 monitoring close to SC may play an important role in
identifying those at highest risk of progression. In addition to
this, individuals with at least 1 CD4 cell count#500 cells per
cubic millimeter are at an increased risk of AIDS/death com-
pared with individuals whose CD4 remain above 500 cells
per cubic millimeter.
We have shown that low CD4 cell counts ,100 cells
per cubic millimeter near SC is rare, but low CD4 near SC can
TABLE 2. Minimum CD4 Percentiles Within 1 year of SC by
HIV Risk Group and Age Categories in the Pre-cART Era
Using the CASCADE Data Set
,20 ‡20–30 ‡30–40 ‡40 Overall
1%
MSM 165 49 27 30 35
IDU 244 53 22 185 40
MSW 154 19 27 23 27
OTH — 65 0 24 19
Overall 156 49 24 24 30
5%
MSM 220 168 156 124 161
IDU 318 210 141 240 200
MSW 257 168 135 95 156
OTH — 136 48 64 112
Overall 257 180 148 118 166
10%
MSM 270 237 223 213 224
IDU 338 269 220 339 265
MSW 300 255 220 190 225
OTH — 240 182 192 200
Overall 307 250 220 204 231
25%
MSM 342 352 340 315 340
IDU 439 425 343 364 405
MSW 440 370 350 268 350
OTH — 404 289 328 318
Overall 389 378 340 311 352
50%
MSM 450 500 487.5 441 484.5
IDU 597 600 510 419.5 583
MSW 560 519 491 430 501.5
OTH — 546 500 474 502
Overall 530 535 491 440 506
75%
MSM 638 676 650 614 654
IDU 778 825 766 725 815
MSW 840 732 722.5 603 751
OTH 667 726 800 612 721
Overall 717 736 680 612 705.5
90%
MSM — 875 842 830 856
IDU 947 1063 1045 1029 1057
MSW 997 979 970 824 950
OTH 842.5 977 1154 800 942
Overall 947 966 907 830 933
100%
MSM 1250 1704 1875 1584 1875
IDU 1984 2105 1744 2420 2420
MSW 1453 2231 2156 1625 2231
OTH — 1704 2068 1357 2068
Overall 1984 2231 2156 2420 2420
IDU, injection drug users; MSM, men who have sex with men; MSW,
heterosexual contact; OTH, hemophiliacs or unknown.
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have other research implications. Our definition can be useful
for researching extreme phenotypes, particularly for genetic
studies aiming to identify rare causal variants by looking at
extreme ends of HIV disease progression.29,30 In addition to
genetic implications, low CD4 near SC can have impact on
HIV incidence measurements. HIV incidence measures such
as The Recent Incidence Testing Algorithm aim to identify
individuals infected within 4–6 months of sampling but
exclude individuals who have AIDS, on ART or are identified
with low CD4 as these individuals have been shown to be
misclassified as recently infected.31 Our study suggests that
up to 5% of the HIV-positive population tested in the first 6
months of SC will have a CD4 below 200 and thus would be
misclassified as longstanding infection according to The
Recent Incidence Testing Algorithm. These results suggest
the need for an incidence estimate correction factor to account
for low CD4 cell counts near SC.
Individuals experiencing confirmed low CD4 meas-
urements ,200 cells per cubic millimeter had more than
a 2-fold increased risk of AIDS/death compared with mini-
mum CD4 measurement alone. Although this may suggest
that a confirmatory CD4 has a higher prognostic value of
disease progression than a single CD4 alone, it is unusual
for individuals to have a confirmed CD4 so close to SC,
shown by our reduced numbers for this population. We were
able to analyze repeated low CD4 measurements because
these data were restricted to the pre-cART era; however, it
is unlikely that in the cART era naive low confirmed CD4
measurements would be available, as all individuals with 1
CD4 ,200 cells per cubic millimeter are recommended to
be on treatment.
Subtype was missing for .80% of individuals in this
analysis, and comprised mainly subtype B (90%), which com-
pared with other HIV subtypes, has previously been shown to
have different rates of CD4 cell levels near SC and CD4 rates
of decline suggesting these results may not be generalizable to
other HIV subtypes.32 We stratified the analysis by geograph-
ical origin and the same trend of higher risk of disease pro-
gression with lower CD4 cell counts was observed, suggesting
these results are generalizable in different global epidemics.
Our study has several strengths. First, the availabil-
ity of SC estimation is essential to identifying individuals
with rapid disease progression. Without laboratory evi-
dence of SC, individuals entering care with low
CD4 would be termed late presenters instead of rapid
progressors.33 Second, the availability of data in an era
when ART was not used early in the course of disease
allowed us to assess rapid progression without the inter-
action of ART on disease progression. In the cART era,
individuals with CD4 ,350 cells per cubic millimeter
would be on cART and the impact of low CD4 ,100 cells
per cubic millimeter near SC would not be fully under-
stood. Finally, the large sample size of our cohort allows
us to compare between different possible combinations of
this rare phenotype.
Our study has limitations. SC illness and HIV test
intervals ,31 days have been shown to be associated with
faster disease progression,34,35 suggesting our proportion
and risk estimates could be overinflated because of the
increased likelihood of individuals seeking care when
experiencing SC illness, although the midpoint method of
estimating SC was used for 85% of seroconverters. We
were unable to test if rapid progressors are more likely to
report SC illness, as this is unknown in .70% of the CAS-
CADE data set. However, among 1481 individuals in our
study with known SC illness status, . 50% of individuals
reported of SC illness with CD4 count ,350 cells per
cubic millimeter, where ,50% of individuals reported no
SC illness in those with a CD4 count $350 cells per cubic
millimeter (data not shown). Although our study only
TABLE 3. HR for Time to AIDS/Death by Nadir CD4 Measured Within 1 year of SC Using the CASCADE Data Set
CD4 Value, cells/mm3
Within 6 Months of SC Within 1 Year of SC
N (Fail) HR (95% CI)*
Mean AIDS-Free
Survival (95% CI)† N (Fail) HR (95% CI)*
Mean AIDS-Free
Survival (95% CI)†
Nadir CD4
#100 58 (37) 12.8 (9.0 to 18.2)‡ 3.1 (2.1 to 4.1) 138 (94) 15.0 (11.9 to 18.9)‡ 2.9 (2.3 to 3.6)
100–200 97 (40) 2.9 (2.1 to 4.1)‡ 5.6 (4.7 to 6.5)§ 218 (91) 3.6 (2.9 to 4.5)‡ 5.5 (5.0 to 6.1)§
200–350 409 (134) 2.3 (1.9 to 2.8)‡ 6.3 (5.9 to 6.6)§ 857 (267) 2.1 (1.8 to 2.4)‡ 6.7 (6.5 to 7.0)§
350–500 607 (180) 1.6 (1.3 to 1.9)‡ 7.0 (6.7 to 7.3)§ 1185 (316) 1.5 (1.3 to 1.7)‡ 7.4 (7.2 to 7.6)§
.500 1654 (359) 1‡ 8.0 (7.8 to 8.1)§ 2478 (501) 1‡ 8.1 (7.9 to 8.3)§
Confirmed CD4
#100 14 (10) 49.3 (23.4 to 104.2) 2.1 (0.4 to 3.7) 64 (51) 37.5 (26.5 to 53.1)‡ 1.8 (1.1 to 2.6)
100–200 33 (17) 7.4 (4.2 to 13.0) 3.6 (2.3 to 5.0) 92 (40) 6.3 (4.5 to 8.8)‡ 4.9 (4.0 to 5.7)§
200–350 118 (36) 2.5 (1.7 to 3.7) 5.6 (4.9 to 6.4)§ 342 (106) 2.4 (1.9 to 3.0)‡ 6.3 (5.9 to 6.7)§
350–500 186 (61) 1.6 (1.2 to 2.3) 6.1 (5.5 to 6.7)§ 577 (171) 1.8 (1.5 to 2.1)‡ 6.8 (6.4 to 7.1)§
.500 543 (130) 1 7.3 (6.9 to 7.7)§ 1566 (344) 1‡ 7.9 (7.7 to 8.1)§
*Adjusted for sex, risk group, SC age, SC year, log-rank test P , 0.001.
†Mean AIDS-free survival at 10 years of follow-up.
‡Cox proportional hazards P , 0.05.
§Statistically greater than #100 cells per cubic millimeter category (P , 0.001).
CI, confidence interval; HR, hazard ratio.
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investigates seroconverters, it has been shown that HIV
progression, in particular CD4 decline, among sero-
converters is similar to that of the general HIV-positive
population suggesting our results are generalizable to the
HIV-positive population.36
In conclusion, individuals with at least 1 CD4 #100
cells per cubic millimeter in the first year of SC are a rare and
extreme group who are at a very high risk of rapid disease
progression. Given that the HIV test intervals in this study are
consistent with HIV testing guidelines,37–40 our study allows
clinicians to identify individuals at risk of progression at an
early stage for whom immediate initiation of therapy may be
indicated. This study has also helps to identify an extreme
HIV phenotype that increases power to detect rare variants in
causal viral and host genetics of rapid HIV disease progres-
sion. This may, in turn, lead to targeted treatments for indi-
viduals at the greatest risk of progression. We suggest future
research use at least 1 CD4 #100 cells per cubic millimeter
within 1 year of SC as a definition for rapid progression.
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EPIDEMIOLOGY AND PREVENTION
Limiting Cumulative HIV Viremia Copy-Years by Early
Treatment Reduces Risk of AIDS and Death
Ashley D. Olson, MA,* A. Sarah Walker, PhD,* Amitabh B. Suthar, PhD,† Caroline Sabin, PhD,‡
Heiner C. Bucher, MD, MPH,§ Inma Jarrin, PhD,k¶ Santiago Moreno, MD,#
Santiago Perez-Hoyos, PhD,** Kholoud Porter, PhD,* and Deborah Ford, PhD,* on behalf of CASCADE
Collaboration in EuroCoord
Background: Viremia copy-years (VCY), a time-updated measure of
cumulative HIV exposure, predicts AIDS/death; although its utility in
deciding when to start combination antiretroviral therapy (cART)
remains unclear. We aimed to assess the impact of initiating versus
deferring cART on risk of AIDS/death by levels of VCY both
independent of and within CD4 cell count strata $500 cells per
cubic millimeter.
Methods: Using Concerted Action on Seroconversion to AIDS and
Death in Europe (CASCADE) data, we created a series of nested
“trials” corresponding to consecutive months for individuals $16
years at seroconversion after 1995 who were cART-naive and AIDS-
free. Pooling across all trials, time to AIDS/death by CD4, and VCY
strata was compared in those initiating vs. deferring cART using Cox
models adjusted for: country, sex, risk group, seroconversion year,
age, time since last HIV-RNA, and current CD4, VCY, HIV-RNA,
and mean number of previous CD4/HIV-RNA measurements/year.
Results: Of 9353 individuals, 5312 (57%) initiated cART and 486
(5%) acquired AIDS/died. Pooling CD4 strata, risk of AIDS/death
associated with initiating vs. deferring cART reduced as VCY
increased. In patients with high CD4 cell counts, $500 cells per
cubic millimeter, there was a trend for a greater reduction for those
initiating vs. deferring with increasing VCY (P = 0.09), with the
largest benefit in the VCY $100,000 copy-years/mL group [hazard
ratio (95% CI) = 0.41 (0.19 to 0.87)].
Conclusions: For individuals with CD4 $500 cells per cubic
millimeter, limiting the cumulative HIV burden to ,100,000 copy-
years/mL through cART may reduce the risk of AIDS/death.
Key Words: viremia copy-years, seroconverters, when to start,
cART initiation, CD4 cell count, HIV-RNA
(J Acquir Immune Defic Syndr 2016;73:100–108)
INTRODUCTION
Although CD4 cell counts are used routinely to monitor
adults with HIV infection, viral loads also have an important role
in the monitoring and staging of adults with HIV.1,2 One or 2
values of an individual’s viral load are often used to determine
combination antiretroviral therapy (cART) failure, their risk of
transmitting HIV to others, and to tailor first-line cART
regimens.3–5 However, assessment of an individual’s viral load
at a single point in time fails to capture cumulative exposure to
HIV replication which may have been over a period of 10 years
or more. Several investigators have proposed that a measure of
cumulative viral burden might provide useful additional infor-
mation and, in particular, a measurement of viremia copy-years
(VCY) has been proposed.6 VCY is akin to cigarette pack-years
when assessing exposure to tobacco; A VCY of 1000 copy-
years/mL is the equivalent to an individual having a viral load of
1000 copies per milliliter for an entire year or a viral load of 500
copies per milliliter for 2 years. The measurement of VCY has
been shown to predict death and AIDS in both the absence6 and
presence7,8 of cART, independently of the individual’s most
recent CD4 count and viral load. This independent association
suggests that cumulative HIV burden is associated with an
increased risk of development of clinical events through
mechanisms other than immunodeficiency.
United States guidelines recommend immediate cART
initiation, regardless of CD4 cell count5,9 due to evidence that
exposure to uncontrolled viremia is associated with an increased
risk of death, AIDS, and non-AIDS events.5,10–12 The START
(Starting Antiretroviral Treatment Early Improves Outcomes for
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HIV-Infected Individuals) trial has recently reported that waiting
to initiate cART until CD4 ,350 cells per cubic millimeter
increases the likelihood of serious illness or death compared with
immediate initiation.13 VCY serves as a measurement of
cumulative exposure to HIV, and so it is important to determine
whether VCY contributes to the likelihood of illness and death
and whether cART initiation before the accrual of VCY could
help optimize clinical and public health HIV outcomes.
Randomized trials are unlikely to be conducted to
determine whether accrual of viremia VCY before cART
initiation increases mortality because of the difficulty and
expertise in enrolling participants soon after seroconversion,
and because cART is now recommended in many asymptomatic
populations. In addition, there is substantial potential for lead-
time bias in analyses using VCY because of variability in the
extent of HIV replication an individual will have been exposed to
previous enrollment into care. One way to limit this bias is to
restrict analyses to participants with serial viral load measure-
ments since a known seroconversion date; such data are available
from the Concerted Action on Seroconversion to AIDS and
Death in Europe (CASCADE) Collaboration, an international
multicenter collaboration of data from persons with well-
estimated dates of HIV seroconversion. Previous analyses of
CASCADE data have shown a protective effect of initiating
cART on AIDS/death at CD4 ,500 cells per cubic millimeter
[hazard ratio (HR) 0.59 (95% CI: 0.43 to 0.81) and HR 0.75
(0.49–1.14) in CD4 cell strata 200–349 and 350–499, respec-
tively], but no evidence for a reduction in risk at CD4$500 cells
per cubic millimeter [HR 1.10 (0.67–1.79)].14 Here we examine
the effect of initiating or deferring cART at different levels of
VCY on HIV disease progression. We investigate whether or not
individuals with CD4 $500 cells per cubic millimeter but high
VCY would benefit from starting cART.
METHODS
Study Population
Data from CASCADE in EuroCoord (www.EuroCoord.
net) 2013 data update were used for this analysis.15 Briefly,
CASCADE is a cohort collaboration of 29 cohorts of individ-
uals with well-estimated dates of HIV seroconversion from
Europe (94%), Australia (2%), Canada (0.5%), and Sub-Saharan
Africa (3%). Date of seroconversion is estimated as the midpoint
between the last negative and first positive HIV antibody test
results with a maximum of 3 years between the test dates (85%),
laboratory evidence of acute seroconversion (real-time poly-
merase chain reaction positivity of incomplete Western blot)
(13%), the date of seroconversion illness with a negative and
positive test no more than 3 years apart (2%), or by a probability
distribution to determine the most likely date of transmission for
men with hemophilia infected with HIV after transfusion with
clotting factor concentrates (,1% of the sample).
All cohorts contributing to CASCADE received ethical
approval from their individual ethics review boards.
Adults ($16 years old) seroconverting in the cART era
(post 1995) were included provided they had at least 1 HIV-
RNA measurement between 4 and 12 months after seroconver-
sion. Two Sub-Saharan African cohorts were excluded from this
analysis as their CD4 cell count and cART initiation patterns are
different from those in industrialized country cohorts.16
Study Design
We created a series of sequential nested “trials”
corresponding to consecutive months of follow-up beginning
4 months after seroconversion, where each month represents
the baseline month for a new trial (Fig. 1). As described
previously, this approach allows appropriate adjustment for
time-dependent confounding.17,18 We created new trials with
all eligible individuals for each month between January 1996
and May 2013. Individuals were eligible for a trial if they
were cART-naive before the baseline month, had a CD4 or
HIV-RNA measurement 12 months before the baseline
month, and were AIDS-free until the end of the baseline
month. Time to AIDS/death was compared in those who
initiated cART in each baseline month versus those who
deferred, pooling across all trials.
AIDS events in the first year of seroconversion were not
considered as disease progression outcomes, but rather as
severe seroconversion illness. In addition, invasive candidi-
asis was not considered an outcome in this analysis as it is
typically less severe and associated with longer survival
compared with other AIDS-defining conditions.19–22
Viremia Measurements
If HIV-RNA could be continuously measured within an
individual from seroconversion [with the viral load distribu-
tion at any time t called as V(t)], then VCY would be
calculated as the area under the HIV-RNA curve, or the
integral of HIV-RNA from seroconversion to time t = T.
VCY ¼
ZT
SC
VðtÞdt:
However, in practice, we do not have continuously measured
viral loads, but rather snapshots of HIV-RNA measurements for
each individual at irregularly spaced intervals (usually approxi-
mately 3 monthly). The best approximation to the integral with
the data available can be obtained through use of the trapezoidal
rule, which is how we approximated VCY for the remainder of
this analysis. At any given time point, J, say, VCY(J) is given
by:VCYðJÞ ¼ PJj¼1 tðjÞ2tðj21Þ∗V ðjÞþVðj21Þ2 . We examined
HIV-RNA data for implausible values and identified 3 individ-
uals whose HIV-RNA dropped by factors of 4, 26, and 87
between consecutive measurements and without apparently
starting cART. These are far greater drops than would be
expected based on the known biological variation of HIV-
RNA.23,24 As all 3 individuals were recorded as having started
cART in the following month, we assumed that the date of cART
initiation had been incorrectly recorded, and reset the cART start
dates for these individuals to 1 month before that recorded.
To estimate HIV exposure equally for all individuals, we
removed HIV-RNA measurements taken in the first 3 months of
seroconversion, as we were unlikely to capture the well-
documented peak in viremia shortly after seroconversion25 for
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all individuals. In addition, we assumed that HIV-RNA measure-
ments remained relatively stable over the period 4–12 months
(consistent with findings of the viral load stabilizing after the
initial peak in viremia), allowing us to make the assumption that
an individual’s first available HIV-RNA over the period 4–12
months was equal to their HIV-RNA at month 4.
Data Analysis
We describe baseline characteristics between those who
initiated or deferred cART during the study period. We
estimated the HRs for initiating versus deferring cART by
levels of VCY (,10,000 copy-years/mL, $10,000–19,999
copy-years/mL, $20,000–49,999 copy-years/mL, $50,000–
99,999 copy-years/mL, $100,000 copy-year/mL) pooled
across and stratified by CD4 cell count strata (initiate at CD4
,350 cells/mm3 compared with initiate at higher values,$350
cells/mm3, and initiate at ,500 cells/mm3 compared with
initiate at higher values, $500 cells/mm3) using Cox pro-
portional hazards models. We adjusted for trial-independent
factors including country of care, sex, HIV transmission risk
group, seroconversion year, and trial-dependent factors of
current age, time since last HIV-RNA measurement, CD4,
VCY, HIV-RNA, and mean number of previous CD4/HIV-
RNA measurements per year. Trial-dependent factors were
ascertained before the baseline month to ensure they were
measured before the decision to initiate or defer cART in the
current month. Continuous variables were modeled using
restricted cubic splines, all with 3 knots with the exception of
current CD4 which was modeled with 5 knots.26 Most
individuals contributed to more than 1 trial, so we used a robust
variance estimator to account for within-person correlation. To
investigate whether a threshold existed where cART initiation
showed the most benefit, we fitted interactions between initiating
cART and VCY as a continuous variable with a 3-knot spline.
Furthermore, we investigated whether there was a ben-
efit of incorporating other measures of viremia into the
decision about when to initiate cART, namely, current HIV-
RNA (most recent measurement), average HIV-RNA (mean
of all previous measurements), and maximum HIV-RNA
(maximum of all previous measurements). To compare results
between all HIV-RNA measurements with VCY, we used the
same inclusion criteria for all analyses. We used the Akaike27
information criteria (AIC), a measure of the relative quality of
statistical models which evaluates trade-off between model
complexity and goodness of fit, to determine which measure
of viremia best fits the data.
RESULTS
Baseline Characteristics
The CASCADE 2013 update contains information on
30,006 individuals, of whom 21,082 seroconverted in the cART
era, during or after 1996. Of those, we excluded 916 individuals
from African cohorts and 10,813 individuals without at least 1
cART-naive HIV-RNA measurement within 4–12 months of
seroconversion, leaving 9353 individuals in the analysis.
Among those seroconverting in the cART era (n =
21,082), men who have sex between men were slightly over-
represented in this analysis compared with those excluded (80%
vs. 62%) and those who likely acquired HIV through sex
between men and women were slightly underrepresented (9%
vs. 29%). Date of seroconversion was later in those included in
this analysis [November 2005 (July 2002–August 2008)] than in
those excluded [July 2004 (July 2000–March 2008)] explained
by availability of routine HIV-RNA measurements within the
cohorts. All other baseline characteristics were similar among
those included and excluded from this analysis (data not shown).
Of 9353 individuals, 5312 (57%) initiated cART, 326
(3%) acquired AIDS, and 160 (2%) died. Median [interquar-
tile range (IQR) [25th–75th percentile] follow-up was 4.1
(1.8, 7.2) years. Most individuals were men (85%), and
modes of HIV transmission included sex between men (71%),
sex between men and women (21%), injection drug use (4%),
and unknown (4%). Median (IQR) CD4 at cART initiation
was 342 (265, 450) cells per cubic millimeter and did not vary
by VCY category. Median (IQR) seroconversion age was 33
(27, 40) years between 1996 and 2013. Individuals contrib-
uted to a median (IQR) of 21 (13, 36) trials.
Individuals who initiated cART typically had much
lower CD4 cell counts and higher HIV-RNA values than
those deferring cART. Men were also more likely to defer in
the lower viral copy-years strata (Table 1).
FIGURE 1. A diagram of the “trials”
construction. Individuals are assessed
for eligibility at the beginning of each
month (respective trial baseline).
Each eligible individual is classified as
having initiated or deferred cART in
the baseline month. Time is mea-
sured from the beginning of the fol-
lowing month until AIDS, death, or
censoring for each eligible individual
(excluding any with an outcome
during the baseline month). Cox
proportional hazards models are
used to assess the effect of initiating
compared with deferring cART on
time to AIDS/death, pooled across all
trials.
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Viremia Copy-Years
Pooling across CD4 cell count strata, HRs for the effect
of initiating cART compared with deferring on time to AIDS/
death significantly decreased as VCY increased (P-trend ,
0.001). For example, at times when the VCY was in the range
10,000–20,000 copy-years/mL, there was only a modest 9%
reduction in the hazard of AIDS/death associated with
immediate initiation of cART compared with deferral
[HR = 0.91 (95% CI: 0.57 to 1.46)], whereas at times when
the VCY was .100,000 copy-years/mL, the estimated
reduction in risk of AIDS/death associated with immediate
versus deferred initiation was 56% [HR = 0.44 (95% CI: 0.35
TABLE 1. Baseline Characteristic for Individuals Who Initiated or Deferred cART by Levels of VCY
Characteristic Initiated cART Deferred cART
VCY , 10,000 copy-years/mL
“Trial” observations, N 651 50,349
Follow-up, median (IQR) person-years 3.3 (1.4, 6.8) 4.2 (2.1, 7.0)
Male, N (%) 398 (61) 38,869 (77)
Seroconversion year 2005 (2000, 2009) 2004 (2001, 2007)
Seroconversion age 30 (26, 37) 33 (27, 39)
CD4 cell count median (IQR), mm3 397 (291, 567) 637 (486, 826)
HIV-RNA copies/mL median (IQR) * 3.7 (3.2, 4.1) 3.4 (3.0, 3.8)
VCY median (IQR) * 3.6 (3.2, 3.8) 3.5 (3.0, 3.8)
VCY $ 10,000–19,999 copy-years/mL
Trial observations, N 488 22,825
Follow-up, median (IQR) person-years 3.0 (1.4, 6.0) 4.0 (2.0, 6.6)
Male, N (%) 382 (78) 19,348 (85)
Seroconversion year 2006 (2002, 2009) 2005 (2002, 2007)
Seroconversion age 33 (26, 40) 32 (27, 39)
CD4 cell count median (IQR), mm3 360 (282, 475) 553 (437, 707)
HIV-RNA copies/mL median (IQR) * 4.3 (3.9, 4.6) 4.1 (3.7, 4.4)
VCY median (IQR) * 4.2 (4.1, 4.2) 4.2 (4.1, 4.2)
VCY $ 20,000–49,999 copy-years/mL
Trial observations, N 1026 39,675
Follow-up, median (IQR) person-years 3.3 (1.4, 6.6) 3.9 (1.9, 6.5)
Male, N (%) 853 (83) 34,804 (88)
Seroconversion year 2006 (2001, 2008) 2004 (2002, 2007)
Seroconversion age 34 (28, 41) 33 (27, 39)
CD4 cell count median (IQR), mm3 355 (277, 466) 523 (417, 662)
HIV-RNA copies/mL median (IQR) * 4.6 (4.3, 4.9) 4.3 (3.9, 4.6)
VCY median (IQR) * 4.5 (4.4, 4.6) 4.5 (4.4, 4.6)
VCY $ 50,000–99,999 copy-years/mL
Trial observations, N 950 30,925
Follow-up, median (IQR) person-years 3.1 (1.4, 5.7) 3.8 (1.8, 6.2)
Male, N (%) 837 (88) 27,657 (89)
Seroconversion year 2005 (2002, 2008) 2004 (2002, 2006)
Seroconversion age 33 (27, 41) 33 (27, 39)
CD4 cell count median (IQR), mm3 340 (272, 440) 492 (393, 628)
HIV-RNA copies/mL median (IQR) * 4.8 (4.4, 5.1) 4.5 (4.2, 4.8)
VCY median (IQR) * 4.9 (4.8, 4.9) 4.8 (4.8, 4.9)
VCY $ 100,000 copy-years/mL
Trial observations, N 2102 44,581
Follow-up, median (IQR) person-years 3.5 (1.6, 5.6) 3.9 (1.8, 6.2)
Male, N (%) 1928 (92) 41,702 (94)
Seroconversion year 2005 (2002, 2007) 2004 (2001, 2006)
Seroconversion age 35 (29, 42) 33 (28, 40)
CD4 cell count median (IQR), mm3 320 (246, 411) 467 (370, 591)
HIV-RNA copies/mL median (IQR) * 5.2 (4.8, 5.5) 4.9 (4.5, 5.2)
VCY median (IQR) * 5.3 (5.2, 5.6) 5.3 (5.1, 5.5)
*Log10 copies per milliliter.
IQR, 25th and 75th percentiles.
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to 0.55)], Table 2. Among individuals initiating with CD4
$350 cells per cubic millimeter, there was a modest trend
(P = 0.11) toward a greater benefit of immediate initiation of
cART (vs. deferral), although the results continued to suggest
some benefit of earlier initiation among the group with VCY
.100,000 copy-years/mL [HR = 0.68 (95% CI: 0.49 to 0.94)],
Table 2. As expected among individuals initiating with CD4
,350 cells per cubic millimeter, immediate initiation was
beneficial in all VCY categories (all HR , 1) (see Table,
Supplemental Digital Content, http://links.lww.com/QAI/A817).
Modeling initiation of cART by VCY as a continuous
variable showed the same trends as the categorical analysis,
Figure 2. No obvious threshold of copy-years was found;
however, pooling CD4 cell count categories, the upper bound
of the 95% CI first fell below one when VCY passed 17,343
copies-years/mL, suggesting that among individuals with
VCY values above this threshold, immediate initiation of
cART may result in a reduction in the risk of AIDS/death.
Stratifying by CD4 cell count, in those with CD4 $350 cells
per cubic millimeter, the upper bound of the 95% CI fell
below one when VCY surpassed 52,826 copy-years/mL,
again suggesting that among individuals with high CD4 cell
counts and VCY values above this threshold, immediate
initiation of cART may result in a reduction in the risk
of AIDS/death.
Using a CD4 count threshold of 500 cells per cubic
millimeter showed similar results. For those with CD4 $500
cells per cubic millimeter, the greatest benefit of initiation was
seen when VCY .100,000 copy-years/mL [HR = 0.41 (0.19,
0.87), P-trend = 0.09], Table 2. Modeling VCY continuously,
the upper bound of the 95% CI in those with CD4 $500 cells
per cubic millimeter fell below one when VCY surpassed 38,152
copy-years/mL. In those with a CD4 count,500 cells per cubic
millimeter, there was an overall benefit of treatment initiation in
VCY categories .10,000 copy-years/mL (see Table, Supple-
mental Digital Content, http://links.lww.com/QAI/A817).
Other Measures of Viremia
Pooling CD4 strata, the HRs for the effect of initiating
cART on time to AIDS/death decreased as most recent HIV-
RNA increased (P-trend , 0.001) with the largest benefit of
initiation seen when current HIV-RNA exceeded 100,000
copies/mL [HR = 0.45 (0.36, 0.57)]. Among individuals with
a CD4 count $350 cells per cubic millimeter, there was
a modest trend (P-trend = 0.08) for an increased benefit of
immediate initiation (vs. deferral) as the current HIV-RNA
increased, with the largest benefit of immediate initiation seen
if the current HIV-RNA was .100,000 copies/mL [HR =
0.65 (0.47, 0.89)], Table 2. Stratifying by CD4, there was
a benefit of initiating versus deferring for all individuals with
CD4 ,350 cells per cubic millimeter regardless of current
HIV-RNA level, as expected from the VCY analysis. The
same trends were seen when modeling VCY and current HIV-
RNA continuously, Figure 2, and when considering average
and maximum viremia (data not shown).
Using a CD4 threshold of 500 cells per cubic millime-
ter, similar results were obtained for the average and
maximum viremia (data not shown).
Pooling CD4 strata, model fit was best for VCY
(minimum AIC, 230115) compared with current (increase in
AIC = 238), average (increase in AIC = 124), and maximum
HIV-RNA (increase in AIC = 163). Maximum HIV-RNA fits
the model best in the CD4 ,500 cells per cubic millimeter
strata (minimum AIC, 1024345; increase in AIC = 32, 128,
15 for VCY, current, and average HIV-RNA, respectively, for
TABLE 2. The Effect of Initiation Compared With Deferring cART on Time to AIDS/Death by VCY Alone by CD4 Cell Count Strata
($350, $500 Cells/mm3)
All Patients CD4 ‡ 350 Cells/mm3 CD4 ‡ 500 Cells/mm3
Events,
N HR (95% CI) P, AIC
Events,
N HR (95% CI) P, AIC
Events,
N HR (95% CI) P
VCY, copy-
years/mL
,10,000 198 1.10 (0.74 to 1.63) 0.001* 181 1.04 (0.63 to 1.73) 0.51* 138 0.81 (0.36 to 1.80) 0.56*
10,000–20,000 202 0.91 (0.57 to 1.46) ,0.001† 175 0.79 (0.40 to 1.58) 0.11† 116 0.96 (0.37 to 2.52) 0.09†
20,000–50,000 260 0.69 (0.50 to 0.94) 230,115.30‡ 227 0.88 (0.61 to 1.29) 186,803.80‡ 166 0.70 (0.37 to 1.31) 113,258.00‡
50,000–100,000 242 0.56 (0.40 to 0.80) 206 0.60 (0.36 to 1.01) 146 0.45 (0.18 to 1.09)
.100,000 225 0.44 (0.35 to 0.55) 182 0.68 (0.49 to 0.94) 117 0.41 (0.19 to 0.87)
Current HIV-RNA,
copies/mL
,10,000 180 1.14 (0.81 to 1.61) 0.001* 167 1.37 (0.89 to 2.09) 0.03* 161 0.86 (0.46 to 1.61)§ 0.40*
10,000–20,000 ʇ 140 0.63 (0.36 to 1.08) ,0.001† 121 0.54 (0.22 to 1.33) 0.08† — 0.08†
20,000–50,000 211 0.53 (0.37 to 0.76) 230,353.40‡ 182 0.55 (0.34 to 0.89) 187,014.80‡ 132 0.58 (0.28 to 1.23) 113,454.30‡
50,000–100,000 202 0.62 (0.45 to 0.86) 163 0.80 (0.57 to 1.25) 107 0.61 (0.28 to 1.31)
.100,000 202 0.45 (0.36 to 0.57) 195 0.65 (0.47 to 0.89) 120 0.38 (0.19 to 0.77)
*p-heterogeneity (df = 4).
†p-trend (df = 1).
‡AIC, Akaike information criterion.
§By chance, there were no failures among initiators in the CD4 $500 cells per cubic millimeter, VCY 10,000–20,000 category, so this category is ,20,000 copies per milliliter.
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copy-years, current, average, and maximum HIV-RNA,
respectively). In the CD4 $500 cells per cubic millimeter
strata, VCY gave the best model fit (minimum AIC =
113,258.00, increase in AIC = 196, 84, for current, average,
and maximum HIV-RNA, respectively).
DISCUSSION
Pooling CD4 cell count strata, there is a benefit of
initiating cART as the cumulative and absolute HIV-RNA
increases, with benefits observed as the total VCY exceeds
approximately 17,500 copy-years/mL. What is of clinical
interest, however, is whether there is benefit of immediate
cART initiation in individuals with healthy immune systems
(CD4 $500 cells per cubic millimeter) and high levels of
viremia. Among individuals with CD4 $500 cells per cubic
millimeter, we found a modest benefit of earlier cART
initiation for those with high cumulative and absolute HIV-
RNA .100,000 copy-years/mL and copies per milliliter,
associated with reducing risk of AIDS/death by 59% (13%–
81%) and 62% (23%–81%). Our results support the recent
evidence from the START trial28 which found serious illness
or death was reduced by 53% among those treated immedi-
ately vs. waiting to initiate until CD4 cell count dropped
below 350 cells per cubic millimeter.13
All measures of viremia showed consistent and similar
results with an increased benefit of cART initiation with
increasing VCY. Among the pooled and separate CD4 cell
count strata, there was not a single viremia measure that
consistently showed best model fit using AIC. VCY fits best
when pooling CD4 and in the CD4 $350 cells per cubic
millimeter strata, whereas average viremia fits best in the CD4
,350 cells per cubic millimeter strata. Although VCY
incorporates cumulative HIV burden, it requires frequent
HIV-RNA measurements from the start of infection, which
are not available in most HIV-positive individuals. Even if such
measurements are available, cumulative viremia is difficult and
time-consuming to calculate. Average and maximum HIV-RNA
also require frequent measurements from seroconversion, so too
are not relevant for most HIV-positive individuals. Current
HIV-RNA, however, is a measure that is easily obtained from
all HIV-positive individuals and is therefore of greatest
clinical relevance.
Although observational studies are not designed to
inform the “when to start” question, we provide evidence that
cART initiation is beneficial when CD4 cell counts fall below
350 cells per cubic millimeter, supporting other observational
studies.14,29–31 The START trial has recently reported a modest
absolute risk reduction of AIDS, other serious illnesses, and
death for cART initiation at CD4 cell counts above 500 cells
per cubic millimeter11 compared with deferring initiation to
CD4 below 350 cells per cubic millimeter.13 Our analysis,
using data before guidelines recommending immediate cART
initiation, suggests that benefit is likely to be greatest in those
with highest viremia burden and adds to the body of evidence
which informs clinical guidelines.32
We reflected the dynamic process of initiating cART by
allowing individuals to contribute information to multiple
trials rather than just considering a single point in time. This
provided estimates of the average benefit of initiating cART
compared with deferring cART at particular levels of CD4
cell counts and cumulative exposure to HIV-RNA. Our
estimates can therefore be used to inform trade-offs between
initiating treatment at varying points in disease progression
compared with the lifelong challenges of initiating therapy,
such as adherence and adverse effects.
The availability of HIV-RNA data from HIV serocon-
version allowed us to investigate when to start treatment based
on a variety of measures of viremia captured during the life
course of HIV infection. Of particular importance, there is
potential for lead-time bias33 when measuring cumulative
exposure to viremia in sero-prevalent cohorts which is
essentially eliminated in this sero-converter study as we have
serial HIV-RNA measurements taken from the date of
seroconversion. This is, therefore, the first study, to our
knowledge, that has compared the benefit of cART initiation
FIGURE 2. The effect of initiating
compared with deferring cART on
time to AIDS/death by VCY and CD4
cell count modeled continuously
with 3 knot splines using the CAS-
CADE data set.
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by these levels of viremia in combination with CD4 cell count.
Nevertheless, despite nearly 10,000 seroconverters being
included, we were not able to assess the impact of initiating
versus deferring within the CD4 strata where decisions on
whether cART should be initiated have previously been most
controversial (CD4 .350 cells/mm3).
In addition to AIDS and death, there are several other
non–AIDS defining conditions that can affect morbidity and
mortality. Increased exposure to viremia has been shown to
be associated with cardiovascular disease,34 multimorbidity,35
and AIDS and non-AIDS malignancies,5,36,37 so had these
data been available, our estimates could have shown a stronger
benefit of cART initiation. CASCADE does not currently
collect data on non–AIDS conditions.
Like all observational studies, our estimates rely on the
assumption of no unmeasured confounding. We adjusted for
some of the most important factors in deciding when to
initiate therapy, but it is possible that other unmeasured
factors, such as comorbidities or likelihood of adherence,
played a role in the initiation of cART in our population. The
HRs above one for cART initiation versus deferred treatment,
albeit with wide confidence intervals, in the group with low
current HIV-RNA suggest we may lack information on some
confounders; this could be a particular concern among those
with a CD4 count $350 cells per cubic millimeter, a group
for which not all treatment guidelines recommended initiation
of cART during the study period.
It is unlikely that randomized evidence will ever be
available on when to initiate cART by these measures of
viremia, so applying robust statistical methods to large
observational data sets presented here will likely provide
the best evidence that will ever be available. Our data suggest
that deferring cART in an individual unwilling or unable to
start treatment immediately may not impact the risk of AIDS/
death provided a healthy CD4 cell count ($350, 500 cells/
mm3) and low VCY (,50,000 copy-years/mL) are main-
tained. However, we found consistently that AIDS and death
were delayed among those who initiated treatment with CD4
cell counts $350 cells per cubic millimeter and VCY
.100,000 copy-years/mL.
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H I V / A I D S M A J O R A R T I C L E
Boosted Lopinavir– Versus Boosted Atazanavir–
Containing Regimens and Immunologic,
Virologic, and Clinical Outcomes: A Prospective
Study of HIV-Infected Individuals in High-
Income Countries
The HIV-CAUSAL Collaborationa
Background. Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or
ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recom-
mended and alternative first-line antiretroviral regimens. However, these guidelines are based on limited evidence
from randomized clinical trials and clinical experience.
Methods. We compared these regimens with respect to clinical, immunologic, and virologic outcomes using
data from prospective studies of human immunodeficiency virus (HIV)-infected individuals in Europe and the Unit-
ed States in the HIV-CAUSAL Collaboration, 2004–2013. Antiretroviral therapy–naive and AIDS-free individuals
were followed from the time they started a lopinavir or an atazanavir regimen. We estimated the ‘intention-to-treat’
effect for atazanavir vs lopinavir regimens on each of the outcomes.
Results. A total of 6668 individuals started a lopinavir regimen (213 deaths, 457 AIDS-defining illnesses or
deaths), and 4301 individuals started an atazanavir regimen (83 deaths, 157 AIDS-defining illnesses or deaths).
The adjusted intention-to-treat hazard ratios for atazanavir vs lopinavir regimens were 0.70 (95% confidence interval
[CI], .53–.91) for death, 0.67 (95% CI, .55–.82) for AIDS-defining illness or death, and 0.91 (95% CI, .84–.99) for
virologic failure at 12 months. The mean 12-month increase in CD4 count was 8.15 (95% CI, −.13 to 16.43) cells/µL
higher in the atazanavir group. Estimates differed by NRTI backbone.
Conclusions. Our estimates are consistent with a lower mortality, a lower incidence of AIDS-defining illness, a
greater 12-month increase in CD4 cell count, and a smaller risk of virologic failure at 12 months for atazanavir com-
pared with lopinavir regimens.
Keywords. lopinavir; atazanavir; HIV; mortality; observational studies.
Most clinical guidelines for treatment of patients with
human immunodeficiency virus (HIV) recommend
first-line regimens consisting of either a ritonavir-boosted
protease inhibitor (bPI) or a nonnucleoside reverse tran-
scriptase inhibitor (NNRTI) in combination with
2 nucleoside reverse transcriptase inhibitors (NRTIs).
Two of the most commonly prescribed bPIs are
lopinavir and atazanavir. The European AIDS Clinical
Society, the US Department of Health and Human Ser-
vices, the British HIVAssociation, and the International
AIDS Society–USA panel all currently recommend ata-
zanavir over lopinavir [1–4], but have recommended lo-
pinavir over atazanavir in the past. The World Health
Organization recommends atazanavir and lopinavir
equally as part of second-line therapy [5].
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However, these guidelines are based on limited evidence as
these regimens have not been extensively examined in previous
studies. In particular, the guidelines are largely based on clinical
experience and the results of a single randomized trial, the CAS-
TLE study [6, 7]. This trial compared ritonavir-boosted atazana-
vir with ritonavir-boosted lopinavir in combination with
tenofovir and emtricitabine and found that the proportions
with HIV RNA <50 copies/mL and the mean increases in
CD4 cell count were similar between arms at the end of fol-
low-up. However, follow-up was limited to 48 and 96 weeks,
clinical outcomes such as death and AIDS-defining illness
were not assessed, and estimates for AIDS-free individuals
(who are an increasing proportion of initiators of antiretroviral
therapy) were not able to be estimated.
A more recent trial, the NORTHIV study, compared ritona-
vir-boosted atazanavir vs ritonavir-boosted lopinavir in combi-
nation with 2 NRTIs of the physician’s choice. The estimates for
immunologic and virologic outcomes were similar to those of
the CASTLE study [8]. Again, follow-up was limited (48 and
144 weeks), no clinical outcomes were evaluated, and estimates
were not reported for AIDS-free individuals.
Here we aim to complement the randomized trials by provid-
ing new evidence on clinical outcomes. We examine deaths and
AIDS-defining illnesses among AIDS-free patients who start a
first-line regimen consisting of either ritonavir-boosted lopina-
vir or ritonavir-boosted atazanavir with an NRTI backbone in a
large collaboration of prospective cohort studies from the Unit-
ed States and Europe. We also study short-term immunologic
and virologic outcomes for comparison with the CASTLE and
NORTHIV studies.
METHODS
Study Population
The HIV-CAUSAL Collaboration has been described elsewhere
[9]. In brief, the collaboration includes several prospective co-
hort studies from 6 European countries and the United States:
UK CHIC (United Kingdom), ATHENA (the Netherlands),
FHDH-ANRS CO4 (France), Aquitaine (France), SHCS (Swit-
zerland), PISCIS (Spain), CoRIS (Spain), VACS-VC (United
States veterans), AMACS (Greece), UK Register of HIV Sero-
converters (United Kingdom), ANRS PRIMO (France), and
GEMES (Spain). All cohorts included in the HIV-CAUSAL
Collaboration were assembled prospectively and are based on
data collected for clinical purposes within national healthcare
systems with universal access to care. Each cohort in the collab-
oration collects data on all CD4 cell counts, HIV RNA levels,
treatment initiations, AIDS-defining illnesses, and deaths.
For each individual, follow-up started at the initiation of an
eligible antiretroviral regimen (baseline). Our analysis was re-
stricted to HIV-infected individuals who met the following
eligibility criteria at baseline dates between 2004 and 2013;
age ≥18 years, previously antiretroviral therapy naive, no histo-
ry of an AIDS-defining illness [10], no pregnancy (when infor-
mation was available), and CD4 cell count and HIV RNA
measurements within 6 months prior to baseline. For the anal-
ysis of clinical outcomes, follow-up ended at the occurrence of
the outcome, 12 months after the most recent laboratory mea-
surement (ie, we considered an individual to be lost to follow-
up if and when he/she had no new CD4 or RNA measurements
for 12 months), pregnancy (if known), or the cohort-specific
administrative end of follow-up (ranging from September
2010 to March 2013), whichever occurred first. For the analysis
of immunologic and virologic outcomes, follow-up ended on
average at 12 months after baseline.
Outcomes
We considered clinical, immunologic, and virologic outcomes.
The clinical outcomes of interest were death from any cause and
clinical AIDS-defining illness [10] or death. Dates of death were
identified using a combination of national and local mortality
registries and clinical records as described elsewhere [9], and
AIDS-defining illnesses were ascertained by the treating
physicians.
The immunologic outcome of interest was the 12-month
change in CD4 cell count after baseline. If CD4 cell count
was not measured exactly 12 months after baseline, we used
the closest measurement within 2 months. Similarly, the viro-
logic outcome of interest was virologic failure defined as HIV
RNA >50 copies/mL at 12 ± 2 months.
Antiretroviral Regimens
We considered 2 types of first-line regimens: lopinavir and ata-
zanavir regimens. The analysis was restricted to individuals who
started ritonavir, an NRTI backbone, and either lopinavir or
atazanavir at baseline. Individuals were excluded if they started
an ineligible drug (ie, an NNRTI, an integrase inhibitor, a fusion
inhibitor, or a PI other than ritonavir, lopinavir, or atazanavir)
or both lopinavir and atazanavir at baseline.
Statistical Methods
We fit pooled logistic models to estimate the hazard ratio of
each clinical outcome for atazanavir vs lopinavir regimens.
Both models included a regimen indicator (1: atazanavir, 0: lo-
pinavir), cohort, month of follow-up (modeled as a restricted
cubic spline with 4 knots at 1, 6, 24, and 60 months), and the
following baseline covariates: sex, age (<35, 35–49, ≥50 years),
race (white, black, other, or unknown), geographic origin
(Western countries, sub-Saharan Africa, other, or unknown),
mode of HIV acquisition (heterosexual, homosexual/bisexual,
injection drug use, other/unknown), CD4 cell count (<200, 200–
299, 300–399, 400–499, ≥500 cells/µL), HIV RNA (<10 000,
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10 000–100 000, >100 000 copies/mL), calendar year (2004–
2007, ≥2008), and time since HIV diagnosis (<1 year, 1–4
years, ≥5 years, or unknown). For the immunologic outcome,
we fit a linear regression model with the same covariates to es-
timate the 12-month change in CD4 cell count for atazanavir vs
lopinavir regimens among those with measurements at 12 ± 2
months. For the virologic outcome, we fit a modified Poisson
regression model [11] with the same covariates to estimate
the risk ratio of virologic failure at 12 months for atazanavir
vs lopinavir regimens among those with measurements at
12 ± 2 months.
Under the assumption that we measured and successfully ad-
justed for all confounders, the estimated coefficient for the reg-
imen indicator in the adjusted models can be interpreted as the
‘intention-to-treat’ effect that would have been estimated from
an open-label randomized trial with similar adherence and fol-
low-up. Because we defined the clinical regimens of interest in
terms of the first-line regimen only, it was unnecessary to adjust
for joint determinants of switching and death. The Supplemen-
tary Appendix Table shows estimates from unadjusted models.
For the 2 clinical outcomes, we also estimated absolute risks
by fitting adjusted models such as the one described above that
also included product (“interaction”) terms between the regi-
men indicator and month of follow-up with spline terms. The
models’ predicted values were then used to estimate the 5-year
survival and 5-year AIDS-free survival curves from baseline.
For death, we also estimated the hazard ratio in subsets de-
fined by baseline calendar year, sex, age, mode of HIV acquisi-
tion, baseline CD4 cell count, and baseline HIV RNA. For
AIDS-defining illness or death, we also estimated the hazard
ratio in subsets defined by NRTI backbone. Because of limited
numbers of deaths, we were not able to look at subsets defined
by NRTI backbone for our death-only outcome.
Sensitivity Analyses
Because the lower limit of detection was unknown in <5% of
observations with HIV RNA between 50 and 400 copies/mL,
we conducted a sensitivity analysis in which we defined virolog-
ic failure as HIV RNA >400 copies/mL.
In another sensitivity analysis, we allowed a 6-month grace
period for individuals to complete one of the regimens of inter-
est as opposed to requiring individuals to start all of the drugs in
their regimen simultaneously. Individuals were artificially cen-
sored if and when they started an ineligible drug before com-
pleting a regimen or at 6 months from baseline if their
regimen was not yet complete. As previously described, to ad-
just for potential selection bias due to the artificial censoring, we
estimated unstabilized inverse probability weights [12] via
pooled logistic models for artificial censoring that included
the time-fixed covariates and time-varying CD4 cell count (re-
stricted cubic spline with 5 knots at 10, 200, 350, 500, and 1000
cells/µL), HIV RNA (<10 000, 10 000–100 000, >100 000 cop-
ies/mL), AIDS-defining illness (when the outcome was death
alone), and time since last laboratory measurement (0, 1–2,
3–4, 5–6, ≥7 months). Note that inverse-probability weighting
was not necessary in our main analysis, as treatment was deter-
mined at baseline.
Several other sensitivity analyses were also performed. For all
4 outcomes, we used continuous as opposed to categorical base-
line covariates, weighted by the inverse probability of remaining
uncensored due to infrequent laboratory measurements, and in-
vestigated the effect of including chronic hepatitis C infection
[13] as a baseline covariate. For the immunologic and virologic
outcomes, we also weighted by the inverse probability of re-
maining alive and having a measurement at 12 ± 2 months
after baseline as a form of competing risk analysis.
All 95% confidence intervals (CIs) were estimated via a non-
parametric bootstrap with 500 samples. All analyses were con-
ducted with SAS software version 9.3 (SAS Institute, Cary,
North Carolina).
RESULTS
The dataset included 10 969 individuals, of whom 6668 fol-
lowed a lopinavir regimen and 4301 followed an atazanavir reg-
imen. Table 1 shows the characteristics of the study population
by regimen type at baseline. Women, individuals aged <35 years
at baseline, those from non-Western countries, those with the
lowest baseline CD4 cell counts, those with the highest baseline
HIV RNA levels, and those starting treatment before 2008 were
more likely to initiate lopinavir than atazanavir.
In the mortality analysis, the median follow-up time was 40
(interquartile range [IQR], 20–61) months for the lopinavir reg-
imens and 27 (IQR, 14–45) months for the atazanavir regimens.
In the AIDS-defining illness or death analysis, the median fol-
low-up time was 37 (IQR, 18–60) months for the lopinavir reg-
imens and 26 (IQR, 13–44) months for the atazanavir regimens.
There were 3322 individuals lost to follow-up in the death anal-
ysis, of whom 2366 followed a lopinavir regimen and 956 fol-
lowed an atazanavir regimen. In the AIDS or death analysis,
3228 were lost to follow-up, of whom 2290 followed a lopinavir
regimen and 938 followed an atazanavir regimen.
As shown in Table 2, 213 and 83 individuals died and 457
and 157 individuals developed an AIDS-defining illness or
died among those initiating a lopinavir and an atazanavir regi-
men, respectively. Compared with lopinavir, the hazard ratio for
atazanavir was 0.70 (95% CI, .53–.91) for death and 0.67 (95%
CI, .55–.82) for AIDS or death.
Table 2 also shows the 12-month adjusted mean change in
CD4 cell count and the number with virologic failure at
12 ± 2 months. Compared with lopinavir, the estimated mean
change in CD4 cell count for atazanavir was 8.15 (95% CI,
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−.13 to 16.43) cells/µL. The mean CD4 cell count would have
increased from 269 to 470 cells/µL over 12 months had all indi-
viduals taken a lopinavir regimen, and from 269 to 478 cells/µL
had all individuals taken an atazanavir regimen.
Among those initiating lopinavir and atazanavir regimens,
26% and 24%, respectively, had HIV RNA >50 copies/mL at
12 months. Compared with lopinavir, the risk ratio of virologic
failure for atazanavir was 0.91 (95% CI, .84–.99).
Figure 1 plots the estimated 5-year survival and 5-year AIDS-
free survival. The survival was 96.1% (95% CI, 95.5%–96.7%)
for the lopinavir regimens and 97.1% (95% CI, 96.5%–97.8%)
for the atazanavir regimens. The 5-year survival difference
was 1.0% (95% CI, .1%–1.9%). The AIDS-free survival propor-
tion was 92.3% (95% CI, 91.5%–93.1%) for the lopinavir regi-
mens and 94.4% (95% CI, 93.5%–95.4%) for the atazanavir
regimens. The 5-year AIDS-free survival difference was 2.2%
(95% CI, .9%–3.4%).
In subset analyses, the mortality hazard ratio was 0.45 (95%
CI, .26–.77) when we restricted to baseline calendar years 2008
and beyond; 0.65 (95% CI, .49–.88) when we restricted to men,
0.59 (95% CI, .41–.87) when we restricted to individuals aged
<50 years; 0.69 (95% CI, .52–.91) when we restricted to non–
injection drug users; 0.62 (95% CI, .46–.84) when we restricted
to those with baseline CD4 cell counts <350 cells/µL; 0.57 (95%
CI, .37–.88) when we restricted to those with baseline viral loads
>100 000 copies/mL; and 0.72 (95% CI, .54–.96) when we re-
stricted to those from Western countries.
Table 3 shows the number and percentage of individuals
taking recommended NRTI backbones by regimen type.
Backbones consisting of abacavir/lamivudine and tenofovir/
emtricitabine were more frequently used with atazanavir, whereas
backbones of zidovudine/lamivudine and tenofovir/lamivudine
were more frequently used with lopinavir. Table 3 also shows
the hazard ratio for AIDS or death by NRTI backbone. Com-
pared with lopinavir, the hazard ratio for atazanavir ranged
from 0.50 (95% CI, .38–.65) for tenofovir/emtricitabine to 1.12
(95% CI, .48–2.60) for zidovudine/lamivudine.
None of the sensitivity analyses yielded appreciably different
results (data not shown), with the exception of the alternative
definition of virologic failure. When we defined virologic failure
as HIV RNA >400 copies/mL, 14% and 10% of those initiating
lopinavir and atazanavir, respectively, had HIV RNA >400 cop-
ies/mL at 12 months. The risk ratio of virologic failure (HIV
RNA >400 copies/mL) was 0.79 (95% CI, .69–.90) for atazana-
vir vs lopinavir (see Supplementary Appendix Table).
DISCUSSION
The clinical effectiveness of ritonavir-boosted atazanavir vs ri-
tonavir-boosted lopinavir has not been directly studied in ran-
domized trials, which have focused on short-term immunologic
Table 1. Characteristics of 10 969 Therapy-Naive HIV-Infected
Individuals at Baseline, HIV-CAUSAL Collaboration, 2004–2013
Characteristic
No. of Individuals (%)
Lopinavir
(n = 6668)
Atazanavir
(n = 4301)
Total
(n = 10 969)
Sex
Male 4429 (66.4) 3372 (78.4) 7801 (71.1)
Female 2239 (33.6) 929 (21.6) 3168 (28.9)
Age, years
<35 2741 (41.1) 1435 (33.4) 4176 (38.1)
35–50 2877 (43.1) 2035 (47.3) 4912 (44.8)
>50 1050 (15.7) 831 (19.3) 1881 (17.1)
Geographic origin
Western countries 4295 (64.4) 3215 (74.8) 7510 (68.5)
Sub-Saharan Africa 1526 (22.9) 601 (14) 2127 (19.4)
Other 629 (9.4) 348 (8.1) 977 (8.9)
Unknown 218 (3.3) 137 (3.2) 355 (3.2)
Acquisition group
Heterosexual 3118 (46.8) 1444 (33.6) 4562 (41.6)
Homosexual 2254 (33.8) 1892 (44) 4146 (37.8)
Injection drug use 362 (5.4) 187 (4.3) 549 (5)
Other/unknowna 934 (14) 778 (18.1) 1712 (15.6)
CD4 count, cells/µL
<200 2634 (39.5) 1226 (28.5) 3860 (35.2)
200–299 1808 (27.1) 1245 (28.9) 3053 (27.8)
300–399 1124 (16.9) 1030 (23.9) 2154 (19.6)
400–499 537 (8.1) 427 (9.9) 964 (8.8)
≥500 565 (8.5) 373 (8.7) 938 (8.6)
HIV RNA, copies/mL
<10 000 1290 (19.3) 827 (19.2) 2117 (19.3)
10 000–100 000 2579 (38.7) 1958 (45.5) 4537 (41.4)
>100 000 2799 (42) 1516 (35.2) 4315 (39.3)
Calendar year
2004–2007 4220 (63.3) 1396 (32.5) 5616 (51.2)
≥2008 2448 (36.7) 2905 (67.5) 5353 (48.8)
Cohort
UK CHIC 1055 (15.8) 704 (16.4) 1759 (16)
ATHENA 498 (7.5) 380 (8.8) 878 (8)
FHDH-ANRS CO4 2558 (38.4) 1491 (34.7) 4049 (36.9)
Aquitaine 433 (6.5) 322 (7.5) 755 (6.9)
SHCS 723 (10.8) 421 (9.8) 1144 (10.4)
PISCIS/AMACS 491 (7.4) 182 (4.2) 673 (6.1)
CoRIS 271 (4.1) 152 (3.5) 423 (3.9)
Seroconvertersb 489 (7.3) 553 (12.9) 1042 (9.5)
VACS-VC 150 (2.2) 96 (2.2) 246 (2.2)
HCV infection
Definite/probable 119 (1.8) 116 (2.7) 235 (2.1)
Possible 324 (4.9) 139 (3.2) 463 (4.2)
None 6225 (93.4) 4046 (94.1) 10 271 (93.6)
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.
a Other/unknown acquisition group included all VACS-VC participants.
b Includes the UK Register of HIV Seroconverters, ANRS PRIMO, and GEMES
(Grupo Español Multicéntrico para el Estudio de Seroconvertores-Haemophilia)
cohorts.
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and virologic outcomes. Our study compared atazanavir vs lo-
pinavir regimens with respect to clinical outcomes among anti-
retroviral-naive, AIDS-free individuals in Europe and the
United States. We estimated a 30% mortality reduction and a
33% reduction in a combined endpoint of death and AIDS-
defining illness for atazanavir vs lopinavir. We also found that
atazanavir had a beneficial but modest effect on immunologic
and virologic outcomes.
Unlike previous observational studies [14, 15], we designed
our observational analysis to emulate the intention-to-treat
analysis of a randomized clinical trial in which antiretroviral-
naive, AIDS-free adults are randomized to receive either ritona-
vir-boosted lopinavir or ritonavir-boosted atazanavir with an
NRTI backbone. Our estimates are based on less restrictive cri-
teria, and therefore are potentially more relevant to the general
population of HIV-infected patients than those of the CASTLE
Table 2. Clinical, Immunologic, and Virologic Outcomes for Regimens Based on Atazanavir (n = 4301) Versus Lopinavir (n = 6668),
HIV-CAUSAL Collaboration, 2004–2013
Outcome Treatment No. of Outcomes HR (95% CI)
Death Lopinavir 213 1 (Ref.)
Atazanavir 83 0.70 (.53–.91)
AIDS or death Lopinavir 457 1 (Ref.)
Atazanavir 157 0.67 (.55–.82)
Adjusted Mean
Change, Cells/µLa
Change From Baseline,
Cells/µL (95% CI)
CD4 cell count Lopinavir 201.11 1 (Ref.)
Atazanavir 209.26 8.15 (–.13 to 16.43)
No. Failedb Risk Ratioc (95% CI)
Virologic failure (HIV RNA
>50 copies/mL)
Lopinavir 1260 1 (Ref.)
Atazanavir 683 0.91 (.84–.99)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; Ref., reference.
a Based on 4881 and 2864 individuals with CD4 cell count measurements at 12 ± 2 months in the lopinavir and atazanavir arms, respectively.
b Based on 4812 and 2878 individuals with HIV RNA measurements at 12 ± 2 months in the lopinavir and atazanavir arms, respectively.
c Adjusted for the baseline covariates (sex, age, race, geographic origin, mode of acquisition, CD4 cell count, HIV RNA, calendar year, and years since HIV diagnosis).
Figure 1. Survival (left) and AIDS-free survival (right) for atazanavir vs lopinavir, HIV-CAUSAL Collaboration, 2004–2013. The curves are standardized by
the baseline covariates listed in the Table 2 footnotes.
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[6, 7] and NORTHIV studies [8]. When we more closely emu-
lated the design and inclusion criteria of the CASTLE study (ie,
baseline HIV RNA ≥5000 copies/mL, and an NRTI backbone
of tenofovir and emtricitabine), we estimated a risk ratio of vi-
rologic failure of 1.00 (95% CI, .89–1.13), similar to 1.06 (95%
CI, .73–1.53) from our meta-analysis of the 2 trials. Our study,
however, may still differ from the CASTLE and NORTH IV
studies in several ways.
In the CASTLE Study, both arms had a backbone of tenofovir
and emtricitabine. In the NORTHIV study, as in our study, the
prescribing physician could select the backbone. We conducted
analyses restricted to 4 recommended backbones for the out-
come AIDS-defining illness or death. Our estimates differed
by NRTI backbone. Although we found little difference between
lopinavir and atazanavir for those on the NRTI backbones
abacavir/lamivudine, zidovudine/lamivudine, and tenofovir/
lamivudine, our results may suggest an interaction between
lopinavir and tenofovir/emtricitabine that results in lower regi-
men potency. As this is the most commonly used NRTI back-
bone, this interaction merits further investigation.
In the CASTLE and NORTHIV studies, individuals received
400 mg/100 mg of lopinavir/ritonavir twice daily. We do not
know whether individuals on lopinavir regimens in our study
were taking their medication once or twice daily. Although
once-daily regimens are generally associated with better adher-
ence, this is unlikely to be a source of bias as both schedules
performed similarly in randomized clinical trials [16–18].
As with all observational estimates, ours rely on the un-
testable assumption that we have successfully measured and
adjusted for all confounders. In this analysis, we measured
and adjusted for sex, age, race, geographic origin, mode of
HIV acquisition, CD4 cell count, HIV RNA, calendar year,
and years since HIV diagnosis. If further adjustment is neces-
sary to account for confounding factors responsible for large
prognostic differences between patients initiating lopinavir vs
atazanavir, the assumption would not hold.
One of these confounding factors might be adherence if lopi-
navir was more often prescribed to individuals whose future ad-
herence was questionable (eg, because of markers of poor health
such as hepatic diseases) even in the absence of a clinical indica-
tion for switching or treatment discontinuation. However, we
measured and adjusted for several proxies for adherence, includ-
ing HIV RNA, calendar year, intravenous drug use, years since
HIV diagnosis, and time since last laboratory measurement.
Another potential confounding factor is concomitant medi-
cation use. For example, ritonavir-boosted atazanavir is not rec-
ommended for use with antacids and other drugs that raise
gastric pH [2], whereas ritonavir-boosted lopinavir may lead
to increased statin use because of unfavorable lipid changes
and increased risk of myocardial infarction [19–21]. Although
we could not adjust for non–antiretroviral drug use, the magni-
tude of the reported associations makes it unlikely that our
immunologic and virologic estimates can be fully explained
by use of antacids, statins, or other drugs.
In summary, our findings extend those of randomized trials
from immunologic and virologic outcomes to clinical outcomes.
Although we provide new evidence upon which the next set of
guidelines can be based, our findings do not support changes to
the current guidelines. Future studies need to consider the effects
of lopinavir and atazanavir on other clinical outcomes including
non-AIDS-defining illnesses, when paired with specific backbones,
particularly tenofovir/emtricitabine, and over longer periods.
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Table 3. AIDS or Death by Recommended Nucleoside Reverse
Transcriptase Inhibitor Backbone, HIV-CAUSAL Collaboration,
2004–2013
Backbone
No. of Individuals (%)
HR for Atazanavir vs
Lopinavira (95% CI)
Lopinavir
(n = 6668)
Atazanavir
(n = 4301)
Abacavir/
lamivudine
719 (10.8) 658 (15.3) 0.83 (.48–1.42)
Tenofovir/
emtricitabine
2875 (43.1) 3286 (76.4) 0.50 (.38–.65)
Zidovudine/
lamivudine
2407 (36.1) 88 (2) 1.12 (.48–2.60)
Tenofovir/
lamivudine
237 (3.6) 140 (3.3) 0.67 (.30–1.46)
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Adjusted for the baseline covariates (sex, age, race, geographic origin, mode
of acquisition, CD4 cell count, human immunodeficiency virus [HIV] RNA,
calendar year, and years since HIV diagnosis).
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Temporal trends of transmitted HIV drug resistance in
a multinational seroconversion cohort
Ashley Olsona, Norbert Bannertb, Anders So¨nnerborgc,
Carmen de Mendozad, Matthew Pricee,f, Robert Zangerleg,
Marie-Laure Chaixh, Maria Prinsi, Anne-Marte Bakken Kranj,k,
John Gilll, Dimitrios Paraskevism, Kholoud Portera,
for CASCADE Collaboration in EuroCoordM
Background: The rate of transmitted drug resistance (TDR) may increase with wider use
of antiretroviral therapy and can contribute to therapeutic failure. We analysed time
trends in TDR among HIV seroconverters.
Methods: Using CASCADE data of individuals with well estimated dates of HIV
seroconversion, we examined HIV nucleotide sequences collected prior to antiretrovi-
ral therapy use from 1996–2012. All samples were taken within 12 months of testing
HIV positive. Using logistic regression, we examined the association between TDR and
year of seroconversion, adjusting for confounders.
Results: Of 4717 individuals seroconverting between 1996 and 2012, median (IQR)
age at seroconversion was 33 (27, 39) years. The majority (3839; 92%) were male,
mainly exposed through MSM (3767; 80%), and infected with subtype B (3464; 73%).
Overall, 515 (11%) individuals had at least one drug resistance-related mutation;
280 individuals with nucleoside reverse transcriptase, 185 with nonnucleoside reverse
transcriptase, and 144 with protease inhibitor mutations. Estimated TDR prevalence
was 19.4% (8.2, 36.0) in 1996, significantly decreasing to 8.5% (5.9, 11.9) in 2012
[odds ratio (OR; 95% confidence interval (CI))¼0.92 (0.90, 0.95) per year increase].
Individuals exposed through sex between men and women were significantly less likely
to have been infected with a drug-resistant strain [OR (95% CI)¼0.59 (0.41, 0.87)
compared with MSM], and there was marginal evidence that sampling during acute
infection was associated with higher odds of resistance [OR (95% CI)¼1.20 (0.97, 1.7),
P¼0.093] compared with later sampling.
Conclusion: TDR has decreased over calendar time although a significant proportion of
new infections still carry resistance-related mutations.
Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Combination antiretroviral therapy (cART) is effective at
suppressing plasma HIV RNA to undetectable levels [1]
thereby improving patient prognosis [2,3] and reducing
the risk of onward transmission of HIV when viral
suppression is achieved [4]. However, poor adherence
[5–9] can lead to the development of mutations [10]
which are associated with HIV drug resistance and
subsequent cART failure. Individuals failing treatment
have worse health outcomes [11–13], are less likely to
benefit from newer drugs, and can pass drug resistant
strains of HIV to others [14]. Given this concern,
international guidelines recommend that newly diag-
nosed individuals are tested for evidence of resistance to
optimize the selection of first-line cARTregimes [15,16].
Recent data from cART-naive seroprevalent cohorts
suggest the prevalence of TDR has either stabilized
[17,18] or decreased from 2002 to 2009 [19–21]. Given
that timing of HIV infection is not known for individuals
in seroprevalent cohorts; however, estimated TDR rates
may reflect historical trends but not necessarily trends
among those recently infected. Furthermore, because of
the reversion of a number of mutations to wild-type over
time in the absence of cART [22], analysis of TDR rates
among seroprevalent cohorts may under-estimate actual
TDR prevalence. Trends of TDR among HIV sero-
converters are unclear with some studies showing
increased TDR between 1987 and 2003 [23] or stability
between 1996 and 2007 [24].
Temporal trends of transmitted drug resistance (TDR)
among individuals recently infected need to be moni-
tored as new drugs and classes are introduced to inform
clinical decision making. We aim to describe the temporal
trends of TDR among recently infected individuals using
CASCADE data of HIV seroconverters, and to identify
predictors of TDR.
Methods
Study population
We used pooled data from the Concerted Action on
SeroConversion to AIDS and Death in Europe (CAS-
CADE) 2014 data release on HIV-1 seroconverters in
EuroCoord (www.EuroCoord.net), which has been
described in detail elsewhere [25]. Briefly, CASCADE
is a cohort collaboration of 31 772 HIV-1 seroconverters
from 16 countries across Europe (95%), Australia (1%),
Canada (1%), and Sub-Saharan Africa (3%). Date of HIV
seroconversion was estimated most commonly (87%) as
the midpoint between the last documented negative and
the first documented positive HIV antibody test dates
with an interval of less than 3 years between the two dates.
The remaining individuals had seroconversion dates
estimated through laboratory evidence of seroconversion
(PCR positivity in the absence of HIV antibodies or
antigen positivity with fewer than four bands on western
blot – 10%), or as the date of seroconversion illness with
both an earlier documented negative and a later positive
HIV test not more than 3 years apart (2%).
We restricted our analysis to those with documented
seroconversion in the cARTera (>1995) with at least one
viral genetic sequence within the first year of testing
positive for HIV while still being ART naive. Additionally,
we restricted the analysis to those seroconverting before
1 January 2013 as to allow at least 1 year of follow-up.
Resistance and subtype analysis
Genotypic resistance data were derived from sequencing
of the protease and reverse transcriptase genes performed
by laboratories in the country of care using a variety of in-
house and commercial resistance assays. The Stanford
HIVdb algorithm 7.0 was used centrally to analyse
all nucleotide sequences (http://hivdb.stanford.edu);
updated on 27 February 2014) [26]. Subtype was analysed
and assigned centrally using the REGA algorithm [27].
An individual was categorized as having a transmitted
HIV-1 drug resistance-associated mutation if their virus
contained one or more mutations from the Surveillance
Drug Resistance Mutations list defined by the WHO
[28]. We further derived susceptibility to antiretroviral
drugs using the Stanford HIV database algorithm.
Individuals were considered to have high level of
resistance if the Stanford score was higher than 3. Using
this algorithm, we further identified mutations associated
with drugs of current first-line recommendations
according to the European AIDS Clinical Society
guidelines (categories A and B) [29].
Statistical methods
Proportions and their associated 95% confidence intervals
(CI) were calculated using exact CIs for binomially
distributed data. Linear logistic regression was used to assess
the time trends of TDR as there was no statistical evidence
for departures from linearity using natural cubic splines
[30]. Time trend models were adjusted for sex, HIV
transmission risk group, seroconversion age, and HIV
diagnosis during acute HIV infection, defined as laboratory
evidence of HIV seroconversion or having an HIV test
interval of less than 30 days. Age at HIV seroconversion was
modelled linearly as there was no evidence for departures
from linearity using natural cubic splines. Owing to small
numbers, we were not able to evaluate the time trends of
individual mutations. Instead, we list the most common
mutations over the calendar period.
In a sensitivity analysis, we restricted our analysis to
include only individuals infected with subtype B as our
cohort consists predominantly of subtype B (>70%), and
HIV genetic diversity may influence the emergence and
type of resistance mutations.
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Results
Baseline characteristics
We analysed data from 4717 seroconverters in CAS-
CADE with at least one ART-naive nucleotide sequence
available during the first year following HIV seroconver-
sion. Median age at HIV seroconversion was 33
(IQR¼ 27, 39) years, and the most common HIV
transmission risk group was MSM (80%) followed by sex
between men and women (MSW, 15%), people who
inject drugs (PWID, 3%) and unknown (n¼ 101, 2%).
HIV subtype was mainly B (n¼ 3464, 73%), followed by
C (n¼ 288, 8%), A (n¼ 240, 6%), and a recombinant
form (n¼ 176, 4%), Table 1. Median (IQR) time from
HIV seroconversion to sample collection was 124 (44,
256) days, and did not differ between those with and
without mutations associated with HIV drug resistance
(P¼ 0.31, data not shown). Of the 4717 seroconverters,
1222 (26%) were diagnosed with HIV during acute HIV
infection, a proportion which did not differ between
those with and without mutations associated with HIV
drug resistance (P¼ 0.26, data not shown). The majority
of individuals were receiving care in Germany (34%), the
UK (21%), or Sweden (12%).
Transmitted drug resistance
Overall, 203 (4.3%; 95% CI¼ 3.7–4.9) individuals had
one mutation and 515 (10.9%; 95% CI¼ 10.0–11.8) had
one or more mutations associated with TDR. Among
these 515 individuals, 93 (2.0%; 1.6–2.4), 98 (2.1%; 1.7–
2.5), and 67 (1.4%; 1.1–1.8) had one mutation associated
with nucleoside reverse transcriptase inhibitors (NRTI),
non-NRTIs (NNRTI), or protease inhibitors, respectively,
and 280 (5.9%; 5.2–6.6), 185 (3.9%; 3.4–4.5), and 144
(3.1%; 2.6–3.6), had one or more mutations associated
with NRTI, NNRTI, or protease inhibitors, respectively.
The most frequent mutations (>5% of individuals with
mutations) related to NRTIs were 41L (n¼ 91; 18%), 215S
(n¼ 61; 12%), 184V (n¼ 34; 7%), 67N (n¼ 30; 6%),
210W (n¼ 28; 5%) 219Q (n¼ 27; 5%). For NNRTIs, the
most common mutation was 103N (n¼ 119; 23%) and, for
protease inhibitors these were 90M (n¼ 39; 8%), 46I
(n¼ 31; 6%), and 46L (n¼ 26; 5%) (Supplementary Table
1; http://links.lww.com/QAD/B203). In total, 436 (9%)
individuals had mutations associated with a single class, 79
(2%) had mutations associated with two or more classes,
and 15 (<1%%) had mutations associated with three classes
(NRTI, NNRTI, and protease inhibitor).
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Table 1. Baseline characteristics for individuals in CASCADE data of HIV seroconverters between 1996 and 2012; a comparison of individuals
with at least one ART-naive nucleotide sequence available within 1 year of testing positive for HIV, and the remaining individuals.
Individuals with <1 nucleotide sequence Individuals without sequences
Characteristic N¼4717 n¼17 574 P value
Seroconversion year 2007 (2004, 2010) 2004 (2000, 2008) <0.001
Seroconversion age 33 (27, 39) 33 (27, 39) 0.89
Males 4327 (92%) 13,911 (80%) <0.001
HIV risk groupa
MSM 3767 (80%) 10,611 (60%) <0.001
MSW 715 (15%) 5056 (29%)
PWID 134 (3%) 1001 (6%)
OTH/UNK 101 (2%) 906 (5%)
Acute HIV infectionb 1222 (26%) 2340 (13%) <0.001
HIV test interval (days) 179 (26, 381) 278 (108, 541) <0.001
Country/continent of cohort
Germany 1,607 (34%) 775 (4%) <0.001
UK 1,029 (22%) 1,061 (6%)
Sweden 524 (11%) 299 (2%)
Spain 400 (8%) 795 (5%)
Africa 323 (7%) 590 (3%)
Austria 229 (5%) 150 (1%)
Netherlands 197 (4%) 241 (1%)
France 183 (4%) 10,257 (60%)
Italy 93 (2%) 2,293 (13%)
Canada 70 (1%) 111 (1%)
Greece 62 (1%) 192 (1%)
Subtype
B 3465 (73%)
C 288 (6%)
A 240 (5%)
CRF01_AEc 120 (3%)
CRF02_AGc 112 (2%)
Other recombinant forms 226 (5%)
Other/unknown 268 (6%)
All numbers are N (%) or median (interquartile range).
aMSM; MSW, sex between men and women; OTH/UNK, other/unknown; PWID, people who inject drugs; UK.
bHIV test interval <30 days or laboratory evidence of acute HIV infection.
cCirculating recombinant form.
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We observed a significant decline in the prevalence of
TDR to any class during 1996–2012, the calendar year of
seroconversion; odds ratio (OR)¼ 0.92 (95% CI; 0.90,
0.95) per year, starting at 19.4% (8.2, 36.0) in 1996 and
falling to 8.5% (5.9, 11.9) in 2012. The same decreasing
trend over time was observed for transmitted NRTI
resistance, OR¼ 0.89 (0.86, 0.91) per year, NNRTI
resistance, OR¼ 0.96 (0.93, 1.00) per year, and protease
inhibitor resistance, OR¼ 0.93 (0.89, 0.97) per year
(Table 2, Fig. 1).
In more recent years (2007–2012), data were available on
2546 individuals, 216 [8.5% (7.4, 9.6)] of whom had a
mutation associated with TDR. Among these individuals,
98 (3.8%; 3.1–4.6), 89 (3.5%; 2.8–4.2), and 62 (2.4%;
1.8–3.1), had one or more mutations associated with
NRTI, NNRTI, or protease inhibitor, respectively. The
most common mutations in this time period include
NTRI mutations 41L (n¼ 34; 16%), 215S (n¼ 26; 12%),
and 215D (n¼ 15; 7%); NNRTI mutation 103N (n¼ 56;
26%); and protease inhibitor mutations 90M (n¼ 19; 9%)
and 46L (n¼ 12; 6%).
In a sensitivity analysis, restricting to those infected with
subtype B, we observed the same trends of TDR
decreasing over the calendar period (data not shown).
Findings were also consistent across all CASCADE
participating cohorts.
Drug susceptibility
Of 4717 individuals, 296 (6.3%; 5.5–7.0) had a
transmitted mutation associated with high-level resistance
to a drug according to the Stanford HIV database
algorithm, 190 (4.0%; 3.5–4.6) of these were associated
with an agent in a recommended first-line treatment
regimen with efavirenz having the highest proportion of
high-level resistance, Fig. 2. In total, 102 (2.2%; 1.8–2.6),
163 (3.5%; 2.9–4.0), and 83 (1.8%; 1.4–2.2), individuals
had at least one transmitted mutation associated with high
level of resistance to NRTIs, NNRTIs, and protease
inhibitor, respectively. Among the 2546 individuals
seroconverting more recently (2007–2012), 154 [6.0%
(5.2, 7.0)] had a transmitted mutation associated with
high-level resistance; 93 (3.7%; 3.0–4.5), 42 [1.6% (1.2,
2.2)], 91 [3.6% (2.9, 4.4)], 46 [1.8% (1.3, 2.4)] with high-
level resistance associated with a first-line regimen,
NRTIs, NNRTIs, and protease inhibitors, respectively.
During the calendar period of observation, the rate
of transmitted high-level drug resistance declined;
OR¼ 0.97 (95% CI; 0.94, 1.0005) per year, P¼ 0.054.
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Table 2. Predictors of transmitted HIV drug resistance for individuals with at least one ART-naive nucleotide sequence within 1 year of testing
positive for HIV: CASCADE data of HIV seroconverters.
Any TDR
OR (95% CI) P
NRTI TDR
OR (95% CI) P
NNRTI TDR
OR (95% CI) P
PI TDR
OR (95% CI) P
SC year 0.92 (0.90, 0.95) <0.001 0.89 (0.86, 0.91) <0.001 0.96 (0.93, 1.001) 0.059 0.93 (0.89, 0.97) 0.001
sex (female vs. male) 1.19 (0.73, 1.93) 0.48 1.47 (0.72, 2.98) 0.29 0.65 (0.30, 1.37) 0.25 2.03 (0.92, 4.47) 0.08
risk group 0.03b 0.002b 0.95b 0.34b
MSM 1 1 1 1
MSW 0.59 (0.41, 0.87) 0.38 (0.21, 0.70) 1.08 (0.65, 1.81) 0.56 (0.28, 1.11)
PWID 0.62 (0.33, 1.16) 0.46 (0.19, 1.12) 0.79 (0.28, 2.20) 0.63 (0.21, 1.87)
OTH/UNK 1.01 (0.54, 1.87) 1.23 (0.58, 2.62) 1.03 (0.37, 2.87) 1.04 (0.37, 2.96)
Age group 0.60b 0.95b 0.96b 0.003b
<25 1 1 1 1
25–34 1.11 (0.84, 1.47) 0.94 (0.66, 1.35) 1.03 (0.67, 1.59) 1.34 (0.78, 2.31)
35–45 1.02 (0.76, 1.38) 0.92 (0.63, 1.35) 0.95 (0.59, 1.52) 1.12 (0.61, 2.04)
45 and above 1.22 (0.86, 1.74) 1.03 (0.65, 1.63) 0.94 (0.53, 1.66) 2.61 (1.42, 4.77)
Acute HIV infectiona 1.20 (0.97, 1.47) 0.093 1.10 (0.83, 1.46) 0.50 1.15 (0.83, 1.60) 0.40 1.14 (0.78, 1.67) 0.49
CI, confidence interval; MSW, sex between men and women; NRTI, nucleoside reverse transcriptase inhibitors; OR, odds ratio; OTH/UNK,
other/unknown; PI, protease inhibitor; PWID, people who inject drugs; SC, seroconversion; TDR, transmitted drug resistance.
aHIV test interval <30 days or laboratory evidence of acute HIV infection.
bP value for heterogeneity.
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Fig. 1. Temporal trends in transmitted drug resistance over
time for individuals with at least one ART naive nucleotide
sequence within one year of testing positive for HIV: CAS-
CADE data of HIV seroconverters. NNRTI, nonnucleoside
reverse transcriptase inhibitors; NRTI, nucleoside reverse
transcriptase inhibitors; PI, protease inhibitors; TDR, trans-
mitted drug resistance. Statistically significant decline
(P<0.01 for TDR, NRTI, and PI) in the prevalence of trans-
mitted drug resistance over time using linear mixed models.
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A significant decreasing trend over time was observed for
high-level resistance to first-line regimens, OR¼ 0.92
(0.87, 0.97), P less than 0.001 per year and high-level
NRTI resistance, OR¼ 0.89 (0.85, 0.93),P less than 0.001
per year. The same trend was observed in high-level
protease inhibitor resistance, OR¼ 0.96 (0.91, 1.01),
P¼ 0.18 per year. There was no evidence of a decrease in
high-level NNRTI resistance over calendar time, although
levels have remained relatively low throughout the period
of observation of our study at 3.4%.
Predictors of transmitted drug resistance
There was significant heterogeneity between HIV
transmission risk group and any TDR and NRTI
TDR with those exposed through MSW having a lower
probability of being infected with a drug-resistant strain
compared to MSM. Older individuals were more likely to
have been infected with a protease inhibitor resistant
strain (P¼ 0.003) as were females, although the evidence
for females was modest [OR¼ 2.03 (0.92, 4.47,
P¼ 0.08)]. Individuals diagnosed during acute HIV
infection were slightly more likely to be infected with a
resistant strain, OR¼ 1.20 (0.97, 1.47; Table 2). Of the
1222 individuals in our study diagnosed during acute
HIV infection, 144 (11.8%) had at least one mutation
associated with TDR compared with 10.9% of individu-
als with TDR diagnosed later in infection.
When we restricted to those seroconverting in more
recent years (2007–2012), older age was the only
significant predictor for transmitted HIV drug resistance;
OR¼ 1.58 (1.01, 2.45; P¼ 0.043), 1.50 (0.94, 2.41;
P¼ 0.092), and 1.93 (1.13, 3.29; P¼ 0.016) for ages 25–
34, 35–44, and 45 and above, respectively, compared
with those aged 15–25 years at seroconversion.
Discussion
The prevalence of TDR and high-level resistance among
individuals with recent HIV infection decreased between
1996 and 2012. Our estimates provide a realistic
estimation of actual TDR in those years as our study
was restricted to analysing viral sequences from individ-
uals sampled close to the time of HIV seroconversion.
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Fig. 2. High level resistance (Stanford scores >3; solid bars indicate a score of 5, checked bars indicate a score of 4) associated
with first-line antiretroviral drugs recommended by the European AIDS clinical Society for individuals with at least one ART-
naive nucleotide sequence within 1 year of testing positive for HIV: CASCADE data of HIV seroconverters. ABC, abacavir; ATV/r,
atazanavir; DRV/r, darunavir; EVF, efavirenz; FTC, emtricitabine; LPV/r, lopinavir; NRTIs, Nucleoside reverse transcriptase
inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; RPV, rilpivirine; TDF, tenofovir; 3TC,
lamivudine. Adapted with permission [29].
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Our results confirm and expand findings from studies of
ART-naive individuals with unknown duration of HIV
infection [19,20], and consistent with European reports of
TDR with unknown duration of HIV infection [31,32].
Of note, although we show clear evidence for a decline in
TDR rates over time, the 8.5% TDR prevalence in the
most recent years highlights a moderate but ongoing risk
of being infected with drug resistant virus remains.
We detected moderate evidence of an association
between TDR and sampling during acute HIV infection.
This suggests that TDR may be associated with
seroconversion symptoms, possibly leading to presenta-
tion to care and HIV diagnosis during acute infection. It
may also simply reflect that TDR rates are underestimated
if genotypic resistance testing is not performed close to
seroconversion because of reversion of mutations to wild
type in the absence of drug selective pressure [11]. Of
note, we found a similar proportion of TDR, 11.8%,
among those diagnosed during acute infection through-
out our period of study. There was also a similar
association between TDR and acute HIV infection
[OR¼ 1.16 (0.84, 1.58)], although this did not reach
statistical significance as fewer individuals contributed to
these analyses.
We also found evidence that MSM were more likely to
have been infected with resistant strains compared with
PWID and MSW. This has been reported by a number of
studies in high-income countries [33–36] and may be
because of historical access to HIV care, where MSM
have been typically more exposed to ART than other risk
groups [37], particularly the use of thymidine analogues
such as stavudine and zidovudine, the mutations
associated with which are known to be persistent [38].
This is supported by the differentially higher rates of
NRTI mutation among MSM compared with other risk
groups; 6.5, 4.5, and 3.2% among MSM, PWID, and
MSW, respectively. The high prevalence of TDR among
the MSM especially the last years, could also be because of
the high incidence of HIV in this group in Western
Europe, where in some cases transmissions may have
occurred in transmission clusters of resistant strains in
this population.
Our study has a number of limitations. Although we
analysed data only from HIV seroconverters to assess
actual TDR trends by year of infection, it is known that
risk behaviour differs between seroconverters and
nonseroconverter HIV-positive individuals [39,40], and
that such behaviour may put them at greater risk of
becoming infected with drug-resistant HIV. The preva-
lence of TDR, however, in our cohort was similar to that
reported among other (seroprevalent) cohorts in Europe
[19,20,24,41] suggesting that our time trends for TDR
are generalizable to the HIV-positive population in
Europe. However, our numbers outside Europe are small,
so although our estimates were consistent across all
CASCADE cohorts, our estimates might not be as robust
and generalizable in lower income countries. It is also
feasible that there were treatment misclassifications and
patients with prior ARTexperience were included in our
analysis. Research by the UK HIV Drug Resistance
Database suggests that if there is more than a 4%
misclassification, time trends could be distorted [42].
Being that integrase inhibitors are a new drug class, we
were not able to provide temporal trend estimates for
mutations associated with integrase inhibitors, as data on
such mutations were limited, where only two individuals
had a resistance mutation associated with integrase
inhibitor raltegravir. In addition, those with genotypic
tests tended to be different than those without genotypic
tests, where individuals with genotype tests tended to
seroconvert in later years, were more likely to be MSM,
present with acute HIV infection, and have shorter HIV
test intervals. Also, certain countries tended to test more
for genotypic resistance (e.g. Germany and the UK)
compared with other countries (e.g. France). We may,
therefore, have underestimated the overall prevalence of
TDR, given that the risk was higher in earlier years. It is
unlikely, however, that the preferential inclusion of MSM
among sequenced individuals will have affected our main
finding of a decreasing TDR trend given that the
proportion of MSM sequined has remained stable at
about 60% over the calendar period.
In conclusion, we found a steady decline in TDR among
individuals newly infected with HIV between 1996
(19.4% TDR) and 2012 (8.5% TDR). Although the rate
of transmitted drug-resistant HIV has decreased, a not
insubstantial proportion of newly infected individuals are
being diagnosed with drug-resistant strains. Given that
resistance testing among such individuals remains cost-
effective for baseline resistance above 1% [43], testing for
evidence of TDR remains justifiable.
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EPIDEMIOLOGY
Virological Blips and Predictors of Post Treatment Viral
Control After Stopping ART Started in Primary HIV Infection
Sarah Fidler, MD,* Ashley D. Olson, MA,† Heiner C. Bucher,‡ Julie Fox, PhD,§ John Thornhill, PhD,*
Charles Morrison, MD,k Roberto Muga, MD,¶ Andrew Phillips,† John Frater, PhD,#
and Kholoud Porter† on behalf of CASCADE Collaboration in EuroCoord
Background: Few individuals commencing antiretroviral therapy
(ART) in primary HIV infection (PHI) maintain undetectable
viremia after treatment cessation. Associated factors remain unclear
given the importance of the phenomenon to cure research.
Methods: Using CASCADE data of seroconverters starting ART in
PHI (#6 months from seroconversion), we estimated proportions
experiencing viral blips (.400 copies followed by ,400 copies HIV-
RNA/mL without alteration of regimen) while on ART. We used Cox
models to examine the association between time from ART stop to loss
of control (2 consecutive measurements .1000 copies per milliliter)
and magnitude and frequency of blips while on ART, time from
seroconversion to ART, time on ART, adjusting for mean number of
HIV-RNA measurements/year while on ART, and other confounders.
Results: Seven hundred seventy-eight seroconverters started ART
in PHI with $3 HIV-RNA measurements. Median interquartile
range (IQR) ART duration was 16.2 (8.0–35.9) months, within
which we observed 13% with $1 blip. Of 228 who stopped ART,
119 rebounded; time to loss of control was associated with longer
interval between seroconversion and ART initiation [hazard ratio
(HR) = 1.16 per month; 1.04, 1.28], and blips while on ART (HR =
1.71 per blip; 95% confidence interval = 0.94 to 3.10). Longer time
on ART (HR = 0.84 per additional month; 0.76, 0.92) was associated
with lower risk of losing control. Of 228 stopping ART, 22 (10%)
maintained post treatment control (PTC), ie, HIV-RNA ,50 copies
per milliliter $24 months after ART cessation.
Conclusion: HIV viral blips on therapy are associated with
subsequent viral rebound on stopping ART among individuals
treated in PHI. Longer duration on ART is associated with a greater
chance of PTC.
Key Words: cure, viral blips, primary HIV infection, post treatment
control (PTC)
(J Acquir Immune Defic Syndr 2017;74:126–133)
INTRODUCTION
Effective combination antiretroviral therapy (ART) con-
trols HIV-1 viral replication to levels below the limit of detection
of current laboratory assays,1–3 confers improved clinical out-
come,4 and prevents onward transmission.5 However, during
suppressive therapy many patients experience transient detectable
viremia, or “blips,”6 defined as detectable plasma viremia .50
copies HIV-RNA/mL which subsequently returns to,50 copies
without alteration of ART regimen.7,8 Among such individuals
subsequent viral failure remains infrequent if blip levels remain
low6,9 but, where virological failure ensued, the best predictor
was a blip magnitude of .400 copies HIV-1 RNA/mL.10,11
Furthermore, for most patients achieving HIV-RNA ,50 copies
per milliliter, approximately 1–3 copies of plasma HIV-RNA can
be detected using more sensitive assays.12
ART is not a cure for HIV-1 infection—a consequence of
an inaccessible reservoir of virally infected cells.13–15 Novel
approaches exploring “HIV-cure” strategies are under develop-
ment. At present, although not routinely recommended, the
only true test of “cure or remission” within the context of these
trials is to stop ART, but only where planned and carefully
monitored. It remains uncertain which individuals might be best
placed to safely interrupt therapy.
For rare individuals initiating ART in primary HIV
infection (PHI), plasma viremia remains undetectable after
treatment interruption (TI). This phenotype has been termed
post treatment control (PTC)16 and seems to be more common
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among individuals stopping treatment initiated during PHI;
a disease stage where the viral reservoir is smaller compared
with chronic infection,17,18 where immune dysfunction is less19
and ART induced immunological recovery is often better.20
Assessing PTC necessarily requires a TI. For most individuals,
a TI results in viral load rebound,21–23 which is more rapid
among those initiating in chronic infection than in PHI.
Furthermore, although this rebound has been shown to confer
an increased risk of all-cause mortality for those interrupting
ART initiated in chronic infection,15 viral recrudescence
increases the risk of onward transmission after TI, irrespective
of disease stage. Therefore, if TI is planned in the context of
cure research, it needs to be HIV-RNA guided and closely
monitored, as prolonged TI guided by CD4 has been shown to
increase morbidity/mortality.15 Predictive markers that can
evaluate individuals at increased likelihood of achieving PTC
will be valuable tools in the design of future cure trials.
Although the exact mechanisms underlying PTC
remain unknown, important predictors include low levels of
viral reservoirs before TI, early initiation of ART, and longer
duration of therapy.16 This is supported by data from the
SPARTAC trial24,25 where pre-TI levels of HIV-1 DNA also
predicted viral rebound26 after ART cessation and data from
early treatment studies in primates.27
The source and mechanism for viral blips remains
uncertain; however,28 and although blips may reflect
transient periods of reduced ART adherence,29,30 or
variations between viral load assays,31 the frequency and
magnitude of blips on ART might also be related to the size
of the proviral reservoir32,33 and intermittent immune
activation.34,35 We, therefore, explored the frequency,
magnitude, and predictive value of measured viral blips
on the probability of achieving PTC among a cohort of
treated HIV-1 seroconverters interrupting ART started
initiated in PHI.
METHODS
Data Source
We used pooled data from the CASCADE 2014 data
release in EuroCoord (www.EuroCoord.net) of seroconverter
cohorts across Europe, Australia, Canada, and Sub-Saharan
Africa. The collaboration has been previously described,36 in
brief date of HIV seroconversion in CASCADE is estimated
most commonly as the midpoint between the last documented
HIV negative and the first HIV-positive antibody test dates
with an interval of#3 years between the 2 dates (87%). Dates
of seroconversion for the remaining individuals (10%) is
estimated through laboratory evidence of acute infection
(HIV DNA polymerase chain reaction positivity in the
absence of HIV antibodies or antigen positivity with ,4
bands on Western blot), or as the date of HIV seroconversion
illness with both an earlier documented negative and a later
positive HIV test not more than 3 years apart (2%). Fiebig
staging is not part of the algorithm for estimating date of
seroconversion.37
All cohorts contributing to CASCADE received ethics
approval from their individual ethics review boards.
Inclusion Criteria
Only adults older than 16 years starting ART within 6
months of estimated HIV seroconversion (PHI) with at least 3
HIV-RNA measurements while on ART were eligible for this
analysis. Eligibility criteria and numbers, therefore, differ from
our previous publication on proportions achieving PTC.20
Blips
We characterized the proportion of individuals experienc-
ing blips while on ART initiated in PHI, and the associated exact
95% confidence intervals (CIs) for binomial distributed data. We
also identified individuals with multiple blips while on ART. We
used a modified definition of blip as a single plasma HIV-RNA
measure .400 copies per milliliter in a previously suppressed
individual followed by subsequent viral suppression (,400
copies per milliliter) without change in ART regimen.1 Any
magnitude of viremia episode was considered as a blip, as we
were interested in the effect of blips regardless of the reasons for
them. To be classified as having a blip or not, we included only
individuals with HIV-RNA measured with assays detecting
#400 copies per milliliter. Periods of unsuppressed viremia
occurring during ART changes were attributed to the change in
regimen and did not contribute to the analysis of blip rates.
In a sensitivity analysis on blip definitions, we defined
additional blip thresholds of HIV-RNA .50, .100, and
.200 copies per milliliter. The number of individuals
included in this sensitivity analysis was smaller than the
numbers included in the main analysis as fewer individuals
were measured with assays detecting lower values.
Loss of Viremic Control
We used Kaplan–Meier methods to describe time from
ART cessation to loss of viremic control and examined asso-
ciated factors using Cox proportional hazards models. Loss of
control was defined as the second of 2 consecutive HIV-1
RNA measurements .1000 copies per milliliter. Factors of
interest were time on ART, time between HIV-1 seroconver-
sion to ART initiation, plasma HIV-RNA at seroconversion,
ART initiation year, CD4 T-cell count at ART initiation, CD4
T-cell count at ART cessation, ART class, age at HIV-1
seroconversion, sex, HIV-1 transmission risk group, and
magnitude and frequency of blips while on ART. As rebound
is more likely to be observed in those with more frequent
measurements, we also adjusted for the mean number of HIV-
RNA measurements/year while on ART. This also served as
a proxy for adherence and engagement in care. Linear terms for
all continuous variables were used, as there was no evidence
for departures from linearity using natural cubic splines.38
We preformed several sensitivity analyses for the
analysis of loss of viremic control. We defined blips as
.50, .100, and .200 copies per milliliter, and we included
covariates on the magnitude and frequency of each blip
threshold. We also defined loss of control as the second of 2
consecutive HIV-RNA measurements greater than the given
blip threshold. In additional, we limited our analysis to
individuals who were on ART for at least 1 year before
stopping treatment.
J Acquir Immune Defic Syndr  Volume 74, Number 2, February 1, 2017 Predictors of Post Treatment Control After Stopping ART
Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 127
141
Post Treatment Controllers
PTC was defined as remaining ,50 copies per milliliter
for at least 24 months after ART stops. Once PTC was
achieved, we used a strict definition for loss of PTC status as
the first of 2 consecutive HIV-RNA measurements.50 copies
per milliliter. Because there were very few PTCs, we did not
formally analyze factors related to post treatment control.
RESULTS
Baseline Characteristics
Of 31,772 individuals in CASCADE, 22,688 were
defined as PHI in the ART era ($1995). Of these, 778 started
ART within 6 months of seroconversion and had at least 3 HIV-
RNA measurements. Of these, 228 (30%) subsequently stopped
ART; reasons for stopping ART are unknown.
Among the 778 individuals starting ART in PHI, the
majority were male (92%) seroconverting between 1995 and
2013 at median (IQR) age of 34 (28–42) years. Risk factors
for HIV-1 infection were sex between men (75%), sex
between men and women (17%), injecting drug use (4%), or
other/unknown (5%). ART regimens included Nucleoside/
Nucleotide Reverse Transcriptase Inhibitors NRTI back-
bone with protease inhibitor (PI) based (45%) or nonnucleo-
side reverse-transcriptase inhibitor based (37%) and other
triple combinations (18%). Median interquartile range (IQR)
time to ART initiation from seroconversion was 2.3
(0.7–4.1) months and median (IQR) time spent on ART
initiated in PHI was 16.2 (8.0–35.9) months. Initial
HIV-RNA measurement after HIV diagnosis was median
5.3 (4.5–5.9) log10 copies per milliliter and median CD4
at ART initiation was 477 (316–658) cells per cubic
millimeter, Table 1.
Baseline characteristics for the subset of individuals
subsequently stopping ART initiated in PHI (n = 228) were
similar to all those starting ART in PHI (n = 778), with the
exception of seroconversion year and time spent on ART, as
TABLE 1. Baseline Characteristics of Individuals Initiating ART Within 6 Months of HIV-1 Seroconversion, Those Subsequently
Stopping ART, and Post Treatment Controllers (PTC) in CASCADE
Started ART Subsequently Stopped ART PTC
Total, N 778 228 22
Sex, N (%)
Male 714 (92) 206 (90) 16 (73)
Female 64 (8) 22 (10) 6 (27)
Risk group
MSM 581 (75) 167 (73) 10 (45)
MSW 129 (17) 46 (20) 28 (36)
IDU 28 (4) 10 (4) 2 (9)
OTH 40 (5) 5 (2) 2 (9)
ART initiation class, N (%)
NNRTI 288 (37) 87 (38) 12 (55)
PI 347 (45) 103 (45) 7 (32)
3 N 95 (12) 32 (14) 3 (14)
3 Class 11 (1) 4 (2) 0
Fusion inhibitor 6 (1) 0 0
Integrase inhibitor 30 (4) 2 (1) 0
SC yr, median (IQR) 2004 (2000–2010) 2001 (1999–2005) 2001 (2000–2003)
SC age, yrs, median (IQR) 34 (28–42) 33 (28–41) 35 (28–39)
Time on ART, mo, median (IQR) 16.2 (8.0–35.9) 11.0 (4.2–21.3) 17.4 (6.3–27.6)
Time from SC to ART, mo, median (IQR) 2.3 (0.7–4.1) 2.2 (0.5–3.9) 3.1 (0.6–5.3)
Initial HIV-RNA (log10 copies/mL) 5.3 (4.5, 5.9) 5.3 (4.6, 5.9) 4.9 (4.6, 5.6)
# HIV-RNA measurements per year, median (IQR) 3 (1–4) 1 (1–4.2) 3.5 (1–4.0)
HIV-RNA at ART cessation (log10 copies/mL), median
(IQR)‡
— 0 (0–1.8) 0 (0–1.7)
CD4 at ART initiation 477 (316, 658) 494 (360, 701) 562 (230, 710)
CD4 at ART cessation, median (IQR) — 709 (519–917) 738 (506–890)
Blips, % (95% CI), % 1 blip, copies/mL
.50 13 (11 to 16), 78 11 (7 to 18), 87 7 (1 to 44), 0
.100 9 (7 to 12), 85 9 (5 to 16), 85 7 (1 to 42), 100
.200 6 (5 to 9), 79 9 (5 to 15), 77 9 (3 to 43), 100
.400 7 (6 to 9), 84 9 (6 to 14), 89 7 (2 to 36), 100
‡0 indicates undetectable HIV-RNA.
3 class, drugs from 3 or more classes; 3N, 3 nucleoside reverse-transcriptase inhibitors; IDU, injection drug use; MSM, men who have sex with men; MSW, sex between men and
women; NNRTI, nonnucleoside reverse-transcriptase inhibitors; OTH, other; SC, seroconversion.
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those subsequently stopping ART seroconverted in slightly
earlier years, median (IQR) 2001 (1999–2005), and spent
slightly less time on ART, median 11.0 (4.2–21.3) months.
Blip rates were similar among individuals starting ART in
PHI and individuals subsequently interrupting therapy,
Table 1.
Blips While on ART
Of those starting ART in PHI with HIV-1 plasma
HIV-RNA measured using assays detecting #400 copies
per milliliter, we observed 7% (95% CI: 6 to 9) of
individuals with 1 blip over 400 copies per milliliter, the
majority (84%) of whom we observed only 1 blip. Among
those that blipped over 400 copies per milliliter, median
(IQR) time to the first blip was 1.0 (0.6–2.5) year and,
among those with multiple blips, median (IQR) time
between blips was 0.7 (0.6–1.1) years. Median (IQR) time
to recover from a blip was 57 (32–111) days. Similarly, we
observed at least 1 blip in 13% (11–16), 9% (7, 12), and 6%
(5, 9) over 50, 100, and 200 copies per milliliter, respec-
tively, and the majority, again, of whom we observed only 1
blip. Blip rates were similar among those who subsequently
stopped ART, Table 2.
Factors Associated With Loss of Control After
Stopping ART
Among the 228 individuals stopping ART, 22 (10%)
individuals fulfilled the definition of PTC. Viral rebound was
observed in 119 (52%) individuals; 23%, 37%, and 45% were
observed to have rebounded by 3, 6, and 9 months,
respectively. Median (95% CI) time to rebound was 10.3
(7.6 to 16.4) months. Several factors were independently
associated with loss of control. Each blip .400 copies per
milliliter was associated with a 71% increased risk of loss of
control [hazard ratio (HR) = 1.71 (0.94, 3.10)], as was longer
interval between seroconversion and ART initiation [HR =
1.16 per additional month (1.04, 1.28)]. More frequent HIV-
RNA measurements while on ART were also associated with
loss of control [HR = 1.10 per mean additional measurement/
year increase (1.02, 1.17)] (Table 3).
Conversely, longer time spent on ART was indepen-
dently associated with a decreased risk in loss of control [HR
(95% CI) = 0.84 per 6 month increase (0.76 to 0.92)], as was
later year of ART initiation [HR = 0.91 (0.84, 0.98)] (Table
3). There was no evidence of an association between loss of
control and CD4 T-cell count at ART initiation, ART
initiation class, seroconversion age, sex, or HIV-1 trans-
mission risk group.
Using different blip thresholds, we observed an
increased risk of loss of virologic control per increase in
number of blips of similar magnitude to the results presented
for blips .400 copies per milliliter in Table 1, although this
did not reach statistical significance as fewer individuals
contributed to these analyses. For each additional blip we
found, HR = 1.96 (0.71, 5.38), 1.66 (0.88, 3.13), and 1.65
(0.90, 3.05) for blips of .50, 100, and 200 copies per
milliliter, respectively. Defining loss of control as
HIV-RNA .500 copies per milliliter resulted in similar
time to rebound (Fig. 1), and factors associated with
rebound remained the same as for the main analysis (data
not shown). Time from the start of ART to the first blip
was not associated with time to virologic rebound (data
not shown).
Restricting to individuals who had been on ART for
a year or more before stopping reduced the number of
individuals included in analysis to 91. Time spent on ART
and number of blips .400 copies per milliliter retained the
same magnitude of association, as in the main analysis,
although no longer remained statistically significant effects
for time spent on ART or number of blips .400 copies per
TABLE 2. Characteristics of Blips Among Individuals Initiating ART Within 6 Months of HIV-1 Seroconversion, Those Subsequently
Stopping ART, and Post Treatment Controllers (PTC) in CASCADE
Started ART Subsequently Stopped ART PTC
Total, N 778 228 22
Any blips*, % (95% CI), copies/mL
.50 13 (11 to 16) 11 (7 to 18) 7 (1 to 44)
.100 9 (7 to 12) 9 (5 to 16) 7 (1 to 42)
.200 6 (5 to 9) 9 (5 to 15) 9 (3 to 43)
.400 7 (6 to 9) 9 (6 to 14) 7 (2 to 36)
Time to first blip†, yrs 0.9 (0.5, 1.9) 0.8 (0.4, 1.2) 1.7 (1.2, 2.3)
Multiple blips‡, %, copies/mL
.50 22 (14, 33) 13 (3, 45) —
.100 15 (7, 27) 15 (3, 51) —
.200 21 (10, 37) 23 (6, 57) —
.400 16 (9, 29) 11 (2, 39) —
Time between blips§, yrs 0.7 (0.6, 1.1) 2.6 (1.0, 4.2) —
*Denominator changes with varying blip thresholds due to different number of individuals with the required lower limits of detection.
†Among those with at least 1 blip .400 copies per milliliter, median (IQR).
‡Percentage of individuals with multiple blips among those with at least 1 blip. One PTC had blips .50,100 copies per milliliter and 2 had blips .200,400 copies per milliliter.
§Among those with multiple blips .400 copies per milliliter, median (IQR).
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milliliter [HR = 0.90 (0.78, 1.03) and 2.31 (0.71,
7.48), respectively].
Post Treatment Controllers
Of the 228 individuals interrupting ART, 22 (10.3%)
achieved PTC status. ART initiation combinations for these
22 PTCs included nonnucleoside reverse-transcriptase inhib-
itor-based (n = 12; 55%), PI-based (n = 7; 32%), or triple
nucleoside reverse-transcriptase inhibitors (3N) (n = 3; 14%)
regimens. The proportion of PTCs for who we observed blips
while on ART was slightly lower compared with the 206
individuals interrupting ART not achieving PTC status. We
observed only 1 PTC with a blip .50 copies per milliliter,
compared with 14 [12% (7, 19)] of all other individuals. Post
treatment controllers also spent slightly longer time on ART
compared with all other individuals interrupting ART, median
(IQR) 17.4 (6.3–27.6) months for PTCs compared with 10.9
(3.6–19.0) months. The first HIV-RNA measurement after
HIV diagnosis was slightly lower among PTCs with a median
(IQR) 4.9 (4.6–5.6) log10 copies per milliliter compared with
5.3 (4.6–5.9) log10 copies per milliliter and the CD4 at ART
initiation was slightly higher among PTCs with a median
(562, 230–710) cells per mm3 compared with 493 (363–690)
cells per mm3 among the remaining 206 individuals inter-
rupting ART. Median number of HIV-RNA measurements
per year after ART interruption was similar among PTCs and
non-PTCs at 1 measure/year. Heterogeneity in time from
HIV-1 seroconversion to ART initiation was small because of
the inclusion criteria of starting ART within 6 months of HIV
seroconversion and was, therefore, similar between post
treatment controllers and all other individuals.
DISCUSSION
Using the large CASCADE dataset of individuals with
well-estimated dates of HIV seroconversion, we provide the
first evidence that frequency and magnitude of viral blips
while on ART initiated in PHI is associated with viral
rebound among individuals interrupting ART started in PHI.
The prevalence of PTC (defined by 2 years of undetect-
able viremia after TI) in our cohort is estimated to be 10.3%.
This is not dissimilar to other cohorts reporting PTC23,39–41
and slightly lower than the VISCONTI study (15.6%).16 That
said, most cohorts report few or none, including among early
treated populations.42–46 In comparison with VISCONTI, the
duration of ART was shorter in our cohort, but shorter time
from HIV diagnosis to ART initiation was also predictive of
PTC in both cohorts.
Although much data exist for the predictive value of
blips on subsequent viral failure among individuals on ART
in chronic stages of HIV disease,47–49 it is difficult to
extrapolate this to PTC. The source of viral blips on ART
is unclear. They may, for example, represent release of virus
from transient, random activation of latently infected cells,34
fluctuations in levels of persistent viral replication on ART,50
sanctuary sites of suboptimal antiretroviral penetrance,51 or
nonadherence to ART regimens. One explanation for our
findings is that initiating ART early in PHI results in fewer
viral blips of lower magnitude because of the smaller HIV-1
viral reservoir achieved among these individuals.52,53 Unfor-
tunately, samples were not available to determine HIV-1
DNA measurements to test this assumption, although this is
consistent with data from SPARTAC showing that levels of
total HIV-1 DNA measured at TI predict time to loss of
control.24
The associations observed in our cohort between timing
of ART initiation, duration of therapy, and PTC were linear
and, accordingly, we were unable to determine an optimal
period beyond which ART initiation after seroconversion
may be too late to achieve PTC. These are key questions that
need to be addressed in prospective studies to inform future
cure trial designs and help develop algorithms to predict
TABLE 3. Multivariable Analysis of the Factors Associated With
Virologic Rebound Among Those Stopping ART Initiated
Within 6 Months of HIV Seroconversion Using the CASCADE
Dataset
HR (95% CI) P
Time on ART (per 6-month increase)* 0.84 (0.76 to 0.92) ,0.001
Time from SC to ART (per month
increase)†
1.16 (1.04 to 1.28) 0.006
# blips .400 copies/mL
(per additional blip)
1.71 (0.94 to 3.10) 0.077
# mean HIV-RNA measurements/year
(per additional measurement)
1.10 (1.02 to 1.17) 0.005
HIV-RNA at SC (per log10 increase)‡ 1.15 (0.98 to 1.35) 0.086
ART initiation yr (per year increase) 0.91 (0.84 to 0.98) 0.016
Time from ART to viral suppression
(per month increase)‡§
0.99 (0.97 to 1.02) 0.93
CD4 at ART initiation (per 100
cells/mm3 increase)k
0.99 (0.90 to 1.08) 0.75
CD4 at ART cessation (per 100
cells/mm3 increase)k
1.10 (1.01 to 1.20) 0.035
ART class 0.33
NNRTI 1
PI 0.92 (0.57 to 1.48)
3 N 1.32 (0.74 to 2.36)
3 Class 0.24 (0.03 to 1.79)
Integrase inhibitor 0.77 (0.10 to 6.12)
SC age 1.00 (0.98 to 1.02) 0.77
Sex 0.49
Male 1
Female 0.75 (0.33 to 1.69)
HIV risk group 0.28
MSM 1
MSW 0.84 (0.44 to 1.58)
IDU 0.53 (0.14 to 2.03)
OTH 0.23 (0.03 to 1.73)
*Per 6 month increase.
†Per month increase.
‡Per log10 increase.
§HIV-RNA ,50 copies per milliliter.
kper 100 cells per mm3 increase.
3 class, drugs from 3 or more classes; 3N, 3 nucleoside reverse transcriptase
inhibitors; IDU, injection drug use; MSM, men who have sex with men; MSW, sex
between men and women; NNRTI, nonnucleoside reverse-transcriptase inhibitors; OTH,
other; SC, seroconversion.
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likelihood of PTC. Of note, while HIV-1 HIV-RNA and
initial CD4 count measurement at diagnosis of PHI are known
to predict disease progression,54 for those initiating immedi-
ate ART in our cohort, these parameters did not appear to
influence subsequent PTC status, suggesting that the mech-
anisms underpinning the 2 processes may be different.
Host genetic factors may also determine PTC status,
although we were not able to explore these factors. In the
VISCONTI cohort there was no evidence for enrichment of
protective HLA Class I alleles and only weak HIV-specific
immunity was observed.
The data presented from this large cohort should be
interpreted within the limitations of any observational study.
First, for those individuals with a measurable viral blip, we
assumed that ART was continuous through this period and
a viral blip is not the result of temporary poor adherence,
absorption, or the assay used; however, irrespective of the
cause, the presence of a blip predicted viral rebound and hence
must be incorporated into any algorithm for future HIV cure
trials.55 Second, reasons for ART initiation and subsequent
cessation for eligible individuals are unknown and those
stopping may differ in important characteristics from those
not stopping, although short-course ART in PHI was not an
uncommon treatment strategy by a number of clinicians during
the time.24,39,40 In any case, baseline HIV-RNA and CD4
measurements at ART initiation were similar for those sub-
sequently stopping and those not stopping ART. It is, therefore,
unlikely that reasons for stopping ART initiated in PHI were
related to outcome but we acknowledge, as with all observa-
tional studies, that unmeasured confounding factors may
remain, including in the choice of whether or not to initiate
ART in PHI. Third, the absence of data on ART adherence is
a limitation of these analyses, and blips may, therefore be, as
a result of periods of nonadherence or viral breakthrough. We
included the number viral load measurements as a surrogate of
adherence in the multivariate analyses. In any case, our findings
are of clinical relevance to clinicians as they highlight that
patients experiencing blips, regardless of the reason, are more
likely to experience viral failure on therapy56,57 and less likely to
achieve PTC if ART is stopped. Finally, frequency of
monitoring HIV-RNA and assay variability are likely to affect
blip detection, which may account for some of the observed
differences in the significance and proportion of intermittent
low-level viremia for ART-treated individuals.8,9 It is also
possible that frequency of HIV-RNAmonitoring could influence
the definition of virologic failure rate in this analysis or clinical
practise reflects concerns with ART adherence. The median
number of HIV-RNA measurements per year on ART were
similar to the frequency off ART [1 (1, 4.2) and 1.6 (1, 2.9),
respectively]. We have attempted to correct for measurement
frequency by including it as a variable in our Cox models. We
were not, however, able to correct for assay variability because of
the limited sample size and as it was unknown for .50%
of HIV-RNA measurements. In addition, we did not distinguish
between boosted and unboosted PIs but, to account for these
unmeasured changes in treatment quality over time, we adjusted
for ART initiation year. It is possible that newer more potent
ART regimens, including integrase inhibitors, not routinely
available at the time of this analysis, could additionally impact
on size of reservoir and viral blips on therapy.55
Stopping ART within the setting of a cure study should
be undertaken within close clinical and laboratory monitoring
and extrapolation of observational data into a study design in
terms of individual health risks and risks of onward viral
transmission must be made with caution. Both individual
potential risks and the risk of onward viral transmission,
should viral rebound ensue, also need to be taken
into account.
In conclusion, findings from this large observational
cohort of treated seroconverters stopping ART indicate that
the absence of viral blips .400 copies HIV-1 RNA/mL in
individuals treated with early ART, close to the time of PHI
diagnosis predicted a better chance of subsequent after
treatment viremic control after ART cessation.
FIGURE 1. Time from ART cessation to
virologic rebound, defined as HIV-RNA
$500, 1000 copies per mL, among those
stopping ART initiated within 6 months
of HIV seroconversion in CASCADE.
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Objectives
Five to eight per cent of HIV-positive individuals initiating abacavir (ABC) experience potentially
fatal hypersensitivity reactions (HSRs). We sought to describe the proportion of individuals initiating
ABC and to describe the incidence and factors associated with HSR among those prescribed ABC.
Methods
We calculated the proportion of EuroSIDA individuals receiving ABC-based combination
antiretroviral therapy (cART) among those receiving cART after 1 January 2009. Poisson regression
was used to identify demographic, and current clinical and laboratory factors associated with ABC
utilization and discontinuation.
Results
Between 2009 and 2016, of 10 076 individuals receiving cART, 3472 (34%) had ever received
ABC-based cART. Temporal trends of ABC utilization were also heterogeneous, with 28% using
ABC in 2009, dropping to 26% in 2010 and increasing to 31% in 2016, and varied across regions
and over time. Poisson models showed lower ABC utilization in older individuals, and in those
with higher CD4 cell counts, higher cART lines, and prior AIDS. Higher ABC utilization was
associated with higher HIV RNA and poor renal function, and was more common in Central-East
and Eastern Europe and lowest during 2014. During 779 person-years of follow-up (PYFU) in 2139
individuals starting ABC after 1 January 2009, 113 discontinued ABC within 6 weeks of initiation
for any reason [incidence rate (IR) 14.5 (95% confidence interval (CI) 12.1, 17.5) per 100 PYFU], 13
because of reported HSR [IR 0.3 (95% CI 0.1, 1.0) per 100 PYFU] and 35 because of reported HSR/
any toxicity [IR 4.5 (95% CI 3.2, 6.3) per 100 PYFU]. There were no factors significantly associated
with ABC discontinuation because of reported HSR/any toxicity.
Conclusions
ABC remains commonly used across Europe and the incidence of discontinuation because of
reported HSR was low in our study population.
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Introduction
In the absence of genetic screening, hypersensitivity reac-
tion (HSR) presents in approximately 5–8% of persons liv-
ing with HIV (PLHIV) initiating abacavir [1,2](ABC). HSR
can vary in severity and clinical manifestation indicative
of multiorgan involvement and includes fever, skin rash,
and constitutional, gastrointestinal tract and respiratory
symptoms [1–5]. In rare cases, HSR is fatal [6,7]. The risk
of ABC HSR is high for patients who test positive for the
human leucocyte antigen (HLA)-B*5701 allele [1,8,9];
however, ABC HSRs have been reported at a lower fre-
quency in patients who do not carry this allele and there-
fore risk for HSR can be reduced by HLA-B*5701
screening [1,3]. ABC should never be initiated in patients
with a positive HLA-B*5701 status, and ABC re-challenge
among those previously experiencing HSR is contraindi-
cated, as acute onset of potentially fatal symptoms has
been reported [2,10–12].
ABC remains a commonly used drug throughout Eur-
ope and is recommended as a part of first-line therapy
by national and international guidelines [13,14]; it is
therefore important to continually examine the safety of
ABC over time. A previous 2008 report using data from
EuroSIDA, a longitudinal cohort collaboration across 35
countries in Europe plus Israel and Argentina [15],
showed an HSR incidence within 3 months of starting
ABC of 22.1 [95% confidence interval (CI) 18.7, 25.4] per
100 person-years of follow-up (PYFU) with a decreasing
trend for ABC discontinuation because of HSR over time
[16]. HSR caused by ABC typically presents within
6 weeks of therapy initiation [4,17], and presentation of
HSR later than 8 weeks after ABC initiation is almost
always attributable to other causes [18].
The objectives of this study were twofold. First, the
aim was to describe the proportion of individuals across
Europe on combination antiretroviral therapy (cART)
receiving an ABC-based regimen from 1 January 2009 to
1 April 2016 and the factors associated with ABC initia-
tion. Secondly, we sought to describe the cumulative fre-
quency of, incidence of, and factors associated with ABC
discontinuation because of reported HSR or because of
reported HSR/any toxicity among those starting ABC
after 1 January 2009 as part of a cART regimen.
Methods
Study population
EuroSIDA is a longitudinal observational cohort study that
was initiated in 1994, and has been previously described
[15]. The data collected include start and stop dates for
each antiretroviral drug used, reasons for discontinuing an
antiretroviral drug and clinical events. Further details on
data collected can be found at www.cphiv.dk.
Individuals from the EuroSIDA cohort over the age of
16 years at enrolment receiving cART (at least three
drugs from any class, excluding ritonavir) after 1 January
2009 were included in the ABC utilization over time
analysis. All persons starting ABC-based cART after 1
January 2009 were eligible for inclusion for analyses of
reported HSR-related discontinuation.
Statistical methods
Among those receiving cART and under active follow-up,
the proportion of individuals who received ABC at the
midpoint of each calendar year (1 July) from 1 January
2009 onwards and by geographical region was summa-
rized using descriptive statistics. Active follow-up was
defined as having a first visit date before and last visit
date after the midpoint of the year.
Factors associated with ABC utilization were investi-
gated using Poisson regression with generalized estimat-
ing equations (GEEs) to control for the inclusion of
repeated exposures and events. Baseline was defined as 1
January 2009 or enrolment into EuroSIDA, whichever
occurred later. Individuals off ABC contributed follow-up
until ABC initiation, the last EuroSIDA visit date or death,
whichever occurred first. If an individual stopped ABC
they were allowed to re-enter the analysis, and once again
were considered eligible for starting ABC. Factors that
were significantly associated with ABC initiation (P < 0.1)
in univariate analyses were included in multivariable
models. Factors investigated were gender, age, ethnicity,
HIV transmission risk group, region of care, calendar year,
CD4 cell count, nadir CD4 cell count, HIV RNA, line of
cART regimen, hepatitis B and C status, previous AIDS
diagnosis, Framingham 10-year elevated cardiovascular
disease (CVD) risk [19], chronic kidney disease (CKD), and
Data on Adverse Drugs (D:A:D) CKD risk [20,21]. Line of
cART regimen captured the extent of previous antiretrovi-
ral treatment and treatment failure and was defined as a
change in at least two antiretroviral drugs accompanied
by an HIV RNA > 500 HIV-1 RNA copies/mL, or more
than 6 months off treatment before starting a new ther-
apy. CKD was defined as two consecutive estimated
glomerular filtration rate (eGFR) values < 60 more than
3 months apart using the Chronic Kidney Disease Epide-
miology Collaboration (CKD EPI) formula [22].
For the second objective, analysing reported HSR-related
discontinuation, individuals were included if they initiated
ABC as part of cART after 1 January 2009. Individuals with
prior ABC exposure were included, and individuals who
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started ABC more than once after 1 January 2009 could
contribute multiple exposure periods. Baseline was defined
as the start of an ABC-containing regimen, 1 January 2009
or recruitment to EuroSIDA, whichever occurred later. This
was an on-treatment analysis where individuals con-
tributed follow-up until 6 weeks after ABC initiation, ABC
discontinuation for any cause, death or their last visit date,
whichever occurred first. The primary outcome was discon-
tinuation because of reported HSR. We also analysed a
composite outcome of discontinuation because of reported
HSR or any toxicity, as well as investigating all reasons
for discontinuation to account for underreporting and
potentially undiagnosed HSR cases.
Factors associated with reported HSR or any toxicity-
related discontinuation were identified in a multivariable
Poisson regression model using GEE to adjust for
repeated events; those that were significant (P < 0.1)
in univariable analyses were included in multivariable
models.
Results
Baseline characteristics
Among 10 076 individuals in EuroSIDA receiving cART
between 1 January 2009 and 1 April 2016, 3472 (34%;
Table 1 Baseline characteristics of all participants, split by abacavir (ABC) use (total vs. no ABC vs. ever ABC) in the EuroSIDA cohort from 1
January 2009 to 1 April 2016
Total No ABC ABC
P-valuen % n % n %
Gender
Female 7408 74 4926 75 2482 72 0.001
Male 2668 27 1678 25 990 29
Region of care in Europe
South 2819 28 1962 30 857 25 < 0.001
West 2478 25 1672 25 806 23
North 2187 22 1348 20 839 24
Central-East 1430 14 897 14 533 15
East 1162 12 725 11 437 13
Ethnicity
White 8827 88 5773 87 3054 88 0.291
Black 563 6 361 6 202 6
Asian 163 2 108 2 55 2
Other/unknown 523 5 362 6 161 5
HIV risk group
MSM 4054 40 2701 41 1353 39 0.171
IDU 2198 22 1438 22 760 22
Heterosexual 3138 31 2012 31 1126 32
Other/unknown 686 7 453 7 233 7
Calendar year*,† 2009 (2009, 2011) 2009 (2009, 2011) 2011 (2009, 2010) 0.001
Baseline age (years)† 45 (37, 52) 45 (37, 51) 51 (38, 52) 0.001
Baseline HIV RNA (copies/mL)† 49 (39, 74) 49 (39, 71) 71 (33, 90) < 0.001
Baseline CD4 cell count (cells/lL)† 490 (337, 688) 488 (340, 679) 679 (333, 709) 0.385
CKD
No 7354 84 5597 85 1757 51 < 0.001
Yes 172 2 106 2 66 2
Missing 1232 14 901 14 1649 47
AIDS
No 6848 68 4559 69 2289 66 0.001
Yes 3228 32 2045 31 1183 34
cART line
First 5859 58 3815 58 2044 59 < 0.001
Second 2043 20 1307 20 736 21
Third 964 10 611 9 353 10
≥ Fourth 1210 12 871 13 339 10
Baseline is defined as entry to the study which was on 1 January 2009 or enrolment in EuroSIDA, whichever occurred later. Percentages are column percentages.
Region of care in Europe includes: South: Argentina, Greece, Israel, Italy, Portugal and Spain; West: Austria, Belgium, France, Germany, Luxembourg
and Switzerland; North: Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and the UK; Central-East: Bosnia and Herzegovina,
Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia and Slovenia; East: Belarus, Estonia, Georgia, Latvia, Lithuania, Russian
Federation and Ukraine.
CKD, chronic kidney disease; cART, combination antiretroviral therapy; MSM, men who have sex with men; IDU, injecting drug use.
*Calendar year for the first ABC utilization date in the follow-up period.
†Values are median (interquartile range).
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95% CI 34–35%) had ever received ABC during follow-up
(Table 1). Seventy-four per cent were male and 27% were
female, with HIV risk groups of men who have sex with
men (MSM) (40%), injecting drug users (IDUs) (22%),
heterosexual (31%) and other/unknown (7%). The highest
proportion received care in Southern Europe (28%)
followed by Western Europe (25%), Northern Europe
(22%), Central-East Europe (14%), and Eastern Europe
(12%). Median baseline age was 45 years [interquartile
range (IQR) 37, 52 years]. In general, demographic char-
acteristics among those exposed to ABC were similar to
characteristics in those not exposed, apart from baseline
age, with those receiving ABC slightly older than those
not receiving ABC. Baseline HIV RNA values among
those initiating ABC were slightly higher compared with
those not exposed to ABC, and there was also a higher
prevalence of AIDS among those initiating ABC.
ABC utilization and factors associated with starting ABC
ABC utilization significantly varied over time, starting at
28% in 2009, dropping to 26% in 2010 and increasing to
31% in 2016 (P-heterogeneity from univariate analysis
< 0.001) (Fig. 1). There was a significant interaction
between region and time, where ABC utilization in North-
ern Europe decreased, Southern and Eastern Europe
increased and Western and Central-East Europe remained
relatively consistent with time (P-interaction < 0.001).
Using multivariable Poisson regression, factors associ-
ated with lower rates of ABC utilization were older age
[incidence rate ratio (IRR) 0.73 (95% CI 0.59, 0.90) for the
highest age quintile (> 58 years) compared with the low-
est (18–41 years)], higher CD4 cell count [IRR 0.68 (95%
CI 0.56, 0.82) for CD4 count > 500 cells/lL compared
with < 200 cells/lL), and exposure to more cART treat-
ment regimens [IRR 0.55 (95% CI 0.46, 0.66) for at least
fourth-line compared with first-line regimens], and hav-
ing a previous AIDS diagnosis [IRR 0.9 (95% CI 0.8, 1.0)
compared with those without a previous AIDS diagnosis].
Higher ABC utilization rates were associated with higher
HIV RNA [IRR 1.92 (95% CI 1.47, 2.51) for HIV
RNA > 100 000 copies/mL compared with < 500 copies/
mL], CKD [IRR 2.62 (95% CI 2.06, 3.34) compared with
those without CKD], and higher D:A:D CKD risk score
[IRR 1.18 (95% CI 1.01, 1.38) for those at high risk com-
pared with low risk]. There was heterogeneity in ABC uti-
lization among regions; those in Central-East and Eastern
Europe were more likely to initiate ABC compared with
those in Southern Europe [IRR 1.58 (95% CI 1.35, 1.84)
and 1.71 (95% CI 1.42, 2.05), respectively]. Persons under
follow-up in 2014 were less likely to start ABC compared
with those under follow-up in 2009 [IRR 0.69 (95% CI
0.57, 0.85)] (Fig. 2).
Discontinuation of ABC
Among 2139 individuals initiating ABC after 1 January
2009, contributing 778 PYFU, 113 individuals (5.3%) dis-
continued ABC within 6 weeks of ABC initiation, an inci-
dence rate (IR) of 14.51 (95% CI 12.07, 17.45) per 100
PYFU. The most common single reason for discontinua-
tion within the first 6 weeks was unknown, followed by
the patient’s wish/decision, then other causes. Thirteen
individuals (0.6%) discontinued because of reported HSR
[IR 1.67 (95% CI 0.97, 2.87) per 100 PYFU] and 35 (4.6%)
discontinued because of reported HSR or any toxicity [IR
4.49 (95% CI 3.23, 6.26) per 100 PYFU] (Table 2).
As only 13 persons discontinued because of reported
HSR, we could not formally investigate factors associated
with reported HSR-related discontinuation. Expanding the
endpoint to discontinuation because of reported HSR or
any toxicity did not identify any factors associated with
discontinuation. The strongest factor associated with dis-
continuation for reported HSR/any toxicity was nadir
CD4 cell count, where those with a nadir CD4 cell count
of 350–500 cells/lL were at the highest risk of discontin-
uing because of reported HSR/any toxicity [IRR 1.60
(95% CI 0.59, 4.37) compared with those with CD4 count
< 200 cells/lL; P-heterogeneity = 0.078]. This analysis
had limited power as there were few events (n = 35).
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Fig. 1 Percentage of patients prescribed abacavir at the midpoint of
each year, overall and in each region by year, in the EuroSIDA
cohort from 2009 to 2016. Region of care in Europe includes: South:
Argentina, Greece, Israel, Italy, Portugal and Spain; West: Austria,
Belgium, France, Germany, Luxembourg and Switzerland; North:
Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden
and the UK; Central-East: Bosnia and Herzegovina, Bulgaria, Croatia,
Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia and
Slovenia; East: Belarus, Estonia, Georgia, Latvia, Lithuania, Russian
Federation and Ukraine.
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Seven individuals died within 6 weeks of initiating
ABC, all with advanced HIV disease and other comorbidi-
ties. HSR was not reported among these individuals and
was unlikely to have been the cause of these deaths.
Discussion
Despite the risk of HSR, ABC remains a commonly used
antiretroviral drug across Europe in EuroSIDA. Among
individuals initiating ABC-based cART after 2009, there
were very few discontinuations within 6 weeks of ABC
initiation, and discontinuation rates because of reported
hypersensitivity reactions were 0.3 (95% CI 0.1, 1.0) per
100 PYFU. There were seven deaths within 6 weeks of
starting ABC, but these were likely to have been from
causes unrelated to ABC HSR reactions.
ABC utilization was lower among individuals who had
been exposed to more treatment regimens and had previ-
ous ABC exposure. Because there is evidence to suggest
ABC re-challenge should be avoided [5,12,23], it is possi-
ble this result is attributable to lower ABC prescription
rates among those already exposed to ABC. Unexpectedly,
higher ABC utilization was associated with CKD and
higher D:A:D CKD risk scores, although this could be
attributed to confounding by indication. Use of tenofovir
has been linked to kidney disease [24] and individuals on
18–41
41–47
47–52
52–58
> 58
South
West
North
Central-East
East
2009
2010
2011
2012
2013
2014
2015
2016
< 200
200–350
350–500
> 500
< 500
500–1 k
1–10 k
10–100 k
> 100 k
1st line
2nd line
3rd line
4th line
No CKD
CKD
Age quintile (years)
Region of care
Calendar year
CD4 count (cells/µL)
HIV RNA (copies/mL)
Line of regimen
CKD
0.5 0.6 0.7 0.8 0.9 1 2 3 4 5
Multivariable incidence rate ratio (95% CI)
Fig. 2 Multivariable incidence rate ratios for abacavir (ABC) utilization in the EuroSIDA cohort from 1 January 2009 to 1 April 2016. All clinical
and laboratory variables are time updated. Chronic kidney disease (CKD) was defined as two consecutive estimated glomerular filtration rate
values <60 more than 3 months apart using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula. Other variables in the
model include gender, Framingham cardiovascular disease 10-year elevated risk, hepatitis C virus and hepatitis B virus status, Data on Adverse
Drugs (D:A:D) CKD risk score and previous AIDS diagnosis. Region of care in Europe includes: South: Argentina, Greece, Israel, Italy, Portugal
and Spain; West: Austria, Belgium, France, Germany, Luxembourg and Switzerland; North: Denmark, Finland, Iceland, Ireland, the Netherlands,
Norway, Sweden and the UK; Central-East: Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slo-
vakia and Slovenia; East: Belarus, Estonia, Georgia, Latvia, Lithuania, Russian Federation and Ukraine. CI, confidence interval.
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tenofovir with decreasing renal function are likely to dis-
continue tenofovir [25] and be switched to ABC [26], a
drug with no reported adverse effect on renal function.
Changes over time and within regions in use of abacavir
probably reflect marketing and availability of abacavir.
Overall, the rate of discontinuation of ABC in the first
6 weeks after starting ABC was low, being similar to the
findings of phase II clinical trials [27,28], but slightly
lower than previous EuroSIDA findings [16], although the
previous EuroSIDA report had a much larger window to
observe reported HSR cases (3 months vs. 6 weeks in our
study). The rate of stopping because of reported HSR or
the composite endpoint of reported HSR or any toxicity
was also low, which could indicate the effectiveness of
screening for HLA-B*5701, better patient care and a
greater understanding of HSR among treating physicians.
Screening uptake for the HLA-B*5701 allele has probably
avoided many HSR reactions in recent years. EuroSIDA
does not collect genetic screening information; thus, it is
unknown which individuals were tested for HLA-B*5701,
or whether the frequency of testing varied between
regions and/or over calendar time.
It is possible that we found low rates of discontinua-
tion as a consequence of using a 6-week window from
ABC initiation, but it is well established that this is when
HSR is most likely to occur [18]. Even so, compared with
early cART, where discontinuation rates at 3 months were
reported to be between 10 and 15%[29,30], discontinua-
tion because of ABC was low, indicating the effectiveness
of screening for HLA-B*5701, improved patient manage-
ment, improved antiretroviral regimens, reduction in
toxicities, and improved adherence [31]. We found no
factors significantly associated with ABC discontinuation
because of reported HSR/any toxicity, although this
might partly be attributable to low power as few patients
discontinued.
Along with lack of data on HLA-B*5701 screening,
there are other limitations to our study. Most notably, the
symptoms of HSR can be difficult to distinguish from
other adverse events in the population, possibly leading
to over- or underreporting of discontinuation because of
reported HSR. EuroSIDA also only collects one reason for
discontinuing a drug, so if HSR and another simultaneous
reason for discontinuation occurred, HSR may have not
been reported as the reason for discontinuation in our
data. We have investigated underreporting by using a
composite outcome of reported HSR or any toxicity, with
consistent results. Finally, the validity of our models
depends on the assumption that we appropriately
adjusted for confounding; it is, however, possible that
our models have residual confounding by indication.
Nonetheless, EuroSIDA is in a unique position to compare
and describe treatment patterns as a consequence of the
standardized nature of the data collection and the inclu-
sion of countries for which there are no national cohorts
or surveillance structures.
This study also has several strengths, including the use
of a large data set from a heterogeneous population and
the inclusion of data from Eastern Europe. In addition,
EuroSIDA covers the period 1994–2016 with consistent
records of all antiretroviral use and reasons for stopping,
allowing comparisons of temporal trends of ABC utiliza-
tion and subsequent HSR. There has also been consis-
tency in the way data on antiretrovirals and the
subsequent reasons for stopping over our study duration
have been collected.
In summary, ABC remains a commonly used drug
throughout Europe, and the incidence of reported HSR
among those on ABC is low, probably attributable to
screening for HLA-B*5701, improved patient care and a
greater understanding and awareness of HSR.
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General Hospital “G Gennimatas”; H Sambatakou, Ippokra-
tion General Hospital, Athens. Hungary: (J Szlavik), Szent
Laslo Hospital, Budapest. Iceland: (M Gottfredsson), Land-
spitali University Hospital, Reykjavik. Ireland: (F.
Mulcahy), St James’s Hospital, Dublin. Israel: (I Yust), D
Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G
Hassoun, Rambam Medical Center, Haifa; H Elinav, M
Haouzi, Hadassah University Hospital, Jerusalem; D Elbirt,
ZM Sthoeger, AIDS Center (Neve Or), Jerusalem. Italy: (A.
D’Arminio Monforte), Istituto Di Clinica Malattie Infettive
e Tropicale, Milan; R Esposito, I Mazeu, C Mussini, Univer-
sita Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S
Maria Annunziata, Firenze; V Vullo, M Lichtner, University
di Roma la Sapienza, Rome; M Zaccarelli, A Antinori, R
Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive
Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N
Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo,
Osp. L. Sacco, Milan. Latvia: (B Rozentale), Infectology
Centre of Latvia, Riga. Lithuania: (V. Uzdaviniene) Vilnius
University Hospital Santaros Klinikos, Vilnius; R Mat-
ulionyte, Centro Poliklinika, Vilnius, Vilnius University
Hospital Santaros Klinikos, Vilnius. Luxembourg: (T
Staub), R Hemmer, Centre Hospitalier, Luxembourg.
Netherlands: (P Reiss), Academisch Medisch Centrum bij
de Universiteit van Amsterdam, Amsterdam. Norway: (DH
Reikvam), A Maeland, J Bruun, Ulleval Hospital, Oslo.
Poland: (B Knysz), J Gasiorowski, M Inglot, Medical
University, Wroclaw; A Horban, E Bakowska, Centrum
Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A Grzeszc-
zuk, Medical University, Bialystok; M Parczewski, K
Maciejewska, B Aksak-Was, Medical Univesity, Szczecin;
M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii
AIDS, Chorzow; T Smiatacz, M Gensing, Medical Univer-
sity, Gdansk; E Jablonowska, E Malolepsza, K Wojcik,
Wojewodzki Szpital Specjalistyczny, Lodz; I. Mozer-
Lisewska, Poznan University of Medical Sciences, Poznan.
Portugal: (L. Caldeira), Hospital Santa Maria, Lisbon; K
Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez,
Hospital Curry Cabral, Lisbon. Romania: (R Radoi), C
Oprea, Spitalul Clinic de Boli Infectioase si Tropicale: Dr.
Victor Babes, Bucuresti. Russia: (A Panteleev), O Panteleev,
St Petersburg AIDS Centre, St Peterburg; A Yakovlev,
Medical Academy Botkin Hospital, St Petersburg; T Trofi-
mora, Novgorod Centre for AIDS, Novgorod, I Khromova,
Centre for HIV/AIDS & Infectious Diseases, Kaliningrad; E
Kuzovatova, Nizhny Novgorod Scientific and Research
Institute of Epidemiology and Microbiology named after
Academician I.N. Blokhina, Nizhny Novogrod; E. Boro-
dulina, E Vdoushkina, Samara State Medical University,
Samara. Serbia: (D Jevtovic), The Institute for Infectious
and Tropical Diseases, Belgrade. Slovenia: (J Tomazic),
University Clinical Centre Ljubljana, Ljubljana. Spain: (JM
Gatell), JM Miro, Hospital Clinic Universitari de Barcelona,
Barcelona; S Moreno, JM Rodriguez, Hospital Ramon y
Cajal, Madrid; B. Clotet, A Jou, R Paredes, C Tural, J Puig,
I Bravo, Hospital Germans Trias i Pujol, Badalona; P
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Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital
Sant Pau, Barcelona; JM Laporte, Hospital Universitario de
Alava, Vitoria-Gasteiz. Sweden: (K Falconer), A Thalme, A
Sonnerborg, Karolinska University Hospital, Stockholm; A
Blaxhult, Venh€alsan-Sodersjukhuset, Stockholm; L Flam-
holc, Malm€o University Hospital, Malm€o. Switzerland: (A.
Scherrer), R Weber, University Hospital Zurich; M Cavas-
sini, University Hospital Lausanne, Lausanne; A Calmy,
University Hospital Geneva, Geneva; H Furrer, University
Hospital Bern, Bern; M Battegay, University Hospital Basel,
Basel; P Schmid, Cantonal Hospital, St. Gallen. Ukraine: A.
Kuznetsova, Kharkov State Medical University, Kharkov;
G. Kyselyova, Crimean Republican AIDS Centre, Simfer-
opol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention
and Control CTR, Lviv. UK: (B Gazzard), St Stephen’s
Clinic, Chelsea and Westminster Hospital, London; AM
Johnson, E Simons, S Edwards, Mortimer Market Centre,
London; A Phillips, MA Johnson, A. Mocroft, Royal Free
and University College Medical School, London (Royal
Free Campus); C Orkin, Royal London Hospital, London; J
Weber, G Scullard, Imperial College School of Medicine at
St Mary’s, London; A. Clarke, Royal Sussex County Hospi-
tal, Brighton; C Leen, Western General Hospital, Edin-
burgh.
The following centres have previously contributed data
to EuroSIDA: Infectious Diseases Hospital, Sofia, Bulgaria.
Ho^pital de la Croix Rousse, Lyon, France. Ho^pital de la
Pitie-Salpetiere, Paris, France. Unite INSERM, Bordeaux,
France. Ho^pital Edouard Herriot, Lyon, France. Bernhard
Nocht Institut f€ur Tropenmedizin, Hamburg, Germany. 1st
I.K.A Hospital of Athens, Athens, Greece. Ospedale Riu-
niti, Divisione Malattie Infettive, Bergamo, Italy. Ospedale
di Bolzano, Divisione Malattie Infettive, Bolzano, Italy.
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli,
Italy. Derer Hospital, Bratislava, Slovakia. Hospital Carlos
III, Departamento de Enfermedades Infecciosas, Madrid,
Spain. Kiev Centre for AIDS, Kiev, Ukraine. Luhansk State
Medical University, Luhansk, Ukraine. Odessa Region
AIDS Center, Odessa, Ukraine.
EuroSIDA Steering Committee: J Gatell, B. Gazzard, A.
Horban, I. Karpov, M. Losso, A. d’Arminio Monforte, C.
Pedersen, M. Ristola, A. Phillips, P. Reiss, J Lundgren, J.
Rockstroh, A. Scherrer, I. Aho, LD Rasmussen, V Svedhem,
G Wandeler, C. Pradier, N. Chkhartishvili, R. Matulionyte,
C. Oprea, JD Kowalska, J. Begovac, J Miro, G Guaraldi, R.
Paredes; Chair: J. Rockstroh; Study Co-leads: A. Mocroft, O
Kirk.
EuroSIDA staff: Coordinating Centre Staff: O. Kirk, L
Peters, A Bojesen, D Raben, D Kristensen, K. Laut, JF
Larsen, D Podlekareva, B Nykjær; Statistical Staff: A.
Mocroft, A. Phillips, A Cozzi-Lepri, L Shepherd, S Amele,
A. Pelchen-Matthews.
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Antiretroviral penetration into the CNS
and incidence of AIDS-defining
neurologic conditions
ABSTRACT
Objective: The link between CNS penetration of antiretrovirals and AIDS-defining neurologic
disorders remains largely unknown.
Methods: HIV-infected, antiretroviral therapy–naive individuals in the HIV-CAUSAL Collaboration
who started an antiretroviral regimen were classified according to the CNS Penetration Effec-
tiveness (CPE) score of their initial regimen into low (,8), medium (8–9), or high (.9) CPE score.
We estimated “intention-to-treat” hazard ratios of 4 neuroAIDS conditions for baseline regimens
with high and medium CPE scores compared with regimens with a low score. We used inverse
probability weighting to adjust for potential bias due to infrequent follow-up.
Results: A total of 61,938 individuals were followed for a median (interquartile range) of 37
(18, 70) months. During follow-up, there were 235 cases of HIV dementia, 169 cases of toxo-
plasmosis, 128 cases of cryptococcal meningitis, and 141 cases of progressive multifocal leuko-
encephalopathy. The hazard ratio (95% confidence interval) for initiating a combined
antiretroviral therapy regimen with a high vs low CPE score was 1.74 (1.15, 2.65) for HIV demen-
tia, 0.90 (0.50, 1.62) for toxoplasmosis, 1.13 (0.61, 2.11) for cryptococcal meningitis, and 1.32
(0.71, 2.47) for progressive multifocal leukoencephalopathy. The respective hazard ratios (95%
confidence intervals) for a medium vs low CPE score were 1.01 (0.73, 1.39), 0.80 (0.56, 1.15),
1.08 (0.73, 1.62), and 1.08 (0.73, 1.58).
Conclusions:We estimated that initiation of a combined antiretroviral therapy regimen with a high
CPE score increases the risk of HIV dementia, but not of other neuroAIDS conditions. Neurology®
2014;83:134–141
GLOSSARY
cART 5 combined antiretroviral therapy; CI 5 confidence interval; CPE 5 CNS Penetration Effectiveness; ICD-9 5 Inter-
national Classification of Diseases, ninth revision; NNRTI 5 nonnucleoside reverse transcriptase inhibitor.
AIDS-defining neurologic disorders, or neuroAIDS, include HIV dementia and the opportun-
istic infections toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoenceph-
alopathy.1–3 The incidence of neuroAIDS in developed countries decreased after the
introduction of combined antiretroviral therapy (cART) in 1996,2,4–9 but antiretroviral drug–
related neurotoxicity remains a concern.2,10–12
The risk of neuroAIDS may depend on the concentration of antiretrovirals in the CNS, which
is a function of their ability to penetrate the blood-brain barrier. Greater exposure of antiretrovirals
in the CNS may decrease the HIV RNA in the CSF,13 but may also be neurotoxic.14,15 One
proposed method to assess a drug’s penetrative ability into the CNS is via the CNS Penetration
Effectiveness (CPE) ranking system. In cohort studies to date, lower CPE ranks are associated with
higher CSF HIV RNA after adjusting for a number of clinical variables.13,16–18
While the association between CPE rank and CSF HIV RNA is reported, the connection
between CPE rank and clinical outcomes remains unclear.17,19–22 A randomized controlled trial
comparing a CNS-targeted therapy to a non-CNS–targeted therapy among 49 individuals with
HIV-associated neurocognitive disorders found no difference in improvement of neurocognitive
Authors’ affiliations are listed at the end of the article.
Contributors to the HIV-CAUSAL Collaboration are listed on the Neurology® Web site at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
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performance after 16 weeks.23 An observa-
tional study in the United Kingdom found a
similar incidence of neuroAIDS in individuals
with high and low CPE scores.24
Herein, we present estimates of the effect of
CPE score on the incidence of 4 neuroAIDS
conditions among individuals withHIV-1 infec-
tion included in a large multinational collabora-
tion of cohort studies from Europe and the
United States.
METHODS Standard protocol approvals, registrations,
and patient consents. Research using the HIV-CAUSAL
Collaboration was determined to be nonhuman subjects research
by the Institutional Review Board of the Harvard School of
Public Health because it involves the study of existing data that
are analyzed in such a manner that the subjects cannot be
identified, as set forth in US federal regulations. Written
informed consent from patients was not required because all data
were completely anonymized.
Study population. The HIV-CAUSAL Collaboration includes
prospective cohort studies from 6 European countries and the
United States. All cohorts included in the HIV-CAUSAL
Collaboration were assembled prospectively and are based on
data collected for clinical purposes from national health care
systems that offer universal access to care. Each cohort in the
collaboration collected data prospectively, including all CD4
cell counts, HIV RNA measurements, treatment initiations,
deaths, and AIDS-defining illnesses (including the events of
interest: HIV dementia, toxoplasmosis, cryptococcal meningitis,
and progressive multifocal leukoencephalopathy).
The individual cohort studies used in these analyses are UK
CHIC (United Kingdom), ATHENA (the Netherlands), FHDH-
ANRSCO4 (France), SHCS (Switzerland), PISCIS (Spain), CoRIS/
CoRIS-MD (Spain), VACS-VC (US veterans), AMACS (Greece),
and AQUITAINE (France). Four cohorts of seroconverters with rel-
atively high CD4 counts did not have any neuroAIDS events and
were excluded from the analyses.
We restricted our analyses to individuals with HIV-1 infection
whomet the following criteria at baseline (starting in January 1998):
age 18 years or older, no history of AIDS (defined as the onset of any
category C AIDS-defining illness),25 antiretroviral therapy naive
(as defined elsewhere26), no pregnancy (when information was avail-
able), CD4 cell count and HIV RNA measured within the previous
6 months, and initiating a complete antiretroviral regimen (see
below) consisting only of drugs with known CPE ranks.
We conducted separate analyses for the following neuroAIDS
events: HIV dementia, toxoplasmosis, cryptococcal meningitis, or
progressive multifocal leukoencephalopathy. Non-Hodgkin lym-
phoma was not included as an event because we could not differen-
tiate primary brain lymphoma from other types of non-Hodgkin
lymphoma. We also looked at a combined endpoint of any of the
3 opportunistic infections (toxoplasmosis, cryptococcal meningitis,
or progressive multifocal leukoencephalopathy). The date of neuro-
AIDS was identified by the treating physicians. One of the contrib-
uting cohorts (VACS) used ICD-9 codes to identify incident
neuroAIDS cases. The other contributing cohorts used diagnostic
procedures that reflect standard clinical practice in Europe rather
than standardized research criteria.
For each patient, follow-up started on the date of initiation of
a complete antiretroviral regimen—defined as treatment with at
least 2 nucleoside reverse transcriptase inhibitors plus either one
or more protease inhibitors, one or more nonnucleoside reverse
transcriptase inhibitors (NNRTIs), one entry/fusion inhibitor, or
one integrase inhibitor—and ended at death, 12 months after the
most recent laboratory measurement, pregnancy (if known), the
cohort-specific administrative end of follow-up (ranging between
December 2003 and February 2013) or the event of interest,
whichever occurred earlier.
Assessment of antiretroviral CNS exposure. The 2010 CPE
ranking system is a proposed method for measuring the penetra-
tive ability of different antiretroviral drugs into the CNS. Each
drug is given a rank ranging from 1 to 4 based on pharmacoki-
netic and pharmacodynamic data, drug characteristics, results of
clinical studies, and effectiveness in reducing CSF viral load or
improving cognition. A rank of 4 represents the best penetration
or effectiveness.14,16 The CPE score for a given regimen is calculated
by summing the ranks of each drug in the regimen. We categorized
the CPE score for a regimen as low (,8), medium (8–9), or high
(.9) based on the distribution of the data (the cut points were
approximately at the median and the 75th percentile) (figure 1).
Because our estimates may be sensitive to the chosen cut points, we
also treated the CPE score as a continuous variable.
Statistical methods. Using a pooled logistic regression model,
we estimated the average “intention-to-treat” neuroAIDS hazard
ratio for a high and a medium baseline CPE score compared with a
low baseline CPE score. Under the assumption that the monthly
probability of an event is small (a condition satisfied in our study),
the parameters of our pooled logistic model closely approximate the
parameters of a Cox proportional hazards model.27 We computed
these estimates separately for each of the 4 neuroAIDS conditions as
well as for the combined endpoint of opportunistic infections. The
model included month of follow-up (restricted cubic splines with
4 knots at 1, 6, 24, and 60 months) and the following baseline
covariates: CD4 cell count (,200, 200–299, $300 cells/mL), HIV
RNA level (,10,000, 10,000–100,000, .100,000 copies/mL), sex,
acquisition group (heterosexual, homosexual/bisexual, injection drug
use, other or unknown), calendar year (1998, 1999–2000, 2001–
2003, $2004), age (,35, 35–50, .50 years), geographic origin
(North America or Western Europe, Sub-Saharan Africa, other, or
unknown), race (white, black, other, or unknown), years since HIV
diagnosis (,1, 1–4, $5 years or unknown), whether or not the
regimen was an NNRTI-based regimen, and cohort.
The variables we adjusted for in our models are associated
with CPE score and widely known to be associated with the out-
comes of interest. For example, a baseline CD4 cell count ,200
cells/mL, a baseline HIV RNA.100,000 copies/mL, and a base-
line age.50 years were associated with an increased odds of both
HIV dementia and the combined endpoint of opportunistic in-
fections compared with a baseline CD4 cell count$300 cells/mL,
a baseline HIV RNA ,10,000 copies/mL, and a baseline age
,35 years, respectively (data not shown).
To adjust for potential selection bias due to infrequent follow-
up, we computed inverse probability weights. Each patient in the
above logistic models received a time-varying weight inversely pro-
portional to the estimated probability of not being censored, for each
month that patient was followed.28,29 We fit a pooled logistic model
using the baseline covariates listed above, the baseline CPE score
category, and the most recent measurement of the following time-
varying covariates: CD4 cell count (restricted cubic spline with 5
knots at 10, 200, 350, 500, and 1,000 cells/mL), HIV RNA level
(,5,000, 5,000–10,000, 10,000–100,000,.100,000 copies/mL),
time since last laboratory measure (0, 1–2, 3–4, 5–6, $7 months),
and AIDS (any category C AIDS-defining illness other than the
neuroAIDS condition of interest), and estimated each patient’s
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probability of remaining uncensored in each month of follow-up.
The models for the weights were fit before the final models. The
weights were stabilized as described elsewhere28 and were then used
to fit the final weighted regression model. The estimated weights for
each of the 5 outcomes had mean 1.00 (first percentile: 0.96; 99th
percentile: 1.20).
We used robust variance estimators that take into account the
procedure of weight estimation to compute 95% confidence in-
tervals (CIs) for each of our estimates.30 Under the assumption
that the measured covariates are sufficient to adjust for confound-
ing and selection bias, our approach emulates a nonblinded ran-
domized trial in which patients were assigned to regimens with
1 of 3 CPE score categories.28
Several sensitivity analyses were performed for the outcome
HIV dementia: we (1) varied the CPE score of regimens that were
boosted with ritonavir because the CPE score category for
boosted ritonavir is somewhat ambiguous in 2 regimens; (2)
restricted the analysis to VACS in order to additionally adjust
for the VACS Index31; (3) excluded VACS from the analysis;
(4) estimated stabilized inverse probability weights to adjust for
potential selection bias due to death, a competing risk32; (5)
excluded cases of HIV dementia occurring in the first year; and
(6) restricted the analysis to individuals who initiated therapy
before the introduction of the first CPE scoring system in
2008. Exclusion of 0.15% of individuals with unusual treatment
combinations (e.g., boosted nelfinavir and unboosted darunavir)
did not materially affect the estimates. We also considered an
alternative categorization of the CPE score by dividing the lowest
category into 2 smaller categories (,6 and 6 to ,8), and esti-
mated the average log hazard ratios using a model that included a
flexible functional form for the continuous CPE score (restricted
cubic spline with 4 knots at 5, 7, 9, and 12). We fit a pooled
logistic model containing this form of the CPE score as well as the
previously listed baseline covariates, and adjusted for potential
selection bias due to infrequent follow-up as previously described.
All analyses were conducted with SAS 9.3 (SAS Institute, Cary,
NC). The LOGISTIC procedure was used to fit the weighted
regression models, and a nonparametric bootstrap with 500 sam-
ples was used to compute 95% CIs.
RESULTS A total of 61,938 individuals met the eli-
gibility criteria for our study; 38,786 (62%) initiated
a regimen with a low CPE score, 17,687 (29%) with a
medium CPE score, and 5,465 (9%) with a high CPE
score. The mean score for individuals on an NNRTI-
based regimen was 8.2 and the mean for individuals on
a non-NNRTI–based regimen was 7.3. Table 1 shows
the baseline characteristics of the study population by
CPE score category. Individuals with a high CPE score
were more likely to be female, heterosexual, initiating
therapy before 2004, and of Sub-Saharan African
origin. The median (interquartile range) follow-up
time was 37 (18, 70) months.
During follow-up, there were 235 cases of HIV
dementia, 169 cases of toxoplasmosis, 128 cases of
cryptococcal meningitis, and 141 cases of progressive
multifocal leukoencephalopathy. Forty individuals
developed 2 of the 4 neuroAIDS conditions, and
one individual developed 3. The incidence rate (per
10,000 person-years) was 9.0 for HIV dementia,
6.5 for toxoplasmosis, 4.9 for cryptococcal meningi-
tis, and 5.4 for progressive multifocal leukoencepha-
lopathy. The median (interquartile range) time from
cART initiation to the event of interest was 14 (2, 39)
months for HIV dementia, 4 (1, 16) months for
toxoplasmosis, 10 (1, 25) months for cryptococcal
Figure 1 Number initiating treatment by CPE score
Number of individuals initiating treatment by CNS Penetration Effectiveness (CPE) score (range 4–16), HIV-CAUSAL
Collaboration, 1998–2013.
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meningitis, and 3 (1, 14) months for progressive mul-
tifocal leukoencephalopathy.
Table 2 shows the 3 most frequently used cART
regimens with high, medium, and low CPE scores.
Compared with initiating a cART regimen with a low
CPE score, the hazard ratio (95% CI) for initiating a
cART regimen with a high CPE score was 1.74 (1.15,
2.65) for HIV dementia, 0.90 (0.50, 1.62) for toxo-
plasmosis, 1.13 (0.61, 2.11) for cryptococcal menin-
gitis, and 1.32 (0.71, 2.47) for progressive multifocal
Table 1 Baseline characteristics by CPE score category, HIV-CAUSAL Collaboration, 1998–2013
Baseline characteristics
Persons, % (n)
Low CPE score
(n 5 38,786)
Medium CPE score
(n 5 17,687)
High CPE score
(n 5 5,465)
CD4 cell count, cells/mL
<200 37.8 (14,674) 44.9 (7,939) 43.5 (2,377)
200 to <300 25.5 (9,890) 25.6 (4,521) 24.2 (1,320)
‡300 36.7 (14,222) 29.5 (5,227) 32.3 (1,768)
HIV RNA, copies/mL
<10,000 18.6 (7,215) 17.9 (3,172) 20.5 (1,121)
10,000–100,000 41.6 (16,136) 40.6 (7,176) 41.9 (2,292)
>100,000 39.8 (15,435) 41.5 (7,339) 37.6 (2,052)
Sex
Male 80.0 (31,016) 74.4 (13,157) 66.2 (3,618)
Female 20.0 (7,770) 25.6 (4,530) 33.8 (1,847)
Race
White 23.9 (9,285) 23.3 (4,125) 17.8 (970)
Black 13.9 (5,373) 20.0 (3,541) 21.9 (1,198)
Other 62.2 (24,128) 56.7 (10,021) 60.3 (3,297)
Age, y
<35 34.6 (13,418) 35.5 (6,280) 41.9 (2,289)
35–50 47.4 (18,382) 47.1 (8,327) 43.6 (2,384)
>50 18.0 (6,986) 17.4 (3,080) 14.5 (792)
Origin
North America or Western Europe 60.3 (23,373) 54.7 (9,671) 53.1 (2,903)
Sub-Saharan Africa 13.7 (5,321) 19.9 (3,516) 23.4 (1,277)
Other 9.3 (3,600) 7.5 (1,326) 6.6 (359)
Unknown 16.7 (6,492) 17.9 (3,147) 16.9 (926)
Acquisition group
Heterosexual 33.1 (12,853) 40.3 (7,129) 45.5 (2,488)
Homosexual/bisexual 41.8 (16,214) 32.2 (5,706) 28.4 (1,554)
Injection drug user 5.9 (2,264) 6.9 (1,213) 7.7 (418)
Other/unknown 19.2 (7,455) 20.6 (3,639) 18.4 (1,005)
Calendar year
1998 7.4 (2,865) 7.2 (1,283) 6.0 (326)
1999–2000 8.5 (3,291) 14.6 (2,578) 29.1 (1,593)
2001–2003 8.7 (3,362) 24.8 (4,381) 41.3 (2,257)
‡2004 75.4 (29,268) 53.4 (9,445) 23.6 (1,289)
Regimen
NNRTI-based 47.2 (18,295) 59.4 (10,501) 74.6 (4,079)
non-NNRTI–based 52.8 (20,491) 40.6 (7,186) 25.4 (1,386)
Abbreviations: CPE 5 CNS Penetration Effectiveness; NNRTI 5 nonnucleoside reverse transcriptase inhibitor.
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leukoencephalopathy (table 3). Compared with a low
CPE score, the respective hazard ratios (95% CIs) for
a medium CPE score were 1.01 (0.73, 1.39), 0.80
(0.56, 1.15), 1.08 (0.73, 1.62), and 1.08 (0.73,
1.58). Figure 2 shows the log hazard ratio against
the continuous CPE score for the combined end-
point of opportunistic infections and for HIV
dementia (see figure e-1 on the Neurology® Web site
at Neurology.org for the individual opportunistic
infections).
The hazard ratio of HIV dementia for a high
CPE score vs a low CPE score did not vary substan-
tially by CD4 cell count, age, sex, and type of cART
regimen (NNRTI-based vs non-NNRTI–based),
but the 95% CIs were wide (data not shown). The
hazard ratios and 95% CIs did not change with dif-
ferent specifications of the functional form for
month of follow-up (data not shown). None of the
sensitivity analyses described in the previous section
yielded appreciably different results (table e-1).
Varying the cut points of the CPE score did not
materially change the point estimates but resulted
in wider CIs. Excluding cases of HIV dementia
occurring in the first year of follow-up (table e-2)
did not materially change the estimates of the effect
of CPE score on HIV dementia.
Table 2 Most frequently used cART regimens with a low, medium, and high CPE
score, HIV-CAUSAL Collaboration, 1998–2013
Regimen No. of initiators CPE score (category)
Efavirenz, tenofovir, emtricitabine 14,839 7 (low)
Nelfinavir, zidovudine, lamivudine 3,368 7 (low)
Lopinavir, ritonavir, tenofovir, emtricitabine 3,342 7 (low)
Efavirenz, zidovudine, lamivudine 5,346 9 (medium)
Lopinavir, ritonavir, zidovudine, lamivudine 3,823 9 (medium)
Efavirenz, lamivudine, abacavir 1,837 8 (medium)
Nevirapine, zidovudine, lamivudine 3,373 10 (high)
Indinavir, ritonavir, zidovudine, lamivudine 757 10 (high)
Efavirenz, zidovudine, lamivudine, abacavir 409 12 (high)
Abbreviations: cART 5 combined antiretroviral therapy; CPE 5 CNS Penetration
Effectiveness.
Table 3 Hazard ratios for CPE score, HIV-CAUSAL Collaboration, 1998–2013
CPE score Person-years No. of events
Unadjusted
hazard ratio 95% CI
Adjusted
hazard ratioa 95% CI
HIV dementia
Low 140,962 127 1.00 Reference 1.00 Reference
Medium 86,799 72 0.97 0.72, 1.30 1.01 0.73, 1.39
High 32,097 36 1.55 1.06, 2.26 1.74 1.15, 2.65
Opportunistic infectionsb
Low 140,553 245 1.00 Reference 1.00 Reference
Medium 86,455 134 1.09 0.88, 1.34 0.99 0.80, 1.22
High 31,985 49 1.18 0.87, 1.62 1.08 0.77, 1.52
Toxoplasmosis
Low 140,983 106 1.00 Reference 1.00 Reference
Medium 86,807 45 0.86 0.60, 1.22 0.80 0.56, 1.15
High 32,099 18 0.94 0.57, 1.57 0.90 0.50, 1.62
Cryptococcal meningitis
Low 141,098 64 1.00 Reference 1.00 Reference
Medium 86,818 48 1.35 0.92, 1.98 1.08 0.73, 1.62
High 32,121 16 1.43 0.83, 2.48 1.13 0.61, 2.11
Progressive multifocal
leukoencephalopathy
Low 141,109 81 1.00 Reference 1.00 Reference
Medium 86,849 43 1.12 0.77, 1.64 1.08 0.73, 1.58
High 32,116 17 1.36 0.80, 2.33 1.32 0.71, 2.47
Abbreviations: CI 5 confidence interval; CPE 5 CNS Penetration Effectiveness.
aAdjusted for cohort, month of follow-up, baseline CD4 cell count, baseline HIV RNA level, sex, acquisition group, calendar
year, age, geographic origin, race, years since HIV infection, and type of drug regimen, as well as time-varying CD4 cell
count, RNA level, time since last measurement, and AIDS. Stabilized inverse probability weights were used to account for
censoring due to infrequent follow-up.
b Includes toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy.
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DISCUSSION We estimated that the incidence of
HIV dementia increases by more than 70% after ini-
tiating an antiretroviral regimen with a high CPE
score compared with a low score. However, we found
little change in the incidence of toxoplasmosis, cryp-
tococcal meningitis, and progressive multifocal leuko-
encephalopathy. These results are unexpected, and
the interpretation of our effect estimates needs to be
tempered by the limitations of our study.
In the only published study that has considered
CPE scores in relation to neuroAIDS among HIV-
positive individuals, the incidence of neuroAIDS
was similar for a baseline CPE score of 10 or greater
and for a baseline CPE score of 4 or less, but the
small number of events resulted in a wide 95% CI
(hazard ratio: 0.95; 95% CI: 0.53, 1.72). Further-
more, the study was not restricted to antiretroviral
therapy–naive individuals and effect estimates for
individual neuroAIDS conditions such as HIV
dementia were not provided.24 Other studies of the
association between CPE scores and risk of cognitive
impairment (but not neuroAIDS) have had conflict-
ing results.17,19–21,33
Our findings that CPE score does not affect the
incidence of opportunistic infections may not be par-
ticularly surprising, because the development of these
neuroAIDS conditions may be very closely connected
to the degree of impaired cell-mediated immunity
and not associated with antiretroviral penetration.4,5
In contrast, antiretroviral penetration into the brain
may lead to deposition of b-amyloid plaques, which
has been proposed as a possible explanation for a harm-
ful effect of high CPE score on HIV dementia.34 One
study observed a higher percentage of extracellular
b-amyloid in cART-treated patients than in untreated
HIV-positive individuals,35 and HIV-positive individ-
uals with HIV-associated dementia have higher levels
of intraneuronal b-amyloid immunoreactivity com-
pared with HIV-positive individuals without HIV-
associated dementia.34–36 However, the underlying
mechanism through which antiretroviral penetration
could cause HIV dementia remains unknown. The
hypothesis that antiretroviral penetration increases
the incidence of HIV dementia via deposition of
b-amyloid plaques requires further research to deter-
mine whether these associations are in fact causal.
Alternative pathways including antiretroviral-related
direct neuronal damage and mitochondrial toxicity
should also be evaluated.15
Another explanation for the higher dementia risk
for regimens with a high CPE score is that these regi-
mens are less effective to treat HIV disease, for exam-
ple, because of incomplete adherence: 68% of
individuals in the study deviated from their initial reg-
imen at some point. However, both the high average
proportion of follow-up spent on the initial regimen
(58%) and the lack of a strong association between
CPE score and opportunistic infections do not sup-
port this explanation.
Similar to any other observational study, the valid-
ity of our estimates relies on the untestable assump-
tion that the measured covariates were sufficient to
adjust for confounding and selection bias. It is possi-
ble that consideration of CPE scores is a factor for de-
cisions concerning antiretroviral regimens in patients
with neurocognitive symptoms. If individuals with
neurocognitive symptoms are more likely to initiate
antiretroviral regimens with higher CPE scores, the
estimated effect on dementia might be explained by
this confounding by indication. If this were the case,
we would expect the estimated effect on dementia to
disappear or to attenuate after a certain amount of
time. However, excluding cases of HIV dementia
occurring in the first year of follow-up does not mate-
rially change the results. Furthermore, restricting the
Figure 2 Estimated log hazard ratios and 95% confidence intervals
Estimated log hazard ratios and 95% confidence intervals for opportunistic infections (A)
(toxoplasmosis, cryptococcal meningitis, or progressive multifocal leukoencephalopathy)
and HIV dementia (B) comparing each CNS Penetration Effectiveness (CPE) score with a
CPE score of 4 (lowest), HIV-CAUSAL Collaboration, 1998–2013.
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analysis to individuals who initiated therapy before
the introduction of the first CPE scoring system in
2008 does not affect the results.
Some limitations of our study should be noted.
First, with relatively few events, the 95% CIs around
our effect estimates are wide. However, our study is
the largest one to date on this topic. Second, the cohorts
included in this analysis are from developed countries;
our results may not be generalizable to resource-limited
settings or to other health care systems. Third, with the
exception of VACS, the contributing cohorts used diag-
nostic procedures that reflect standard clinical practice
in Europe. Excluding VACS from the analysis, how-
ever, did not significantly alter the results. Fourth, while
our effect estimates are adjusted for cohort, we were not
able to adjust for the individual centers within each
cohort. Thus, some residual confounding due to cen-
ters within each cohort is theoretically possible. Finally,
the average duration of follow-up in our study was
approximately 3 years. Future studies will be needed
to investigate the effect of antiretroviral penetration
on the long-term incidence of neuroAIDS, as well as
the effect of newer antiretrovirals that are not well rep-
resented in current studies, including ours.
We estimated that initiation of a cART regimen
with a high CPE score increases the risk of HIV
dementia, but not of other neuroAIDS conditions.
These findings should be interpreted cautiously, and
additional studies are needed to examine the effect of
CPE score on the incidence of HIV dementia more
closely. Together with additional data on the safety
and effectiveness of different cART regimens, these re-
sults may be useful to plan the management of individ-
uals with HIV infection.
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Opportunistic infections and AIDS malignancies early
after initiating combination antiretroviral therapy in
high-income countries
The HIV-CAUSAL Collaboration
Background: There is little information on the incidence of AIDS-defining events which
have been reported in the literature to be associated with immune reconstitution
inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation.
These events include tuberculosis, mycobacterium avium complex (MAC), cytomega-
lovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes
simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis
and candidiasis.
Methods: We identified individuals in the HIV-CAUSAL Collaboration, which includes
data from six European countries and theUS, whowere HIV-positive between 1996 and
2013, antiretroviral therapy naive, aged at least 18 years, had CD4þ cell count andHIV-
RNA measurements and had been AIDS-free for at least 1 month between those
measurements and the start of follow-up. For each AIDS-defining event, we estimated
the hazard ratio for no cART versus less than 3 and at least 3 months since cART
initiation, adjusting for time-varying CD4þ cell count and HIV-RNA via inverse
probability weighting.
Results: Out of 96562 eligible individuals (78% men) with median (interquantile
range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases
varied between 898 for tuberculosis and 113 for PML. Compared with non-cART
initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART
initiation were 1.21 (0.90–1.63) for tuberculosis, 2.61 (1.05–6.49) for MAC, 1.17
(0.34–4.08) for CMV retinitis, 1.18 (0.62–2.26) for PML, 1.21 (0.83–1.75) for HSV,
1.18 (0.87–1.58) for Kaposi sarcoma , 1.56 (0.82–2.95) for NHL, 1.11 (0.56–2.18) for
cryptococcosis and 0.77 (0.40–1.49) for candidiasis.
Conclusion: With the potential exception of mycobacterial infections, unmasking IRIS
does not appear to be a common complication of cART initiation in high-income
countries.  2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2014, 28:2461–2473
Keywords: HIV, immune reconstitution inflammatory syndrome, incidence,
inverse probability weighting, unmasking
Introduction
Combined antiretroviral therapy (cART) has dramati-
cally reduced morbidity and mortality associated with
HIV infection [1–4]. cART restores the immune
response against opportunistic infections, but some
patients experience an inflammatory reaction within
weeks or months after cART initiation [5,6]. This
immune reconstitution inflammatory syndrome (IRIS),
whose pathogenesis is not fully elucidated, can result
in clinical worsening of existing opportunistic
infections after commencing cART (paradoxical IRIS)
or in the appearance soon after cART initiation
of a new and previously unrecognised oppor-
tunistic infections (unmasking IRIS) [7]. IRIS,
may be associated with significant morbidity, is a
diagnostic challenge and complicates clinical manage-
ment [7].
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IRIS has been described in patients with opportunistic
infections and AIDS malignancies caused by infections
[8–17] as well as in patients with non-infectious
conditions, such as rheumatoid arthritis and sarcoidosis,
although with a different immunopathogenesis [18,19].
Whereas there is a solid body of literature documenting
reactions associated with immune restoration for myco-
bacterial infections both in the HIV-negative [20] and
the HIV-positive population [21–24], our knowledge
of IRIS for other conditions is mainly based upon case
studies of patients on cART. Most of these describe
cases of paradoxical phenomena and only a few studies
have reported on unmasking IRIS. Further, because
case definitions have not been implemented in large
observational databases, it has been problematic to
estimate its magnitude.
The HIV-CAUSAL Collaboration has recently reported
an increase in tuberculosis incidence shortly after cART
initiation which was particularly marked in patients with
CD4þ cell counts below 50 cells/ml, a pattern strongly
suggestive of unmasking IRIS [25]. This pattern was not
seen for Pneumocystis jirovecii pneumonia. Here we update
and extend our study to the effect of cART on AIDS-
defining events suggested to be associated with IRIS in
the literature: tuberculosis, mycobacterium avium complex
(MAC), cytomegalovirus (CMV) retinitis, progressive
multifocal leukoencephalopathy (PML), herpes simplex
virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma
(NHL), cryptococcosis and candidiasis. For each of these
AIDS-defining events, we explore whether changes in
incidence after cART initiation are compatible with
unmasking IRIS.
Methods
Study population
We used data from the HIV-CAUSAL collaboration,
which include HIV-positive individuals from prospective
cohorts in six European countries and the United States
[25]. All cohorts are based on routinely collected data in
clinical practice within settings with universal access to
care. Initiation of cARTwas defined as the date on which
an individual initiated treatment with at least two
nucleoside reverse transcriptase inhibitors and either
one or more protease inhibitors, one non-nucleoside
reverse transcriptase inhibitors, one entry/fusion inhibi-
tor or one integrase inhibitor.
Analyses included individuals who were HIV-positive
between 1996 and 2013 aged 18 years or more, and had a
CD4þ cell count and an HIV-RNA measurement within
6 months of each other while antiretroviral therapy
(ART) naive. Individuals’ follow-up started at baseline,
defined as the date when all the inclusion criteria were
met, and ended at outcome diagnosis, death, 12 months
after the most recent laboratory measurement or cohort-
specific administrative censoring, whichever occurred
earlier. To prevent the misclassification of undiagnosed
prevalent opportunistic infections and AIDS malignancies
as incident cases, and thus, minimise the inclusion of cases
of paradoxical IRIS, our analyses excluded HIV-positive
individuals who were not AIDS-free during the baseline
month.
Outcomes
We considered as primary outcomes all AIDS-events
previously suggested to be associated with IRIS. We
included tuberculosis, CMV retinitis, cryptococcosis,
PML and Kaposi sarcoma because these were the most
common AIDS-defining events in a systematic review of
IRIS in observational studies [11]. We included MAC
because its association with IRIS was observed soon after
antiretroviral therapy was introduced [21]. We included
NHL because rare manifestations of IRIS have been
reported [10,26]. We included candidiasis and HSV
(often not considered in association with IRIS) because a
large cohort study of cART initiators in the United States
[12] reported them as the most common IRIS-related
events.
The diagnostic criteria for the AIDS-defining events [27]
were those routinely used in clinical practice in each
of the participating countries. Information on use of
prophylaxis drugs for these conditions is not collected by
the HIV-CAUSAL Collaboration because prophylaxis for
these conditions is not widely implemented in most of the
participating cohorts.
For each outcome, our working definition for unmasking
IRIS was a newly diagnosed and non-previously detected
AIDS-defining event in the first 3 months after starting
cART.
Statistical methods
All analyses were conducted separately for each outcome.
We computed incidence rates as number of cases per 1000
person-years and estimated the hazard ratio of each
outcome for (i) cART versus no cART and (ii) no cART
versus less than 3 and at least 3 months since cART
initiation. We then estimated the cumulative incidence up
to 3 months after cART initiation [28].
To estimate the hazard ratios, we used a pooled logistic
model for risk of the outcome at month mþ1 that included
a time-varying indicator for ever use of cART through
month m, month of follow-up m (restricted cubic splines
with five knots) and the following baseline covariates:
CD4þ cell count (<50, 50–99 100–199 200–349 350–
499, or 500 cells/ml) HIV-RNA level (<4, 4–5 or >5
log10 copies/ml), sex, transmission group (heterosexual,
MSM, injecting drug users, or other/unknown), calendar
year (1996–1998, 1999–2000, 2001–2003 or 2004–
2013), age (<35, 35–50, or >50 years), geographical
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origin (Western countries, sub-Saharan Africa, other, or
unknown), time since HIV infection diagnosis (<3 versus
3 months) and cohort.
As cART is more likely to be initiated in individuals with
a low CD4þ cell count and a high HIV-RNA level,
estimates from the previous models have to be adjusted for
these time-dependent confounders. Because CD4þ cell
count and HIV-RNA are affected by prior treatment,
adding them as time-dependent covariates in the logistic
regression model may introduce bias [29]. Therefore, we
used inverse probability weighting to adjust for time-
varying CD4þ cell count and HIV-RNA. Formally,
under the assumption that all time-varying predictors of
both cART and AIDS were included in the analyses, the
weighted model estimates the parameters of a marginal
structural Cox model [30].
Each patient in the analysis received a time-dependent
weight inversely proportional to the probability of
having its own observed history of cART initiation, as
described elsewhere [30]. To estimate each patient’s
probability of cART initiation in each month, we fit a
pooled logistic model that included the covariates listed
above for the outcome model and the most recent
measurement of the following time-dependent
covariates: CD4þ cell count (restricted cubic splines
with five knot), HIV-RNA level (<4, 4–5 or >5
log10 copies/ml), AIDS (yes or no) and time since last
laboratory measurement. Inverse probability weights
were also estimated to adjust for potential selection bias
because of censoring by infrequent measurement. Both
the cART initiation and censoring weights were
stabilized and their product used to fit the weighted
pooled logistic model. To avoid the influence of
outliers on the variance of the estimates, we truncated
the weights at a maximum of 10 which affected less
than 1% of the individuals. The estimated weights used
in the analyses had a mean of 1.01. Truncation did not
materially change the hazard ratio estimates. We
computed conservative 95% confidence intervals for
the log hazard ratio by using a variance estimator that
accounts for the estimation of the weights.
We performed several sensitivity analyses: (i) we estimated
the hazard ratio of no cART versus time since cART
initiation categories less than 4 and at least 4 months, (ii)
in addition to censoring follow-up at 12 months without
a laboratory measurement, we censored at 18 and
24 months after the last measurement, (iii) the start of
follow-up was delayed by 3 months to exclude prevalent
cases, iv) we lagged CD4þ cell count and HIV-RNA level
14 or 21 days to ensure that cART initiation was
predicted using prior measurements, (v) we estimated
inverse probability weights for censoring by death (so that
estimates can be interpreted as if all deaths could be
prevented) and (vi) we included patients who started
cART during the first month after baseline.
All analyses were conducted with SAS, version 9.3 (SAS
Institute Inc., Cary, North Carolina, USA).
Results
Our analysis included 96 562 eligible individuals who
contributed 377 324 person-years during a median
[interquantile range (IQR)] follow-up of 31 [13,65]
months. Table 1 shows their baseline characteristics: 78%
were men and 70% started follow-up after 2000. The
median [IQR] CD4þ cell count, HIV-RNA and age at
baseline were 405 [263 570] cells/ml, 4.4 [3.8,5.0]
log10 copies/ml and 36 [30,43] years, respectively.
Fifty-seven percent of the included patients initiated
cART during follow-up; the median [IQR] CD4þ cell
count, HIV-RNA and age at cART initiation were 279
[187 380] cells/ml, 4.7 [4.0,5.2] log10 copies/ml and 38
(32,46) years, respectively.
The incidence rate (per 1000 person-years) ranged
between 2.3 for tuberculosis and 0.3 for CMV retinitis
and PML. For all outcomes, incidence rates were lower
for higher CD4þ cell count, younger age and lower HIV-
RNA level at baseline (Fig. 1). Appendix 1, http://
links.lww.com/QAD/A579 shows the number of cases
and incidence rates for each outcome by baseline
characteristics. The hazard ratios (95% confidence
intervals) for cART versus no cART were less than 1
for all outcomes, and ranged between 0.13 (0.05–0.38)
for cryptococcosis and 0.76 (0.58–1.00) for HSV.
Appendix 2, http://links.lww.com/QAD/A579 shows
the weighted and unweighted hazard ratio estimates.
The median [IQR] CD4þ cell count at event diagnosis
was 291 [161 440] cells/ml for tuberculosis, 34 [10 189]
cells/ml for MAC, 38 [10 189] cells/ml for CMV retinitis,
185 [72 310] cells/ml for PML, 360 [199 535] cells/ml for
HSV, 322 [186 457] cells/ml for Kaposi sarcoma, 318
[192 466] cells/ml for NHL, 55 [19 149] cells/ml for
cryptococcosis and 241 [100 399] cells/ml for candidiasis.
Table 2 presents the hazard ratios of each outcome by time
since initiation of cART. Compared with non-cART
initiation, the hazard ratios up to 3 months after cART
initiation were 1.21 (0.90–1.63) for tuberculosis, 2.61
(1.05–6.49) for MAC, 1.17 (0.34–4.08) for CMV
retinitis, 1.18 (0.62–2.26) for PML, 1.21 (0.83–1.75)
for HSV, 1.18 (0.87–1.58) for Kaposi sarcoma, 1.56
(0.82–2.95) for NHL, 1.11 (0.56–2.18) for cryptococ-
cosis and 0.77 (0.40–1.49) for candidiasis. The hazard
ratios 3 months since cART initiation compared with
non-cART initiation ranged between 0.06 (0.02–0.19)
for cryptococcosis and 0.69 (0.51–0.92) for HSV. The
hazard ratio up to 3 months after cART initiation for any
of the explored AIDS event compared with non-cART
initiation was 1.25 (1.05,1.48).
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Simplex
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35–50
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2.2 0.2 0.1 0.1 1.1
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0.5
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0.5
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1.3
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1.4
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0.48 (0.36, 0.64) 0.51 (0.27, 0.95) 0.24 (0.09, 0.66) 0.41 (0.15, 1.09) 0.76 (0.58, 1.00) 0.22 (0.15–0.32) 0.51 (0.36, 0.73) 0.13 (0.05, 0.38) 0.18 (0.12, 0.26)Hazard ratio
Fig. 1. Incidence rates of AIDS-defining events per 1000 person-year of follow-up, HIV-CAUSAL Collaboration 1996–2013.
cART, combined antiretroviral therapy; CMV, cytomegalovirus; MAC, Mycobacterium avium complex; PML, progressive
multifocal leukoencephalopathy.
Table 1. Baseline characteristics of study participants, HIV-CAUSAL Collaboration 1996–2013.
Individuals
Median [IQR]
follow-up, months Person-years cART initiators (%)
CD4þ cell count (cells/ml)
<50 3522 27 [11, 64] 13088.33 2784 (79%)
50–100 3061 33 [12, 71] 12360.83 2468 (81%)
100–200 8641 34 [14, 73] 35951.17 7018 (81%)
200–350 21807 33 [14, 70] 88392.08 15648 (72%)
350–500 24553 31 [14, 67] 96822 13854 (56%)
>500 34978 30 [13, 62] 130709.67 13372 (38%)
HIV-RNA, log10 copies/ml
<4 30596 29 [13, 61] 114836.42 12650 (41%)
4–5 43419 32 [14, 67] 171358 25928 (60%)
>5 22547 34 [14, 71] 91129.67 16566 (73%)
Sex
Male 75049 32 [14, 67] 295646.25 43038 (57%)
Female 21513 29 [13, 65] 81677.83 12106 (56%)
Age (years)
<35 44698 30 [13, 63] 169760.17 23362 (52%)
35–50 40154 33 [14, 70] 162430.83 23980 (60%)
50 11710 32 [12, 67] 45133.08 7802 (67%)
Transmission group
Heterosexual 30060 31 [14, 67] 117387.58 17814 (59%)
Homo/bi-sexual 39971 35 [16, 71] 166591.83 23014 (58%)
Injection drug-use 8201 24 [11, 56] 29432.17 3817 (47%)
Other/unknown 18330 26 [11, 58] 63912.5 10499 (57%)
Geographical origin
Western countries 57041 31 [13, 67] 224174.75 32765 (57%)
Sub-Saharan Africa 12497 29 [13, 62] 44686.75 7453 (60%)
Rest of world 7577 27 [13, 55] 25211.42 4054 (54%)
Unknown country 19447 34 [15,74] 83251.17 10872 (56%)
Calendar period
1996–1998 20317 38 [14, 118] 112796.42 11251 (55%)
1999–2000 8940 40 [14, 110] 44845.33 5276 (59%)
2001–2003 16639 43 [16, 98] 77702 9742 (59%)
2004–2013 50666 27 [12,50] 141980.33 28875 (57%)
Overall 96562 31 [13,65] 377324.08 55144 (57%)
cART, combined antiretroviral therapy; IQR, interquantile range.
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The hazard ratio estimates by time since cART initiation
stratified by CD4þ cell count, HIV-RNA level, age and
sex for events with more than 500 cases (tuberculosis,
Kaposi sarcoma, NHL, candidiasis and HSV) are
presented in Appendices 3–7, http://links.lww.com/
QAD/A579. The risk of tuberculosis up to 3 months after
cART initiation was 1.77 (0.78,4.00) in patients with
baseline CD4þ cell count <50 cells/ml, 2.10 (1.07,4.11)
in patients with age less than 50 years and 1.21 (0.84,1.74)
in males.
The hazard ratio estimates did not materially change in
sensitivity analyses (Appendix 7, http://links.lww.com/
QAD/A579). The cumulative incidence (95% confi-
dence intervals) at 3 months following cART initiation
ranged between 0.17% (0.14–0.20%) for tuberculosis and
0.02% (0.01–0.04%) for CMV retinitis. The cumulative
incidence for any of the outcomes at 2 months following
cART initiation was 0.67% (0.60–0.74%).
Discussion
Our study suggests that cART initiation reduces the
overall incidence of tuberculosis, MAC, CMV retinitis,
PML, HSV, Kaposi sarcoma, NHL, cryptococcosis and
candidiasis. In spite of this net overall reduction, there was
evidence of an increased risk of MAC up to 3 months
after cART initiation. The 3-month risk was also slightly
elevated for tuberculosis, CMV retinitis, HSV, Kaposi
sarcoma and NHL, but the 95% confidence intervals were
wide. The epidemiological patterns observed for MAC
and tuberculosis are consistent with a relevant proportion
of unmasking IRIS among the diagnosis; for the other
conditions the evidence is less compelling. For candi-
diasis, the evidence did not support unmasking IRIS.
Our results build on previous findings reported by the
HIV-CAUSAL Collaboration with follow-up through
2007. We now report a lower incidence of tuberculosis
(2.3 versus 3.2 cases per 1000 person-years) and a lower
increase in tuberculosis incidence soon after cART
initiation (21 versus 36%). Since median CD4þ cell count
at tuberculosis diagnosis has not increased over time
(results not shown), these changes might be explained by a
combination of random variability, temporal trends in
tuberculosis incidence, and with enhanced pre-cART
screening due to increased awareness of tuberculosis-
related IRIS.
Although IRIS has been most often reported for
opportunistic infections, IRIS associated with malig-
nancies has also been described [9,10]. Like previous
studies [31,32], we found small increases in risk of NHL
and Kaposi sarcoma up to 3 months of cART initiation,
but the 95% confidence intervals were wide. Given that
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Table 2. Hazard ratios of AIDS-defining events by time since initiation of combined antiretroviral therapy, HIV-CAUSAL Collaboration 1996–
2013.
Time since
cART initiation N cases Person-years
Incidence rates of events
per 1000 person-year
Hazard ratio
(95% confidence intervals)
Tuberculosis No cART 422 143523.33 2.9 1
<3 months 97 9259.00 10.5 1.21 (0.90–1.63)
3 months 379 236095.92 1.6 0.36 (0.26–0.49)
MAC No cART 46 143936.50 0.3 1
<3 months 37 9306.83 4.0 2.61 (1.05–6.49)
3 months 80 238799.67 0.3 0.31 (0.16–0.59)
CMV retinitis No cART 35 143938.83 0.2 1
<3 months 12 9308.42 1.3 1.17 (0.34,4.08)
3 months 58 238917.67 0.2 0.13 (0.04–0.39)
PML No cART 38 143944.00 0.3 1
<3 months 19 9307.42 2.0 1.18 (0.62–2.26)
3 months 56 238960.75 0.2 0.21 (0.06–0.71)
HSV No cART 254 143476.42 1.8 1
<3 months 42 9282.00 4.5 1.21 (0.83–1.75)
3 months 324 236713.50 1.4 0.69 (0.51–0.92)
Kaposi sarcoma No cART 404 143755.17 2.8 1
<3 months 95 9250.67 10.3 1.18 (0.87–1.58)
3 months 249 236065.50 1.1 0.14 (0.10–0.21)
NHL No cART 198 143875.92 1.4 1
<3 months 38 9288.17 4.1 1.56 (0.82–2.95)
3 months 252 237871.50 1.1 0.40 (0.27–0.58)
Cryptococcosis No cART 60 143924.67 0.4 1
<3 months 21 9305.67 2.3 1.11 (0.56,2.18)
3 months 58 238860.92 0.2 0.06 (0.02–0.19)
Candidiasis No cART 275 143745.33 1.9 1
<3 months 36 9275.67 3.9 0.77 (0.40–1.49)
3 months 224 237213.75 0.9 0.13 (0.09–0.20)
cART, combined antiretroviral therapy; CMV, cytomegalovirus; HSV, herpes simplex virus ; NHL, non-Hodgkin lymphoma; MAC,Mycobacterium
avium complex; PML, progressive multifocal leukoencephalopathy.
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the development of these cancers should be preceded by
exposure to causative agents, the increased incidence for
malignancies up to 3 months after cART initiation is
consistent with unmasking IRIS leading to increased
clinical symptoms, and thus, diagnostic steps in the case of
prevalent subclinical cancers.
We also found that the risk at 3 months of cART initiation
for any of the events was less than 0.7%. This risk is much
lower than that reported in a meta-analysis (between 38%
for CMV retinitis and 6% for Kaposi sarcoma) [11] and in
the HIV Outpatient Study cohort (between 23% for
candidiasis and 0.5% for PML) [12]. As these previous
studies were not restricted to AIDS-free patients, their
risk estimates encompass both paradoxical IRIS and
unmasking IRIS. In fact, the risk of unmasking IRIS may
be even lower because our study cannot distinguish cases
of unmasking IRIS from new cases unrelated to IRIS.
Further ascertainment bias may account for some of the
cases recorded early after cART initiation, as these might
have been previously undiagnosed cases due to more
intensive clinical screening in newly treated patients.
However, the fact that we found no significant initial
increase in risk despite this potential bias strengthens our
conclusions that unmasking IRIS for the explored events
is not common after cART initiation in patients starting
cART in recent times in the European and North
American setting.
Our study had several limitations. First, like all
observational studies, the validity of our estimates relies
on the assumption of no unmeasured confounding.
Although we adjusted our models for CD4þ cell count
and HIV-RNA levels, the most important factors used by
clinicians to decide whether to start cART, we cannot
exclude the possibility that other unmeasured variables
related to cART initiation could have also played a role.
Second, we assumed that patients remained on therapy
once it was initiated. If the diagnoses of the examined
AIDS-defining events were largely occurring in individ-
uals who had stopped cARTor had poor adherence, then
we might have underestimated the effect of cART
initiation on the risk of the explored events. On the
contrary, this bias is unlikely to have affected our
conclusions on the trends in incidence up to 3 months
after cART initiation. Finally, given the small number of
events occurring during the first months of cART for
some of the outcome events, we could not yet explore
whether the effect of cART differed by patients
characteristics that may be associated with development
of IRIS. This is particularly important for baseline CD4þ
cell count [11,25] because unmasking IRIS is mainly
observed in patients with very low CD4þ cell counts,
who were a minority in our study population.
In summary, this study suggests that, with the exception
of mycobacterial infections, unmasking IRIS is not
common after cART initiation in AIDS-free patients in
Europe and the United States. In order to make an early
diagnosis and provide adequate treatment, clinicians
should rule out MAC and tuberculosis meticulously in
patients at risk before starting cART and monitor closely
for these opportunistic infections during the early phases
of treatment.
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cohort (Santiago Pérez-Hoyos); Sweden Swedish InfCare HIV Cohort, Sweden (Anders Sönnerborg); 
Switzerland Swiss HIV Cohort Study (Heiner C. Bucher, Huldrych Günthard, Alexandra Scherrer); 
Ukraine Perinatal Prevention of AIDS Initiative (Ruslan Malyuta); United Kingdom Public Health 
England (Gary Murphy), UK Register of HIV Seroconverters (Kholoud Porter, Anne Johnson, Andrew 
Phillips, Abdel Babiker), University College London (Deenan Pillay); African cohorts: Genital 
Shedding Study (US: Charles Morrison; Family Health International, Robert Salata, Case Western 
Reserve University, Uganda: Roy Mugerwa, Makerere University, Zimbabwe: Tsungai Chipato, 
University of Zimbabwe); International AIDS Vaccine Initiative (IAVI) Early Infections Cohort (Kenya, 
Rwanda, South Africa, Uganda, Zambia: Matt A. Price, IAVI, USA; Jill Gilmour, IAVI, UK; Anatoli 
Kamali, IAVI, Kenya; Etienne Karita, Projet San Francisco, Rwanda). 
EuroCoord Executive Board: Fiona Burns, University College London, UK; Geneviève Chêne, 
University of Bordeaux, France; Dominique Costagliola (Scientific Coordinator), Institut National de 
la Santé et de la Recherche Médicale, France; Carlo Giaquinto, Fondazione PENTA, Italy; Jesper 
Grarup, Region Hovedstaden, Denmark; Ole Kirk, Region Hovedstaden, Denmark; Laurence Meyer, 
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Institut National de la Santé et de la Recherche Médicale, France; Heather Bailey, University College 
London, UK; Alain Volny Anne, European AIDS Treatment Group, France; Alex Panteleev, St. 
Petersburg City AIDS Centre, Russian Federation; Andrew Phillips, University College London, UK, 
Kholoud Porter, University College London, UK; Claire Thorne, University College London, UK. 
EuroCoord Council of Partners: Jean-Pierre Aboulker, Institut National de la Santé et de la 
Recherche Médicale, France; Jan Albert, Karolinska Institute, Sweden; Silvia Asandi, Romanian 
Angel Appeal Foundation, Romania; Geneviève Chêne, University of Bordeaux, France; Dominique 
Costagliola (chair), INSERM, France; Antonella d’Arminio Monforte, ICoNA Foundation, Italy; 
Stéphane De Wit, St. Pierre University Hospital, Belgium; Peter Reiss, Stichting HIV Monitoring, 
Netherlands; Julia Del Amo, Instituto de Salud Carlos III, Spain; José Gatell, Fundació Privada Clínic 
per a la Recerca Bíomèdica, Spain; Carlo Giaquinto, Fondazione PENTA, Italy; Osamah Hamouda, 
Robert Koch Institut, Germany; Igor Karpov, University of Minsk, Belarus; Bruno Ledergerber, 
University of Zurich, Switzerland; Jens Lundgren, Region Hovedstaden, Denmark; Ruslan Malyuta, 
Perinatal Prevention of AIDS Initiative, Ukraine; Claus Møller, Cadpeople A/S, Denmark; Kholoud 
Porter, University College London, United Kingdom; Maria Prins, Academic Medical Centre, 
Netherlands; Aza Rakhmanova, St. Petersburg City AIDS Centre, Russian Federation; Jürgen 
Rockstroh, University of Bonn, Germany; Magda Rosinska, National Institute of Public Health, 
National Institute of Hygiene, Poland; Manjinder Sandhu, Genome Research Limited; Claire Thorne, 
University College London, UK; Giota Touloumi, National and Kapodistrian University of Athens, 
Greece; Alain Volny Anne, European AIDS Treatment Group, France. 
EuroCoord External Advisory Board: David Cooper, University of New South Wales, Australia; Nikos 
Dedes, Positive Voice, Greece; Kevin Fenton, Public Health England, USA; David Pizzuti, Gilead 
Sciences, USA; Marco Vitoria, World Health Organisation, Switzerland. 
EuroCoord Secretariat: Silvia Faggion, Fondazione PENTA, Italy; Lorraine Fradette, University 
College London, UK; Richard Frost, University College London, UK; Andrea Cartier, University 
College London, UK; Dorthe Raben, Region Hovedstaden, Denmark; Christine Schwimmer, 
University of Bordeaux, France; Martin Scott, UCL European Research & Innovation Office, UK. 
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EuroSIDA cohort collaboration 
 
EuroSIDA was supported by the European Union's Seventh Framework Programme for research, 
technological development and demonstration under EuroCoord grant agreement number 260694. 
Current support includes unrestricted grants from Bristol‐Myers Squibb, Gilead, GlaxoSmithKline 
LLC, Janssen R&D, Merck and Co. Inc., and Pfizer Inc. The participation of centres from Switzerland 
was supported by The Swiss National Science Foundation (grant number 108787). The study was 
also supported by a grant (grant number DNRF126) from the Danish National Research Foundation. 
This analysis was funded by ViiV Healthcare. 
The multi‐centre study group, EuroSIDA (national coordinators in parentheses): Argentina: (M 
Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (B Schmied), Pulmologisches 
Zentrum der Stadt Wien, Vienna; R Zangerle, Medical University Innsbruck, Innsbruck. Belarus: (I. 
Karpov), A Vassilenko, Belarus State Medical University, Minsk; VM Mitsura, Gomel State Medical 
University, Gomel; D Paduto, Regional AIDS Centre, Svetlogorsk. Belgium: (N Clumeck), S De Wit, M 
Delforge, Saint‐Pierre Hospital, Brussels; E Florence, Institute of Tropical Medicine, Antwerp; L. 
Vandekerckhove, University Ziekenhuis Gent, Gent. Bosnia‐Herzegovina: (V Hadziosmanovic), 
Klinicki Centar Univerziteta Sarajevo, Sarajevo. Croatia: (J Begovac), University Hospital of Infectious 
Diseases, Zagreb. Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, 
Charles University Hospital, Plzen. Denmark: G Kronborg, T Benfield, Hvidovre Hospital, 
Copenhagen; J Gerstoft, T Katzenstein, Rigshospitalet, Copenhagen; NF Møller, C Pedersen, Odense 
University Hospital, Odense; L. Ostergaard, Skejby Hospital, Aarhus; L Wiese, Roskilde Hospital, 
Roskilde; LN Nielsen, Hillerod Hospital, Hillerod. Estonia: (K Zilmer), West‐Tallinn Central Hospital, 
Tallinn; J Smidt, Nakkusosakond Siseklinik, Kohtla‐Järve. Finland: (M Ristola), I Aho, Helsinki 
University Central Hospital, Helsinki. France: (J‐P Viard), Hôtel‐Dieu, Paris; P‐M Girard, Hospital 
Saint‐Antoine, Paris; C Pradier, E Fontas, Hôpital de l'Archet, Nice; C Duvivier, Hôpital Necker‐
Enfants Malades, Paris. Germany: (J Rockstroh), Universitäts Klinik, Bonn; G Behrens, Medizinische 
Hochschule, Hannover; O Degen, University Medical Center Hamburg‐Eppendorf, Infectious 
Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stefan, JW Goethe University 
Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, 
Cologne. Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology Research 
Center, Tbilisi. Greece: (P Gargalianos), G Xylomenos, K Armenis, Athens General Hospital “G 
Gennimatas”; H Sambatakou, Ippokration General Hospital, Athens. Hungary: (J Szlávik), Szent Lásló 
Hospital, Budapest. Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik. Ireland: 
(F. Mulcahy), St James's Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel 
Aviv; E Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University 
Hospital, Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusalem. Italy: (A. D'Arminio 
Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R Esposito, I Mazeu, C Mussini, 
Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, 
M Lichtner, University di Roma la Sapienza, Rome; M Zaccarelli, A Antinori, R Acinapura, M Plazzi, 
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, 
Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan. Latvia: (B Rozentale), 
Infectology Centre of Latvia, Riga. Lithuania: (V. Uzdaviniene) Vilnius University Hospital Santaros 
Klinikos, Vilnius; R Matulionyte, Centro Poliklinika, Vilnius, Vilnius University Hospital Santaros 
Klinikos, Vilnius. Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg. Netherlands: 
(P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam. Norway: 
(DH Reikvam), A Maeland, J Bruun, Ullevål Hospital, Oslo. Poland: (B Knysz), J Gasiorowski, M Inglot, 
Medical University, Wroclaw; A Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; 
R Flisiak, A Grzeszczuk, Medical University, Bialystok; M Parczewski, K Maciejewska, B Aksak‐Was, 
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Medical Univesity, Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; 
T Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, 
Wojewodzki Szpital Specjalistyczny, Lodz; I. Mozer‐Lisewska, Poznan University of Medical Sciences, 
Poznan. Portugal: (L. Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, 
Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. Romania: (R Radoi), C Oprea, Spitalul Clinic de Boli 
Infectioase si Tropicale: Dr. Victor Babes, Bucuresti. Russia: (A Panteleev), O Panteleev, St 
Petersburg AIDS Centre, St Peterburg; A Yakovlev, Medical Academy Botkin Hospital, St Petersburg; 
T Trofimora, Novgorod Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & Infectious 
Diseases, Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research Institute of 
Epidemiology and Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E. 
Borodulina, E Vdoushkina, Samara State Medical University, Samara. Serbia: (D Jevtovic), The 
Institute for Infectious and Tropical Diseases, Belgrade. Slovenia: (J Tomazic), University Clinical 
Centre Ljubljana, Ljubljana. Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, 
Barcelona; S Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B. Clotet, A Jou, R Paredes, C 
Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, 
MA Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria‐
Gasteiz. Sweden: (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital, Stockholm; 
A Blaxhult, Venhälsan‐Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, Malmö. 
Switzerland: (A. Scherrer), R Weber, University Hospital Zurich; M Cavassini, University Hospital 
Lausanne, Lausanne; A Calmy, University Hospital Geneva, Geneva; H Furrer, University Hospital 
Bern, Bern; M Battegay, University Hospital Basel, Basel; P Schmid, Cantonal Hospital, St. Gallen. 
Ukraine: A. Kuznetsova, Kharkov State Medical University, Kharkov; G. Kyselyova, Crimean 
Republican AIDS Centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and Control 
CTR, Lviv. UK: (B Gazzard), St Stephen's Clinic, Chelsea and Westminster Hospital, London; AM 
Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, A. 
Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); C Orkin, 
Royal London Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St 
Mary's, London; A. Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western General 
Hospital, Edinburgh. 
The following centres have previously contributed data to EuroSIDA: Infectious Diseases Hospital, 
Sofia, Bulgaria. Hôpital de la Croix Rousse, Lyon, France. Hôpital de la Pitié‐Salpétière, Paris, France. 
Unité INSERM, Bordeaux, France. Hôpital Edouard Herriot, Lyon, France. Bernhard Nocht Institut 
für Tropenmedizin, Hamburg, Germany. 1st I.K.A Hospital of Athens, Athens, Greece. Ospedale 
Riuniti, Divisione Malattie Infettive, Bergamo, Italy. Ospedale di Bolzano, Divisione Malattie 
Infettive, Bolzano, Italy. Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy. Dérer 
Hospital, Bratislava, Slovakia. Hospital Carlos III, Departamento de Enfermedades Infecciosas, 
Madrid, Spain. Kiev Centre for AIDS, Kiev, Ukraine. Luhansk State Medical University, Luhansk, 
Ukraine. Odessa Region AIDS Center, Odessa, Ukraine. 
EuroSIDA Steering Committee: J Gatell, B. Gazzard, A. Horban, I. Karpov, M. Losso, A. d'Arminio 
Monforte, C. Pedersen, M. Ristola, A. Phillips, P. Reiss, J Lundgren, J. Rockstroh, A. Scherrer, I. Aho, 
LD Rasmussen, V Svedhem, G Wandeler, C. Pradier, N. Chkhartishvili, R. Matulionyte, C. Oprea, JD 
Kowalska, J. Begovac, J Miro, G Guaraldi, R. Paredes; Chair: J. Rockstroh; Study Co‐leads: A. Mocroft, 
O Kirk. 
EuroSIDA staff: Coordinating Centre Staff: O. Kirk, L Peters, A Bojesen, D Raben, D Kristensen, K. 
Laut, JF Larsen, D Podlekareva, B Nykjær; Statistical Staff: A. Mocroft, A. Phillips, A Cozzi‐Lepri, L 
Shepherd, S Amele, A. Pelchen‐Matthews. 
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HIV-CAUSAL cohort collaboration 
 
This research was supported by the National Institutes of Health (grant number R01 AI102634).  
UK CHIC: Steering Committee: Jonathan Ainsworth, Jane Anderson, Abdel Babiker, Valerie Delpech, 
David Dunn, Martin Fisher, Brian Gazzard, Richard Gilson, Mark Gompels, Teresa Hill, Margaret 
Johnson, Clifford Leen, Chloe Orkin, Andrew Phillips, Deenan Pillay, Caroline Sabin (PI), Memory 
Sachikonye, Achim Schwenk, John Walsh. Central co-ordination: Research Department of Infection 
& Population Health, UCL, London (T Hill, S Huntington, S Jose, A Phillips, C Sabin, A Thornton); 
Medical Research Council Clinical Trials Unit (MRC CTU), London (D Dunn, A Glabay). Participating 
centres: Bart's and The London NHS Trust, London (C Orkin, J Lynch, J Hand, C de Souza); Brighton 
and Sussex University Hospitals NHS Trust (M Fisher, N Perry, S Tilbury, D Churchill); Chelsea and 
Westminster NHS Trust, London (B Gazzard, M Nelson, M Waxman, D Asboe, S Mandalia); Health 
Protection Agency Centre for Infections London (V Delpech); Homerton University Hospital NHS 
Trust, London (J Anderson, S Munshi, D Awosika); King’s College Hospital, London (F Post, H Korat, 
C Taylor, Z Gleisner, F Ibrahim, L Campbell); UCL Medical School and The Mortimer Market Centre, 
London (R Gilson, N Brima, I Williams); North Bristol NHS Trust (M Gompels, S Allen); North 
Middlesex University Hospital NHS Trust, London (A Schwenk, J Ainsworth, C Wood, S Miller); Royal 
Free NHS Trust and Department of Infection & Population Health, UCL, London (M Johnson, M 
Youle, F Lampe, C Smith, H Grabowska, C Chaloner, D Puradiredja); Imperial College Healthcare NHS 
Trust, London (J Walsh, N Mackie, A Winston, J Weber, F Ramzan); The Lothian University Hospitals 
NHS Trust, Edinburgh (C Leen, A Wilson); University of Leicester NHS Trust (A Palfreeman, A Moore, 
L Fox); South Tees Hospitals NHS Foundation Trust (D Chadwick, K Baillie); Woolwich NHS Trust (S 
Kegg, P Main); Coventry NHS Trust (S Allan); St. George’s NHS Trust (P Hay, M Dhillon); York (F 
Martin, S Douglas). ATHENA: Director: P Reiss, Stichting HIV Monitoring, Amsterdam. Data analysis 
group: DO Bezemer, LAJ Gras, AM Kesselring, AI van Sighem, C Smit. Data collection: S Zaheri. 
Participating centres (*Site coordinating physicians): Medisch Centrum Alkmaar, Alkmaar: G van 
Twillert*, W Kortmann*. Flevoziekenhuis, Almere: J Branger*. Academic Medical Center of the 
University of Amsterdam, Amsterdam: JM Prins*, TW Kuijpers, HJ Scherpbier, JTM van der Meer, 
FWMN Wit, MH Godfried, P Reiss, T van der Poll, FJB Nellen, JMA Lange, SE Geerlings, M van Vugt, 
D Pajkrt, JC Bos, M van der Valk, ML Grijsen, WJ Wiersinga. Onze Lieve Vrouwe Gasthuis, 
Amsterdam: K Brinkman*, WL Blok, PHJ Frissen, WEM Schouten, GEL van den Berk. Sint Lucas 
Andreas Ziekenhuis, Amsterdam: J Veenstra*, KD Lettinga. Slotervaartziekenhuis, Amsterdam: JW 
Mulder*, SME Vrouenraets, FN Lauw. Stichting Medisch Centrum Jan van Goyen, Amsterdam: A van 
Eeden*, DWM Verhagen. VU Medisch Centrum, Amsterdam: MA van Agtmael*, RM Perenboom, 
FAP Claessen, M Bomers, EJG Peters. Rijnstate, Arnhem: C Richter*, JP van der Berg, EH Gisolf. 
HagaZiekenhuis, Den Haag: EF Schippers*, C van Nieuwkoop, EP van Elzakker. Medisch Centrum 
Haaglanden, Den Haag: EMS Leyten*, LBS Gelinck. Catharina Ziekenhuis, Eindhoven: MJH Pronk*, 
B Bravenboer. Medisch Spectrum Twente, Enschede: GJ Kootstra*, CE Delsing. Universitair Medisch 
Centrum Groningen, Goningen: HG Sprenger*, R Doedens (until June, 2012), EH Scholvinck, S van 
Assen, WFW Bierman. Kennemer Gasthuis, Haarlem: R Soetekouw*, RW ten Kate. Medisch 
Centrum Leeuwarden, Leeuwarden: MGA van Vonderen*, DPF van Houte. Leids Universitair 
Medisch Centrum, Leiden: FP Kroon*, JT van Dissel, SM Arend, MGJ de Boer, H Jolink, HJM ter 
Vollaard, MP Bauer. MC Zuiderzee, Lelystad: S Weijer*, R el Moussaoui. Academisch Ziekenhuis 
Maastricht, Maastricht: S Lowe*, G Schreij, A Oude Lashof, D Posthouwer. Universitair Medisch 
Centrum Sint Radboud, Nijmegen: PP Koopmans*, M Keuter, AJAM van der Ven, HJM ter Hofstede, 
ASM Dofferhoff, A Warris, R van Crevel. Erasmus Medisch Centrum, Rotterdam: ME van der Ende*, 
TEMS de Vries-Sluijs, CAM Schurink, JL Nouwen, MH Nispen tot Pannerden, A Verbon, BJA Rijnders, 
ECM van Gorp, RJ Hassing, AWM Smeulders. Erasmus Medisch Centrum–Sophia, Rotterdam: NG 
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Hartwig, GJA Driessen. Maasstad Ziekenhuis, Rotterdam: JG den Hollander*, K Pogany. Sint 
Elisabeth Ziekenhuis, Tilburg: JR Juttmann*, MEE van Kasteren. Universitair Medisch Centrum 
Utrecht, Utrecht: AIM Hoepelman*, T Mudrikova, MME Schneider, CAJJ Jaspers, PM Ellerbroek, JJ 
Oosterheert, JE Arends, MWM Wassenberg, RE Barth. Wilhelmina Kinderziekenhuis, Utrecht: SPM 
Geelen, TFW Wolfs, LJ Bont. Admiraal De Ruyter Ziekenhuis, Vlissingen: M van den Berge*, A 
Stegeman. Isala Klinieken, Zwolle: PHP Groeneveld*, MA Alleman, JW Bouwhuis. FHDH-ANRS CO4: 
Scientific committee: S Abgrall, F Barin, M Bentata, E Billaud, F Boué, C Burty, A Cabié, D Costagliola, 
L Cotte, P De Truchis, X Duval, C Duvivier, P Enel, L Fredouille-Heripret, J Gasnault, C Gaud, J Gilquin, 
S Grabar, C. Katlama, MA Khuong, JM Lang, AS Lascaux, O Launay, A Mahamat, M Mary-Krause, S 
Matheron, JL Meynard, J Pavie, G Pialoux, F Pilorgé, I Poizot-Martin, C Pradier, J Reynes, E Rouveix, 
A Simon, P Tattevin, H Tissot-Dupont, JP Viard, N Viget. DMI2 coordinating center: French Ministry 
of Health (Valérie Salomon), Technical Hospitalization Information Agency, ATIH (N Jacquemet). 
Statistical analysis center: U943 INSERM et UPMC (S Abgrall, D Costagliola, S Grabar, M Guiguet, E 
Lanoy, L Lièvre, M Mary-Krause, H Selinger-Leneman), INSERM Transfert (JM Lacombe, V Potard). 
COREVIH: Paris area: Corevih Ile de France Centre (GH Pitié-Salpétrière: F Bricaire, S Herson, C 
Katlama, A Simon; Hôpital Saint-Antoine: N Desplanque, PM Girard, JL Meynard, MC Meyohas, O 
Picard; Hôpital Tenon: J Cadranel, C Mayaud, G Pialoux), Corevih Ile de France Est (Hôpital Saint-
Louis: JP Clauvel, JM Decazes, L Gerard, JM Molina; GH Lariboisière-Fernand Widal: M Diemer, P 
Sellier; Hôpital Avicenne: M Bentata, P Honoré; Hôpital Jean Verdier: V Jeantils, S Tassi; Hôpital 
Delafontaine: D Mechali, B Taverne), Corevih Ile de France Nord (Hôpital Bichat-Claude Bernard: E 
Bouvet, B Crickx, JL Ecobichon, S Matheron, C Picard-Dahan, P Yeni), Corevih Ile de France Ouest 
(Hôpital Ambroise Paré: H Berthé, C Dupont; Hôpital Louis Mourier: C Chandemerle, E Mortier; 
Hôpital Raymond Poincaré: P de Truchis), Corevih Ile de France Sud (Hôpital Européen Georges 
Pompidou: D Tisne-Dessus, L Weiss; GH Tarnier-Cochin: D Salmon; Hôpital Saint-Joseph: I Auperin, 
J Gilquin; Hôpital Necker adultes: L Roudière, JP Viard; Hôpital Antoine Béclère: F Boué, R Fior; 
Hôpital de Bicêtre: JF Delfraissy, C Goujard; Hôpital Henri Mondor: C Jung, Ph Lesprit; Hôpital Paul 
Brousse: D Vittecoq). Outside Paris area: Corevih Alsace (CHRU de Strasbourg: P Fraisse, JM Lang, D 
Rey; CH de Mulhouse: G Beck-Wirth), Corevih de l’Arc Alpin (CHU de Grenoble: JP Stahl, P Lecercq), 
Corevih Auvergne-Loire (CHU de ClermontFerrand: F Gourdon, H Laurichesse; CHRU de Saint-
Etienne: A Fresard, F Lucht); Corevih Basse-Normandie (CHRU de Caen: C Bazin, R Verdon), Corevih 
Bourgogne (CHRU de Dijon: P Chavanet), Corevih Bretagne (CHU de Rennes: C Arvieux, C Michelet), 
Corevih Centre (CHRU de Tours: P Choutet, A Goudeau, MF Maître), Corevih Franche-Comté (CHRU 
de Besançon: B Hoen; CH de Belfort: P Eglinger, JP Faller); Corevih Haute-Normandie (CHRU de 
Rouen: F Borsa-Lebas, F Caron), Corevih Languedoc-Roussillon (CHU de Montpellier: J Reynes; CHG 
de Nîmes: JP Daures), Corevih Lorraine (Nancy Hôpital de Brabois: T May, C Rabaud; CHRU de Reims: 
JL Berger, G Rémy), Corevih de Midi-Pyrénées (Toulouse CHU Purpan: E Arlet-Suau, L Cuzin, P 
Massip, MF Thiercelin Legrand; Toulouse Hôpital la Grave: G Pontonnier; Toulouse CHU Rangueil), 
Corevih Nord-Pas de Calais (CH de Tourcoing: N Viget, Y Yasdanpanah), Corevih PACA Est (Nice 
Hôpital Archet 1: P Dellamonica, C Pradier, P Pugliese; CHG Antibes-Juan les Pins: K Aleksandrowicz, 
D Quinsat), Corevih PACA Ouest (Marseille Hôpital de la Conception: I Ravaux, H Tissot-Dupont; 
Marseille Hôpital Nord: JP Delmont, J Moreau; Marseille Institut Paoli Calmettes: JA Gastaut; 
Marseille Hôpital SainteMarguerite: I Poizot-Martin, F Retornaz, J Soubeyrand; Marseille Centre 
pénitentiaire des Baumettes: A Galinier, JM Ruiz; CHG d’Aix-En-Provence: T Allegre, PA Blanc; CH 
d’Arles: D Bonnet-Montchardon; CH d’Avignon: G Lepeu; CH de Digne Les Bains: P Granet-Brunello; 
CH de Gap: JP Esterni, L Pelissier; CH de Martigues: R Cohen-Valensi, M Nezri; CHI de Toulon: S 
Chadapaud, A Laffeuillade), Corevih Pays de la Loire (CHRU de Nantes: E Billaud, F Raffi), Corevih de 
la Vallée du Rhône (Lyon Hôpital de la Croix-Rousse: A Boibieux, D Peyramond; Lyon Hôpital 
Edouard Herriot: JM Livrozet, JL Touraine; Lyon Hôtel-Dieu: L Cotte, C Trepo). Overseas: Corevih 
Guadeloupe (CHRU de Pointe-à-Pitre: M Strobel; CH Saint-Martin: F Bissuel), Corevih Guyane (CHG 
de Cayenne: R Pradinaud, M Sobesky), Corevih Martinique (CHRU de Fort-de-France: A Cabié), 
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Corevih de La Réunion (CHD Félix Guyon: C Gaud, M Contant). Swiss HIV Cohort Study (SHCS): 
Aubert V, Barth J, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, 
Cavassini M, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory 
Committee), Fux CA, Gorgievski M, Günthard H (President of the SHCS), Haerry D (deputy of 
"Positive Council"), Hasse B, Hirsch HH, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kovari H, 
Kouyos R, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, 
Pantaleo G, Rauch A (Chairman of the Scientific Board), Regenass S, Rickenbach M (Head of Data 
Center), Rudin C (Chairman of the Mother & Child Substudy), Schmid P, Schultze D, Schöni-Affolter 
F, Schüpbach J, Speck R, Staehelin C, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. PISCIS: 
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Appendix 3 – HICDEP data tables 
 
tblART - Antiretroviral treatment 
 
holds type of antiretroviral drug, start and stop dates and reason for stopping 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) identifies patient 
ART_ID character. see coding table for valid codings. represents the antiretroviral treatment 
ART_SD yyyy-mm-dd date of initiation of treatment 
ART_SD_A character: see coding of date precision precision of date "Initiation of 
Treatment" 
ART_ED yyyy-mm-dd date of stopping treatment 
ART_ED_A character: see coding of date precision precision of date "Stopping of 
Treatment" 
ART_RS character. see coding table for valid codings. reason for stopping treatment 
 
Additional fields 
 
Depending on the aim of the study it might be needed to gather both the dosage and the frequency of the dosage taken. However 
many cohorts do not collect this date and thus these fields are optional. 
 
Field name Format Description 
ART_RS2 character. see coding table for valid codings. Second reason for stopping treatment 
ART_RS3 character. see coding table for valid codings. Third reason for stopping treatment 
ART_RS4 character. see coding table for valid codings. Fourth reason for stopping treatment 
ART_DO numeric 
Dosage (mg or mL) per intake unless 
ART_FR=-1 
 
 
 
 
 
ART_FR 
numeric: 
 
• -1 = Frequency not known. ART_DO contains 
dosage per day 
• 0.33 = 1 dose every third day 
• 0.5 = 1 dose every second day 
• 1 = 1 daily dose/qd 
• 2 = 2 daily doses/bid 
• 3 = 3 daily doses/tid 
• 4... = code gives number of daily doses 
 
 
 
 
 
Frequency 
 
 
GENERIC 
numeric: 
 
• 1 = Branded 
• 2 = Generic 
• 9 = Unknown 
 
 
Was this a branded or generic drug? 
 
 
 
 
 
ART_FORM 
numeric: 
 
• 1 = Tablet/capsule 
• 2 = Syrup/Suspension 
• 3 = Combination of 1 and 2 
• 4 = Powder 
• 5 = Subcutaneous 
• 6 = Intravenous 
• 7 = Intramuscular 
• 9 = Unknown 
 
 
 
 
 
What formulations of the drug was 
given? 
 
 
ART_COMB 
numeric: 
 
• 0 = Individual drug 
• 1 = Part of a fixed-dose combination 
• 9 = Unknown 
 
 
Was the drug given as part of a fixed-
dose combination? 
ART_START_RS numeric: see coding table for valid codings Reason for starting/receiving ART 
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It may also be necessary to record the start and end time: 
 
Field name Format Description 
ART_ST hh:mm Start hour and minute of the 
day 
ART_ET hh:mm Stop hour and minute of the 
day 
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tblBAS - Basic clinical, background and demographic information 
 
holds basic information such as demographics, basic clinical information, date of AIDS diagnosis, death and drop-out information 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
BIRTH_D yyyy-mm-dd Birth date 
BIRTH_D_A character: see coding of date precision optional precision annotation for birth 
date 
FRSVIS_D yyyy-mm-dd First seen at clinic 
ENROL_D yyyy-mm-dd Date of enrolment into the cohort 
ENROL_D_A character: see coding of date precision 
optional precision annotation for date 
of enrolment into the cohort 
 
 
GENDER 
numeric: 
 
• 1 = Male 
• 2 = Female 
• 9 = Unknown 
 
 
Gender/sex 
HEIGH numeric (metric): 999 = Unknown Height of patient at visit/most current 
MODE numeric. see coding table for valid codings. Mode of infection 
ORIGIN 
character (1-3 letter/numeric codes). see coding 
table for valid codings. 
Country or region of birth 
ETHNIC numeric. see coding table for valid codings. 
Ethnicity of patient. Please take the 
additional notes into consideration 
when using this field. 
 
EDU_LVL 
 
numeric. see coding table for valid codings. 
Last completed education Level. 
ISCED97 refers to the ?1997 
International Standard Classification of 
Education 
HIV_POS_D yyyy-mm-dd Date of first positive HIV test 
SEROCO_D yyyy-mm-dd Date of seroconversion 
 
 
RECART_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
Has the patient ever received 
antiretroviral treatment? This includes 
all antiretroviral therapy given as 
Treatment even if given by another 
Center or program but excludes 
antiretroviral drugs given only for 
PMTCT or other prophylaxis. 
 
 
 
RECART_D 
 
 
 
yyyy-mm-dd 
Date of first antiretroviral Treatment 
Initiation. Leave blank if ART not yet 
initiated. This should be the first date 
at which antiretroviral therapy, 
regardless of Regimen, was given as 
Treatment irrespective of whether it 
was given at this center/program or 
not. It excludes antiretroviral regimens 
given only for PMTCT or other 
prophylaxis. 
RECART_D_A character: see coding of date precision 
optional date precision annotation for 
date 
RECART_D. 
 
LTART_D 
 
yyyy-mm-dd 
Date last assessed for ART. If started 
ART, last date known to be on ART, or 
if not on ART, last date ART free. 
 
 
AIDS_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
Has the patient ever been given an 
AIDS diagnosis? (i.e. WHO stage 3 or 
4 or CDC category C diagnosis) 
AIDS_D yyyy-mm-dd If yes, date of AIDS diagnosis 
AIDS_D_A character: see coding of date precision optional precision annotation for date 
AIDS_D 
 
Additional fields 
 
For mode of infection and origin a set of other fields are often used to capture what cannot be coded. These fields are represented 
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here as optional fields as it is the intention that the suggested codes applied to the MODE and ORIGIN should be able to cover all 
possible values. 
 
Field name Format Description 
MODE_OTH character Mode of infection OTHER 
ORI_OTH character Origin of patient OTHER 
CENS_D yyyy-mm-dd 
The last date the database has been 
updated for this patient 
 
 
 
SEROHOW 
numeric: 
 
• 1 = Midpoint between last neg/first pos test 
• 2 = Lab evidence of seroconversion 
• 3 = Seroconversion illness 
• 4 = Other 
• 9 = Unknown 
 
 
 
For Seroconverters only: How was the 
seroconversion date determined? 
 
 
NAIVE_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the patient ART-naïve upon 
enrollment? 
 
 
PROPH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
Prior to enrollment, has the Patient 
been exposed to antiretroviral therapy 
for prophylaxis such as PMTCT, 
PREP, or PEP? 
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tblCENTER 
holds information about the Center (e.g. geographical localisation, type of clinic) where the patient is receiving HIV care 
 
Core Fields 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
 
Field name Format Description 
CENTER 
character Code for Clinic/Center/Hospital where 
patient is seen. Needs to be unique 
within each Region. 
PROGRAM character 
Program or region with which the 
center is associated. Links 
to tblPROGRAM. 
NAME 
character Proper name to identify center 
COUNTRY character 
3-letter ISO code 
PROVINCE character 
(Optional) Proper name to identify 
province 
DISTRICT 
character 
(Optional) Proper name to identify 
district 
CITY character (Optional) Proper name to identify city 
GEOCODE_LAT numeric Latitude 
GEOCODE_LON numeric Longitude 
RURAL numeric: 
1 = Urban 
2 = Mostly urban 
3 = Mostly rural 
4 = Rural 
9 = Unknown 
Code for the site situation (facility 
location) 
LEVEL numeric: 
1 = Health centre 
2 = District hospital 
3 = Regional, provincial or university hospital 
9 = Unknown 
Code for level of care 
ADULTPED character: "PED","ADULT", or "BOTH" Population the center serves 
OPEN_D yyyy-mm-dd (Optional) Date of opening of dataset: 
earliest date for which data were 
included from this site 
CLOSE_D yyyy-mm-dd (Optional) Date of closing of dataset 
ADD_CENTER yyyy-mm-dd 
Inclusion date: date that the site was 
added to the cohort 
DROP_CENTER yyyy-mm-dd 
(Optional) Exclusion date: date that 
the site was dropped from the cohort 
SURVEY_INTERNET numeric: 
1 = sufficient Access to complete online surveys 
2 = degraded Access making online Survey 
completion difficult 
3 = no internet access 
9 = Unknown 
Quality of internet access for 
completing online Surveys. 
 
SURVEY_PAPER 
numeric: 
1 = site has resources to print and transfer Surveys 
2 = site has resources to print, but not Transfer 
surveys 
3 = site does not have resources to print, but can 
transfer surveys 
4 = site Needs assistance in both printing and 
transferring surveys 
8 = not applicable 
9 = Unknown 
 
Resources for printing and transferring 
paper surveys to a central location for 
data entry. 
LAST_REVIEWED_D • yyyy-mm-dd Date when Center data in this table 
was last reviewed and/or updated. 
LAST_REVIEWED_D_A • character: see coding of date precision Optional precision annotation for last 
review date LAST_REVIEW_D 
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tblCEP - Clinical Events and Procedures 
 
holds type and date of adverse events including serious non-AIDS conditions 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
EVENT_ID numeric 
Unique Event Identifier (foreign key to 
the different event tables) 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
CEP_D yyyy-mm-dd date of event 
CEP_ID character. see coding table for valid codings. identifies type of event 
CEP_SPEC character. see coding table for valid codings. further specification 
CEP_V numeric. See coding table for interpretation. 
Depending on CEP_ID and 
CEP_SPEC: value of given event 
 
SRCDOC_Y 
numeric: 
 
• 1 = Yes 
• 0 = No 
 
whether the source documentation is 
available 
SRCDOC_D yyyy-mm-dd date for source documentation 
verification 
 
VERIFY_Y 
numeric: 
 
• 1 = Yes 
• 0 = No 
 
Has the monitor verified the source 
documentation? 
VERIFY_D yyyy-mm-dd date for monitor verification 
 
APPROV_Y 
numeric: 
 
• 1 = Yes 
• 0 = No 
 
final verification/approval 
APPROV_D yyyy-mm-dd final verification date 
APPROV_S character signature for final verification 
 
Additional fields 
 
Field name Format Description 
 
 
CEP_Y 
numeric: 
 
• 1 = Yes 
• 0 = No 
• 9 = Unknown 
 
 
has the patient had an event? 
CEP_NAME character full name of the event 
CEP_DESCRIP character full description of the event 
 
 
 
CEP_R_Y 
numeric: 
 
• 0 = not related 
• 1 = definitive 
• 2 = remote/unlikely 
• 3 = possible 
• 4 = probable 
 
 
 
relation to treatment 
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tblDIS - CDC-C and WHO Stage Diseases 
 
holds type and date of CDC-C diseases and malignancies. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
DIS_ID character. see coding table for valid codings. Code to identify event 
DIS_D yyyy-mm-dd Start date of event (Date of disease 
diagnosis) 
DIS_WD numeric. see coding table for valid codings. Means/Certainty of diagnosis 
DIS_OTH1 character 
Other location, only to be filled out if 
DIS_ID 
code alone is not sufficient 
1 DIS_OTH might be part of the record's unique identification 
 
Additional fields 
 
Please see tblCEP for specification on optional fields. 
 
Field name Format Description 
DIS_ED yyyy-mm-dd 
End date of Event (If end date is 
available, disease outcome should be 
specified) 
DIS_ED_A character: see coding of date precision 
optional precision annotation for end of 
infection date DIS_ED 
DIS_SITE numeric. see coding table for valid codings. Event site 
DIS_OUTCOME numeric. see coding table for valid codings. Disease outcome 
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tblLAB - Laboratory values 
 
holds type, date, value and unit of laboratory tests. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
LAB_ID character. see coding table for valid codings. Code representing the measurement 
LAB_D yyyy-mm-dd Date of measurement/sample 
LAB_D_A character: see coding of date precision 
optional precision annotation for date 
of measurement/sample 
 
 
LAB_R 
numeric: 
 
• 1 = Positive (including trace, 1+, 2+, etc.) 
• 0 = Negative 
• 9 = Unknown/borderline 
 
 
Measurement result 
LAB_V 
numeric: -1 = undetectable or detection limit as 
negative value 
Value of measurement 
LAB_U numeric. see coding table for valid codings. Unit of measurement 
 
Additional fields 
 
Other detailed information regarding the patient and the measurement would be relevant, like the proposed fasting information shown 
below. 
 
Field name Format Description 
 
 
LAB_FA 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Was the blood sample taken while 
fasting? 
LAB_ST character. see coding table for valid codings. Code representing the specimen type 
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tblLAB_BP - Laboratory values - Blood pressure 
 
holds date, diastolic and systolic values and unit of blood pressure measurements. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
BP_D yyyy-mm-dd Date of Measurement/Sample 
BP_D_A character: see coding of date precision 
Precision annotation variable for 
measurement date 
BP_SYS numeric Systolic Blood Pressure 
BP_DIA numeric Diastolic Blood Pressure 
BP_U numeric. see coding table for valid codings. Unit of measurement 
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tblLAB_CD4 - Laboratory values 
 
holds date and value of CD4 measurements. 
 
Note: If needed, a CD8 table (tblLAB_CD8) could be formed from the same structure. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
CD4_D yyyy-mm-dd Date of measurement 
CD4_V 
numeric (per microliter): -1 = undetectable or 
detection limit as negative value 
Value of CD4 measurement 
 
Additional fields 
 
CD4_V is assumed to contain absolute CD4 cell counts per mL as standard. In case CD4 % (with respect to CD45+ lymphocytes as 
denominator) should be collected as well, please append the following field to the table: 
 
Field name Format Description 
 
CD4_U 
numeric with codes (or full string): 
 
• 1 = cells/µl 
• 2 = % 
 
Unit of measurement 
CD4_D_A character: see coding of date precision precision of measurement date 
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tblLAB_RES - Resistance testing 
 
holds background information on the resistance test, laboratory, library, kit, software and type of test 
 
Note: This table is tightly linked to tblLAB_RES_LVL_1, tblLAB_RES_LVL_2 and tblLAB_RES_LVL_3. 
 
Resistance should be reported at lowest level of interpretation possible ? so if the nucleotide sequence is available this should be reported 
rather than the list of mutations or resistance scores. However, the resistance test results should be captured if they have been part of the 
physician?s treatment decisions for the patient. 
 
Non-amplifiable resistance tests should not be reported. 
 
These four tables are designed to capture several possible formats the clinics and cohorts might have recorded resistance test data 
in. Once this data is gathered it should like all other tables be quality assessed. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
TEST_ID character (or numeric if possible) 
An arbitrary value identifying a 
resistance test result 
SAMPLE_D yyyy-mm-dd 
Date of the actual sample taken (NOT 
the test date) 
SAMPLE_D_A character: see coding of date precision optional precision annotation for date 
of sample 
SEQ_DT yyyy-mm-dd hh:mm 
Date and time when the sequencing 
was performed 
SEQ_DT_A character: see coding of date precision 
optional precision annotation for date 
of sequencing 
LAB character 
Name of laboratory where the test was 
performed 
LIBRARY character 
Library/algorithm used to identify 
resistance mutations 
REFSEQ character 
Name/identifier of reference strain 
used to find mutations 
KIT character 
Vendor and version/name of the kit 
used for the test 
SOFTWARE character 
Software and version used to 
determine resistance 
 
 
TESTTYPE 
numeric: 
 
• 1 = Genotype (e.g., GeneXpert, NAAT/LPA 
• 2 = Phenotype (e.g., culture) 
• 9 = Other 
 
 
Type of test 
PATHOGENTYPE 
character: MeSH terminology 
?https://meshb.nlm.nih.gov/#/fieldSearch 
Type of pathogen 
 
VIRUSTYPE 
numeric: 
 
• 1 = HIV 
• 2 = HCV 
 
Type of Virus 
SUBTYPE character Subtype of HIV- or HCV-RNA 
 
Additional fields 
 
As shown with the core fields, the TEST_ID is the link between the 3 levels of data and the test background information table. Some 
prior assessment of the assigned test identifiers has to be done in order to avoid duplicates. 
In a running database the duplicate issues are easily resolved by adding a unique auto-generated key as the identifier between 3 
levels of data and the test background information table. 
 
Along with the TEST_ID it might be necessary to store the ID assigned to the sample at both the testing laboratory but also the centres 
laboratory in order to track the sample. 
 
Field name Format Description 
SAMP_LAB character (or numeric if possible) 
The assigned sample ID at the lab 
where the resistance test is preformed. 
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SAMP_INT character (or numeric if possible) The assigned sample ID from the 
centre. 
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tblLAB_RES_LVL_1 - Nucleotide sequences (PRO, RT, GP41, GP120) 
 
holds nucleoside sequence for the PRO and RT sequences. No entry is made if the test was a phenotype test. 
 
Note: This table is tightly linked to tblLAB_RES. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
TEST_ID character (or numeric if possible) Identifier linking this record to 
tblLAB_RES 
 
 
 
SEQTYPE 
character: 
 
• PRO = PRO sequence 
• RT = RT sequence 
• GP41 = GP41 sequence 
• GP120 = GP120 sequence 
 
 
 
Type of nucleotide sequence if 
available 
SEQ_START numeric Start position for the sequence 
SEQ_STOP numeric Stop position for the sequence 
SEQ_NUC character Nucleotide sequence if available 
 
Additional fields 
 
In cases where the amino acid sequence is collected rather than the nucleotide sequence, the field SEQ_NUC might be replaced with 
SEQ_AA, which is the nucleotide sequence, expressed in an amino acid sequence: 
 
Field name Format Description 
SEQ_AA character 
Amino acid sequence if available 
(empty if test was phenotype) 
However using the amino acid sequence does not give the same detail of data as the nucleoside sequence: wobbles in the nucleoside 
sequence can either complicate the reading and alignment of the amino acid sequence or the wobbles can be lost and silent mutations 
are lost. 
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tblLAB_RES_LVL_2 - Mutations 
 
holds mutations and positions of PRO and RT sequences. 
 
Note: This table is tightly linked to tblLAB_RES. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
TEST_ID character (or numeric if possible) Identifier linking this record to 
tblLAB_RES 
 
 
 
GENE 
character: 
 
• PRO = PRO sequence 
• RT = RT sequence 
• GP41 = GP41 sequence 
• GP120 = GP120 sequence 
 
 
Type of sequence/gene (PRO, RT, 
GP41, GP120) 
AA_POS numeric Position of the mutation in the 
sequence 
 
 
AA_POS_SUB 
character: 
 
• a = first 
• b = second 
• etc. 
 
 
Subposition used to code insertions 
AA_FOUND_1 character. empty = Amino acid has been deleted. Mutation (Amino acid) found in the 
sequence 
AA_FOUND_2 character. empty = Amino acid has been deleted. 
Mutation (Amino acid) found in the 
sequence (if more than 1) 
AA_FOUND_3 character. empty = Amino acid has been deleted. 
Mutation (Amino acid) found in the 
sequence (if more than 2) 
AA_FOUND_4 character. empty = Amino acid has been deleted. 
Mutation (Amino acid) found in the 
sequence (if more than 3) 
AA_FOUND_# could be extended if mixtures with more than 4 amino acids are found. 
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tblLAB_RES_LVL_3 - Resistance test result 
 
holds resistance result in relation to antiretroviral drug. 
 
Note: This table is tightly linked to tblLAB_RES. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
TEST_ID character (or numeric if possible) Identifier linking this record to 
tblLAB_RES 
ATC_CODE character ?ATC code of the medication 
RES_SCOR character 
Score of resistance or 
recommendation given from the test. 
 
Additional fields 
 
For phenotype test results it will be necessary to extend the table with a field to store the cut-off value: 
 
Field name Format Description 
RES_CUT character Cut-off value for phenotype test result 
 character:  
 
RES_SCOR_ID 
• S = sensitive 
• L = low level 
 
Coded score of the resistance or 
recommendation given from the test 
 • I = intermediate  
 • H = high level  
However using the amino acid sequence does not give the same detail of data as the nucleoside sequence: wobbles in the nucleoside 
sequence can either complicate the reading and alignment of the amino acid sequence or the wobbles can be lost and silent mutations 
are lost. 
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tblLAB_RNA - Laboratory values 
 
holds date, value, detection limit and type of viral assay. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
RNA_D yyyy-mm-dd Date of Measurement/Sample 
RNA_D_A character: see coding of date precision 
Precision annotation variable for date 
of measurement 
RNA_V 
numeric: -1 = undetectable or detection limit as 
negative value 
HIV-RNA measurement value 
RNA_L numeric Lower Limit of HIV-RNA Assay 
RNA_T numeric. see coding table for valid codings. 
IF AVAILABLE, What type of VIRAL 
ASSAY was used for this 
measurement? 
 
Additional fields 
 
Field name Format Description 
RNA_UL numeric IF AVAILABLE, Upper Limit of assay 
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tblLAB_VIRO - Laboratory values - viro-/serology 
 
holds test results for viro-/serological tests (hepatitis etc.) 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
VS_ID character. see coding table Viral test 
VS_D yyyy-mm-dd Measurement date 
VS_D_A character: see coding of date precision 
optional precision annotation for date 
of measurement 
 
 
VS_R 
numeric: 
 
• 1 = Positive 
• 0 = Negative 
• 9 = Unknown/borderline 
 
 
Measurement result 
VS_V numeric 
Measurement value (HCV-RNA & 
HBV-DNA only) (copies/ml) 
VS_U character. see coding table for valid codings. Measurement unit 
 
Additional fields 
 
Field name Format Description 
VS_LL numeric IF AVAILABLE, Lower limit of assay 
VS_UL numeric IF AVAILABLE, Upper limit of assay 
VS_T character. see coding table for valid codings. 
IF AVAILABLE, type of ASSAY used 
for this measurement 
VS_ST character Specimen type 
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tblLTFU - Death and drop-out 
 
holds data in death and drop-out 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
 
DROP_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
 
Has the patient dropped out? 
DROP_D yyyy-mm-dd If patient has dropped out, date of last 
visit 
DROP_D_A character: see coding of date precision optional precision annotation for date 
of last visit 
DROP_RS numeric. see coding table for valid codings. Reason for drop 
 
DEATH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
 
Has the patient died? 
DEATH_D yyyy-mm-dd Date of Death 
DEATH_D_A character: see coding of date precision optional precision annotation for date 
of death 
 
 
SUD_DEATH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Sudden Death? 
 
 
EXP_DEATH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Expected Death? 
 
 
AUTOP_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Was an autopsy Performed? 
DEATH_R1 character. see coding table for valid codings. Cause of death 
 
 
 
DEATH_RC1 
character with codes: 
 
• I = Immediate cause 
• U = Underlying cause/condition 
• C = Contributing cause 
• N = Not available 
 
 
Coding of causal relation of the code 
given in DEATH_R1 to the death 
DEATH_R2 character. see coding table for valid codings. Cause of death 
 
 
 
DEATH_RC2 
character with codes: 
 
• I = Immediate cause 
• U = Underlying cause/condition 
• C = Contributing cause 
• N = Not available 
 
 
Coding of causal relation of the code 
given in DEATH_R2 to the death 
DEATH_R3 character. see coding table for valid codings. Cause of death 
 
 
 
DEATH_RC3 
character with codes: 
 
• I = Immediate cause 
• U = Underlying cause/condition 
• C = Contributing cause 
• N = Not available 
 
 
Coding of causal relation of the code 
given in DEATH_R3 to the death 
 
DEATH_SOURCE 
 
character 
Source of information for coding of 
death (e.g. CoDe within own cohort, 
CoDe from D:A:D, CoDe from ART-
CC, etc.) 
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MOTHERDEATH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Hast the patient's biological mother 
died? 
MOTHERDEATH_D yyyy-mm-dd Date of death of the patient's biological 
mother 
MOTHERDEATH_D_A character: see coding of date precision 
optional precision annotation for date 
of death of patient's mother 
 
 
FATHERDEATH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Hast the patient's biological father 
died? 
FATHERDEATH_D yyyy-mm-dd Date of death of the patient's biological 
father 
FATHERDEATH_D_A character: see coding of date precision 
optional precision annotation for date 
of death of patient's father 
List of DEATH_R# and DEATH_RC# should be continued for as many reasons that are recorded. 
 
The DEATH_RC# fields should enable cohorts to transfer data in accordance with the ?Coding of Death project (CoDe). You are 
welcome to contact the CoDe group for electronic sample forms for detailed collection of data used for the CoDe review process. 
 
CoDe defines 1 immediate, 2 contributing and 1 underlying cause of death. 
 
Additional fields 
 
Field name Format Description 
ICD10_1 character Cause of death as ICD-10 if available 
ICD10_2 character Cause of death as ICD-10 if available 
ICD10_31 character Cause of death as ICD-10 if available 
ICD9_1? character Cause of death as ICD-9 if available 
ICD9_2 character Cause of death as ICD-9 if available 
ICD9_31 character Cause of death as ICD-9 if available 
DEATH_OT character Reason for death ? other - description 
L_ALIVE_D yyyy-mm-dd Last date known to be alive 
L_ALIVE_D_A character: see coding of date precision 
optional precision annotation for last 
date of Information / lknown to be alive 
1: List of ICD10_# and ICD9_#inplace of or together with DEATH_R# and together DEATH_RC# and should be continued for as many reasons that 
are recorded. 
 
CoDe defines 1 immediate, 2 contributing and 1 underlying cause of death. 
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tblMED - Other medication 
 
holds type, start and stop dates for other medication/treatments. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
MED_ID character. see coding table for valid codings. Code representing the treatment 
MED_SD yyyy-mm-dd Date of Initiation of Treatment 
MED_SD_A character: see coding of date precision 
Precision annotation variable for date 
of initiation of drug 
MED_ED yyyy-mm-dd Date of stopping treatment 
MED_ED_A character: see coding of date precision 
Precision annotation variable for date 
of stopping drug 
MED_RS 
character. see coding table for valid codings 
(identical to stopping reasons for ART) 
reason for stopping treatment 
 
Additional fields 
 
Field name Format Description 
MED_RS2 
character. see coding table for valid codings 
(identical to stopping reasons for ART) 
Additional reason for stopping 
treatment 
MED_RS3 
character. see coding table for valid codings 
(identical to stopping reasons for ART) 
Additional reason for stopping 
treatment 
MED_RS4 
character. see coding table for valid codings 
(identical to stopping reasons for ART) 
Additional reason for stopping 
treatment 
MED_DO numeric 
Dosage (mg or mL) per intake unless 
MED_FR=-1 (optional) 
 
 
 
 
 
MED_FR 
numeric: 
 
• -1 = Frequency not known. MED_DO contains 
dosage per day 
• 0.33 = 1 dose every third day 
• 0.5 = 1 dose every second day 
• 1 = 1 daily dose/qd 
• 2 = 2 daily doses/bid 
• 3 = 3 daily doses/tid 
• 4... = code gives number of daily doses 
 
 
 
 
 
Frequency 
 
 
DOT_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown / Not performed 
 
 
Directly observed Treatment (optional) 
 
 
MEDSTART_RS 
numeric: 
 
• 1 = Treatment (incl. for presumptive dx) 
• 2 = Prophylaxis (Primary or secondary) 
• 9 = Unknown 
 
 
Reason for starting medication 
(optional) 
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tblSAMPLES - Blood Samples 
 
This table contains information on the storage of blood, urine and other samples stored in a laboratory. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) patient cohort identifier 
SAMP_LAB_D yyyy-mm-dd date when the sample was taken 
 
 
 
 
SAMP_TYPE 
character: 
 
• BS = blood serum 
• BP = blood plasma 
• C = viable cells 
• D = cell pellet (DNA) 
• S = semen 
• OTH:x = other sample type x (none of the above) 
 
 
 
 
type of the sample 
SAMP_ID character 
identification symbol allowing the 
localization of the sample in the 
laboratory 
SAMP_LAB character laboratory where the samples are 
stored 
SAMP_FREEZE_D yyyy-mm-dd date when the sample was frozen 
SAMP_FREEZE_T hh:mm time when the sample was frozen 
SAMP_ALIQ_NO numeric number of aliquots available 
 
 
SAMP_ALIQ_SIZE 
 
 
numeric 
size of the aliquot: 
 
• in ml for serum, plasma and cell pellet 
aliquots 
• in millions of cells for viable cell 
aliquots 
 
SAMP_ALIQ_U 
character: 
 
• 0 = millions of cells 
• 1 = ml 
 
unit of measurement for the 
SAMP_ALIQ_SIZE 
value 
 
Additional fields 
 
Field name Format Description 
SAMP_LAB_T hh:mm time when the sample was taken 
SAMP_TEMP numeric 
temperature of the storage unit 
containing the samples (in °C) 
 
 
SAMP_DEFROST 
numeric: 
 
• 1 = Yes 
• 0 = No 
• 9 = Unknown 
 
 
have the samples already been 
defrosted? 
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tblVIS - Basic follow-up/visit related data 
 
holds visit related information such as weight, wasting, smoking, occupational status etc. 
 
Core fields 
 
Note: Fields marked bold form the unique identifier for a record of the table. 
 
Field name Format Description 
PATIENT character (or numeric if possible) Code to identify patient (Cohort Patient 
ID) 
VIS_D yyyy-mm-dd Date of patient visit 
VIS_D_A character: see coding of date precision Precision annotation variable for date 
of visit 
CENTER character Center the patient visits. Links to 
tblCENTER. 
WEIGH numeric (metric: kg): 999 = Unknown Weight of patient at visit 
 
 
GAIN_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the patient gaining fat in the 
abdomen, neck, breast or other 
defined locations? 
 
 
LOSS_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the patient experiencing loss of fat 
from extremities, buttocks or face? 
Depending on the collaboration this data might be collected in intervals of a year, e.g. from July last to July this year. In that case all 
visit dates or a fixed number of visit dates for that period should be gathered, if the patient did not have a visit in the defined period, a 
record with the PATIENT id and empty fields for VIS_D etc. should be included. 
 
Additional fields 
 
Field name Format Description 
CDC_STAGE character. see coding table for valid codings. Clinical CDC stage at time of visit? 
 
 
 
WHO_STAGE 
numeric. 
 
• 1 = WHO Stage I 
• 2 = WHO Stage II 
• 3 = WHO Stage III 
• 4 = WHO Stage IV 
• 9 = Unknown 
 
 
 
Clinical WHO stage at time of visit? 
 
 
FAM_Y 
numeric. 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
Family history of CVD: Have any first 
degree relatives experienced 
myocardial infarction or stroke before 
the age of 50 years? 
The following optional fields are meant to be used to document the transition process from adolescent to adult. 
 
Field name Format Description 
 
 
 
 
CLINIC_TYPE 
numeric 
 
• 1 = paediatric 
• 2 = adolescent within paediatric care 
• 3 = adolescent within adult care 
• 4 = adolescent stand alone 
• 5 = adult 
• 9 = missing 
 
 
 
Type of clinic/service the patient is 
currently attending 
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SPEC_TYPE 
numeric 
 
• 1 = Physician providing paediatric care 
• 2 = Physician providing adolescent care 
• 3 = Physician providing adult care 
• 4 = Physician providing paediatric and adult care 
• 5 = other healthcare provider (e.g. nurse) 
• 9 = missing 
 
 
 
 
Type of specialist providing care. 
Combinations if multiple specialists 
are involved (e.g. 23, 45). 
 
 
 
TRANS_STAGE 
numeric 
 
• 0 = transition not started 
• 1 = transition in progress 
• 2 = transition completed 
• 9 = not applicable/missing 
 
Stage of transition from pediatric to 
adult care at current visit. 
Transition has not yet started when the 
patient only sees paediatricians. 
Transition is complete when the 
patient only sees adult physicians. 
The following fields are meant to be used for adolescents and adults. 
 
Field name Format Description 
EMPLOY numeric. see coding table for valid codings. 
What is the patient's current situation 
regarding labour? 
CONTRACT numeric. see coding table for valid codings. 
If the patient is an employee, what is 
the type of the patient's employment 
contract? 
 
 
SMOKING_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the patient currently a smoker? 
 
 
PREG_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the patient currently pregnant? If 
possible, provide additional details in 
tblPREG 
 
 
 
 
GENDER_ID 
numeric: 
 
• 1 = Male 
• 2 = Female 
• 3 = Transgender male 
• 4 = Transgender female 
• 5 = Other 
• 9 = Unknown 
 
 
 
 
Current gender identification 
 
 
SCHOOL 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the patient currently attending 
school or on break for customary 
school holidays? 
 
SCHOOL_LVL 
 
numeric: see coding table 
Current level of education (ISCED97 
refers to the 1997 International 
Standard Classification of Education) 
The following fields are meant to be used for HIV-infected children and adolescents only. 
 
Field name Format Description 
 
 
 
STATUS_KNOWN 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 2 = Disclosure ongoing 
• 9 = Unknown 
 
 
 
Does the patient know his/her HIV 
status? 
The following fields are meant to be used for children and infants. 
 
Field name Format Description 
HEIGH numeric (metric in m). 999 = Unknown Height/length of patient at visit in 
meters (m) 
LIVEWITH numeric. see coding table for valid codings. Child lives with/in 
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HEALTHY_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is child healthy? 
 
 
FEEDOTH_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Is the Patient currently receiving 
Foods or liquids other than breast 
milk? 
 
 
 
 
 
 
CAREGIVER 
numeric: 
 
• 1 = Mother 
• 2 = Father 
• 3 = Sibling 
• 4 = Grandparent 
• 5 = Aunt or Uncle 
• 6 = Self 
• 7 = Other family member 
• 8 = Other non-family member 
• 9 = Unknown 
• 10 = Other non-coded 
 
 
 
 
 
 
Who is the patient's primary caregiver? 
 
 
 
 
 
 
BROUGHT_PATIENT 
numeric: 
 
• 1 = Mother 
• 2 = Father 
• 3 = Sibling 
• 4 = Grandparent 
• 5 = Aunt or Uncle 
• 6 = Self 
• 7 = Other family member 
• 8 = Other non-family member 
• 9 = Unknown 
• 10 = Other non-coded 
 
 
 
 
 
 
Who brought the Patient to this clinic 
visit? 
 
 
HIV_STATUS 
numeric: 
 
• 1 = HIV exposed, status indeterminate 
• 2 = HIV infected 
• 3 = HIV uninfected 
 
 
Current HIV status 
The following fields are meant to be used for infants: 
 
Field name Format Description 
HEIGH_P numeric Height/length of patient at visit in 
percentiles 
WEIGH_P numeric Weight of patient at visit in percentiles 
HEADC numeric 
Head circumference measured in 
millimeters (mm) 
HEADC_P numeric Head circumference in percentiles 
 
 
BREASTF_Y 
numeric: 
 
• 0 = No 
• 1 = Yes 
• 9 = Unknown 
 
 
Currently Breastfeeding? 
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